17,20-lyase deficiency, isolated, 202110 (3)  |CYP17A1, CYP17, P450C17|609300|10q24.3
17-alpha-hydroxylase/17,20-lyase deficiency, 202110 (3)  |CYP17A1, CYP17, P450C17|609300|10q24.3
17-beta-hydroxysteroid dehydrogenase X deficiency, 300438 (3)  |HSD17B10, HADH2, ERAB, MRXS10, MRX17, MRX31, DUPXp11.22|300256|Xp11.2
2-methylbutyrylglycinuria, 610006 (3)  |ACADSB, SBCAD|600301|10q25-q26
3-M syndrome, 273750 (3)  |CUL7|609577|6p21.1
3-Methylcrotonyl-CoA carboxylase 1 deficiency, 210200 (3)  |MCCC1, MCCA|609010|3q25-q27
3-Methylcrotonyl-CoA carboxylase 2 deficiency, 210210 (3)  |MCCC2, MCCB|609014|5q12-q13
3-beta-hydroxysteroid dehydrogenase, type II, deficiency (3)  |HSD3B2|201810|1p13.1
3-hydroxyacyl-CoA dehydrogenase deficiency, 231530 (3)  |HADHSC, SCHAD, HHF4|601609|4q22-q26
3-hydroxyisobutryl-CoA hydrolase deficiency, 250620 (3)  |HIBCH|610690|2q32.2
3-methylglutaconic aciduria, type I, 250950 (3)  |AUH|600529|Chr.9
3-methylglutaconic aciduria, type III, 258501 (3)  |OPA3, MGA3|606580|19q13.2-q13.3
3-methylglutaconic aciduria, type V, 610198 (3)  |DNAJC19, TIM14|608977|3q26.3
3q21q26 syndrome (1)  |EVI1|165215|3q26
46XX true true hermaphroditism, 400045 (3)  |SRY, TDF, TDY|480000|Yp11.3
46XY complete gonadal dysgenesis, 233420 (3)  |DHH|605423|12q13.1
46XY complete gonadal dysgenesis, 400044 (3)  |SRY, TDF, TDY|480000|Yp11.3
46XY gonadal dysgenesis, complete or partial, with 9p24.3 deletion (4)  |DEL9p24.3, C9DELp24.3|154230|9p24.3
46XY gonadal dysgenesis, complete or partial, with or without adrenal failure, 612965 (3)  |NR5A1, FTZF1, FTZ1, SF1, AD4BP, POF7|184757|9q33
46XY gonadal dysgenesis, complete, CBS2-related, 613080 (3)  |CBX2, M33|602770|17q25
46XY partial gonadal dysgenesis, with minifascicular neuropathy, 607080 (3)  |DHH|605423|12q13.1
5-fluorouracil toxicity, 274270 (3)  |DPYD, DPD|612779|1p22
6-mercaptopurine sensitivity, 610460 (3)  |TPMT|187680|6p22.3
ABCD syndrome, 600501 (3)  |EDNRB, HSCR2, ABCDS, WS4A|131244|13q22
ACAD9 deficiency, 611126 (3)  |ACAD9|611103|3q26
ACAT2 deficiency (1) (?)  |ACAT2|100678|6q25.3-q26
ADULT syndrome, 103285 (3)  |TP63, TP73L, KET, EEC3, SHFM4, LMS, RHS, OFC8|603273|3q27
AGAT deficiency, 612718 (3)  |GATM, AGAT|602360|15q15.3
AICA-ribosiduria due to ATIC deficiency, 608688 (3)  |ATIC, PURH, AICAR|601731|2q35
ATP synthase deficiency, nuclear-encoded, 604273 (3)  |ATPAF2, ATP12|608918|17p11.2
Aarskog-Scott syndrome, 305400 (3)  |FGD1, FGDY, AAS, MRXS16|300546|Xp11.21
Abdominal obesity-metabolic syndrome (2)  |AOMS1, SYNX|605552|3q27
Abdominal obesity-metabolic syndrome (2)  |AOMS2|605572|17p12
Abetalipoproteinemia, 200100 (3)  |MTP|157147|4q22-q24
Acampomelic campomelic dysplasia, 114290 (3)  |SOX9, CMD1, SRA1|608160|17q24.3-q25.1
Acatalasemia (3)  |CAT|115500|11p13
Acetabular dysplasia (2)  |ACTD|142700|13q22
Acetyl-CoA carboxylase deficiency (1)  |ACACA, ACAC, ACC1|200350|17q21
Achalasia-addisonianism-alacrimia syndrome, 231550 (3)  |AAAS, AAA|605378|12q13
Acheiropody, 200500 (3)  |LMBR1, ACHP, C7orf2, PPD2|605522|7q36
Achondrogenesis Ib, 600972 (3)  |SLC26A2, DTD, DTDST, D5S1708, EDM4|606718|5q32-q33.1
Achondrogenesis, type IA, 200600 (3)  |TRIP11, TRIP230, CEV14, ACG1A|604505|14q31-q32
Achondrogenesis-hypochondrogenesis, type II, 200610 (3)  |COL2A1|120140|12q13.11-q13.2
Achondroplasia, 100800 (3)  |FGFR3, ACH|134934|4p16.3
Achromatopsia-2, 216900 (3)  |CNGA3, CNG3, ACHM2|600053|2q11
Achromatopsia-3, 262300 (3)  |CNGB3, ACHM3, ACHM1|605080|8q21-q22
Achromatopsia-4 (3)  |GNAT2, ACHM4|139340|1p13
Acid-labile subunit, deficiency of (3)  |IGFALS, ALS|601489|16p13.3
Acne inversa, familial, 1, 142690 (3)  |NCSTN|605254|1q22-q23
Acne inversa, familial, 2, 613736 (3)  |PSENEN, PEN2|607632|19q13.1
Acne inversa, familial, 3, 613737 (3)  |PSEN1, AD3|104311|14q24.3
Acrocallosal syndrome, 200990 (3)  |GLI3, PAPA, PAPB, ACLS|165240|7p13
Acrocapitofemoral dysplasia, 607778 (3)  |IHH, BDA1|600726|2q33-q35
Acrodermatitis enteropathica, 201100 (3)  |SLC39A4, ZIP4|607059|8q24.3
Acrofacial dysostosis, Nager type (2) (?)  |AFD1, AFDN|154400|9q32
Acrokeratosis verruciformis, 101900 (3)  |ATP2A2, ATP2B, DAR|108740|12q23-q24.1
Acromegaloid features, overgrowth, cleft palate, and hernia (2)  |AOCH|606049|Chr.11
Acromegaly, 10220  |GNAS, GNAS1, GPSA, POH, PHP1B, PHP1A, AHO, PHP1C|139320|20q13.2
Acromesomelic dysplasia, Hunter-Thompson type, 201250 (3)  |GDF5, CDMP1, SYNS2, OS5|601146|20q11.2
Acromesomelic dysplasia, Maroteaux type, 602875 (3)  |NPR2, ANPRB, AMDM|108961|9p21-p12
Acropectoral syndrome (2)  |ACRPS|605967|7q36
Acropectorovertebral dysplasia (2)  |ACRPV|102510|2q36
Action myoclonus-renal failure syndrome, 254900 (3)  |SCARB2, CD36L2, LIMPII, AMRF|602257|4q13-q21
Acute insulin response (2)  |AIR|601676|1p31
Acyl-CoA dehydrogenase, long chain, deficiency of, 201460 (3)  |ACADL, LCAD|609576|2q34-q35
Acyl-CoA dehydrogenase, medium chain, deficiency of, 201450 (3)  |ACADM, MCAD|607008|1p31
Acyl-CoA dehydrogenase, short-chain, deficiency of, 201470 (3)  |ACADS, SCAD|606885|12q22-qter
Adenocarcinoma of lung, response to tyrosine kinase inhibitor in, 211980 (3)  |EGFR|131550|7p12.3-p12.1
Adenocarcinoma of lung, somatic, 211980 (3)  |BRAF, NS7|164757|7q34
Adenocarcinoma of lung, somatic, 211980 (3)  |ERBB2, NGL, NEU, HER2|164870|17q21.1
Adenocarcinoma of lung, somatic, 211980 (3)  |PRKN, PARK2, PDJ, LPRS2|602544|6q25.2-q27
Adenocarcinoma, colonic, somatic (3)  |RAD54L, HR54, HRAD54|603615|1p32
Adenocarcinoma, ovarian, somatic, 604370 (3)  |PRKN, PARK2, PDJ, LPRS2|602544|6q25.2-q27
Adenoma, periampullary, somatic (3)  |APC, GS, FPC, BTPS2|611731|5q21-q22
Adenomas, multiple colorectal, 608456 (3)  |MUTYH, MYH|604933|1p34.3-p32.1
Adenomas, salivary gland pleomorphic, 181030 (3)  |PLAG1, SGPA, PSA|603026|8q12
Adenomatous polyposis coli, 175100 (3)  |APC, GS, FPC, BTPS2|611731|5q21-q22
Adenosine deaminase deficiency, partial, 102700 (3)  |ADA|608958|20q13.11
Adenosine triphosphate, elevated, of erythrocytes, 102900 (3)  |PKLR, PK1|609712|1q21
Adenylosuccinase deficiency, 103050 (3)  |ADSL|608222|22q13.1
Adhalinopathy, primary (1)  |SGCA, ADL, DAG2, LGMD2D, DMDA2|600119|17q12-q21.33
Adiponectin deficiency, 612556 (3)  |ADIPOQ, APM1, GBP28, ADIPQTL1|605441|3q27
Adrenal adenoma, somatic (3)  |MEN1|613733|11q13
Adrenal cortical carcinoma, 202300 (3)  |TP53, P53, LFS1|191170|17p13.1
Adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency, 202010 (3)  |CYP11B1, P450C11, FHI|610613|8q21
Adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency (3)  |CYP21A2, CYP21, CA21H|201910|6p21.3
Adrenal hypoplasia, congenital, with hypogonadotropic hypogonadism, 300200 (3)  |DAX1, AHC, AHX, NROB1|300473|Xp21.3-p21.2
Adrenal insufficiency, congenital with or without 46, XY sex reversal (3)  |CYP11A, P450SCC|118485|15q23-q24
Adrenocortical insufficiency (3)  |NR5A1, FTZF1, FTZ1, SF1, AD4BP, POF7|184757|9q33
Adrenocortical tumor, somatic (3)  |PRKAR1A, TSE1, CNC1, CAR, PPNAD1|188830|17q23-q24
Adrenocorticotropic hormone deficiency, 201400 (3)  |TBS19|604614|1q23-q24
Adrenoleukodystrophy, 300100 (3)  |ABCD1, ALD, AMN|300371|Xq28
Adrenoleukodystrophy, neonatal, 202370 (3)  |PEX1, ZWS1|602136|7q21-q22
Adrenoleukodystrophy, neonatal, 202370 (3)  |PEX10, NALD|602859|1p36.32
Adrenoleukodystrophy, neonatal, 202370 (3)  |PEX13, ZWS, NALD|601789|2p15
Adrenoleukodystrophy, neonatal, 202370 (3)  |PEX26|608666|22q11.21
Adrenoleukodystrophy, neonatal, 202370 (3)  |PEX5, PXR1, PTS1R|600414|12p13.3
Adrenomyeloneuropathy, 300100 (3)  |ABCD1, ALD, AMN|300371|Xq28
Adult i phenotype with congenital cataract, 110800 (3)  |GCNT2|600429|6p24-p23
Adult i phenotype without cataract, 110800 (3)  |GCNT2|600429|6p24-p23
Advanced sleep phase syndrome, familial, 604348 (3)  |PER2, FASPS, KIAA0347|603426|2q37.3
Afibrinogenemia, congenital, 202400 (3)  |FGA|134820|4q28
Afibrinogenemia, congenital, 202400 (3)  |FGB|134830|4q28
Agammaglobulinemia 1, 601495 (3)  |IGHM, MU, AGM1|147020|14q32.33
Agammaglobulinemia 2, 613500 (3)  |IGLL1, IGO, IGL5, VPREB2, AGM2|146770|22q11.21
Agammaglobulinemia 3, 613501 (3)  |CD79A, IGA|112205|19q13.2
Agammaglobulinemia 4, 613502 (3)  |BLNK, SLP65, AGM4|604515|10q23.2
Agammaglobulinemia 5, 613506 (3)  |LRRC8A, KIAA1437, AGM5|608360|9q34.13
Agammaglobulinemia 6, 612692 (3)  |CD79B, IGB, B29, AGM6|147245|17q23
Agammaglobulinemia and isolated hormone deficiency, 307200 (3)  |BTK, AGMX1, IMD1, XLA, AT|300300|Xq21.3-q22
Agammaglobulinemia, X-linked 1, 300755 (3)  |BTK, AGMX1, IMD1, XLA, AT|300300|Xq21.3-q22
Agammaglobulinemia, X-linked 2 (2)  |AGMX2, XLA2, IMD6|300310|Xp22
Agenesis of the corpus callosum with peripheral neuropathy, 218000 (3)  |SLC12A6, KCC3A, KCC3B, KCC3, ACCPN|604878|15q13-q14
Aicardi syndrome (2)  |AIC|304050|Xp22
Aicardi-Goutieres syndrome 1, dominant and recessive, 225750 (3)  |TREX1, AGS1, CRV, HERNS|606609|3p21.3-p21.2
Aicardi-Goutieres syndrome 2, 610181 (3)  |RNASEH2B, DLEU8, FLJ11712, AGS2|610326|13q14.1
Aicardi-Goutieres syndrome 3, 610329 (3)  |RNASEH2C, AYP1, FLJ20974, AGS3|610330|11q13.2
Aicardi-Goutieres syndrome 4, 610333 (3)  |RNASEH2A, RNHIA, AGS4|606034|19p13.13
Aicardi-Goutieres syndrome 5, 612952 (3)  |SAMHD1, AGS5, DCIP|606754|20q11.2
Alagille syndrome 2, 610205 (3)  |NOTCH2, AGS2|600275|1p13-p11
Alagille syndrome, 118450 (3)  |JAG1, AGS, AHD|601920|20p12
Aland Island eye disease, 300600 (3)  |CACNA1F, CSNB2, CORDX3, CSNB2A, AIED, OA2|300110|Xp11.23
Albinism, brown oculocutaneous, 203200 (3)  |OCA2, P, PED, D15S12, BOCA, EYCL3, HCL3, SHEP1|611409|15q11.2-q12
Albinism, oculocutaneous, type IA, 203100 (3)  |TYR, SHEP3, CMM8|606933|11q14-q21
Albinism, oculocutaneous, type IB, 606952 (3)  |TYR, SHEP3, CMM8|606933|11q14-q21
Albinism, oculocutaneous, type II, 203200 (3)  |OCA2, P, PED, D15S12, BOCA, EYCL3, HCL3, SHEP1|611409|15q11.2-q12
Albinism, oculocutaneous, type III, 203290 (3)  |TYRP1, CAS2, GP75|115501|9p23
Albinism-deafness syndrome (2)  |ADFN, ALDS|300700|Xq26.3-q27.1
Alcohol sensitivity, acute, 610251 (3)  |ALDH2|100650|12q24.2
Aldosterone to renin ratio raised (3)  |CYP11B2|124080|8q21
Aldosteronism, glucocorticoid-remediable, 103900 (3)  |CYP11B1, P450C11, FHI|610613|8q21
Alexander disease, 203450 (3)  |GFAP|137780|17q21
Alexander disease, 203450 (3)  |NDUFV1, UQOR1|161015|11q13
Alkaptonuria, 203500 (3)  |HGD, AKU|607474|3q21-q23
Allan-Herndon-Dudley syndrome, 300523 (3)  |SLC16A2, DXS128, XPCT|300095|Xq13.2
Alopecia areata 1 (2)  |AA1|104000|18p11.3-p11.2
Alopecia areata 2 (2)  |AA2|610753|16q11-q22
Alopecia universalis, 203655 (3)  |HR, AU, MUHH1|602302|8p21.2
Alopecia with mental retardation syndrome 1 (2)  |APMR1|203650|3q26.3-q27.3
Alopecia with mental retardation syndrome 2 (2)  |APMR2|610422|3q26.2-q26.31
Alopecia, androgenetic (2)  |AFA1, MPB|109200|3q26
Alopecia, androgenetic, 2 (2)  |AGA2|300710|Xq11-q12
Alopecia, androgenetic, 3 (2)  |AGA3|612421|20p11.22
Alopecia, neurologic defects, and endocrinopathy syndrome, 612079 (3)  |RBM28|612074|7q32.1
Alpha-1-antichymotrypsin deficiency (3)  |SERPINA3, AACT, ACT|107280|14q32.1
Alpha-2-plasmin inhibitor deficiency, 262850 (3)  |PLI, SERPINF2|613168|17pter-p12
Alpha-ketoglutarate dehydrogenase deficiency, 203740 (1)  |OGDH|613022|7p14-p13
Alpha-methylacetoacetic aciduria, 203750 (3)  |ACAT1|607809|11q22.3-q23.1
Alpha-methylacyl-CoA racemase deficiency (3)  |AMACR, CBAS4|604489|5p13.2-q11.1
Alpha-thalassemia myelodysplasia syndrome, somatic, 300448 (3)  |ATRX, XH2, XNP, SHS, SFM1, MRXHF1|300032|Xq13
Alpha-thalassemia/mental retardation syndrome, 301040 (3)  |ATRX, XH2, XNP, SHS, SFM1, MRXHF1|300032|Xq13
Alpha-thalassemia/mental retardation syndrome, type 1 (4)  |HBHR, ATR1|141750|16pter-p13.3
Alpha/beta T-cell lymphopenia with gamma/delta T-cell expansion, severe cytomegalovirus infection, and autoimmunity, 609889 (3)  |RAG1|179615|11p13
Alport syndrome, 301050 (3)  |COL4A5, ATS, ASLN|303630|Xq22.3
Alport syndrome, autosomal recessive, 203780 (3)  |COL4A3|120070|2q36-q37
Alport syndrome, autosomal recessive, 203780 (3)  |COL4A4|120131|2q36-q37
Alport syndrome, mental retardation, midface hypoplasia, and elliptocytosis (4)  |AMMEC, DELXq22.3, CXDELq22.3|300194|Xq22.3
Alstrom syndrome, 203800 (3)  |ALMS1, ALSS, KIAA0328|606844|2p13
Alternating hemiplegia of childhood, 104290 (3)  |ATP1A2, FHM2, MHP2|182340|1q21-q23
Alveolar capillary dysplasia with misalignment of pulmonary veins, 265380 (3)  |FOXF1, FKHL5, ACDMPV|601089|16q24
Alveolar soft-part sarcoma, 606243 (3)  |ASPSCR1, RCC17, ASPL, ASPS|606236|17q25
Alzheimer disease 1, familial, 104300 (3)  |APP, AAA, CVAP, AD1|104760|21q21
Alzheimer disease 6, 104300 (2)  |AD6|605526|10q24
Alzheimer disease 8, 104300 (2)  |AD8|607116|20p
Alzheimer disease, late-onset, susceptibility to}, 104300 (3)  |NOS3|163729|7q36
Alzheimer disease, type 3, 607822 (3)  |PSEN1, AD3|104311|14q24.3
Alzheimer disease, type 3, with spastic paraparesis and apraxia, 607822 (3)  |PSEN1, AD3|104311|14q24.3
Alzheimer disease, type 3, with spastic paraparesis and unusual plaques, 607822 (3)  |PSEN1, AD3|104311|14q24.3
Alzheimer disease-10, 104300 (2)  |AD10|609636|7q36
Alzheimer disease-11 (2)  |AD11|609790|9p22.1
Alzheimer disease-2, 104310 (3)  |APOE, AD2, LPG, LDLCQ5|107741|19q13.2
Alzheimer disease-4, 606889 (3)  |PSEN2, AD4, STM2, CMD1V|600759|1q31-q42
Alzheimer disease-5, 104300 (2)  |AD5|602096|12p11.23-q13.12
Alzheimer disease-7 (2)  |AD7|606187|10p13
Amelogenesis imperfecta, hypomaturation type, IIA3, 613211 (3)  |WDR72, AI2A3|613214|15q21.3
Amelogenesis imperfecta, hypomaturation-hypoplastic type, with taurodontism, 104510 (3)  |DLX3, TDO, AI4|600525|17q21.3-q22
Amelogenesis imperfecta, hypoplastic/hypomaturation type, 301200 (3)  |AMELX, AMG, AIH1, AMGX|300391|Xp22.3-p22.1
Amelogenesis imperfecta, type 3, 130900 (3)  |FAM83H, AI3|611927|8q24.3
Amelogenesis imperfecta, type IB, 104500 (3)  |ENAM, AIH2, AI1C|606585|4q21
Amelogenesis imperfecta, type IC, 204650 (3)  |ENAM, AIH2, AI1C|606585|4q21
Amelogenesis imperfecta, type IIA1, 204700 (3)  |KLK4, EMSP1, PRSS17, AI2A1|603767|19q13.4
Amelogenesis imperfecta, type IIA2, 612529 (3)  |MMP20, AI2A2|604629|11q22.3-q23
Amelogenesis imperfecta-3, hypoplastic type (2) (?)  |AIH3|301201|Xq22-q28
Aminoacylase 1 deficiency, 609924 (3)  |ACY1, ACY1D|104620|3p21.1
Amish infantile epilepsy syndrome, 609056 (3)  |SIAT9, ST3GALV|604402|2p11.2
Amyloidosis, 3 or more types, 105200 (3)  |APOA1|107680|11q23
Amyloidosis, Finnish type, 105120 (3)  |GSN|137350|9q34
Amyloidosis, hereditary renal, 105200 (3)  |FGA|134820|4q28
Amyloidosis, hereditary, transthyretin-related, 105210 (3)  |TTR, PALB|176300|18q11.2-q12.1
Amyloidosis, primary localized cutaneous, 105250 (3)  |OSMR, OSMRB|601743|5p13.1
Amyloidosis, renal, 105200 (3)  |LYZ|153450|12q15
Amyotrophic lateral sclerosis 10, with or without FTD, 612069 (3)  |TARDBP, TDP43, ALS10|605078|1p36.2
Amyotrophic lateral sclerosis 11, 612577 (3)  |FIG4, KIAA0274, SAC3, ALS11|609390|6q21
Amyotrophic lateral sclerosis 3 (2)  |ALS3|606640|18q21
Amyotrophic lateral sclerosis 4, juvenile, 602433 (3)  |SETX, SCAR1, AOA2, ALS4|608465|9q34
Amyotrophic lateral sclerosis 6, autosomal recessive, with or without frontotemporal dementia, 608030 (3)  |FUS, TLS, ALS6|137070|16p11.2
Amyotrophic lateral sclerosis 7 (2)  |ALS7|608031|20p13
Amyotrophic lateral sclerosis 8, 608627 (3)  |VAPB, VAPC, ALS8|605704|20q13.3
Amyotrophic lateral sclerosis 9, 611895 (3)  |ANG, RNASE5, ALS9|105850|14q11.2
Amyotrophic lateral sclerosis with frontotemporal dementia 1 (2)  |ALSFTD1|105550|9q21-q22
Amyotrophic lateral sclerosis, CHMP2B-related (3)  |CHMP2B, DMT1, VPS2B|609512|3p11.2
Amyotrophic lateral sclerosis, due to SOD1 deficiency, 105400 (3)  |SOD1, ALS1|147450|21q22.1
Amyotrophic lateral sclerosis, juvenile, 205100 (3)  |ALS2, ALSJ, PLSJ, IAHSP|606352|2q33
Amyotrophic lateral sclerosis-5, juvenile recessive (2)  |ALS5|602099|15q15.1-q21.1
Amyotrophic lateral sclerosis-Parkinsonism/dementia complex 2 (3)  |DJ1, PARK7|602533|1p36
Amyotrophy, hereditary neuralgic, 162100 (3)  |SEPT9, MSF, MSF1, NAPB|604061|17q25
Amytrophic lateral sclerosis 12, 613435 (3)  |OPTN, GLC1E, FIP2, HYPL, NRP, ALS12|602432|10p15-p14
Anal canal carcinoma (2) (?)  |ANC|105580|11q22-qter
Analbuminemia (3)  |ALB|103600|4q11-q13
Anauxetic dysplasia, 607095 (3)  |RMRP, RMRPR, CHH|157660|9p21-p12
Androgen insensitivity, 300068 (3)  |AR, DHTR, TFM, SBMA, KD, SMAX1, HYSP1|313700|Xq11-q12
Androgen insensitivity, partial, with or without breast cancer, 312300 (3)  |AR, DHTR, TFM, SBMA, KD, SMAX1, HYSP1|313700|Xq11-q12
Anemia, X-linked, without thrombocytopenia (3)  |GATA1, GF1, ERYF1, NFE1, XLTT|305371|Xp11.23
Anemia, congenital dyserythropoietic, type I, 224120 (3)  |CDAN1, CDA1|607465|15q15
Anemia, dyserythropoietic congenital, type II, 224100 (3)  |SEC23B, CDAN2, HEMPAS|610512|20p11.2
Anemia, dyserythropoietic congenital, type IV, 613673 (3)  |KLF1, EKLF, INLU, HBFQTL6|600599|19p13.13-p13.12
Anemia, hemolytic, Rh-null, regulator type, 268150 (3)  |RHAG, RH50A|180297|6p21.1-p11
Anemia, hemolytic, due to UMPH1 deficiency, 266120 (3)  |NT5C3, UMPH1, PSN1|606224|7p15-p14
Anemia, hypochromic microcytic, 206100 (3)  |NRAMP2|600523|12q13
Anemia, megaloblastic, due to DHFR deficiency (1) (?)  |DHFR|126060|5q11.2-q13.2
Anemia, neonatal hemolytic, fatal and near-fatal (3)  |SPTB, SPH2, EL3, HS2|182870|14q22-q23.2
Anemia, sideroblastic, X-linked, 300751 (3)  |ALAS2, ANH1, ASB, XLDPP, XLSA, ANH1|301300|Xp11.21
Anemia, sideroblastic, pyridoxine-refractory, autosomal recessive, 205950 (3)  |GLRX5, C14orf87, PRO1238, FLB4739|609588|14q32
Anemia, sideroblastic, pyridoxine-refractory, autosomal recessive, 205950 (3)  |SLC25A38|610819|3p22.1
Anemia, sideroblastic, with ataxia, 301310 (3)  |ABCB7, ABC7, ASAT|300135|Xq13.1-q13.3
Aneurysm, intracranial berry, 1 (2)  |ANIB1|105800|7q11.2
Aneurysm, intracranial berry, 2 (2)  |ANIB2|608542|19q13
Aneurysm, intracranial berry, 3 (2)  |ANIB3|609122|1p36.13-p34.3
Aneurysm, intracranial berry, 4 (2)  |ANIB4|610213|5p15.2-p14.3
Aneurysm, intracranial berry, 5 (2)  |ANIB5|610402|2p15-q14
Aneurysm, intracranial berry, 7 (2)  |ANIB7|612161|11q24-q25
Aneurysm, intracranial berry, 8 (2)  |ANIB8|612162|14q23
Aneurysmal bone cysts (2)  |ANBC|606179|16q22
Angelman syndrome, 105830 (3)  |MECP2, RTT, PPMX, MRX16, MRX79, AUTSX3, MRXSL, MRXS13, MRX79, MRX16|300005|Xq28
Angelman syndrome, 105830 (3)  |UBE3A, ANCR|601623|15q11-q13
Angelman syndrome-like, 105830 (3)  |CDKL5, STK9, ISSX, EIEE2|300203|Xp22
Angio serpiginosum (2)  |AGSPX|300652|Xp11.3-q12
Angioedema, hereditary, type III, 610618 (3)  |F12, HAF, HAE3|610619|5q33-qter
Angioedema, hereditary, types I and II, 106100 (3)  |C1NH, HAE1, HAE2, SERPING1|606860|11q11-q13.1
Angiofibroma, somatic (3)  |MEN1|613733|11q13
Angiopathy, hereditary, with nephropathy, aneurysms, and muscle cramps, 611773 (3)  |COL4A1|120130|13q34
Aniridia, 106210 (3)  |PAX6, AN2, MGDA|607108|11p13
Anisomastia (2)  |ANMA|605746|16q13-q21
Anonychia congenita, 206800 (3)  |RSPO4, CRISTIN4|610573|20p13
Anosmia, isolated congenital (2)  |ANIC|107200|18p11.23-q12.2
Anterior segment anomalies and cataract (3)  |EYA1, BOR|601653|8q13.3
Anterior segment mesenchymal dysgenesis, 107250 (3)  |FOXE3, FKHL12, ASMD|601094|1p32
Anterior segment mesenchymal dysgenesis, 107250 (3)  |PITX3, CTPP4|602669|10q25
Antiphospholipid syndrome, familial (2) (?)  |ATPLS|107320|6p21.3
Antithrombin III deficiency, 613118 (3)  |AT3|107300|1q23-q25
Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis, 201750 (3)  |POR|124015|7q11.2
Antley-Bixler syndrome, 207410 (  |FGFR2, BEK, CFD1, JWS|176943|10q26
Anxiety-related personality traits, 607834 (3)  |SLC6A4, HTT, OCD1|182138|17q11.1-q12
Aortic aneurysm, ascending, and dissection (3)  |FBN1, MFS1, WMS, SSKS|134797|15q21.1
Aortic aneurysm, familial abdominal 1 (2)  |AAA1, AAA|100070|19q13
Aortic aneurysm, familial abdominal 2 (2)  |AAA2|609782|4q31
Aortic aneurysm, familial thoracic 1 (2)  |AAT1, FAA1|607086|11q23.3-q24
Aortic aneurysm, familial thoracic 2 (2)  |AAT2, FAA2|607087|5q13-q14
Aortic aneurysm, familial thoracic 4, 132900 (3)  |MYH11, AAT4, FAA4|160745|16p13.13-p13.12
Aortic aneurysm, familial thoracic 6, 611788 (3)  |ACTA2, ACTSA, AAT6|102620|10q22-q24
Aortic valve disease, 109730 (3)  |NOTCH1, TAN1|190198|9q34.3
Apert syndrome, 101200 (3)  |FGFR2, BEK, CFD1, JWS|176943|10q26
Aphakia, congenital primary, 610256 (3)  |FOXE3, FKHL12, ASMD|601094|1p32
Aplasia of lacrimal and salivary glands, 180920 (3)  |FGF10|602115|5p13-p12
Aplastic anemia, 609135 (3)  |TERC, TRC3, TR|602322|3q21-q28
Apnea, postanesthetic (3)  |BCHE, CHE1|177400|3q26.1-q26.2
ApoA-I and apoC-III deficiency, combined (3)  |APOA1|107680|11q23
Apolipoprotein A-II deficiency (3)  |APOA2|107670|1q21-q23
Apolipoprotein C3 deficiency (3)  |APOC3|107720|11q23
Apparent mineralocorticoid excess, hypertension due to (3)  |HSD11B2, HSD11K|218030|16q22
Argininemia, 207800 (3)  |ARG1|608313|6q23
Argininosuccinic aciduria, 207900 (3)  |ASL|608310|7cen-q11.2
Ariculocondylar syndrome (2)  |ARCODS|602483|1p21.1-q23.3
Aromatase deficiency, 613546 (3)  |CYP19A1, CYP19, ARO|107910|15q21.1
Aromatase excess syndrome, 139300 (3)  |CYP19A1, CYP19, ARO|107910|15q21.1
Aromatic L-amino acid decarboxylase deficiency, 608643 (3)  |DDC|107930|7p11
Arrhythmogenic right ventricular dysplasia 1, 107970 (3)  |TGFB3|190230|14q24
Arrhythmogenic right ventricular dysplasia 2, 600996 (3)  |RYR2, VTSIP, ARVD2, ARVC2|180902|1q42.1-q43
Arrhythmogenic right ventricular dysplasia 5, 604400 (1) (?)  |LAMR1, LAMBR|150370|3p21.3
Arrhythmogenic right ventricular dysplasia 8, 607450 (3)  |DSP, KPPS2, PPKS2|125647|6p24
Arrhythmogenic right ventricular dysplasia, familial, 10, 610193 (3)  |DSG2, ARVD10, ARVC10, CMD1BB|125671|18q12.1-q12.2
Arrhythmogenic right ventricular dysplasia, familial, 11, 610476 (3)  |DSC2, DSC3, ARVD11|125645|18q12.1
Arrhythmogenic right ventricular dysplasia, familial, 12, 611528 (3)  |JUP, DP3, PDGB, ARVD12|173325|17q21
Arrhythmogenic right ventricular dysplasia, familial, 5, 604400 (3)  |TMEM43, ARVD5, ARVC5|612048|3p25
Arrhythmogenic right ventricular dysplasia, familial, 9, 609040 (3)  |PKP2, ARVD9|602861|12p11
Arrhythmogenic right ventricular dysplasia-3 (2)  |ARVD3|602086|14q12-q22
Arrhythmogenic right ventricular dysplasia-4 (2)  |ARVD4|602087|2q32.1-q32.3
Arrhythmogenic right ventricular dysplasia-6 (2)  |ARVD6|604401|10p14-p12
Arrhythmogenic right ventricular dysplasia-7 (2)  |ARVD7, ARVC7|609160|10q22.3
Arterial calcification, generalized, of infancy, 208000 (3)  |ENPP1, PDNP1, NPPS, M6S1, PCA1, ARHR2|173335|6q22-q23
Arterial tortuosity syndrome, 208050 (3)  |SLC2A10, GLUT10, ATS|606145|20q13.1
Arthrogryposis multiplex congenita, distal, type 1, 108120 (3)  |TPM2, TMSB, AMCD1, DA1, DA2B, NEM4|190990|9p13.2-p13.1
Arthrogryposis multiplex congenita, distal, type 2B, 601680 (3)  |TNNI2, AMCD2B, DA2B, FSSV|191043|11p15.5
Arthrogryposis multiplex congenita, neurogenic (2)  |AMCN, AMCN1|208100|5q35
Arthrogryposis, distal, type 2A, 193700 (3)  |MYH3|160720|17p13.1
Arthrogryposis, distal, type 2B, 601680 (3)  |MYH3|160720|17p13.1
Arthrogryposis, distal, type 2B, 601680 (3)  |TPM2, TMSB, AMCD1, DA1, DA2B, NEM4|190990|9p13.2-p13.1
Arthrogryposis, lethal, with anterior horn cell disease, 611890 (3)  |GLE1, GLE1L, LCCS, LCCS1|603371|9q34
Arthrogryposis, renal dysfunction, and cholestasis 1, 208085 (3)  |VPS33B|608552|15q26.1
Arthrogryposis, renal dysfunction, and cholestasis 2, 613404 (3)  |VIPAR, SPE39, C14orf133|613401|14q24.3
Arthropathy, progressive pseudorheumatoid, of childhood, 208230 (3)  |WISP3, PPAC, PPD|603400|6q22-q23
Arthyrgryposis, distal, type 2B, 601680 (3)  |TNNT3, AMCD2B, DA2B, FSSV|600692|11p15.5
Arts syndrome (2)  |ARTS|301835|Xq21.2-q24
Arts syndrome, 301835 (3)  |PRPS1, CMTX5, DFNX1, DFN2|311850|Xq22-q24
Aspartylglucosaminuria, 208400 (3)  |AGA|613228|4q32-q33
Asphyxiating thoracic dystrophy 1 (2)  |ATD1|208500|15q13
Asphyxiating thoracic dystrophy 2, 611263 (3)  |IFT80, KIAA1374, WDR56, ATD2|611177|3q24-q26
Asphyxiating thoracic dystrophy 3, 613091 (3)  |DYNC2H1, DNCH2, DHC2, ATD3|603297|11q13.5
Asthma and nasal polyps, 208550 (3)  |TBX21, TBET|604895|17q21.3
Ataxia with isolated vitamin E deficiency, 277460 (3)  |TTPA, TTP1, AVED|600415|8q13.1-q13.3
Ataxia, cerebellar, Cayman type, 601238 (3)  |ATCAY, CLAC, KIAA1872|608179|19p13.3
Ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia, 208920 (3)  |APTX, AOA, AOA1|606350|9p13.3
Ataxia, posterior column, with retinitis pigmentosa, 609033 (3)  |FLVCR1, AXPC1, PCARP|609144|1q31.3
Ataxia, sensory, autosomal dominant (2)  |SNAX1, ADSA|608984|8p12-q12.1
Ataxia, spastic 2, autosomal recessive (2)  |SATX2|611302|17p13
Ataxia, spastic, 3, autosomal recessive (2)  |SPAX3, ARSAL|611390|2q33-q34
Ataxia, spastic, 4, 613672 (3)  |MTPAP, PAPD1, SPAX4|613669|10p11.23
Ataxia-ocular apraxia-2, 606002 (3)  |SETX, SCAR1, AOA2, ALS4|608465|9q34
Ataxia-telangiectasia, 208900 (3)  |ATM, ATA, AT1|607585|11q22.3
Ataxia-telangiectasia-like disorder, 604391 (3)  |MRE11A, MRE11, ATLD|600814|11q21
Atelosteogenesis II, 256050 (3)  |SLC26A2, DTD, DTDST, D5S1708, EDM4|606718|5q32-q33.1
Atelosteogenesis, type III, 108721 (3)  |FLNB, SCT, AOI, LRS1|603381|3p14.3
Atelostogenesis, type I, 108720 (3)  |FLNB, SCT, AOI, LRS1|603381|3p14.3
Athabaskan brainstem dysgenesis syndrome, 601536 (3)  |HOXA1, HOX1F, BSAS|142955|7p15.3
Atopy, 147050 (3)  |SPINK5, LEKTI|605010|5q32
Atransferrinemia, 209300 (3)  |TF|190000|3q21
Atrial fibrillation, 608583 (3)  |GJA5, CX40|121013|1q21.1
Atrial fibrillation, familial, 1 (2)  |ATFB1|608583|10q22-q24
Atrial fibrillation, familial, 2 (2)  |ATFB2|608988|6q14-q16
Atrial fibrillation, familial, 3, 607554 (3)  |KCNQ1, KCNA9, LQT1, KVLQT1, ATFB3, SQT2|607542|11p15.5
Atrial fibrillation, familial, 4, 611493 (3)  |KCNE2, MIRP1, LQT6, ATFB4|603796|21q22.1
Atrial fibrillation, familial, 6, 612201 (3)  |NPPA, PND, ANP, ATFB6|108780|1p36.2
Atrial fibrillation, familial, 7, 612240 (3)  |KCNA5, ATFB7|176267|12p13
Atrial fibrillation, familial, 8 (2)  |ATFB8|613055|16q22
Atrial septal defect 3 (3)  |MYH6, ASD3, MYHCA, CMD1EE, CMH14|160710|14q12
Atrial septal defect 4, 611363 (3)  |TBX20, ASD4|606061|7p15-p14
Atrial septal defect 5, 612794 (3)  |ACTC1, CMD1R, CMH11, ASD5, LVNC4|102540|15q14
Atrial septal defect 6, 613087 (3)  |TLL1, TLL, ASD6|606742|4q32-q33
Atrial septal defect with atrioventricular conduction defects, 108900 (3)  |NKX2E, CSX, CHNG5|600584|5q34
Atrial septal defect, secundum type (2)  |ASD1|108800|5p
Atrial septal defect-2, 607941 (3)  |GATA4|600576|8p23.1-p22
Atrichia with papular lesions, 209500 (3)  |HR, AU, MUHH1|602302|8p21.2
Atrioventricular block, second-degree (3)  |NKX2E, CSX, CHNG5|600584|5q34
Atrioventricular canal defect, 600309 (2)  |AVSD1, AVCD|606215|1p31-p21
Atrioventricular septal defect, 600309 (3)  |GJA1, CX43, ODDD, SDTY3, ODOD, HSS|121014|6q21-q23.2
Atrioventricular septal defect, partial, with heterotaxy syndrome, 606217 (3)  |CRELD1, AVSD2|607170|3p25.3
Auditory neuropathy, autosomal dominant, 1 (2)  |AUNA1|609129|13q14-q21
Auditory neuropathy, autosomal recessive, 1, 601071 (3)  |OTOF, DFNB9, NSRD9, AUNB1|603681|2p23-p22
Aural atresia, congenital (2)  |CAA|607842|18q22.3-q23
Autism, chromosome 22q13.3 deletion syndrome-related (3)  |SHANK3, PSAP2, PROSAP2, KIAA1650, DEL22q13.3|606230|22q13.3
Autoimmune disease, susceptibility to, 6, 613551 (3)  |SIAE, AIS6|610079|11q24
Autoimmune disease, syndromic multisystem, 613385 (3)  |ITCH, AIP4, NAPP1|606409|20q11.22-q11.23
Autoimmune lymphoproliferative syndrome type IV (3)  |NRAS, ALPS4, NS6|164790|1p13.2
Autoimmune lymphoproliferative syndrome, type IA, 601859 (3)  |TNFRSF6, APT1, FAS, CD95, ALPS1A|134637|10q24.1
Autoimmune lymphoproliferative syndrome, type II, 603909 (3)  |CASP10, MCH4, ALPS2|601762|2q33-q34
Autoimmune lymphoproliferative syndrome, type IIB, 607271 (3)  |CASP8, MCH5, ALPS2B|601763|2q33
Autoimmune polyendocrinopathy syndrome , type I, with or without reversible metaphyseal dysplasia, 240300 (3)  |AIRE, APECED, APS1|607358|21q22.3
Autonomic nervous system dysfunction (3)  |DRD4|126452|11p15.5
Axenfeld-Rieger syndrome, type 1, 180500 (3)  |PITX2, IDG2, RIEG1, RGS, IGDS2|601542|4q25-q26
Axenfeld-Rieger syndrome, type 3, 602482 (3)  |FOXC1, FKHL7, FREAC3, IRID1, RIEG3|601090|6p25
Azoospermia due to perturbations of meiosis, 270960 (3)  |SYCP3, SCP3, COR1|604759|12q23
Azoospermia, 415000 (3)  |USP9Y, DFFRY|400005|Yq11.2
B-cell non-Hodgkin lymphoma, high-grade (3)  |BCL7A, BCL7|601406|12q24.1
BCG and salmonella infection, disseminated, 209950 (1)  |IL12B, NKSF2|161561|5q31.1-q33.1
BCG infection, generalized familial, 209950 (3)  |IFNGR1|107470|6q23-q24
BRESHECK syndrome (2)  |BRESEK|300404|Chr.X
Baller-Gerold syndrome, 218600 (3)  |RECQL4, RTS, RECQ4|603780|8q24.3
Bamforth-Lazarus syndrome, 241850 (3)  |FOXE1, FKHL15, TITF2, TTF2|602617|9q22
Band-like calcification with simplified gyration and polymicrogyria, 251290 (3)  |OCLN, BLCPMG|602876|5q13.1
Bannayan-Riley-Ruvalcaba syndrome, 153480 (3)  |PTEN, MMAC1, GLM2|601728|10q23.31
Bardet-Biedl syndrome 1, 209900 (3)  |BBS1|209901|11q13
Bardet-Biedl syndrome 10, 209900 (3)  |BBS10, C12orf58, FLJ23560|610148|12q21.2
Bardet-Biedl syndrome 11, 209900 (3)  |TRIM32, HT2A, LGMD2H, BBS11|602290|9q31-q34.1
Bardet-Biedl syndrome 12, 209900 (3)  |BBS12, FLJ35630, C4orf24|610683|4q27
Bardet-Biedl syndrome 13, 209900 (3)  |MKS1, MKS, BBS13|609883|17q23
Bardet-Biedl syndrome 14, 209900 (3)  |CEP290, KIAA0373, 3H11AG, JBTS5, SLSN6, LCA10, BBS14|610142|12q21.3
Bardet-Biedl syndrome 15, 209900 (3)  |C2orf86, BBS15|613580|2p15
Bardet-Biedl syndrome 2, 209900 (3)  |BBS2|606151|16q21
Bardet-Biedl syndrome 3, 209900 (3)  |ARL6, BBS3, RP55|608845|3p12-q13
Bardet-Biedl syndrome 4, 209900 (3)  |BBS4|600374|15q22.3-q23
Bardet-Biedl syndrome 5, 209900 (3)  |BBS5|603650|2q31
Bardet-Biedl syndrome 6, 209900 (3)  |MKKS, HMCS, KMS, MKS, BBS6|604896|20p12
Bardet-Biedl syndrome 7, 209900 (3)  |BBS7|607590|4q27
Bardet-Biedl syndrome 8, 209900 (3)  |TTC8, BBS8, RP51|608132|14q32.1
Bardet-Biedl syndrome 9, 209900 (3)  |PTHB1, BBS9|607968|7p14
Bare lymphocyte syndrome, type I, 604571 (3)  |TAP1, ABCB2, TAP1, RING4, PSF1|170260|6p21.3
Bare lymphocyte syndrome, type I, 604571 (3)  |TAPBP, TPSN|601962|6p21.3
Bare lymphocyte syndrome, type I, due to TAP2 deficiency, 604571 (3)  |TAP2, ABCB3, PSF2, RING11|170261|6p21.3
Bare lymphocyte syndrome, type II, complementation group A, 209920 (3)  |MHC2TA, C2TA|600005|16p13
Bare lymphocyte syndrome, type II, complementation group C, 209920 (3)  |RFX5|601863|1q21.1-q21.3
Bare lymphocyte syndrome, type II, complementation group D, 209920 (3)  |RFXAP|601861|13q14
Bare lymphocyte syndrome, type II, complementation group E, 209920 (3)  |RFX5|601863|1q21.1-q21.3
Bart-Pumphrey syndrome, 149200 (3)  |GJB2, CX26, DFNB1A, PPK, DFNA3A, KID, HID|121011|13q11-q12
Barth syndrome, 302060 (3)  |TAZ, EFE2, BTHS, CMD3A, LVNCX|300394|Xq28
Bartter syndrome, type 1, 601678 (3)  |SLC12A1, NKCC2|600839|15q15-q21.1
Bartter syndrome, type 2, 241200 (3)  |KCNJ1, ROMK1|600359|11q24
Bartter syndrome, type 3, 607364 (3)  |CLCNKB|602023|1p36
Bartter syndrome, type 4, digenic, 602522 (3)  |CLCNKB|602023|1p36
Bartter syndrome, type 4a, 602522 (3)  |BSND|606412|1p31
Bartter syndrome, type 4b, digenic, 613090 (3)  |CLCNKA|602024|1p36
Basal cell carcinoma (2) (?)  |MSSE, ESS1|132800|9q31
Basal cell carcinoma, somatic (3)  |SMOH, SMO|601500|7q31-q32
Basal cell carcinoma, somatic, 605462 (3)  |PTCH1, NBCCS, BCNS, HPE7|601309|9q22.3
Basal cell carcinoma, somatic, 605462 (3)  |PTCH2|603673|1p32
Basal cell carcinoma, somatic, 605462 (3)  |RASA1, GAP, CMAVM, PKWS|139150|5q13.3
Basal cell nevus syndrome, 109400 (3)  |PTCH1, NBCCS, BCNS, HPE7|601309|9q22.3
Basal ganglia calcification, idiopathic (2)  |IBGC1|213600|14q
Basal ganglia disease, biotin-responsive, 607483 (3)  |SLC19A3|606152|2q36.3
Basal laminar drusen, 126700 (3)  |HF1, CFH, HUS, ARMD4, AHUS1|134370|1q32
Bazex syndrome (2)  |BZX|301845|Xq24-q27
Beare-Stevenson cutis gyrata syndrome, 123790 (3)  |FGFR2, BEK, CFD1, JWS|176943|10q26
Becker muscular dystrophy, 300376 (3)  |DMD, BMD, CMD3B|300377|Xp21.2
Beckwith-Wiedemann syndrome, 130650 (3)  |CDKN1C, KIP2, BWS|600856|11p15.5
Beckwith-Wiedemann syndrome, 130650 (3)  |H19, D11S813E, ASM1, BWS, WT2|103280|11p15.5
Beckwith-Wiedemann syndrome, 130650 (3)  |KCNQ10T1, LIT1|604115|11p15.5
Beckwith-Wiedemann syndrome, 130650 (3)  |NSD1, ARA267, STO|606681|5q35
Bernard-Soulier syndrome, benign autosomal dominant, 153670 (3)  |GP1BA|606672|17pter-p12
Bernard-Soulier syndrome, type A, 231200 (3)  |GP1BA|606672|17pter-p12
Bernard-Soulier syndrome, type B, 231200 (3)  |GP1BB|138720|22q11.2
Bernard-Soulier syndrome, type C, 231200 (3)  |GP9|173515|3q21
Best macular dystrophy, 153700 (3)  |BEST1, VMD2, ARB, RP50|607854|11q13
Bestrophinopathy, 611809 (3)  |BEST1, VMD2, ARB, RP50|607854|11q13
Beta-2-adrenoreceptor agonist, reduced response to (3)  |ADRB2|109690|5q32-q34
Beta-ureidopropionase deficiency, 613161 (3)  |UPB1, BUP1|606673|22q11.2
Bethlem myopathy, 158810 (3)  |COL6A1, OPLL|120220|21q22.3
Bethlem myopathy, 158810 (3)  |COL6A2|120240|21q22.3
Bethlem myopathy, 158810 (3)  |COL6A3|120250|2q37
Bietti crystalline corneoretinal dystrophy, 210370 (3)  |CYP4V2, BCD|608614|4q35.1
Bifid nose with or without anorectal and renal anomalies, 608980 (3)  |FREM1, C9orf154, BNAR|608944|9p22.3
Bile acid malabsorption, primary, 613291 (3)  |SLC10A2, NTCP2, PBAM|601295|13q33
Bile acid synthesis defect, congenital, 2, 235555 (3)  |AKR1D1, SRD5B1, CBAS2|604741|7q32-q33
Bile acid synthesis defect, congenital, 3 (3)  |CYP7B1, CBAS3, SPG5A|603711|8q21.3
Bile acid synthesis defect, congenital, 4, 214950 (3)  |AMACR, CBAS4|604489|5p13.2-q11.1
Biliary cirrhosis, primary, 1 (2)  |PBC1|109720|3p12-q13.2
Biotinidase deficiency, 253260 (3)  |BTD|609019|3p25
Birk-Barel mental retardation dysmorphism syndrome, 612292 (3)  |KCNK9, TASK3|605874|8q24.1-q24.3
Birt-Hogg-Dube syndrome, 135150 (3)  |FLCN, BHD|607273|17p11.2
Bjornstad syndrome, 262000 (3)  |BCS1L, FLNMS, GRACILE, BJS, PTD|603647|2q33
Bladder cancer, 109800 (3)  |KRAS, KRAS2, RASK2, NS|190070|12p12.1
Bladder cancer, 109800 (3)  |RB1|180200|13q14.1-q14.2
Bladder cancer, somatic, 109800 (3)  |FGFR3, ACH|134934|4p16.3
Blau syndrome, 186580 (3)  |NOD2, CARD15, IBD1, CD, ACUG, PSORAS1|605956|16q12
Bleeding diathesis due to GNAQ deficiency (1)  |GNAQ|600998|9q21
Bleeding disorder due to P2RX1 defect (3)  |P2RX1, P2X1|600845|17p13.3
Bleeding disorder due to P2RY12 defect, 609821 (3)  |P2RY12, P2Y12|600515|3q24-q25
Bleeding disorder due to defective thromboxane A2 receptor (3)  |TBXA2R|188070|19p13.3
Bleeding disorder, east Texas type (2)  |BDET|605913|1q23
Blepharophimosis, epicanthus inversus, and ptosis, type 1, 110100 (3)  |FOXL2, BPES, BPES1, PFRK, POF3|605597|3q23
Blepharophimosis, epicanthus inversus, and ptosis, type 2, 110100 (3)  |FOXL2, BPES, BPES1, PFRK, POF3|605597|3q23
Blood group--Lutheran inhibitor, 111150 (3)  |KLF1, EKLF, INLU, HBFQTL6|600599|19p13.13-p13.12
Bloom syndrome, 210900 (3)  |RECQL3, RECQ2, BLM, BS|604610|15q26.1
Blue cone monochromacy, 303700 (3)  |OPN1LW, RCP, CBP, CBBM|300822|Xq28
Blue cone monochromacy, 303700 (3)  |OPN1MW, GCP, CBD, CBBM|300821|Xq28
Boomerang dysplasia, 112310 (3)  |FLNB, SCT, AOI, LRS1|603381|3p14.3
Borjeson-Forssman-Lehmann syndrome, 301900 (3)  |PHF6, BFLS|300414|Xq26.3
Bornholm eye disease (2)  |MYP1, BED|310460|Xq28
Bosley-Salih-Alorainy syndrome, 601536 (3)  |HOXA1, HOX1F, BSAS|142955|7p15.3
Bothnia retinal dystrophy, 607475 (3)  |RLBP1|180090|15q26
Bowen-Conradi syndrome (2)  |BWCNS|211180|12p13.3
Bowen-Conradi syndrome, 211180 (3)  |EMG1, NEP1, C2F, BWCNS|611531|12p13
Brachiootic syndrome 3, 608389 (3)  |SIX1, BOS3, DFNA23|601205|14q23
Brachydactyly, type A1, 112500 (2)  |BDA1B|607004|5p13.3-p13.2
Brachydactyly, type A1, 112500 (3)  |IHH, BDA1|600726|2q33-q35
Brachydactyly, type A2, 112600 (3)  |BMPR1B, ALK6|603248|4q23-q24
Brachydactyly, type A2, 112600 (3)  |GDF5, CDMP1, SYNS2, OS5|601146|20q11.2
Brachydactyly, type B1, 113000 (3)  |ROR2, BDB1, BDB, NTRKR2|602337|9q22
Brachydactyly, type B2, 611377 (3)  |NOG, SYM1, SYNS1|602991|17q22
Brachydactyly, type C, 113100 (3)  |GDF5, CDMP1, SYNS2, OS5|601146|20q11.2
Brachydactyly, type D, 113200 (3)  |HOXD13, HOX4I, SPD, BDSD|142989|2q31-q32
Brachydactyly, type E, 113300 (3)  |HOXD13, HOX4I, SPD, BDSD|142989|2q31-q32
Brachydactyly, type E2, 613382 (3)  |PTHLH, BDE2|168470|12p12.1-p11.2
Brachydactyly-syndactyly syndrome, 610713 (3)  |HOXD13, HOX4I, SPD, BDSD|142989|2q31-q32
Brachydacytly-mental retardation syndrome, 600430 (3)  |HDAC4, HDACA, BDMR, AHO3|605314|2q37.2
Brachyolmia type 3, 113500 (3)  |TRPV4, VROAC, HMSN2C, CMT2C, SPSMA, SSQTL1|605427|12q24.1
Bradyopsia, 608415 (3)  |RGS9, PERRS|604067|17q23-q24
Bradyopsia, 608415 (3)  |RGS9BP, R9AP, RGS9, PERRS|607814|19q13.11
Brain small vessel disease with Axenfeld-Rieger anomaly, 607595 (3)  |COL4A1|120130|13q34
Brain small vessel disease with hemorrhage, 607595 (3)  |COL4A1|120130|13q34
Brain tumor-polyposis syndrome 2 (3)  |APC, GS, FPC, BTPS2|611731|5q21-q22
Branchiooculofacial syndrome, 113620 (3)  |TFAP2A, AP2TF, BOFS|107580|6p24
Branchiootic syndrome (3)  |EYA1, BOR|601653|8q13.3
Branchiootic syndrome 2 (2)  |BOS2|120502|1q31
Branchiootorenal syndrome 2, 610896 (3)  |SIX5, DMAHP, BOR2|600963|19q13.3
Branchiootorenal syndrome with cataract, 113650 (3)  |EYA1, BOR|601653|8q13.3
Branchiootorenal syndrome, 113650 (3)  |EYA1, BOR|601653|8q13.3
Breast cancer (1)  |BCPR|113721|17p13.3
Breast cancer (1)  |ESR1, ESR|133430|6q25.1
Breast cancer (3)  |TSG101|601387|11p15.2-p15.1
Breast cancer, 114480 (3)  |PPM1D, WIP1|605100|17q22-q23
Breast cancer, 114480 (3)  |SLC22A1L, BWSCR1A, IMPT1|602631|11p15.5
Breast cancer, 114480 (3)  |TP53, P53, LFS1|191170|17p13.1
Breast cancer, 11:22 translocation associated (1)  |BRCATA|600048|11q23
Breast cancer, early-onset, 114480 (3)  |BRIP1, BACH1, FANCJ|605882|17q22
Breast cancer, invasive ductal, 114480 (3)  |RAD54L, HR54, HRAD54|603615|1p32
Breast cancer, lobular, 114480 (3)  |CDH1, UVO, LCAM, ECAD|192090|16q22.1
Breast cancer, somatic, 114480 (3)  |AKT1|164730|14q32.3
Breast cancer, somatic, 114480 (3)  |KRAS, KRAS2, RASK2, NS|190070|12p12.1
Breast cancer, somatic, 114480 (3)  |PIK3CA|171834|3q26.3
Breast cancer, somatic, 114480 (3)  |RB1CC1, CC1, KIAA0203|606837|8q11
Breast cancer, type 3 (2) (?)  |BRCA3, BRCAX|605365|13q21
Brittle cornea syndrome, 229200 (3)  |ZNF469, KIAA1858, BCS|612078|16q24
Brody myopathy, 601003 (3)  |ATP2A1, SERCA1|108730|16p12
Bronchiectasis with or without elevated sweat chloride 1, 211400 (3)  |SCNN1B, BESC1|600760|16p13-p12
Bronchiectasis with or without elevated sweat chloride 2, 613021 (3)  |SCNN1A, BESC2|600228|12p13
Bronchiectasis with or without elevated sweat chloride 3, 613071 (3)  |SCNN1G, PHA1, BESC3|600761|16p13-p12
Brooke-Spiegler syndrome, 605041 (3)  |CYLD1, CDMT, EAC, MFT1|605018|16q12-q13
Brown-Vialetto-Van Laere syndrome, 211530 (3)  |C20orf54, RFT2, BVVLS|613350|20p13
Bruck syndrome 1 (2)  |BRKS1|259450|17p12
Bruck syndrome 2, 609220 (3)  |PLOD2|601865|3q23-q24
Brugada syndrome 1, 601144 (3)  |SCN5A, LQT3, VF1, HB1, SSS1, CMD1E, CDCD2|600163|3p21
Brugada syndrome 2, 611777 (3)  |GPD1L, KIAA0089|611778|3p22.3
Brugada syndrome 3, 611875 (3)  |CACNA1C, CACNL1A1, CCHL1A1, TS|114205|12p13.3
Brugada syndrome 4, 611876 (3)  |CACNB2|600003|10p12
Brugada syndrome 5, 612838 (3)  |SCN1B, GEFSP1|600235|19q13.1
Brugada syndrome 6, 613119 (3)  |KCNE3, HOKPP, HYPP|604433|11q13-q14
Brugada syndrome 7, 613120 (3)  |SCN3B, SCNB3|608214|11q23.3
Brugada syndrome 8, 613123 (3)  |HCN4, SSS2|605206|15q24-q25
Brunner syndrome, 300615 (3)  |MAOA|309850|Xp11.23
Burkitt lymphoma, 113970 (3)  |MYC|190080|8q24.12-q24.13
Buschke-Ollendorff syndrome, 166700 (3)  |LEMD3, MAN1|607844|12q14
C syndrome, 211750 (3)  |CD96, TACTILE|606037|3q13.13
C-like syndrome, 605039 (3)  |CD96, TACTILE|606037|3q13.13
C1q deficiency, type A (3)  |C1QA|120550|1p36.3-p34.1
C1q deficiency, type B (3)  |C1QB|120570|1p36.3-p34.1
C1q deficiency, type C (3)  |C1QG|120575|1p36.3-p34.1
C1r/C1s deficiency, combined (1)  |C1R|216950|12p13
C1r/C1s deficiency, combined (1)  |C1S|120580|12p13
C1s deficiency, isolated (3)  |C1S|120580|12p13
C2 deficiency (3)  |C2|217000|6p21.3
C3 deficiency (3)  |C3, ARMD9, AHUS5|120700|19p13.3-p13.2
C4 deficiency (3)  |C4A, C4S|120810|6p21.3
C4 deficiency (3)  |C4B, C4F|120820|6p21.3
C5 deficiency, 609536 (3)  |C5|120900|9q34.1
C6 deficiency, 612446 (3)  |C6|217050|5p13
C7 deficiency, 610102 (3)  |C7|217070|5p13
C8 deficiency, type I (2)  |C8A|120950|1p32
C8 deficiency, type II (3)  |C8B|120960|1p32
C9 deficiency (3)  |C9|120940|5p13
C9 deficiency with dermatomyositis (3)  |C9|120940|5p13
CATSHL syndrome, 610474 (3)  |FGFR3, ACH|134934|4p16.3
CD59 deficiency, 612300 (3)  |CD59, MIC11|107271|11p13
CD8 deficiency, familial, 608957 (3)  |CD8A|186910|2p12
CDAGS syndrome (2)  |CDAGS|603116|22q12-q13
CHARGE syndrome, 214800 (3)  |CHD7, IS3, KAL5|608892|8q12.1
CHARGE syndrome, 214800 (3)  |SEMA3E, SEMAH, KIAA0331|608166|7q21.11
CHILD syndrome, 308050 (3)  |NSDHL|300275|Xq28
CINCA syndrome, 607115 (3)  |NLRP3, CIAS1, FCU, FCAS, NALP3, PYPAF1|606416|1q44
CK syndrome, 300831 (3)  |NSDHL|300275|Xq28
COACH syndrome, 216360 (3)  |CC2D2A, KIAA1345, MKS6|612013|4p15.3
COACH syndrome, 216360 (3)  |RPGRIP1L, KIAA1005, JBTS7, MKS5|610937|16q12.2
COACH syndrome, 216360 (3)  |TMEM67, MKS3, JBTS6, NPHP11|609884|8q21.13-q22.1
COPD, rate of decline of lung function in, 606963 (3)  |MMP1, CLG|120353|11q22-q23
CPT II deficiency, lethal neonatal, 608836 (3)  |CPT2|600650|1p32
CPT deficiency, hepatic, type IA, 255120 (3)  |CPT1A|600528|11q13
CPT deficiency, hepatic, type II, 600649 (3)  |CPT2|600650|1p32
CR1 deficiency (1)  |CR1, C3BR|120620|1q32
CRASH syndrome, 303350 (3)  |L1CAM, CAML1, HSAS1|308840|Xq28
Caffey disease, 114000 (3)  |COL1A1|120150|17q21.31-q22
Calcification of joints and arteries, 211800 (3)  |NT5E, NT5|129190|6q14-q21
Campomelic dysplasia with autosomal sex reversal, 114290 (3)  |SOX9, CMD1, SRA1|608160|17q24.3-q25.1
Campomelic dysplasia, 114290 (3)  |SOX9, CMD1, SRA1|608160|17q24.3-q25.1
Camptodactyly 1 (2)  |CAMPD1|114200|3q11.2-q13.12
Camptodactyly-arthropathy-coxa vara-pericarditis syndrome, 208250 (3)  |PRG4, CACP, MSF, SZP, HAPO|604283|1q24-q25
Camurati-Engelmann disease, 131300 (3)  |TGFB1, DPD1, CED|190180|19q13.1
Canavan disease, 271900 (3)  |ASPA|608034|17pter-p13
Candidiasis, familial chronic mucocutaneous, autosomal dominant, 613108 (3)  |CLEC7A, CLECSF12, DECTIN1, CANDF4|606264|12p13.2-p12.3
Candidiasis, familial chronic mucocutaneous, autosomal dominant, with or without thyroid disease (2)  |CANDF1, CMCT|114580|2p22.3-p21
Candidiasis, familial chronic mucocutaneous, autosomal recessive, 212050 (3)  |CARD9, CANDF2|607212|9q34.3
Candidiasis, familial chronic nail, with ICAM1 deficiency (2)  |CANDF3, CANDN1, FCNC|607644|11p13-q12
Capillary malformation-arteriovenous malformation, 608354 (3)  |RASA1, GAP, CMAVM, PKWS|139150|5q13.3
Capillary malformations, hereditary (2)  |CMAL|163000|5q13-q22
Carbamoylphosphate synthetase I deficiency, 237300 (3)  |CPS1|608307|2q35
Carboxylesterase 1 deficiency (3)  |CES1, SES1|114835|16q13-q22.1
Carboxypeptidase N deficiency, 212070 (3)  |CPN1, SCPN, CPN|603103|10q24.2
Carcinoid tumor of lung (3)  |MEN1|613733|11q13
Carcinoid tumors, intestinal, 114900 (3)  |SDHD, PGL1|602690|11q23
Cardiac arrhythmia, ankyrin-B-related, 600919 (3)  |ANK2, LQT4|106410|4q25-q27
Cardiac conduction defect, nonspecific, 612838 (3)  |SCN1B, GEFSP1|600235|19q13.1
Cardiac valvu  |FLNA, FLN1, NHBP, OPD1, OPD2, FMD, MNS, CVD1|300017|Xq28
Cardiac valvular dysplasia-1 (2)  |CVD1, XMVD|314400|Xq28
Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency, 604377 (3)  |SCO2|604272|22q13
Cardiofaciocutaneous syndrome, 115150 (3)  |BRAF, NS7|164757|7q34
Cardiofaciocutaneous syndrome, 115150 (3)  |KRAS, KRAS2, RASK2, NS|190070|12p12.1
Cardiofaciocutaneous syndrome, 115150 (3)  |MAP2K1, PRKMK1, MKK1, MEK1|176872|15q21
Cardiofaciocutaneous syndrome, 115150 (3)  |MAP2K2, PRKMK2, MEK2, MKK2|601263|19p13.3
Cardiomyopathy, dilated 1B (2)  |CMD1B, CMPD1, FDC|600884|9q13
Cardiomyopathy, dilated 1C, 601493 (3)  |LDB3, ZASP, CYPHER, KIAA01613, CMD1C, LVNC3|605906|10q22.2-q23.3
Cardiomyopathy, dilated, 115200 (3) (?)  |MYBPC3, CMH4|600958|11p11.2
Cardiomyopathy, dilated, 1A, 115200 (3)  |LMNA, LMN1, EMD2, FPLD, CMD1A, HGPS, LGMD1B|150330|1q21.2
Cardiomyopathy, dilated, 1AA, 612158 (3)  |ACTN2, CMD1AA|102573|1q42-q43
Cardiomyopathy, dilated, 1BB, 612877 (3)  |DSG2, ARVD10, ARVC10, CMD1BB|125671|18q12.1-q12.2
Cardiomyopathy, dilated, 1CC, 613122 (3)  |NEXN, NELIN, CMD1CC|613121|1p32-p31
Cardiomyopathy, dilated, 1D, 601494 (3)  |TNNT2, CMH2, CMD1D, RCM3, LVNC6|191045|1q32
Cardiomyopathy, dilated, 1DD, 613172 (3)  |RBM20|613171|10q25.2
Cardiomyopathy, dilated, 1E, 601154 (3)  |SCN5A, LQT3, VF1, HB1, SSS1, CMD1E, CDCD2|600163|3p21
Cardiomyopathy, dilated, 1EE, 613252 (3)  |MYH6, ASD3, MYHCA, CMD1EE, CMH14|160710|14q12
Cardiomyopathy, dilated, 1F (2)  |CMD1F, CDCD3|602067|6q23
Cardiomyopathy, dilated, 1FF, 613286 (3)  |TNNI3, CMH7, CMD2A, RCM1, CMD1FF|191044|19q13.4
Cardiomyopathy, dilated, 1G, 604145 (3)  |TTN, CMD1G, TMD, LGMD2J, MPRM, HMERF, EOMFC|188840|2q31
Cardiomyopathy, dilated, 1GG, 613642 (3)  |SDHA, SDH1, SDHF, CMD1GG|600857|5p15
Cardiomyopathy, dilated, 1H (2)  |CMD1H|604288|2q14-q22
Cardiomyopathy, dilated, 1I, 604765 (3)  |DES, CMD1I|125660|2q35
Cardiomyopathy, dilated, 1J, 605362 (3)  |EYA4, DFNA10, CMD1J|603550|6q23
Cardiomyopathy, dilated, 1K (2)  |CMD1K|605582|6q12-q16
Cardiomyopathy, dilated, 1L, 606685 (3)  |SGCD, SGD, LGMD2F, CMD1L|601411|5q33
Cardiomyopathy, dilated, 1M, 607482 (3)  |CSRP3, CRP3, CLP, CMD1M, CMH12|600824|11p15.1
Cardiomyopathy, dilated, 1N, 607487 (3)  |TCAP, LGMD2G, CMD1N|604488|17q12
Cardiomyopathy, dilated, 1O, 608569 (3)  |ABCC9, SUR2, CMD1O|601439|12p12.1
Cardiomyopathy, dilated, 1P, 609909 (3)  |PLN, PLB, CMD1P|172405|6q22.1
Cardiomyopathy, dilated, 1Q (2)  |CMD1Q|609915|7q22.3-q31.1
Cardiomyopathy, dilated, 1R, 613424 (3)  |ACTC1, CMD1R, CMH11, ASD5, LVNC4|102540|15q14
Cardiomyopathy, dilated, 1S, 613426 (3)  |MYH7, CMH1, MPD1, CMD1S, SPMM, SPMD|160760|14q12
Cardiomyopathy, dilated, 1T, 613740 (3)  |TMPO, LAP2, CMD1T|188380|12q22
Cardiomyopathy, dilated, 1U, 613694 (3)  |PSEN1, AD3|104311|14q24.3
Cardiomyopathy, dilated, 1V, 613697 (3)  |PSEN2, AD4, STM2, CMD1V|600759|1q31-q42
Cardiomyopathy, dilated, 1W, 611407 (3)  |VCL, CMD1W, CMH15|193065|10q22.1-q23
Cardiomyopathy, dilated, 1X, 611615 (3)  |FKTN, FCMD, CMD1X, LGMD2M, MDDGA4, MDDGB4, MDDGC4|607440|9q31
Cardiomyopathy, dilated, 1Y, 611878 (3)  |TPM1, CMH3, CMD1Y|191010|15q22.1
Cardiomyopathy, dilated, 1Z, 611879 (3)  |TNNC1, CMD1Z, CMH13|191040|3p21.3-p14.3
Cardiomyopathy, dilated, 2A, 611880 (3)  |TNNI3, CMH7, CMD2A, RCM1, CMD1FF|191044|19q13.4
Cardiomyopathy, dilated, 3A, 300069 (3)  |TAZ, EFE2, BTHS, CMD3A, LVNCX|300394|Xq28
Cardiomyopathy, dilated, 3B, 302045 (3)  |DMD, BMD, CMD3B|300377|Xp21.2
Cardiomyopathy, familial hypertrophic, 1, 192600 (3)  |MYH7, CMH1, MPD1, CMD1S, SPMM, SPMD|160760|14q12
Cardiomyopathy, familial hypertrophic, 10, 608758 (3)  |MYL2, CMH10|160781|12q23-q24.3
Cardiomyopathy, familial hypertrophic, 11, 612098 (3)  |ACTC1, CMD1R, CMH11, ASD5, LVNC4|102540|15q14
Cardiomyopathy, familial hypertrophic, 12, 612124 (3)  |CSRP3, CRP3, CLP, CMD1M, CMH12|600824|11p15.1
Cardiomyopathy, familial hypertrophic, 13, 613243 (3)  |TNNC1, CMD1Z, CMH13|191040|3p21.3-p14.3
Cardiomyopathy, familial hypertrophic, 14, 613251 (3)  |MYH6, ASD3, MYHCA, CMD1EE, CMH14|160710|14q12
Cardiomyopathy, familial hypertrophic, 15, 613255 (3)  |VCL, CMD1W, CMH15|193065|10q22.1-q23
Cardiomyopathy, familial hypertrophic, 192600 (3)  |CAV3, LGMD1C, LQT9|601253|3p25
Cardiomyopathy, familial hypertrophic, 192600 (3)  |SLC25A4, ANT1, T1, PEO3, PEO2|103220|4q35
Cardiomyopathy, familial hypertrophic, 2, 115195 (3)  |TNNT2, CMH2, CMD1D, RCM3, LVNC6|191045|1q32
Cardiomyopathy, familial hypertrophic, 3, 115196 (3)  |TPM1, CMH3, CMD1Y|191010|15q22.1
Cardiomyopathy, familial hypertrophic, 4, 115197 (3)  |MYBPC3, CMH4|600958|11p11.2
Cardiomyopathy, familial hypertrophic, 7, 613690 (3)  |TNNI3, CMH7, CMD2A, RCM1, CMD1FF|191044|19q13.4
Cardiomyopathy, familial hypertrophic, 8, 608751 (3)  |MYL3, CMH8|160790|3p
Cardiomyopathy, familial hypertrophic, 9, 188840 (3)  |TTN, CMD1G, TMD, LGMD2J, MPRM, HMERF, EOMFC|188840|2q31
Cardiomyopathy, familial restrictive, 115210 (3)  |TNNI3, CMH7, CMD2A, RCM1, CMD1FF|191044|19q13.4
Cardiomyopathy, familial restrictive, 2 (2)  |RCM2|609578|10q23.3
Cardiomyopathy, familial restrictive, 3, 612422 (3)  |TNNT2, CMH2, CMD1D, RCM3, LVNC6|191045|1q32
Cardiomyopathy, hypertrophic 6, with WPW, 600858 (3)  |PRKAG2, WPWS, CMH6|602743|7q36
Cardiomyopathy, hypertrophic, early-onset fatal (3)  |COX15|603646|10q24
Cardiomyopathy, hypertrophic, midventricular, digenic, 192600 (3)  |MYLK2, MLCK|606566|20q13.3
Carney complex variant, 608837 (3)  |MYH8|160741|17p13.1
Carney complex, type 1, 160980 (3)  |PRKAR1A, TSE1, CNC1, CAR, PPNAD1|188830|17q23-q24
Carney complex, type II (2)  |CNC2|605244|2p16
Carnitine acetyltransferase deficiency (1) (?)  |CRAT, CAT1|600184|9q34.1
Carnitine deficiency, systemic primary, 212140 (3)  |SLC22A5, OCTN2, CDSP, SCD|603377|5q31.1
Carnitine-acylcarnitine translocase deficiency, 212138 (3)  |SLC25A20, CACT, CAC|613698|3p21.31
Carnosinemia (2)  |CNSN|212200|18q21.3
Carotid intimal medial thickness (2)  |CIMT|608447|12q24
Carotid intimal medial thickness 1, 609338 (3)  |PPARG, PPARG1, PPARG2, CIMT1, GLM1|601487|3p25
Carpal tunnel syndrome, familial, 115430 (3)  |TTR, PALB|176300|18q11.2-q12.1
Carpenter syndrome, 201000 (3)  |RAB23|606144|6p11
Cartilage-hair hypoplasia, 250250 (3)  |RMRP, RMRPR, CHH|157660|9p21-p12
Cat eye syndrome (2)  |CECR, CES|115470|22q11
Cataract with late-onset corneal dystrophy, 604219 (3)  |PAX6, AN2, MGDA|607108|11p13
Cataract, Coppock-like, 604307 (3)  |CRYBB2, CRYB2|123620|22q11.2-q12.2
Cataract, Coppock-like, 604307 (3)  |CRYGC, CRYG3, CCL|123680|2q33-q35
Cataract, Marner type, 116800 (3)  |HSF4, CTM|602438|16q21-q22.1
Cataract, anterior polar-1 (2) (?)  |CTAA1|115650|14q24-qter
Cataract, anterior polar-2 (2)  |CTAA2|601202|17p13
Cataract, autosomal dominant nuclear (3)  |CRYAA, CRYA1|123580|21q22.3
Cataract, autosomal dominant, multiple types 1, 611597 (3)  |BFSP2, CP49, CP47|603212|3q21-q25
Cataract, autosomal recessive congenital 2 (2)  |CATC2|610019|3p22-p21
Cataract, autosomal recessive congenital 3 (2)  |CATC3|612968|1p34.3-p32.2
Cataract, autosomal recessive, early-onset, pulverulent (2)  |CAAR|605749|9q13-q22
Cataract, central saccular, with sutural opacities (2)  |CCSSO|605728|15q21-q22
Cataract, cerulean, type 1 (2)  |CCA1|115660|17q24
Cataract, cerulean, type 2, 601547 (3)  |CRYBB2, CRYB2|123620|22q11.2-q12.2
Cataract, congenital (2) (?)  |SORD, SORD1|182500|15q15.3
Cataract, congenital (3)  |PITX3, CTPP4|602669|10q25
Cataract, congenital nuclear, 1 (2)  |CATCN1|609376|19q13
Cataract, congenital nuclear, 2, 609741 (3)  |CRYBB3, CRYB3, CATCN2|123630|22q11.2-q12.2
Cataract, congenital nuclear, autosomal recessive 3, 611544 (3)  |CRYBB1, CATCN3|600929|22q11.2-q12.1
Cataract, congenital zonular, with sutural opacities, 600881 (3)  |CRYBA1, CRYB1|123610|17q11.1-q12
Cataract, congenital, 604219 (3)  |BFSP2, CP49, CP47|603212|3q21-q25
Cataract, congenital, Volkmann type (2)  |CCV|115665|1pter-p36.13
Cataract, congenital, X-linked, 302200 (3)  |NHS, CXN|300457|Xp22.13
Cataract, congenital, autosomal recessive (3)  |CRYAA, CRYA1|123580|21q22.3
Cataract, congenital, cerulean type, 3, 608983 (3)  |CRYGD, CRYG4, CCP|123690|2q33-q35
Cataract, cortical pulverulent, late-onset (3)  |LIM2, MP19|154045|19q13.4
Cataract, cortical, juvenile-onset, 611391 (3)  |BFSP1, CP115|603307|20p12.1-p11.23
Cataract, crystalline aculeiform, 115700 (3)  |CRYGD, CRYG4, CCP|123690|2q33-q35
Cataract, juvenile, with microcornea and glucosuria, 612018 (3)  |SLC16A12, MCT12, CJMG|611910|10q23.3
Cataract, juvenile-onset, 604219 (3)  |BFSP2, CP49, CP47|603212|3q21-q25
Cataract, lamellar 2, 610425 (3)  |CRYBA4, MCOPCT4|123631|22q11.2-q13.1
Cataract, lamellar, 116800 (3)  |HSF4, CTM|602438|16q21-q22.1
Cataract, nonnuclear polymorphic congenital, 601286 (3)  |CRYGD, CRYG4, CCP|123690|2q33-q35
Cataract, nuclear progressive (2)  |CCNP|607304|2p12
Cataract, nuclear progressive (3)  |GJA8, CX50, CAE1|600897|1q21.1
Cataract, nuclear pulverulent (3)  |GJA8, CX50, CAE1|600897|1q21.1
Cataract, polymorphic and lamellar, 604219 (3)  |MIP, AQP0|154050|12q13
Cataract, posterior polar (2)  |CTPP, CPP, CTPA|116600|1pter-p36.1
Cataract, posterior polar 2 (3)  |CRYAB, CRYA2, CTPP2|123590|11q22.3-q23.1
Cataract, posterior polar, 1, 613020 (3)  |EPHA2, ECK, ARCC2|176946|1p36.1
Cataract, posterior polar, 3, 605387 (3)  |CHMP4B, SNF7, CTPP3|610897|20q11.21
Cataract, posterior polar, 4, 610623 (3)  |PITX3, CTPP4|602669|10q25
Cataract, posterior polar, 4, syndromic, 610623 (3)  |PITX3, CTPP4|602669|10q25
Cataract, posterior polar, 5 (2)  |CTPP5|610634|14q22-q23
Cataract, progressive polymorphic cortical (3)  |CRYGS, CRYG8|123730|3q27
Cataract, pulverulent (3)  |CRYBB1, CATCN3|600929|22q11.2-q12.1
Cataract, pulverulent or cerulean, with or without microcornea (3)  |MAF|177075|16q22-q23
Cataract, pulverulent, autosomal dominant (3)  |VIM|193060|10p13
Cataract, sutural, with punctate and cerulean opacities, 607133 (3)  |CRYBB2, CRYB2|123620|22q11.2-q12.2
Cataract, variable zonular pulverulent (3)  |CRYGC, CRYG3, CCL|123680|2q33-q35
Cataract, zonular central nuclear, autosomal dominant (3)  |CRYAA, CRYA1|123580|21q22.3
Cataract, zonular pulverulent-1, 116200 (3)  |GJA8, CX50, CAE1|600897|1q21.1
Cataract, zonular pulverulent-3, 601885 (3)  |GJA3, CX46, CZP3, CAE3|121015|13q11
Cataract-microcornea syndrome, 116150 (3)  |GJA8, CX50, CAE1|600897|1q21.1
Cataracts, punctate, progressive juvenile-onset (3)  |CRYGD, CRYG4, CCP|123690|2q33-q35
Caudal duplication anomaly, 607864 (3)  |AXIN1, AXIN|603816|16p13.3
Caudal regression syndrome, 600145 (3)  |VANGL1, STBM2|610132|1p13
Cavernous malformations of CNS and retina, 116860 (3)  |CCM1, CAM, KRIT1|604214|7q11.2-q21
Cavitary optic disc anomalies (2)  |CODA|611543|12q
Cayler cardiofacial syndrome (2)  |ACF|125520|22q11
Cenani-Lenz syndactyly syndrome, 212780 (3)  |LRP4, MEGF7, CLSS|604270|11p12-p11.2
Central core disease, 117000 (3)  |RYR1, MHS, CCO|180901|19q13.1
Central hypoventilation syndrome, 209880 (3)  |GDNF, HSCR3|600837|5p13.1-p12
Central hypoventilation syndrome, congenital, 209880 (3)  |ASCL1, ASH1|100790|12q22-q23
Central hypoventilation syndrome, congenital, 209880 (3)  |BDNF|113505|11p13
Central hypoventilation syndrome, congenital, 209880 (3)  |EDN3, WS4B, HSCR4|131242|20q13.2-q13.3
Central hypoventilation syndrome, congenital, 209880 (3)  |PMX2B, NBPHOX, PHOX2B, NBLST2|603851|4p12
Central hypoventilation syndrome, congenital, 209880 (3)  |RET, MEN2A, HSCR1|164761|10q11.2
Centrotemporal epilepsy (2)  |ECT, BECTS|117100|11p13
Cerebellar ataxia and mental retardation with or without quadrupedal locomotion 3, 613227 (3)  |CA8, CALS, CARP, CAMRQ3|114815|8q11-q12
Cerebellar ataxia, 604290 (3)  |CP|117700|3q23-q24
Cerebellar ataxia, pure (3)  |CACNA1A, CACNL1A4, SCA6|601011|19p13
Cerebellar atrophy with progressive microcephaly (2)  |CLAM|608027|7q11-q21
Cerebellar atrophy, ataxia, and mental retardation (3)  |SCN8A|600702|12q13
Cerebellar hypoplasia and mental retardation with or without quadrupedal locomotion 1, 224050 (3)  |VLDLR, CARMQ1|192977|9p24
Cerebellar hypoplasia, mental retardation, and quadrupedal locomotion 2 (2)  |CAMRQ2|610185|17p
Cerebellooculorenal syndrome 2 (2)  |CORS2, JBTS2, JBTSB|608091|11p12-q13.3
Cerebral amyloid angiopathy, 105150 (3)  |CST3, ARMD11|604312|20p11.2
Cerebral amyloid angiopathy, Dutch, Italian, Iowa, Flemish, Arctic variants, 605714 (3)  |APP, AAA, CVAP, AD1|104760|21q21
Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy, 125310 (3)  |NOTCH3, CADASIL, CASIL|600276|19p13.2-p13.1
Cerebral cavernous malformations 3, 603285 (3)  |PDCD10, TFAR15, CCM3|609118|3q26.1
Cerebral cavernous malformations-1, 116860 (3)  |CCM1, CAM, KRIT1|604214|7q11.2-q21
Cerebral cavernous malformations-2, 603284 (3)  |C7orf22, CCM2, MGC4067|607929|7p13
Cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma syndrome, 609528 (3)  |SNAP29, CEDNIK|604202|22q11.2
Cerebral palsy, ataxic, autosomal recessive (2)  |ACP|605388|9p12-q12
Cerebral palsy, spastic quadriplegic, 3, 612936 (3)  |AP4M1, CPSQ3|602296|7q22.1
Cerebral palsy, spastic quadriplegic, 612900 (3)  |KANK1, KANK, ANKRD15, KIAA0172|607704|9p24.3
Cerebral palsy, spastic, symmetric, autosomal recessive, 603513 (3)  |GAD1, SCP|605363|2q31
Cerebrooculofacioskeletal syndrome 1, 214150 (3)  |ERCC6, CKN2, COFS1, CSB, ARMD5|609413|10q11
Cerebrooculofacioskeletal syndrome 2, 610756 (3)  |ERCC2, EM9, XPD, COFS2|126340|19q13.2-q13.3
Cerebrooculofacioskeletal syndrome 3 (3)  |ERCC5, XPG, COFS3|133530|13q33
Cerebrooculofacioskeletal syndrome 4, 610758 (3)  |ERCC1, UV20, COFS4|126380|19q13.2-q13.3
Cerebrotendinous xanthomatosis, 213700 (3)  |CYP27A1, CYP27, CTX|606530|2q33-qter
Cerebrovascular disease, occlusive (3)  |SERPINA3, AACT, ACT|107280|14q32.1
Ceroid lipofuscinosis, neuronal 8, 600143 (3)  |CLN8, EPMR|607837|8p23
Ceroid lipofuscinosis, neuronal, 10, 610127 (3)  |CTSD, CPSD, CLN10|116840|11p15.5
Ceroid lipofuscinosis, neuronal, 7, 610951 (3)  |MFSD8, MGC33302|611124|4q28.1-q28.2
Ceroid lipofuscinosis, neuronal, 8, Northern epilepsy variant, 610003 (3)  |CLN8, EPMR|607837|8p23
Ceroid lipofuscinosis, neuronal, variant juvenile type, with granular osmiophilic deposits (3)  |PPT1, CLN1|600722|1p32
Ceroid lipofuscinosis, neuronal-1, infantile, 256730 (3)  |PPT1, CLN1|600722|1p32
Ceroid-lipofuscinosis, neuronal 2, classic late infantile, 204500 (3)  |TPP1, CLN2|607998|11p15.5
Ceroid-lipofuscinosis, neuronal-3, juvenile, 204200 (3)  |CLN3, BTS|607042|16p12.1
Ceroid-lipofuscinosis, neuronal-5, variant late infantile, 256731 (3)  |CLN5|608102|13q21.1-q32
Ceroid-lipofuscinosis, neuronal-6, variant late infantile, 601780 (3)  |CLN6|606725|15q21-q23
Cervical cancer, somatic, 603956 (3)  |FGFR3, ACH|134934|4p16.3
Cervical carcinoma (2)  |ST3|191181|11q13
Chanarin-Dorfman syndrome, 275630 (3)  |ABHD5, CGI58, IECN2, NCIE2|604780|3p21
Char syndrome, 169100 (3)  |TFAP2B, CHAR|601601|6p12
Charcot-Marie-Tooth disease, X-linked recessive, 5, 311070 (3)  |PRPS1, CMTX5, DFNX1, DFN2|311850|Xq22-q24
Charcot-Marie-Tooth disease, axonal, type 2F, 606595 (3)  |HSPB1, HSP27, CMT2F, HMN2B|602195|7q11.23
Charcot-Marie-Tooth disease, axonal, type 2G (2)  |CMT2G|608591|12q12-q13.3
Charcot-Marie-Tooth disease, axonal, type 2K, 607831 (3)  |GDAP1, CMT4A, CMT2K, CMTRIA|606598|8q13-q21.1
Charcot-Marie-Tooth disease, axonal, type 2L, 608673 (3)  |HSPB8, H11, E2IG1, DHMN2, CMT2L, HMN2A|608014|12q24
Charcot-Marie-Tooth disease, axonal, type 2M, 606482 (3)  |DNM2, CMTDIB, CMTDI1, CMT2M|602378|19p13.2
Charcot-Marie-Tooth disease, axonal, type 2N, 613287 (2)  |AARS, CMT2N|601065|16q22
Charcot-Marie-Tooth disease, axonal, with vocal cord paresis, 607706 (3)  |GDAP1, CMT4A, CMT2K, CMTRIA|606598|8q13-q21.1
Charcot-Marie-Tooth disease, dominant intermediate 2 (2)  |CMTDI2|606483|10q24.1-q25.1
Charcot-Marie-Tooth disease, dominant intermediate 3, 607791 (3)  |MPZ, CMT1B, CMTDI3, CHM, DSS|159440|1q22
Charcot-Marie-Tooth disease, dominant intermediate B, 606482 (3)  |DNM2, CMTDIB, CMTDI1, CMT2M|602378|19p13.2
Charcot-Marie-Tooth disease, dominant intermediate C, 608323 (3)  |YARS, CMTDIC, TYRRS, YTS, YRS|603623|1p35
Charcot-Marie-Tooth disease, foot deformity of (3)  |HOXD10, HOX4D|142984|2q31-q32
Charcot-Marie-Tooth disease, recessive intermediate, A, 608340 (3)  |GDAP1, CMT4A, CMT2K, CMTRIA|606598|8q13-q21.1
Charcot-Marie-Tooth disease, recessive intermediate, B, 613641 (3)  |KARS, CMTRIB|601421|16q22.2-q22.3
Charcot-Marie-Tooth disease, type 1A, 118220 (3)  |PMP22, CMT1A, CMT1E, DSS|601097|17p11.2
Charcot-Marie-Tooth disease, type 1B, 118200 (3)  |MPZ, CMT1B, CMTDI3, CHM, DSS|159440|1q22
Charcot-Marie-Tooth disease, type 1C, 601098 (3)  |LITAF, CMT1C|603795|16p13.3-p12
Charcot-Marie-Tooth disease, type 1D, 607678 (3)  |EGR2, KROX20|129010|10q21.1-q22.1
Charcot-Marie-Tooth disease, type 1E, 118300 (3)  |PMP22, CMT1A, CMT1E, DSS|601097|17p11.2
Charcot-Marie-Tooth disease, type 1F, 607734 (3)  |NEFL, CMT2E, CMT1F|162280|8p21
Charcot-Marie-Tooth disease, type 2A1, 118210 (3)  |KIF1B, CMT2A, CMT2A1, NBLST1|605995|1p36.2
Charcot-Marie-Tooth disease, type 2A2, 609260 (3)  |MFN2, KIAA0214, CMT2A2|608507|1p36.2
Charcot-Marie-Tooth disease, type 2B, 600882 (3)  |RAB7, CMT2B, PSN|602298|3q21
Charcot-Marie-Tooth disease, type 2B1, 605588 (3)  |LMNA, LMN1, EMD2, FPLD, CMD1A, HGPS, LGMD1B|150330|1q21.2
Charcot-Marie-Tooth disease, type 2B2, 605589 (3)  |MED25, PTOV2, ARC92, CMT2B2|610197|19q13.3
Charcot-Marie-Tooth disease, type 2D, 601472 (3)  |GARS, SMAD1, CMT2D, HMN5|600287|7p15
Charcot-Marie-Tooth disease, type 2E, 607684 (3)  |NEFL, CMT2E, CMT1F|162280|8p21
Charcot-Marie-Tooth disease, type 2I, 607677 (3)  |MPZ, CMT1B, CMTDI3, CHM, DSS|159440|1q22
Charcot-Marie-Tooth disease, type 2J, 607736 (3)  |MPZ, CMT1B, CMTDI3, CHM, DSS|159440|1q22
Charcot-Marie-Tooth disease, type 4A, 214400 (3)  |GDAP1, CMT4A, CMT2K, CMTRIA|606598|8q13-q21.1
Charcot-Marie-Tooth disease, type 4B1, 601382 (3)  |MTMR2, CMT4B1|603557|11q22
Charcot-Marie-Tooth disease, type 4B2, 604563 (3)  |SBF2, MTMR13, CMT4B2|607697|11p15
Charcot-Marie-Tooth disease, type 4C, 601596 (3)  |SH3TC2, KIAA1985, MNMN|608206|5q32
Charcot-Marie-Tooth disease, type 4D, 601455 (3)  |NDRG1, HMSNL, CMT4D|605262|8q24.3
Charcot-Marie-Tooth disease, type 4F, 145900 (3)  |PRX, CMT4F|605725|19q13.1-q13.2
Charcot-Marie-Tooth disease, type 4H, 609311 (3)  |FGD4, FRABIN, CMT4H|611104|12p11.2
Charcot-Marie-Tooth disease, type 4J, 611228 (3)  |FIG4, KIAA0274, SAC3, ALS11|609390|6q21
Charcot-Marie-Tooth neuropathy, X-linked dominant, 1, 302800 (3)  |GJB1, CX32, CMTX1|304040|Xq13.1
Charcot-Marie-Tooth neuropathy, X-linked recessive, 2 (2)  |CMTX2|302801|Xp22.2
Charcot-Marie-Tooth neuropathy, X-linked recessive, 3 (2)  |CMTX3|302802|Xq26
Chediak-Higashi syndrome, 214500 (3)  |CHS1, LYST|606897|1q42.1-q42.2
Cherubism, 118400 (3)  |SH3BP2, CRPM|602104|4p16.3
Chilblain lupus (2)  |CHBL|610448|3p21
Chilblain lupus, 610448 (3)  |TREX1, AGS1, CRV, HERNS|606609|3p21.3-p21.2
Chloride diarrhea, congenital, Finnish type, 214700 (3)  |SLC26A3, DRA, CLD|126650|7q22-q31.1
Choanal atresia and lymphedema, 613611 (3)  |PTPN14, PEZ|603155|1q32
Cholestasis, benign recurrent intrahepatic, 2, 605479 (3)  |ABCB11, BSEP, SPGP, PFIC2, BRIC2|603201|2q24
Cholestasis, benign recurrent intrahepatic, 243300 (3)  |ATP8B1, FIC1, BRIC, PFIC1|602397|18q21
Cholestasis, familial intrahepatic, of pregnancy, 147480 (3)  |ABCB4, PGY3, MDR3|171060|7q21.1
Cholestasis, progressive canalicular (1)  |VIL1|193040|2q35-q36
Cholestasis, progressive familial intrahepatic 1, 211600 (3)  |ATP8B1, FIC1, BRIC, PFIC1|602397|18q21
Cholestasis, progressive familial intrahepatic 2, 601847 (3)  |ABCB11, BSEP, SPGP, PFIC2, BRIC2|603201|2q24
Cholestasis, progressive familial intrahepatic 3, 602347 (3)  |ABCB4, PGY3, MDR3|171060|7q21.1
Cholestasis, progressive familial intrahepatic 4, 607765 (3)  |HSD3B7, PFIC4|607764|16p12-p11.2
Cholestasis-lymphedema syndrome (2)  |LCS1, CHLS|214900|15q
Cholesteryl ester storage disease, 278000 (3)  |LIPA, CESD|613497|10q23.31
Chondrocalcinosis 2, 118600 (3)  |ANKH, HANK, ANK, CMDJ, CCAL2, CPPDD|605145|5p15.2-p14.1
Chondrocalcinosis with early-onset osteoarthritis (2)  |CCAL1|600668|8q
Chondrodysplasia punctata, X-linked dominant, 302960 (3)  |EBP, CDPX2, CPXD, CPX|300205|Xp11.23-p11.22
Chondrodysplasia punctata, X-linked recessive, 302950 (3)  |ARSE, CDPX1, CDPXR|300180|Xp22.3
Chondrodysplasia punctata, rhizomelic, type 2, 222765 (3)  |GNPAT, DHAPAT|602744|1q42
Chondrodysplasia, Blomstrand type, 215045 (3)  |PTHR1, PTHR, PFE|168468|3p22-p21.1
Chondrodysplasia, Grebe type, 200700 (3)  |GDF5, CDMP1, SYNS2, OS5|601146|20q11.2
Chondrosarcoma, 215300 (3)  |EXT1|608177|8q24.11-q24.13
Chondrosarcoma, extraskeletal myxoid, 612237 (1)  |TAF15, TAF2N, RBP56|601574|17q11.1-q11.2
Chondrosarcoma, extraskeletal myxoid, 612237 (1)  |TFG|602498|3q11-q12
Chondrosarcoma, extraskeletal myxoid, 612237 (3)  |CSMF|600542|9q22
Chordoma (2)  |CHDM|215400|7q33
Chorea, hereditary benign, 118700 (3)  |NKX2-1, TITF1, NKX2A, TTF1|600635|14q13
Choreoacanthocytosis, 200150 (3)  |VPS13A, CHAC|605978|9q21
Choreoathetosis, hypothyroidism, and neonatal respiratory distress, 610978 (3)  |NKX2-1, TITF1, NKX2A, TTF1|600635|14q13
Choreoathetosis/spasticity, episodic (2)  |CSE, DYT9|601042|1p
Chorioathetosis with mental retardation and abnormal behavior (2)  |CAMR, MRXS10|300220|Xp11.2
Choriodal dystrophy, central areolar 2, 613105  |PRPH2, DS, RP7, PRPH, AVMD, AOFMD, CACD2|179605|6p21.1-cen
Chorioretinal atrophy, progressive bifocal (2)  |PBCRA, CRAPB|600790|6q14-q16.2
Choroid plexus papilloma, 260500 (3)  |TP53, P53, LFS1|191170|17p13.1
Choroidal dystrophy, central areolar (2)  |CACD|215500|17p
Choroideremia, 303100 (3)  |CHM, TCD|300390|Xq21.2
Chromosome 10q23 deletion syndrome (4)  |DEL10q23, C10DELq23|612242|10q23
Chromosome 10q26 deletion syndrome (4)  |DEL10q26, C10q26DEL|609625|10q26
Chromosome 11p15-p14 deletion syndrome (4)  |DEL11p15p14, C11DELp15p14|606528|11p15-p14
Chromosome 14q11-q22 deletion syndrome (4)  |DEL14q11q22, C14DELq11q22|613457|14q11-q22
Chromosome 15q13.3 microdeletion syndrome (4)  |DEL15q13.3, MICRODEL15q13.3|612001|15q13.3
Chromosome 15q24 deletion syndrome (4)  |DEL15q24, CHR15DELq24|613406|15q24
Chromosome 15q26-qter deletion syndrome (4)  |DEL15q26qter, C15DELq26qter|612626|15q26-qter
Chromosome 16p12.2-p11.2 deletion syndrome (4)  |DEL16p12.1p11.2, C16DELp12.1p11.2|613604|16q12.2-p11.2
Chromosome 16p13.3 deletion syndrome (4)  |DEL16p13.3, RSTSS|610543|16p13.3
Chromosome 16p13.3 duplication syndrome (4)  |DUP16p13.3, C16DUPq13.3|613458|16p13.3
Chromosome 17p13.3 duplication syndrome (4)  |DUP17p13.3, C17DUPp13.3|613215|17p13.3
Chromosome 17q11.2 deletion syndrome, 1.4Mb (4)  |DEL17q11.2; C17DELq11.2|613675|17q11.2
Chromosome 17q21.31 duplication syndrome (4)  |DUP17q21.31, C17DUPq21.31|613533|17q21.31
Chromosome 17q21.31 microdeletion syndrome (4)  |DEL17q21.31, C17DELq21.31|610443|17q21.31
Chromosome 17q23.1-q23.2 deletion syndrome (4)  |DEL17q23.1q23.2, C17DELq23.1q23.2|613355|17q23.1-q23.2
Chromosome 17q23.1-q23.2 duplication syndrome (4)  |DUP17q23.1q23.2, C17DUPq23.1q23.2|613618|17q23.1-q23.2
Chromosome 18 pericentric inversion (4)  |DUP18pDEL18q, DUP81qDEL18p|609334|18q22
Chromosome 18p deletion syndrome (4)  |DEL18p, C18DELp|146390|18p
Chromosome 18q deletion syndrome (4)  |DEL18q|601808|18q
Chromosome 19p13.13 deletion syndrome (4)  |DEL19p13.13, C19DELp13.13, DUP19p13.13, C19DUPp13.13|613638|19p13.13
Chromosome 19p13.13 duplication syndrome (4)  |DEL19p13.13, C19DELp13.13, DUP19p13.13, C19DUPp13.13|613638|19p13.13
Chromosome 19q13.11 deletion syndrome (4)  |DEL19q13.11, C19DELq13.11|613026|19q13.11
Chromosome 1p32-p31 deletion syndrome (4)  |DEL1p32p31, C1DELp32p31|613735|1p32-p31
Chromosome 1p36 deletion syndrome (4)  |DEL1p36, C1DELp36|607872|1p36
Chromosome 1q21.1 deletion syndrome (4)  |DEL1q21, C1DELq21|612474|1q21.1
Chromosome 1q21.1 duplication syndrome (4)  |DUP1q21, C1DUPq21|612475|1q21.1
Chromosome 1q41-q42 deletion syndrome (4)  |DEL1q41q42, C1DELq41q42|612530|1q41-q42
Chromosome 1q42-q44 deletion syndrome (4)  |DEL1q42q44, C1DELq42q44|612337|1q42-q44
Chromosome 22q11.2 deletion syndrome, distal (4)  |DEL22q11.2, C22DELq11.2|611867|22q11.2
Chromosome 22q11.2 microduplication syndrome (4)  |DUP22q11.2|608363|22q11.2
Chromosome 22q13.3 deletion syndrome, 606232 (3)  |SHANK3, PSAP2, PROSAP2, KIAA1650, DEL22q13.3|606230|22q13.3
Chromosome 2p12-p11.2 deletion syndrome (4)  |DEL2p12p11.2, C2DELp12p11.2|613564|2p12-p11.2
Chromosome 2p16.1-p15 deletion syndrome (4)  |DEL2p16.1-p15, C2DELp161-p15|612513|2p16.1-p15
Chromosome 2q31.1 duplication syndrome (4)  |DUP2q31.1, C2DUPq31.1|613681|2q31.1
Chromosome 2q31.2 deletion syndrome (4)  |DEL2q31|612345|2q31.2
Chromosome 2q32-q33 deletion syndrome (4)  |DEL2q32q33, C2DELq32q33|612313|2q32-q33
Chromosome 3q29 microdeletion syndrome (4)  |DEL3q29, MICRODEL3q29|609425|3q29
Chromosome 3q29 microduplication syndrome (4)  |DUP3q29, MICRODUP3q29|611936|3q29
Chromosome 4q21 deletion syndrome (4)  |DEL4q21, C4DELq21|613509|4q21
Chromosome 4q32.1-q32.2 triplication syndrome (4)  |TRIP4q32.1q32.2, C4TRIPq32.1q32.2|613603|4q32.1-q32.2
Chromosome 5p13 duplication syndrome (4)  |DUP5p13, C5DUPp13|613174|5p13
Chromosome 5q14.3 deletion syndrome, 613443 (4)  |MEF2C, C5DELq14.3; DEL5q14.3|600662|5q14
Chromosome 6pter-p24 deletion syndrome (4)  |DEL6pter, C6DELpter|612582|6pter-p24
Chromosome 6q11-q14 deletion syndrome (4)  |DEL6q11q14, C6DELq11q14|613544|6q11-q14
Chromosome 6q25-q25 deletion syndrome (4)  |DEL6q24q25, C6DELq25q25|612863|6q24-q25
Chromosome 7q11.23 duplication syndrome (4)  |DUP7q11.23, C7DUPq11.23|609757|7q11.23
Chromosome 8p11 myeloproliferative syndrome (4)  |SCLL|613523|8p11
Chromosome 9p deletion syndrome (4)  |DEL9p, C9DELp|158170|9p
Chromosome Xp11.23-p11.22 duplication syndrome (4)  |DUPXp11.23p11.22, CXDUPp11.23p11.22|300801|Xp11.23-p11.22
Chromosome Xp11.3 deletion syndrome (4)  |DELXp11.3, CXDELp11.3|300578|Xp11.3
Chromosome Xp21 deletion syndrome (4)  |DELXp21, CXDELp21|300679|Xp21
Chromosome Xq28 duplication syndrome (4)  |DUPXq28, CXq28|300815|Xq28
Chromosome Xq28 microdeletion syndrome (4)  |DELXq28, MICRODELXq28|300475|Xq28
Chrondrodysplasia, acromesomelic, with genital anomalies, 609441 (3)  |BMPR1B, ALK6|603248|4q23-q24
Chronic granulomatous disease due to deficiency of NCF-1, 233700 (3)  |NCF1|608512|7q11.23
Chronic granulomatous disease due to deficiency of NCF-2, 233710 (3)  |NCF2|608515|1q25
Chronic granulomatous disease, X-linked, 306400 (3)  |CYBB, CGD|300481|Xp21.1
Chronic granulomatous disease, autosomal, due to deficiency of CYBA, 233690 (3)  |CYBA|608508|16q24
Chylomicron retention disease, 246700 (3)  |SAR1B, CMRD, SARA2, ANDD|607690|5q31.1
Ciliary dyskinesia, primary, 1, with our without situs inversus, 244400 (3)  |DNAI1, CILD1, ICS, PCD|604366|9p21-p13
Ciliary dyskinesia, primary, 10, 612518 (3)  |KTU, C14orf104, CILD10|612517|14q21.3
Ciliary dyskinesia, primary, 11, 612649 (3)  |RSPH4A, CILD11|612647|6q22.1
Ciliary dyskinesia, primary, 12, 612650 (3)  |RSPH9, CILD12|612648|6p21.1
Ciliary dyskinesia, primary, 13, 613193 (3)  |LRRC50, ODA7, CILD13|613190|16q24.1
Ciliary dyskinesia, primary, 2 (2)  |CILD2, PCD|606763|19q13.3-qter
Ciliary dyskinesia, primary, 3, with or without situs inversus, 608644 (3)  |DNAH5, HL1, PCD, CILD3|603335|5p15-p14
Ciliary dyskinesia, primary, 4 (2)  |CILD4|608646|15q13.1-q15.1
Ciliary dyskinesia, primary, 5 (2)  |CILD5|608647|16p12.2-p12.1
Ciliary dyskinesia, primary, 6, 610852 (3)  |TXNDC3, SPTRX2, CILD6|607421|7p14-p13
Ciliary dyskinesia, primary, 7, with out without situs inversus, 611884 (3)  |DNAH11, DNAHC11, CILD7, DNAHBL|603339|7p21
Ciliary dyskinesia, primary, 8 (2)  |CILD8|612274|15q24-q25
Ciliary dyskinesia, primary, 9, with our without situs inversus, 612444 (3)  |DNAI2, CILD9|605483|17q25
Cirrhosis due to liver phosphorylase kinase deficiency (3)  |PHKG2, GSD9C|172471|16p12.1-p11.2
Cirrhosis, North American Indian childhood type, 604901 (3)  |CIRH1A, NAIC, TEX292, KIAA1988|607456|16q22
Cirrhosis, cryptogenic (3)  |KRT18|148070|12q13
Cirrhosis, cryptogenic (3)  |KRT8|148060|12q13
Citrullinemia, 215700 (3)  |ASS1, ASS|603470|9q34.1
Citrullinemia, adult-onset type II, 603471 (3)  |SLC25A13, CTLN2|603859|7q21.3
Citrullinemia, type II, neonatal-onset, 605814 (3)  |SLC25A13, CTLN2|603859|7q21.3
Cleft lip/palate-ectodermal dysplasia syndrome, 225060 (3)  |HVEC, PVRL1, PVRR1, PRR1, ED4, OFC7, CLPED1|600644|11q23-q24
Cleft palate and mental retardation, 119540 (3)  |SATB2, KIAA1034|608148|2q33
Cleft palate with ankyloglossia, 303400 (3)  |TBX22, CPX|300307|Xq12-q21
Cleft palate, isolated, 119540 (2)  |UBB|191339|17p12-p11.1
Cleidocranial dysplasia, 119600 (3)  |RUNX2, CBFA1, PEBP2A1, AML3|600211|6p21
Clopidogrel, impaired responsiveness to, 609535 (3)  |CYP2C, CYP2C19|124020|10q24.1-q24.3
Clubfoot, congenital, 119800 (3)  |PITX1, PTX1, BFT, POTX, CCF|602149|5q31
Cockayne syndrome, type A, 216400 (3)  |ERCC8, CKN1, CSA|609412|5q12
Cockayne syndrome, type B, 133540 (3)  |ERCC6, CKN2, COFS1, CSB, ARMD5|609413|10q11
Cocoon syndrome, 613630 (3)  |CHUK, IKBKA, NFKBIKA, IKKA, IKK1|600664|10q24
Coenzyme Q10 deficiency, 607426 (3)  |APTX, AOA, AOA1|606350|9p13.3
Coenzyme Q10 deficiency, 607426 (3)  |CABC1, COQ8, ADCK3, SCAR9, ARCA2|606980|1q42.2
Coenzyme Q10 deficiency, 607426 (3)  |COQ2|609825|4q21-q22
Coenzyme Q10 deficiency, 607426 (3)  |COQ9, C16orf49|612837|16q13
Coenzyme Q10 deficiency, 607426 (3)  |PDSS1, TPT, COQ1|607429|10p12.1
Coenzyme Q10 deficiency, 607426 (3)  |PDSS2, DLP1, C6orf210|610564|6q21
Coffin-Lowry syndrome, 303600 (3)  |RPS6KA3, RSK2, MRX19|300075|Xp22.2-p22.1
Cohen syndrome, 216550 (3)  |COH1|607817|8q22-q23
Colchicine resistance (3)  |ABCB1, PGY1, MDR1, IBD13|171050|7q21.1
Cold-induced autoinflammatory syndrome, familial, 120100 (3)  |NLRP3, CIAS1, FCU, FCAS, NALP3, PYPAF1|606416|1q44
Cold-induced sweating syndrome 1, 610313 (3)  |CLCF1, BSF3, CLC|607672|11q13.3
Cold-induced sweating syndrome, 272430 (3)  |CRLF1, CISS|604237|19p12
Coloboma of optic nerve, 120430 (3)  |PAX6, AN2, MGDA|607108|11p13
Coloboma, ocular, 120200 (3)  |PAX6, AN2, MGDA|607108|11p13
Coloboma, ocular, 120200 (3)  |SHH, HPE3, HLP3, SMMCI, MCOPCB5|600725|7q36
Colon adenocarcinoma (3)  |RAD54B|604289|8q21.3-q22
Colon cancer (1) (?)  |SLC26A3, DRA, CLD|126650|7q22-q31.1
Colon cancer (3)  |BCL10|603517|1p22
Colon cancer (3)  |PTPN12, PTPG1|600079|7q11.23
Colon cancer, advanced (3)  |SRC, ASV, SRC1|190090|20q12-q13
Colon cancer, hereditary nonpolyposis, type 7 (3)  |MLH3, HNPCC7|604395|14q24.3
Colon cancer, somatic, 114500 (3)  |PTPRJ, DEP1|600925|11p11.2
Colorblindness, deutan, 303800 (3)  |OPN1MW, GCP, CBD, CBBM|300821|Xq28
Colorblindness, protan, 303900 (3)  |OPN1LW, RCP, CBP, CBBM|300822|Xq28
Colorblindness, tritan, 190900 (3)  |OPN1SW, BCP, CBT|613522|7q31.3-q32
Colorectal adenomatous polyposis, autosomal recessive, with pilomatricomas, 132600 (3)  |MUTYH, MYH|604933|1p34.3-p32.1
Colorectal cancer (3)  |BAX|600040|19q13.3-q13.4
Colorectal cancer (3)  |CTNNB1|116806|3p22-p21.3
Colorectal cancer (3)  |DCC|120470|18q21.3
Colorectal cancer (3)  |MCC|159350|5q21
Colorectal cancer with chromosomal instability (3)  |BUB1|602452|2q14
Colorectal cancer, 114500 (3)  |AXIN2|604025|17q24
Colorectal cancer, 114500 (3)  |BUB1B, BUBR1|602860|15q15
Colorectal cancer, 114500 (3)  |EP300, RSTS2|602700|22q13
Colorectal cancer, 114500 (3)  |NRAS, ALPS4, NS6|164790|1p13.2
Colorectal cancer, 114500 (3)  |PDGFRL, PDGRL, PRLTS|604584|8p22-p21.3
Colorectal cancer, 114500 (3)  |TP53, P53, LFS1|191170|17p13.1
Colorectal cancer, hereditary nonpolyposis, type 1, 120435 (3)  |MSH2, COCA1, FCC1, HNPCC1|609309|2p22-p21
Colorectal cancer, hereditary nonpolyposis, type 2, 609310 (3)  |MLH1, COCA2, HNPCC2|120436|3p21.3
Colorectal cancer, hereditary nonpolyposis, type 3 (3)  |PMS1, PMSL1, HNPCC3|600258|2q31-q33
Colorectal cancer, hereditary nonpolyposis, type 4 (3)  |PMS2, PMSL2, HNPCC4|600259|7p22
Colorectal cancer, hereditary nonpolyposis, type 5 (3)  |MSH6, GTBP, HNPCC5|600678|2p16
Colorectal cancer, hereditary nonpolyposis, type 6 (3)  |TGFBR2, HNPCC6, AAT3, MFS2, LDS1B, LDS2B|190182|3p22
Colorectal cancer, hereditary nonpolyposis, type I, 613244 (3)  |EPCAM, ACSTD1, TROP1, M4S1, MIC18, DIAR5, HNPCC8|185535|2p21
Colorectal cancer, somatic (3)  |BRAF, NS7|164757|7q34
Colorectal cancer, somatic (3)  |DLC1|604258|8p22-p21.3
Colorectal cancer, somatic, 109800 (3)  |FGFR3, ACH|134934|4p16.3
Colorectal cancer, somatic, 114500 (3)  |AKT1|164730|14q32.3
Colorectal cancer, somatic, 114500 (3)  |APC, GS, FPC, BTPS2|611731|5q21-q22
Colorectal cancer, somatic, 114500 (3)  |FLCN, BHD|607273|17p11.2
Colorectal cancer, somatic, 114500 (3)  |MLH3, HNPCC7|604395|14q24.3
Colorectal cancer, somatic, 114500 (3)  |PIK3CA|171834|3q26.3
Combined C6/C7 deficiency (3)  |C6|217050|5p13
Combined SAP deficiency, 611721 (3)  |PSAP, SAP1|176801|10q22.1
Combined cellular and humoral immune defects with granulomas, 233650 (3)  |RAG1|179615|11p13
Combined cellular and humoral immune defects with granulomas, 233650 (3)  |RAG2|179616|11p13
Combined factor V and VIII deficiency, 227300 (3)  |LMAN1, ERGIC53, F5F8D, MCFD1|601567|18q21.3-q22
Combined hyperlipidemia, familial, 144250 (3)  |LPL, LIPD, HDLCQ11|609708|8p22
Combined immunodeficiency, X-linked, moderate, 312863 (3)  |IL2RG, SCIDX1, SCIDX, IMD4|308380|Xq13
Combined oxidative phosphorylation deficiency 1, 609060 (3)  |GFM1, EFG1, GFM, COXPD1|606639|3q25.1-q26.2
Combined oxidative phosphorylation deficiency 2, 610498 (3)  |MRPS16, COXPD2|609204|10q22.1
Combined oxidative phosphorylation deficiency 3, 610505 (3)  |TSFM, COXPD3|604723|12q13-q14
Combined oxidative phosphorylation deficiency 4, 610678 (3)  |TUFM, EFTU, COXPD4|602389|16p11.2
Combined oxidative phosphorylation deficiency 5, 611719 (3)  |MRPS22, C3orf5, COXPD5|605810|3q23
Combined oxidative phosphorylation deficiency 6, 300816 (3)  |AIFM1, PDCD8, AIF, COXPD6|300169|Xq25-q26
Combined oxidative phosphorylation deficiency 7, 613559 (3)  |C12orf65, COXPD7|613541|12q24.31
Complement component 4, partial deficiency of, 120790 (3)  |C1NH, HAE1, HAE2, SERPING1|606860|11q11-q13.1
Complement factor D deficiency (3)  |CFD, ADN|134350|19p13.3
Complement factor H deficiency, 609814 (3)  |HF1, CFH, HUS, ARMD4, AHUS1|134370|1q32
Complement factor I deficiency, 610984 (3)  |CFI, FI, AHUS3|217030|4q25
Complex I, mitochondrial respiratory chain, deficiency of, 252010 (3)  |NDUFS6|603848|5pter-p15.33
Cone dystrophy 4, 613093 (3)  |PDE6C, PDEA2, COD4|600827|10q24
Cone dystrophy, progressive X-linked, 2 (2)  |COD2|300085|Xq27
Cone dystrophy-3, 602093 (3)  |GUCA1A, GCAP, COD3, CORD14|600364|6p21.1
Cone-rod dystrophy (3)  |AIPL1, LCA4|604392|17p13.1
Cone-rod dystrophy (3)  |UNC119, HRG4|604011|17q11.2
Cone-rod dystrophy 10, 610283 (3)  |SEMA4A, SEMB, RP35, CORD10|607292|1q22
Cone-rod dystrophy 11, 610381 (3)  |RAXL1, QRX, CORD11, ARMD6|610362|19p13.3
Cone-rod dystrophy 12, 612657 (3)  |PROM1, PROML1, AC133, RP41, CORD12, CD133, MCDR2, STGD4|604365|4p15.3
Cone-rod dystrophy 13, 608194 (3)  |RPGRIP1, LCA6, CORD13|605446|14q11
Cone-rod dystrophy 14, 602093 (3)  |GUCA1A, GCAP, COD3, CORD14|600364|6p21.1
Cone-rod dystrophy 15, 613660 (3)  |CDHR1, PCDH21, PRCAD, CORD15|609502|10q23.1
Cone-rod dystrophy 3, 604116 (3)  |ABCA4, ABCR, STGD1, FFM, RP19, CORD3, ARMD2|601691|1p22.1
Cone-rod dystrophy 5, 600977 (3)  |PITPNM3, NIR1, CORD5|608921|17p13.1
Cone-rod dystrophy 6, 601777(3)  |GUCY2D, GUC2D, LCA1, CORD6, RCD2|600179|17p13.1
Cone-rod dystrophy 7, 603649 (3)  |RIMS1, RIM1, RIM, KIAA0340, CORD7|606629|6q12-q13
Cone-rod dystrophy 8 (2)  |CORD8|605549|1q12-q24
Cone-rod dystrophy 9 (2)  |CORD9|612775|8p11
Cone-rod dystrophy 9, 612775 (3)  |ADAM9, MDC9, MCMP, CORD9|602713|8p11.23
Cone-rod dystrophy, X-linked, 3 (2)  |CORDX, COD3|300476|Xp11.4-q13.1
Cone-rod dystrophy, X-linked, 3, 300476 (3)  |CACNA1F, CSNB2, CORDX3, CSNB2A, AIED, OA2|300110|Xp11.23
Cone-rod dystrophy-1, 304020 (3)  |RPGR, RP3, CRD, RP15, COD1, CORDX1|312610|Xp11.4
Cone-rod retinal dystrophy-1 (2)  |CORD1, CRD1|600624|18q21.1-q21.3
Cone-rod retinal dystrophy-2, 120970 (3)  |CRX, CORD2, CRD, LCA7|602225|19q13.3
Congenital bilateral absence of vas deferens, 277180 (3)  |CFTR, ABCC7, CF, MRP7|602421|7q31.2
Congenital cataracts, facial dysmorphism, and neuropathy, 604168 (3)  |CTDP1, FCP1, CCFDN|604927|18q23
Congenital disorder of glycosylation, type IIa, 212066 (3)  |MGAT2, CDGS2, CDG2A|602616|14q21
Congenital disorder of glycosylation, type IIb, 606056 (3)  |GCS1, CDG2B|601336|2p13-p12
Congenital disorder of glycosylation, type IIc, 266265 (3)  |SLC35C1, FUCT1, CDG2C|605881|11p11.2
Congenital disorder of glycosylation, type IId, 607091 (3)  |B4GALT1, GGTB2, GT1, GTB, CDG2D|137060|9p13
Congenital disorder of glycosylation, type IIe, 608779 (3)  |COG7, CDG2E|606978|16p
Congenital disorder of glycosylation, type IIf, 603585 (3)  |SLC35A1, CST, CDG2F|605634|6q15
Congenital disorder of glycosylation, type IIg, 611209 (3)  |COG1, LDLB, KIAA1381, CDG2G|606973|17q25.1
Congenital disorder of glycosylation, type IIh, 611182 (3)  |COG8, DOR1, CDG2H|606979|16q22.1
Congenital disorder of glycosylation, type IIi, 613612 (3)  |COG5, GOLTC1, GTC90, CDG2I|606821|7q31
Congenital disorder of glycosylation, type IIj, 613489 (3)  |COG4, COD1, CDG2J|606976|16q22.1
Congenital disorder of glycosylation, type Ia, 212065 (3)  |PMM2, CDG1A|601785|16p13.3-p13.2
Congenital disorder of glycosylation, type Ib, 602579 (3)  |MPI, PMI1, CDG1B|154550|15q22-qter
Congenital disorder of glycosylation, type Ic, 603147 (3)  |ALG6, CDG1C|604566|1p22.3
Congenital disorder of glycosylation, type Id, 601110 (3)  |ALG3, NOT56L, CDGS4, CDG1D|608750|3q27
Congenital disorder of glycosylation, type Ie, 608799 (3)  |DPM1, MPDS, CDGIE|603503|20q13.13
Congenital disorder of glycosylation, type If, 609180 (3)  |MPDU1, SL15, CDGIF|604041|17p13.1-p12
Congenital disorder of glycosylation, type Ig, 607143 (3)  |ALG12, CDG1G|607144|22q13.33
Congenital disorder of glycosylation, type Ih, 608104 (3)  |ALG8, CDG1H|608103|11pter-p15.5
Congenital disorder of glycosylation, type Ii, 607906 (3)  |ALG2, CDGII|607905|9q22
Congenital disorder of glycosylation, type Ij, 608093 (3)  |DPAGT2, DGPT, CDG1J|191350|11q23.3
Congenital disorder of glycosylation, type Ik, 608540 (3)  |ALG1, HMAT1, HMT1, CDG1K|605907|16p13.3
Congenital disorder of glycosylation, type Il, 608776 (3)  |ALG9, DIBD1, CDG1L|606941|11q23
Congenital disorder of glycosylation, type Im, 610768 (3)  |TMEM15, DK1, SEC59, KIAA1094, CDG1M|610746|9q34.11
Congenital disorder of glycosylation, type In, 612015 (3)  |RFT1, CDG1N|611908|3p21.1
Congenital disorder of glycosylation, type Io, 612937 (3)  |DPM3, CDG1O|605951|1q12-q21
Congenital disorder of glycosylation, type Ip, 613661 (3)  |ALG11, KIAA1266, CDG1P|613666|13q14.3
Congenital disorder of glycosylation, type Iq, 612379 (3)  |SRD5A3, SRD5A2L, CDG1Q|611715|4q12
Congenital heart defects, nonsyndromic, 1, X-linked, 306955 (3)  |ZIC3, HTX1, HTX|300265|Xq26.2
Congenital heart disease, nonsyndromic, 2, 612863 (3)  |TAB2, MAP3K7IP2, KIAA0733, CHTD2|605101|6q25
Congenital hereditary endothelial dystrophy of cornea, autosomal dominant (2)  |CHED1, CHED|121700|20p11.2-q11.2
Conjunctivitis, ligneous, 217090 (3)  |PLG|173350|6q26
Conotruncal anomaly face syndrome, 217095 (3)  |TBX1, DGS, CTHM, CAFS, TGA, DORV, VCFS, DGCR|602054|22q11.2
Contractural arachnodactyly, congenital, 121050 (3)  |FBN2, CCA|612570|5q23-q31
Convulsions, benign familial infantile (2)  |BFIC|601764|19q
Convulsions, benign familial infantile, 2 (2)  |BFIC2|605751|16p12-q12
Convulsions, benign familial infantile, 4 (2)  |BFIC4, BFIS4|612627|1p36.12-p35.1
Convulsions, familial febrile, 1 (2)  |FEB1|121210|8q13-q21
Convulsions, familial febrile, 2 (2)  |FEB2|602477|19p13.3
Convulsions, familial febrile, 4, 604352 (3)  |GPR98, MASS1, VLGR1, KIAA0686, FEB4, USH2C, USH2B|602851|5q14.3
Convulsions, infantile and paroxysmal choreoathetosis (2)  |ICCA|602066|16p12-q12
Coproporphyria, 121300 (3)  |CPOX|612732|3q12
Cornea plana congenita, recessive, 217300 (3)  |KERA, CNA2|603288|12q22
Corneal clouding, autosomal recessive (3)  |APOA1|107680|11q23
Corneal dystrophy and perceptive deafness 1 (2)  |CDPD1|217400|20p13
Corneal dystrophy polymorphous posterior, 2, 609140 (3)  |COL8A2, FECD1, PPCD2|120252|1p34.3-p32.3
Corneal dystrophy, Avellino type, 607541 (3)  |TGFBI, CSD2, CDGG1, CSD, BIGH3, CDG2, EBMD|601692|5q31
Corneal dystrophy, Fuchs endothelial, 1, 136800 (3)  |COL8A2, FECD1, PPCD2|120252|1p34.3-p32.3
Corneal dystrophy, Fuchs endothelial, 3 (2)  |FECD3, FCD2|613267|18q21.2-q21.3
Corneal dystrophy, Fuchs endothelial, 4, 613268 (3)  |SLC4A11, BTR1, NABC1, CHED2, CDPD, FECD4|610206|20p13-p12
Corneal dystrophy, Fuchs endothelial, 5 (2)  |FECD5, FCD3|613269|5q33.1-q35.2
Corneal dystrophy, Fuchs endothelial, 6, 613270 (3)  |ZEB1, TCF8, NIL2A, PPCD3, FECD6|189909|10p11.2
Corneal dystrophy, Fuchs endothelial, 7 (2)  |FECD7, FCD4|613271|9p24.1-p22.1
Corneal dystrophy, Fuchs endothelial, late onset 1 (2)  |FCD1, FECD2|610158|13pter-q12.13
Corneal dystrophy, Groenouw type I, 121900 (3)  |TGFBI, CSD2, CDGG1, CSD, BIGH3, CDG2, EBMD|601692|5q31
Corneal dystrophy, Lisch epithelial (2)  |LECD|300778|Xp22.3
Corneal dystrophy, Reis-Bucklers type, 608470 (3)  |TGFBI, CSD2, CDGG1, CSD, BIGH3, CDG2, EBMD|601692|5q31
Corneal dystrophy, Thiel-Behnke type (2)  |CDB2, CDTB|602082|10q24
Corneal dystrophy, Thiel-Behnke type, 602082 (3)  |TGFBI, CSD2, CDGG1, CSD, BIGH3, CDG2, EBMD|601692|5q31
Corneal dystrophy, congenital stromal, 610048 (3)  |DCN, CSCD|125255|12q21.3
Corneal dystrophy, crystalline, of Schnyder, 121800 (3)  |UBIAD1, TERE1, SCCD|611632|1p36.3
Corneal dystrophy, endothelial, X-linked (2)  |XECD|300779|Xq25
Corneal dystrophy, epithelial basement membrane, 121820 (3)  |TGFBI, CSD2, CDGG1, CSD, BIGH3, CDG2, EBMD|601692|5q31
Corneal dystrophy, gelatinous drop-like, 204870 (3)  |TACSTD2, TROP2, M1S1|137290|1p32
Corneal dystrophy, hereditary polymorphous posterior, 122000 (3)  |VSX1, RINX, PPCD, PPD, KTCN|605020|20p11.2
Corneal dystrophy, lattice type I, 122200 (3)  |TGFBI, CSD2, CDGG1, CSD, BIGH3, CDG2, EBMD|601692|5q31
Corneal dystrophy, lattice type IIIA, 608471 (3)  |TGFBI, CSD2, CDGG1, CSD, BIGH3, CDG2, EBMD|601692|5q31
Corneal dystrophy, posterior polymorphous, 3, 609141 (3)  |ZEB1, TCF8, NIL2A, PPCD3, FECD6|189909|10p11.2
Corneal endothelial dystrophy 2, 217700 (3)  |SLC4A11, BTR1, NABC1, CHED2, CDPD, FECD4|610206|20p13-p12
Corneal endothelial dystrophy and perceptive deafness, 217400 (3)  |SLC4A11, BTR1, NABC1, CHED2, CDPD, FECD4|610206|20p13-p12
Corneal fleck dystrophy, 121850 (3)  |PIKFYVE, PIP5K3|609414|2q35
Cornelia de Lange syndrome 1, 122470 (3)  |NIPBL, CDLS1|608667|5p13.1
Cornelia de Lange syndrome 2, 300590 (3)  |DXS423E, SMC1, CDLS2|300040|Xp11.22-p11.21
Cornelia de Lange syndrome 3, 610759 (3)  |CSPG6, SMC3, HCAP, BAM, CDLS3|606062|10q25
Corpus callosum, agenesis of, with mental retardation, ocular coloboma and micrognathia, 300472 (3)  |IGBP1|300139|Xq13.1-q13.3
Corpus callosum, partial agenesis of, 304100 (3)  |L1CAM, CAML1, HSAS1|308840|Xq28
Cortical dysplasia-focal epilepsy syndrome, 610042 (3)  |CNTNAP2, CASPR2, NRXN4, CDFE, AUTS15, PTHSL1|604569|7q35-q36
Corticosteroid-binding globulin deficiency, 611489 (3)  |CBG, SERPINA6|122500|14q32.1
Cortisol resistance (3)  |NR3C1, GCR, GRL|138040|5q31
Cortisone reductase deficiency, 604931 (3)  |H6PD, GDH, G6PDH|138090|1p36
Cortisone reductase deficiency, 604931 (3)  |HSD11B1, HSD11, HSD11L|600713|1q32-q41
Costello syndrome, 218040 (3)  |HRAS|190020|11p15.5
Coumarin resistance, 122700 (3)  |CYP2A6, CYP2A3, CYP2A, P450C2A|122720|19q13.2
Cousin syndrome, 260660 (3)  |TBX15|604127|1p13
Cowchock syndrome (2)  |NAMSD, NADMR|310490|Xq24-q26.1
Cowden disease, 158350 (3)  |PTEN, MMAC1, GLM2|601728|10q23.31
Cowden-like syndrome, 612359 (3)  |SDHB, SDH2, SDHIP, PGL4|185470|1p36.1-p35
Cowden-like syndrome, 612359 (3)  |SDHD, PGL1|602690|11q23
Cramps, familial, potassium-aggravated (3)  |SCN4A, HYPP, NAC1A, HOKPP2|603967|17q23.1-q25.3
Cranioectodermal dysplasia 2, 613610 (3)  |WDR35, NAOFEN, KIAA1336, CED2|613602|2p24.1
Cranioectodermal dysplasia, 218330 (3)  |IFT122, WDR10, CED|606045|3q21
Craniofacial anomalies, empty sella turcica, corneal endothelial changes, and abnormal retinal and auditory bipolar cells (3)  |VSX1, RINX, PPCD, PPD, KTCN|605020|20p11.2
Craniofacial-deafness-hand syndrome, 122880 (3)  |PAX3, WS1, HUP2, CDHS, WS3|606597|2q35
Craniofacial-skeletal-dermatologic dysplasia (3)  |FGFR2, BEK, CFD1, JWS|176943|10q26
Craniofacioskeletal syndrome (2) (?)  |CFSS|300712|Xq26-q27
Craniofrontonasal dysplasia, 304110 (3)  |EFNB1, EPLG2, CFNS, CFND|300035|Xq12
Craniolenticulosutural dysplasia, 607812 (3)  |SEC23A, CLSD|610511|14q21.1
Craniometaphyseal dysplasia, 123000 (3)  |ANKH, HANK, ANK, CMDJ, CCAL2, CPPDD|605145|5p15.2-p14.1
Craniometaphyseal dysplasia, autosomal recessive (2)  |CMDR|218400|6q21-q22
Cranioosteoarthropathy, 259100 (3)  |HPGD, PGDH1|601688|4q34-q35
Craniosynostosis, Adelaide type (2)  |CRSA, CRS3|600593|4p16
Craniosynostosis, nonspecific (3)  |FGFR2, BEK, CFD1, JWS|176943|10q26
Craniosynostosis, type 1, 123100 (3)  |TWIST1, ACS3, SCS, CRS1|601622|7p21
Craniosynostosis, type 2, 604757 (3)  |MSX2, CRS2, HOX8|123101|5q34-q35
Creatine deficiency syndrome, X-linked, 300352 (3)  |SLC6A8, CRTR|300036|Xq28
Creatine phosphokinase, elevated serum, 123320 (3)  |CAV3, LGMD1C, LQT9|601253|3p25
Creatinine clearance QTL (2)  |CRCL|607135|3p
Creutzfeldt-Jakob disease, 123400 (3)  |PRNP, PRIP|176640|20pter-p12
Crigler-Najjar syndrome, type I, 218800 (3)  |UGT1A1, UGT1, GNT1, BILIQTL1|191740|2q37
Crigler-Najjar syndrome, type II, 606785 (3)  |UGT1A1, UGT1, GNT1, BILIQTL1|191740|2q37
Crisponi syndrome, 601378 (3)  |CRLF1, CISS|604237|19p12
Crouzon syndrome with acanthosis nigricans, 612247 (3)  |FGFR3, ACH|134934|4p16.3
Crouzon syndrome, 123500 (3)  |FGFR2, BEK, CFD1, JWS|176943|10q26
Cryptorchidism, bilateral, 219050 (3)  |LGR8, GREAT|606655|13q13.1
Cryptorchidism, idiopathic, 219050 (3)  |INSL3|146738|19p13.2
Cubitus valgus with mental retardation and unusual facies (2)  |CVMRF|300471|Chr.X
Currarino syndrome, 176450 (3)  |MNX1, HLXB9, HOXHB9, SCRA1|142994|7q36
Cutis laxa with severe pulmonary, gastrointestinal, and urinary abnormalities, 613177 (3)  |LTBP4, LTBP4S, LTBP4L|604710|19q13.1-q13.2
Cutis laxa, AD, 123700 (3)  |ELN|130160|7q11.2
Cutis laxa, autosomal dominant, 123700 (3)  |FBLN5, ARMD3|604580|14q32.1
Cutis laxa, autosomal recessive, 219100 (3)  |FBLN5, ARMD3|604580|14q32.1
Cutis laxa, autosomal recessive, type I, 219100 (3)  |EFEMP2, FBLN4, UPH1|604633|11q13
Cutis laxa, autosomal recessive, type II, 219200 (3)  |ATP6V0A2, WSS, ARCL|611716|12q24.3
Cutis laxa, autosomal recessive, type IIB, 612940 (3)  |PYCR1, PRO3, ARCL2B|179035|17q25.3
Cutis laxa, marfanoid neonatal type (1) (?)  |LAMB1|150240|7q31.1-q31.3
Cylindromatosis, familial, 132700 (3)  |CYLD1, CDMT, EAC, MFT1|605018|16q12-q13
Cystathioninuria, 219500 (3)  |CTH|607657|1p31.1
Cystic fibrosis, 219700 (3)  |CFTR, ABCC7, CF, MRP7|602421|7q31.2
Cystinosis, atypical nephropathic (3)  |CTNS|606272|17p13
Cystinosis, late-onset juvenile or adolescent nephropathic, 219900 (3)  |CTNS|606272|17p13
Cystinosis, nephropathic, 219800 (3)  |CTNS|606272|17p13
Cystinosis, ocular nonnephropathic, 219750 (3)  |CTNS|606272|17p13
Cystinuria, 220100 (3)  |SLC3A1, ATR1, D2H, NBAT|104614|2p16.3
Cystinuria, 220100 (3)  |SLC7A9, CSNU3|604144|19q13.1
Cytochrome c oxidase deficiency, 220110 (3)  |COX6B1|124089|19q13.1
D-2-hydrosyglutaric aciduria 2, 613657 (3)  |IDH2, IDPM, D2HGA2|147650|15q26.1
D-2-hydroxyglutaric aciduria, 600721 (3)  |D2HGDH, D2HGD|609186|2q37.3
D-bifunctional protein deficiency, 261515 (3)  |HSD17B4|601860|5q2
DECR deficiency (2) (?)  |DECR1|222745|8q21.3
DNA ligase I deficiency (3)  |LIG1|126391|19q13.2-q13.3
DNA topoisomerase I, camptothecin-resistant (3)  |TOP1|126420|20q12-q13.1
DNA topoisomerase II, resistance to inhibition of, by amsacrine (3)  |TOP2A, TOP2|126430|17q21-q22
Dandy-Walker malformation, 220200 (2) (?)  |ZIC1|600470|3q24
Dandy-Walker malformation, 220200 (2) (?)  |ZIC4|608948|3q24
Darier disease, 124200 (3)  |ATP2A2, ATP2B, DAR|108740|12q23-q24.1
Darsun syndrome, 612541 (3)  |G6PC3, UGRP, SCN4|611045|17q21
De Sanctis-Cacchione syndrome, 278800 (3)  |ERCC6, CKN2, COFS1, CSB, ARMD5|609413|10q11
De la Chapelle dysplasia, 256050 (3)  |SLC26A2, DTD, DTDST, D5S1708, EDM4|606718|5q32-q33.1
Deafness and male infertility (4)  |DEL15q15.3, C15DELq15.3|611102|15q15.3
Deafness, X-linked 1, 304500 (3)  |PRPS1, CMTX5, DFNX1, DFN2|311850|Xq22-q24
Deafness, X-linked 1, progressive (3)  |TIMM8A, DFN1, DDP, MTS, DDP1|300356|Xq22
Deafness, X-linked 2, 304400 (3)  |POU3F4, DFN3, DFNX2|300039|Xq21.1
Deafness, X-linked 3 (2)  |DFNX3, DFN4|300030|Xp21.2
Deafness, X-linked 4 (2)  |DFNX4, DFN6|300066|Xp22
Deafness, X-linked 5 (2)  |DFNX5, AUNX1|300614|Xq23-q27.3
Deafness, Y-linked 1 (1)  |DFNY1|400043|Chr.Y
Deafness, autosomal dominant 1, 124900 (3)  |DIAPH1, DFNA1, LFHL1|602121|5q31
Deafness, autosomal dominant 10, 601316 (3)  |EYA4, DFNA10, CMD1J|603550|6q23
Deafness, autosomal dominant 11, neurosensory, 601317 (3)  |MYO7A, USH1B, DFNB2, DFNA11|276903|11q13.5
Deafness, autosomal dominant 13, 601868 (3)  |COL11A2, STL3, DFNA13, DFNB53|120290|6p21.3
Deafness, autosomal dominant 15, 602459 (3)  |POU4F3, BRN3C|602460|5q31
Deafness, autosomal dominant 16 (2)  |DFNA16|603964|2q23-q24.3
Deafness, autosomal dominant 17, 603622 (3)  |MYH9, MHA, FTNS, DFNA17|160775|22q11.2
Deafness, autosomal dominant 18 (2)  |DFNA18|606012|3q22
Deafness, autosomal dominant 20/26, 604717 (3)  |ACTG1, DFNA20, DFNA26|102560|17q25.3
Deafness, autosomal dominant 21 (2)  |DFNA21|607017|6p21.3
Deafness, autosomal dominant 22, 606346 (3)  |MYO6, DFNA22, DFNB37|600970|6q13
Deafness, autosomal dominant 22, with hypertrophic cardiomyopathy, 606346 (3)  |MYO6, DFNA22, DFNB37|600970|6q13
Deafness, autosomal dominant 23, 605192 (3)  |SIX1, BOS3, DFNA23|601205|14q23
Deafness, autosomal dominant 24 (2)  |DFNA24|606282|4q35-qter
Deafness, autosomal dominant 25, 605583 (3)  |SLC17A8, VGLUT3, DFNA25|607557|12q23
Deafness, autosomal dominant 27 (2)  |DFNA27|612431|4q12-q13.1
Deafness, autosomal dominant 28, 608641 (3)  |GRHL2, TFCP2L3, DFNA28|608576|8q22
Deafness, autosomal dominant 2A, 600101 (3)  |KCNQ4, DFNA2A|603537|1p34
Deafness, autosomal dominant 2B, 612644 (3)  |GJB3, CX31, DFNA2B|603324|1p35.1
Deafness, autosomal dominant 30 (2)  |DFNA30|606451|15q25-q26
Deafness, autosomal dominant 31 (2)  |DFNA31|608645|6p21.3
Deafness, autosomal dominant 36, 606705 (3)  |TMC1, DFNB7, DFNB11, DFNA36|606706|9q13-q21
Deafness, autosomal dominant 36, with dentinogenesis, 605594 (3)  |DSPP, DPP, DGI1, DFNA39, DTDP2|125485|4q21.3
Deafness, autosomal dominant 3A, 601544 (3)  |GJB2, CX26, DFNB1A, PPK, DFNA3A, KID, HID|121011|13q11-q12
Deafness, autosomal dominant 3B, 612643 (3)  |GJB6, CX30, DFNA3B, HED, ED2, DFNB1B|604418|13q12
Deafness, autosomal dominant 4, 600652 (3)  |MYH14, KIAA2034, DFNA4|608568|19q13.33
Deafness, autosomal dominant 40 (3)  |CRYM, DFNA40|123740|16p13.11-p12.3
Deafness, autosomal dominant 41 (2)  |DFNA41|608224|12q24.32-qter
Deafness, autosomal dominant 43 (2)  |DFNA43|608394|2p12
Deafness, autosomal dominant 44, 607453 (3)  |CCDC50, C3orf6, DFNA44|611051|3q28
Deafness, autosomal dominant 47 (2)  |DFNA47, DFNB83|608652|9p22-p21
Deafness, autosomal dominant 48, 607841 (3)  |MYO1A, DFNA48|601478|12q13-q15
Deafness, autosomal dominant 49 (2)  |DFNA49|608372|1q21-q23
Deafness, autosomal dominant 5, 600994 (3)  |DFNA5|608798|7p15
Deafness, autosomal dominant 50, 613074 (3)  |MIR96, MIRN96, DFNA50|611606|7q32.2
Deafness, autosomal dominant 51 (4)  |DFNA51, C9DUPq21.11, DUP9q21.11|613558|9q21.11
Deafness, autosomal dominant 52 (2)  |DFNA52|607683|4q28
Deafness, autosomal dominant 53 (2)  |DFNA53|609965|14q11.2-q12
Deafness, autosomal dominant 59 (2)  |DFNA59|612642|11p14.2-q12.3
Deafness, autosomal dominant 6/14/38, 600965 (3)  |WFS1, WFRS, WFS, DFNA6, DFNA14, DFNA38|606201|4p16.1
Deafness, autosomal dominant 7 (2)  |DFNA7|601412|1q21-q23
Deafness, autosomal dominant 8/12, 601543 (3)  |TECTA, DFNA8, DFNA12, DFNB21|602574|11q22-q24
Deafness, autosomal dominant 9, 601369 (3)  |COCH, DFNA9|603196|14q12-q13
Deafness, autosomal dominant, with peripheral neuropathy (3)  |GJB3, CX31, DFNA2B|603324|1p35.1
Deafness, autosomal recessive (3)  |GJB3, CX31, DFNA2B|603324|1p35.1
Deafness, autosomal recessive 10, congenital, 605316 (3)  |TMPRSS3, ECHOS1, DFNB8, DFNB10|605511|21q22.3
Deafness, autosomal recessive 12, 601386 (3)  |CDH23, USH1D|605516|10q21-q22
Deafness, autosomal recessive 13 (2)  |DFNB13|603098|7q34-q36
Deafness, autosomal recessive 14 (2)  |DFNB14|603678|7q31
Deafness, autosomal recessive 15 (2)  |DFNB15|601869|3q
Deafness, autosomal recessive 16, 603720 (3)  |STRC, DFNB16|606440|15q15
Deafness, autosomal recessive 17 (2)  |DFNB17|603010|7q31
Deafness, autosomal recessive 18, 602092 (3)  |USH1C, DFNB18|605242|11p15.1
Deafness, autosomal recessive 1A, 220290 (3)  |GJB2, CX26, DFNB1A, PPK, DFNA3A, KID, HID|121011|13q11-q12
Deafness, autosomal recessive 1B, 612645 (3)  |GJB6, CX30, DFNA3B, HED, ED2, DFNB1B|604418|13q12
Deafness, autosomal recessive 2, neurosensory, 600060 (3)  |MYO7A, USH1B, DFNB2, DFNA11|276903|11q13.5
Deafness, autosomal recessive 20 (2)  |DFNB20|604060|11q25-qter
Deafness, autosomal recessive 21, 603629 (3)  |TECTA, DFNA8, DFNA12, DFNB21|602574|11q22-q24
Deafness, autosomal recessive 22, 607039 (3)  |OTOA, DFNB22|607038|16p12.2
Deafness, autosomal recessive 23, 609533 (3)  |PCDH15, DFNB23, USH1F|605514|10q21-q22
Deafness, autosomal recessive 25, 613285 (3)  |GRXCR1|613283|4p13
Deafness, autosomal recessive 26 (2)  |DFNB26|605428|4q31
Deafness, autosomal recessive 27 (2)  |DFNB27|605818|2q23-q31
Deafness, autosomal recessive 28, 609823 (3)  |TRIOBP, KIAA1662|609761|22q13.1
Deafness, autosomal recessive 29 (3)  |CLDN14, DFNB29|605608|21q22.3
Deafness, autosomal recessive 3, 600316 (3)  |MYO15A, DFNB3|602666|17p11.2
Deafness, autosomal recessive 30, 607101 (3)  |MYO3A, DFNB30|606808|10p11.1
Deafness, autosomal recessive 31, 607084 (3)  |WHRN, CIP98, KIAA1526, DFNB31, USH2D|607928|9q32-q34
Deafness, autosomal recessive 33 (2)  |DFNB33|607239|10p11.23-q21.1
Deafness, autosomal recessive 35, 608565 (3)  |ESRRB, ESRL2, DFNB35|602167|14q24.3
Deafness, autosomal recessive 36, 609006 (3)  |ESPN|606351|1p36.3-p36.1
Deafness, autosomal recessive 37, 607821 (3)  |MYO6, DFNA22, DFNB37|600970|6q13
Deafness, autosomal recessive 38 (2)  |DFNB38|608219|6q26-q27
Deafness, autosomal recessive 39, 608265 (3)  |HGF, DFNB39|142409|7q21.1
Deafness, autosomal recessive 40 (2)  |DFNB40|608264|22q11.21-q12.1
Deafness, autosomal recessive 44 (2)  |DFNB44|610154|7p14.1-q11.22
Deafness, autosomal recessive 45 (2)  |DFNB45|612433|1q43-q44
Deafness, autosomal recessive 49, 610153 (3)  |MARVELD2, MARVD2, TRIC, DFNB49|610572|5q13.1
Deafness, autosomal recessive 5 (2)  |DFNB5|600792|14q12
Deafness, autosomal recessive 51 (2)  |DFNB51|609941|11p13-p12
Deafness, autosomal recessive 53, 609706 (3)  |COL11A2, STL3, DFNA13, DFNB53|120290|6p21.3
Deafness, autosomal recessive 55 (2)  |DFNB55|609952|4q12-q13.2
Deafness, autosomal recessive 59, 610220 (3)  |PJVK, DFNB59|610219|2q31.1-q31.3
Deafness, autosomal recessive 6, 600971 (3)  |TMIE, DFNB6|607237|3p21
Deafness, autosomal recessive 61 (3)  |PRES, DFNB61, SLC26A5|604943|7q22.1
Deafness, autosomal recessive 62 (2)  |DFNB62|610143|12p13.2-p11.23
Deafness, autosomal recessive 63, 611451 (3)  |LRTOMT, LRTOMT1, LRTOMT2, DFNB63|612414|11q13.3-q13.4
Deafness, autosomal recessive 65 (2)  |DFNB65|610248|20q13.2-q13.3
Deafness, autosomal recessive 66 (2)  |DFNB66|610212|6p22.3-p21.2
Deafness, autosomal recessive 67, 610265 (3)  |LHFPL5, TMHS, DFNB67|609427|6p21.3
Deafness, autosomal recessive 7, 600974 (3)  |TMC1, DFNB7, DFNB11, DFNA36|606706|9q13-q21
Deafness, autosomal recessive 71 (2)  |DFNB71|612789|8p22-p21.3
Deafness, autosomal recessive 72 (2)  |DFNB72|611918|19p13.3
Deafness, autosomal recessive 74, 613718 (3)  |MSRB3, DFNB74|613719|12q14.3
Deafness, autosomal recessive 77, 613079 (3)  |LOXHD1, DFNB77|613072|18q12-q21
Deafness, autosomal recessive 79 (2)  |DFNB79|613307|9q34.3
Deafness, autosomal recessive 79, 613307 (3)  |TPRN, C9orf75, DFNB79|613354|9q34.3
Deafness, autosomal recessive 8, childhood onset, 601072 (3)  |TMPRSS3, ECHOS1, DFNB8, DFNB10|605511|21q22.3
Deafness, autosomal recessive 82, 613557 (3)  |GPSM2, LGN, PINS, DFNB82|609245|1p13.1
Deafness, autosomal recessive 83 (2)  |DFNB83|613685|9p23-p21.2
Deafness, autosomal recessive 84, 613391 (3)  |PTPRQ, PTPGMC1, DFNB84|603317|12q21.2
Deafness, autosomal recessive 85 (2)  |DFNB85|613392|17p12-q11.2
Deafness, autosomal recessive 9, 601071 (3)  |OTOF, DFNB9, NSRD9, AUNB1|603681|2p23-p22
Deafness, autosomal recessive 91, 613453 (3)  |SERPINB6, PI6, PTI, SPI3, DFNB91|173321|6p25
Deafness, autosomal recessive, 24, 611022 (3)  |RDX, DFNB24|179410|11q23
Deafness, cataract, retinitis pigmentosa, and sperm abnormalities (2)  |DFCTRPS|300719|Chr.X
Deafness, congenital heart defects, and posterior embryotoxon (3)  |JAG1, AGS, AHD|601920|20p12
Deafness, congenital with inner ear agenesis, microtia, and microdontia, 610706 (3)  |FGF3, INT2|164950|11q13
Deafness, digenic GJB2/GJB6, 220290 (3)  |GJB6, CX30, DFNA3B, HED, ED2, DFNB1B|604418|13q12
Deafness, digenic, GJB2/GJB3, 220290 (3)  |GJB3, CX31, DFNA2B|603324|1p35.1
Deafness, neurosensory, autosomal recessive 46 (2)  |DFNB46|609647|18p11.32-p11.31
Deafness, neurosensory, autosomal recessive 47 (2)  |DFNB47|609946|2p25.1-p24.3
Deafness, neurosensory, without vestibular involvement, autosomal dominant (3)  |ESPN|606351|1p36.3-p36.1
Deafness, nonsyndromic (3) (?)  |KIAA1199|608366|15q24
Dehydrated hereditary stomatocytosis (2)  |DHS|194380|16q23-q24
Dehydrated hereditary stomatocytosis, pseudohyperkalemia, and perinatal edema, 603528 (2)  |DHS|194380|16q23-q24
Dejerine-Sottas disease, 145900 (3)  |PMP22, CMT1A, CMT1E, DSS|601097|17p11.2
Dejerine-Sottas neuropathy, 145900 (3)  |EGR2, KROX20|129010|10q21.1-q22.1
Dejerine-Sottas neuropathy, autosomal recessive, 145900 (3)  |PRX, CMT4F|605725|19q13.1-q13.2
Dejerine-Sottas syndrome, 145900 (3)  |MPZ, CMT1B, CMTDI3, CHM, DSS|159440|1q22
Dementia, Lewy body, 127750 (3)  |SNCA, NACP, PARK1, PARK4|163890|4q21
Dementia, Lewy body, 127750 (3)  |SNCB|602569|5q35
Dementia, early-onset progressive, autosomal recessive (3)  |APP, AAA, CVAP, AD1|104760|21q21
Dementia, familial British, 176500 (3)  |ITM2B, BRI, ABRI, FBD|603904|13q14
Dementia, familial Danish, 117300 (3)  |ITM2B, BRI, ABRI, FBD|603904|13q14
Dementia, familial, nonspecific, 600795 (3)  |CHMP2B, DMT1, VPS2B|609512|3p11.2
Dementia, frontotemporal, 600274 (3)  |PSEN1, AD3|104311|14q24.3
Dementia, frontotemporal, with or without parkinsonism, 600274 (3)  |MAPT, MTBT1, DDPAC, MSTD|157140|17q21.1
Dent disease 2, 300555 (3)  |OCRL, LOCR, OCRL1, NPHL2|300535|Xq26.1
Dent disease, 300009 (3)  |CLCN5, CLCK2, NPHL2, DENTS, NPHL1|300008|Xp11.22
Dental anomalies, isolated (3)  |RUNX2, CBFA1, PEBP2A1, AML3|600211|6p21
Dentatorubro-pallidoluysian atrophy, 125370 (3)  |ATN1, DRPLA, HRS, NOD|607462|12p13.31
Dentin dysplasia, type II, 125420 (3)  |DSPP, DPP, DGI1, DFNA39, DTDP2|125485|4q21.3
Dentinogenesis imperfecta, Shields type II, 125490 (3)  |DSPP, DPP, DGI1, DFNA39, DTDP2|125485|4q21.3
Dentinogenesis imperfecta, Shields type III, 125500 (3)  |DSPP, DPP, DGI1, DFNA39, DTDP2|125485|4q21.3
Denys-Drash syndrome, 194080 (3)  |WT1, NPHS4|607102|11p13
Dermatofibrosarcoma protuberans (3)  |PDGFB, SIS|190040|22q12.3-q13.1
Dermatopathia pigmentosa reticularis, 125595 (3)  |KRT14|148066|17q12-q21
Dermoids of cornea (2)  |CND|304730|Xq24-qter
Desbuquois dysplasia, 251450 (3)  |CANT1, SCAN1, DBQD|613165|17q25.3
Desbuquois syndrome (2)  |DBQD|251450|17q25.3
Desmoid disease, hereditary, 135290 (3)  |APC, GS, FPC, BTPS2|611731|5q21-q22
Desmosterolosis, 602398 (3)  |DHCR24, KIAA0018|606418|1p33-p31.1
DiGeorge syndrome, 188400 (3)  |TBX1, DGS, CTHM, CAFS, TGA, DORV, VCFS, DGCR|602054|22q11.2
DiGeorge syndrome/velocardiofacial syndrome complex-2 (2)  |DGCR2, DGS2|601362|10p14-p13
Diabetes insipidus, nephrogenic, 125800 (3)  |AQP2|107777|12q13
Diabetes insipidus, nephrogenic, 304800 (3)  |AVPR2, DIR, DI1, ADHR|300538|Xq28
Diabetes insipidus, neurohypophyseal, 125700 (3)  |AVP, AVRP, VP|192340|20p13
Diabetes mellitus, gestational, 125851 (3)  |GCK, HHF3|138079|7p15-p13
Diabetes mellitus, insulin-dependent, 2, 125852 (3)  |INS, MODY10, IDDM2|176730|11p15.5
Diabetes mellitus, insulin-dependent, 20, 612520 (3)  |HNF1A, TCF1, MODY3, IDDM20|142410|12q24.2
Diabetes mellitus, insulin-dependent, neonatal (2) (?)  |PBCA|600089|6p21.3
Diabetes mellitus, insulin-resistant, with acanthosis nigricans, 610549 (3)  |INSR, HHF5|147670|19p13.2
Diabetes mellitus, ketosis-prone, 612227 (3)  |PAX4, MODY9, KPD|167413|7q32
Diabetes mellitus, neonatal, with congenital hypothyroidism, 610199 (3)  |GLIS3, ZNF515|610192|9p24.3-p23
Diabetes mellitus, noninsulin-dependent, 125853 (3)  |ABCC8, SUR, PHHI, SUR1, HHF1, TNDM2|600509|11p15.1
Diabetes mellitus, noninsulin-dependent, 125853 (3)  |HNF1B, TCF2, HNF2, MODY5, FJHN, HPC11|189907|17q12
Diabetes mellitus, noninsulin-dependent, 2 (2)  |NIDDM2|601407|12q24.2
Diabetes mellitus, noninsulin-dependent, late onset, 125853 (3)  |GCK, HHF3|138079|7p15-p13
Diabetes mellitus, permanent neonatal, 606176 (3)  |ABCC8, SUR, PHHI, SUR1, HHF1, TNDM2|600509|11p15.1
Diabetes mellitus, permanent neonatal, 606176 (3)  |GCK, HHF3|138079|7p15-p13
Diabetes mellitus, permanent neonatal, 606176 (3)  |INS, MODY10, IDDM2|176730|11p15.5
Diabetes mellitus, permanent neonatal, with cerebellar agenesis, 609069 (3)  |PTF1A|607194|10p12.3
Diabetes mellitus, permanent neonatal, with neurologic features, 606176 (3)  |KCNJ11, BIR, PHHI, HHF2, TNDM3|600937|11p15.1
Diabetes mellitus, transient neonatal 2, 610374 (3)  |ABCC8, SUR, PHHI, SUR1, HHF1, TNDM2|600509|11p15.1
Diabetes mellitus, transient neonatal, 1, 601410 (3)  |ZFP57, TNDM1|612192|6p22.1
Diabetes mellitus, transient neonatal, 3, 610582 (3)  |KCNJ11, BIR, PHHI, HHF2, TNDM3|600937|11p15.1
Diabetes mellitus, type 1, 125852 (3)  |INS, MODY10, IDDM2|176730|11p15.5
Diabetes mellitus, type 2, 125853 (3)  |PAX4, MODY9, KPD|167413|7q32
Diabetes mellitus, type II, 125853 (3)  |AKT2|164731|19q13.1-q13.2
Diabetes, permanent neonatal, 606176 (3)  |KCNJ11, BIR, PHHI, HHF2, TNDM3|600937|11p15.1
Diamond-Blackfan anemia 1, 105650 (3)  |RPS19, DBA, DBA1|603474|19q13.2
Diamond-Blackfan anemia 10, 613309 (3)  |RPS26, DBA10|603701|12q
Diamond-Blackfan anemia 2 (2)  |DBA2|606129|8p23.3-p22
Diamond-Blackfan anemia 4, 612527 (3)  |RPS17, RPS17L1, RPS17L2, DBA4|180472|15q
Diamond-Blackfan anemia 5, 612528 (3)  |RPL35A, DBA5|180468|3q29-qter
Diamond-Blackfan anemia 6, 612561 (3)  |RPL5, DBA6|603634|1p22.1
Diamond-Blackfan anemia 7, 612562 (3)  |RPL11, DBA7|604175|1p36.1-p35
Diamond-Blackfan anemia 8, 612563 (3)  |RPS7, DBA8|603658|2p25
Diamond-Blackfan anemia 9, 613308 (3)  |RPS10, DBA9|603632|6p
Diamond-blackfan anemia, 610629 (3)  |RPS24, DBA3|602412|10q22-q23
Diaphragmatic hernia 3, 610187 (3)  |ZFPM2, FOG2, DIH3|603693|8q23
Diaphyseal medullary stenosis with malignant fibrous histiocytoma (2)  |DMSMFH, BDMF|112250|9p22-p21
Diarrhea 3, secretory sodium, congenital, syndromic, 270420 (3)  |SPINT2, HAI2, DIAR3|605124|19q13.1
Diarrhea 4, malabsorptive, congenital, 610370 (3)  |NEUROG3, NGN3, ATOH5|604882|10q21.3
Diarrhea 5, with tufting enteropathy, congenital, 613217 (3)  |EPCAM, ACSTD1, TROP1, M4S1, MIC18, DIAR5, HNPCC8|185535|2p21
Diastrophic dysplasia, 222600 (3)  |SLC26A2, DTD, DTDST, D5S1708, EDM4|606718|5q32-q33.1
Diastrophic dysplasia, broad bone-platyspondylic variant, 222600 (3)  |SLC26A2, DTD, DTDST, D5S1708, EDM4|606718|5q32-q33.1
Dicarboxylicaminoaciduria, 222730 (1) (?)  |SLC1A1, EAAC1|133550|9p24
Digital clubbing, isolated congenital, 119900 (3)  |HPGD, PGDH1|601688|4q34-q35
Dihydropyrimidine dehydrogenase deficiency, 274270 (3)  |DPYD, DPD|612779|1p22
Dihydropyrimidinuria, 222748 (3)  |DPYS, DHP|613326|8q22
Dilated cardiomyopathy with woolly hair and keratoderma, 605676 (3)  |DSP, KPPS2, PPKS2|125647|6p24
Dimethylglycine dehydrogenase deficiency, 605850 (3)  |DMGDH, DMGDHD|605849|5q12.2-q12.3
Diphenylhydantoin toxicity (1)  |EPHX1|132810|1q42.1
Disordered steroidogenesis due to cytochrome P450 oxidoreductase, 613571 (3)  |POR|124015|7q11.2
Donnai-Barrow syndrome, 222448 (3)  |LRP2, DBS|600073|2q24-q31
Dopamine beta-hydroxylase deficiency, 223360 (3)  |DBH|609312|9q34
Dopamine receptor D2, reduced brain density of (3)  |ANKK1|608774|11q23.2
Dosage-sensitive sex reversal, 300018 (3)  |DAX1, AHC, AHX, NROB1|300473|Xp21.3-p21.2
Double-outlet right ventricle, 217095 (3)  |CFC1, CRYPTIC, HTX2|605194|2q21.1
Double-outlet right ventricle, 217095 (3)  |GDF1|602880|19p12
Dowling-Degos disease, 179850 (3)  |KRT5, DDD|148040|12q13
Down syndrome (1)  |DCR, DSCR|190685|21q22.3
Doyne honeycomb degeneration of retina, 126600 (3)  |EFEMP1, FBNL, DHRD|601548|2p16
Dravet syndrome, 607208 (3)  |SCN1A, GEFSP2, SMEI, FEB3A, EIEE6, FHM3|182389|2q24
Duane retraction syndrome 2, 604356 (3)  |CHN1, CHN, ARHGAP2, RHOGAP2, DURS2|118423|2q31-q32.1
Duane syndrome (2)  |DURS1, DUS|126800|8q13
Duane-radial ray syndrome, 607323 (3)  |SALL4, HSAL4|607343|20q13.13-q13.2
Dubin-Johnson syndrome, 237500 (3)  |ABCC2, CMOAT|601107|10q24
Duchenne muscular dystrophy, 310200 (3)  |DMD, BMD, CMD3B|300377|Xp21.2
Dupuytren contracture 1 (2)  |DUPC1|126900|16q11.1-q22
Dyggve-Melchior-Clausen disease, 223800 (3)  |DYM, FLJ90130, DMC, SMC|607461|18q12-q21.1
Dysautonomia, familial, 223900 (3)  |IKBKAP, IKAP|603722|9q31
Dyschromatosis symmetrica hereditaria, 127400 (3)  |ADAR, DRADA, DSH, DSRAD, IFI4, G1P1|146920|1q21.3
Dyschromatosis universalis hereditaria 1 (2)  |DUH1, DUH|127500|6q24.2-q25.2
Dyschromatosis universalis hereditaria 2 (2)  |DUH2|612715|12q21-q23
Dyserythropoietic anemia with thrombocytopenia, 300367 (3)  |GATA1, GF1, ERYF1, NFE1, XLTT|305371|Xp11.23
Dyserythropoietic anemia, congenital, type III (2)  |CDAN3, CDA3|105600|15q21
Dysfibrinogenemia, alpha type, causing bleeding diathesis (3)  |FGA|134820|4q28
Dysfibrinogenemia, alpha type, causing recurrent thrombosis (3)  |FGA|134820|4q28
Dysfibrinogenemia, beta type (3)  |FGB|134830|4q28
Dysfibrinogenemia, gamma type (3)  |FGG|134850|4q28
Dyskeratosis congenita, 127550 (3)  |TERT, TCS1, EST2|187270|5p15.33
Dyskeratosis congenita, 224230 (3)  |NOLA2, NHP2|606470|5q35.3
Dyskeratosis congenita, autosomal dominant, 127550 (3)  |TERC, TRC3, TR|602322|3q21-q28
Dyskeratosis congenita, autosomal dominant, 127550 (3)  |TINF2, TIN2|604319|14q12
Dyskeratosis congenita, autosomal recessive, 224230 (3)  |NOLA3, NOP10|606471|15q14-q15
Dyskeratosis congenita-1, 305000 (3)  |DKC1, DKC|300126|Xq28
Dyskeratosis, hereditary benign intraepithelial (2)  |DKBI|127600|4q35
Dysprothrombinemia, 613679 (3)  |F2|176930|11p11-q12
Dyssegmental dysplasia, Silverman-Handmaker type, 224410 (3)  |HSPG2, PLC, SJS, SJA, SJS1|142461|1p36.1
Dystonia 13, torsion (2)  |DYT13|607671|1p36.32-p36.13
Dystonia 16, 612067 (3)  |PRKRA, PACT, RAX, DYT16|603424|2q31.3
Dystonia 6, torsion, 602629 (3)  |THAP1, DYT6|609520|8p11.21
Dystonia, DOPA-responsive, with or without hyperphenylalainemia, 233910 (3)  |GCH1, DYT5, HPABH4B|600225|14q22.1-q22.2
Dystonia, dopa-responsive, due to sepiapterin reductase deficiency, 612716 (3)  |SPR|182125|2p14-p12
Dystonia, early-onset atypical, with myoclonic features (3)  |DYT1, TOR1A|605204|9q34
Dystonia, juvenile-onset, 607371 (3)  |ACTB|102630|7p22-p12
Dystonia, myoclonic, 159900 (3)  |DRD2|126450|11q23.1
Dystonia, primary cervical (3)  |DRD5, DRD1B, DRD1L2|126453|4p16.1-p15.3
Dystonia-1, torsion, 128100 (3)  |DYT1, TOR1A|605204|9q34
Dystonia-11, myoclonic, 159900 (3)  |SGCE, DYT11|604149|7q21
Dystonia-12, 128235 (3)  |ATP1A3, DYT12, RDP|182350|19q12-q13.2
Dystonia-15, myoclonic (2)  |DYT15|607488|18p11
Dystonia-17, primary torsion (2)  |DYT17|612406|20p11.2-q13.12
Dystonia-7, torsion (2)  |DYT7|602124|18p
Dystonia-Parkinsonism, X-linked, 314250 (3)  |TAF1, TAF2A, CCG1, BA2R, DYT3|313650|Xq13
EBD inversa, 226600 (3)  |COL7A1|120120|3p21.3
EBD, Bart type, 132000 (3)  |COL7A1|120120|3p21.3
EBD, localisata variant (3)  |COL7A1|120120|3p21.3
EEC syndrome-1 (2) (?)  |EEC1|129900|7q11.2-q21.3
Ectodermal dysplasia, 'pure' hair-nail type, 602032 (3)  |KRT85, KRTHB5, HB5|602767|12q13
Ectodermal dysplasia, anhidrotic, X-linked, 305100 (3)  |ED1, EDA, HED, STHAGX1|300451|Xq12-q13.1
Ectodermal dysplasia, anhidrotic, autosomal dominant, 129490 (3)  |EDARADD, ED3, EDA3|606603|1q42.2-q43
Ectodermal dysplasia, anhidrotic, autosomal recessive, 224900 (3)  |EDARADD, ED3, EDA3|606603|1q42.2-q43
Ectodermal dysplasia, anhidrotic, with T-cell immunodeficiency, 612132 (3)  |NFKBIA, IKBA|164008|14q13
Ectodermal dysplasia, ectrodactyly, and macular dystrophy, 225280 (3)  |CDH3, CDHP, PCAD, HJMD|114021|16q22.1
Ectodermal dysplasia, hidrotic, 129500 (3)  |GJB6, CX30, DFNA3B, HED, ED2, DFNB1B|604418|13q12
Ectodermal dysplasia, hypohidrotic, autosomal dominant, 129490 (3)  |EDAR, DL, ED3, EDA3, HRM1|604095|2q11-q13
Ectodermal dysplasia, hypohidrotic, autosomal recessive, 224900 (3)  |EDAR, DL, ED3, EDA3, HRM1|604095|2q11-q13
Ectodermal dysplasia, hypohidrotic, with immune deficiency, 300291 (3)  |IKBKG, NEMO, FIP3, IP2, IPD2, AMCBX1|300248|Xq28
Ectodermal dysplasia-syndactyly syndrome 1, 613573 (3)  |PVRL4, PRR4, EDSS1|609607|1q23.3
Ectodermal dysplasia-syndactyly syndrome 2 (2)  |EDSS2|613576|7p21.2-p14.3
Ectodermal dysplasia/skin fragility syndrome, 604536 (3)  |PKP1|601975|1q32
Ectodermal, dysplasia, anhidrotic, lymphedema and immunodeficiency, 300301 (3)  |IKBKG, NEMO, FIP3, IP2, IPD2, AMCBX1|300248|Xq28
Ectopia lentis, familial, 129600 (3)  |FBN1, MFS1, WMS, SSKS|134797|15q21.1
Ectopia lentis, isolated, autosomal recessive, 225100 (3)  |ADAMTSL4, TSRC1|610113|1q21
Ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3, 604292 (3)  |TP63, TP73L, KET, EEC3, SHFM4, LMS, RHS, OFC8|603273|3q27
Ehlers-Danlos due to tenascin X deficiency, 606408 (3)  |TNXB, TNX, TNXB1, TNXBS, TNXB2|600985|6p21.3
Ehlers-Danlos syndrome, cardiac valvular form, 225320 (3)  |COL1A2|120160|7q22.1
Ehlers-Danlos syndrome, hypermobility type, 130020 (3)  |TNXB, TNX, TNXB1, TNXBS, TNXB2|600985|6p21.3
Ehlers-Danlos syndrome, musculocontractural type , 601776 (3)  |CHST14, D4ST1, ATCS|608429|15q14
Ehlers-Danlos syndrome, progeroid form, 130070 (3)  |B4GALT7, XGALT1, XGPT1|604327|5q35.2-q35.3
Ehlers-Danlos syndrome, type I, 130000 (3)  |COL1A1|120150|17q21.31-q22
Ehlers-Danlos syndrome, type I, 130000 (3)  |COL5A1|120215|9q34.2-q34.3
Ehlers-Danlos syndrome, type I, 130000 (3)  |COL5A2|120190|2q31
Ehlers-Danlos syndrome, type II, 130010 (3)  |COL5A1|120215|9q34.2-q34.3
Ehlers-Danlos syndrome, type III, 130020 (3)  |COL3A1|120180|2q31
Ehlers-Danlos syndrome, type IV, 130050 (3)  |COL3A1|120180|2q31
Ehlers-Danlos syndrome, type VI, 225400 (3)  |PLOD, PLOD1|153454|1p36.3-p36.2
Ehlers-Danlos syndrome, type VIIA, 130060 (3)  |COL1A1|120150|17q21.31-q22
Ehlers-Danlos syndrome, type VIIB, 130060 (3)  |COL1A2|120160|7q22.1
Ehlers-Danlos syndrome, type VIIC, 225410 (3)  |ADAMTS2, NPI|604539|5q23
Ehlers-Danlos syndrome, type VIII (2)  |EDS8|130080|12p13
Eiken syndrome, 600002 (3)  |PTHR1, PTHR, PFE|168468|3p22-p21.1
Elliptocytosis-1, 611804 (3)  |EPB41, EL1|130500|1p36.2-p34
Elliptocytosis-2, 130600 (3)  |SPTA1, EL2, SPH3, HS3, HPP|182860|1q21
Elliptocytosis-3 (3)  |SPTB, SPH2, EL3, HS2|182870|14q22-q23.2
Ellis-van Creveld syndrome, 225500 (3)  |EVC|604831|4p16
Ellis-van Creveld syndrome, 225500 (3)  |LBN, EVC2|607261|4p16
Emanuel syndrome (4)  |DER22t11-22|609029|22q11.2
Emery-Dreifuss muscular dystrophy 4, 612998 (3)  |SYNE1, KIAA0796, KIAA1756, KIAA1262, SCAR8, EDMD4|608441|6q25
Emery-Dreifuss muscular dystrophy 5, 612999 (3)  |SYNE2, NUANCE, KIAA1011, EDMD5|608442|14q23
Emery-Dreifuss muscular dystrophy 6, 300696 (3)  |FHL1, SLIM1, XMPMA, KYOT, FHL1A, FHL1B|300163|Xq27.2
Emery-Dreifuss muscular dystrophy, 310300 (3)  |EMD, EDMD, STA|300384|Xq28
Emery-Dreifuss muscular dystrophy, AD, 181350 (3)  |LMNA, LMN1, EMD2, FPLD, CMD1A, HGPS, LGMD1B|150330|1q21.2
Emery-Dreifuss muscular dystrophy, AR, 181350 (3)  |LMNA, LMN1, EMD2, FPLD, CMD1A, HGPS, LGMD1B|150330|1q21.2
Emphysema due to AAT deficiency, 613490 (3)  |SERPINA1, PI, AAT|107400|14q32.1
Emphysema due to alpha-2-macroglobulin deficiency (1)  |A2M|103950|12p13.3-p12.3
Emphysema-cirrhosis, due to AAT deficiency, 613490 (3)  |SERPINA1, PI, AAT|107400|14q32.1
Encephalocardiomyopathy, neonatal, mitochondrial, due to ATP synthase deficiency, 604273 (3)  |TMEM70|612418|8q21.11
Encephalopahty, lethal, due to defective mitochondrial peroxisomal fission (3)  |DNM1L, DRP1, DVLP, DYMPLE|603850|12p11.21
Encephalopathy, familial, with neuroserpin inclusion bodies, 604218 (3)  |SERPINI1, PI12|602445|3q26
Encephalopathy, neonatal severe, 300673 (3)  |MECP2, RTT, PPMX, MRX16, MRX79, AUTSX3, MRXSL, MRXS13, MRX79, MRX16|300005|Xq28
Encephalopathy, progressive mitochondrial, with proximal renal tubulopathy due to cytochrome c oxidase deficiency (3)  |COX10|602125|17p12-p11.2
Encephalopathy, thiamine-responsive (3)  |SLC19A3|606152|2q36.3
Endocardial fibroelastosis-2 (2)  |TAZ, EFE2, BTHS, CMD3A, LVNCX|300394|Xq28
Endocrine-cerebroosteodysplasia, 612651 (3)  |ICK, MRK, KIAA0936, ECO|612325|6p12.3
Endometrial cancer, 608089 (3)  |MLH3, HNPCC7|604395|14q24.3
Endometrial cancer, familial, 608089 (3)  |MSH6, GTBP, HNPCC5|600678|2p16
Endometrial carcinoma (3)  |MSH3|600887|5q11-q12
Endometrial carcinoma, somatic, 608089 (3)  |CDH1, UVO, LCAM, ECAD|192090|16q22.1
Endometrial stromal tumors (2)  |JAZF1, TIP27|606246|7p15
Endometrial stromal tumors (2)  |JJAZ1, KIAA0160|606245|17q11.2
Endotoxin hyporesponsiveness (3)  |TLR4, ARMD10|603030|9q32-q33
Endplate acetylcholinesterase deficiency, 603034 (3)  |COLQ, EAD|603033|3p25
Enhanced S-cone syndrome, 268100 (3)  |NR2E3, PNR, ESCS, RP37|604485|15q23
Enlarged vestibular aqueduct, 600791 (3)  |FOXI1, FKHL10, FREAC6|601093|5q34
Enlarged vestibular aqueduct, 600791 (3)  |SLC26A4, PDS, DFNB4, EVA, TDH2B|605646|7q31
Enolase deficiency (1)  |ENO1, PPH, MPB1|172430|1pter-p36.13
Enterokinase deficiency, 226200 (3)  |PRSS7, ENTK|606635|21q21
Enuresis, nocturnal, 1 (2)  |ENUR1|600631|13q13-q14.3
Enuresis, nocturnal, 2 (2)  |ENUR2|600808|12q13-q21
Eosinophil peroxidase deficiency, 261500 (3)  |EPX|131399|17q23.1
Eosinophilia, familial (2)  |EOS|131400|5q31-q33
Epidermodysplasia verruciformis, 226400 (3)  |TMC6, EVER1, EV1|605828|17q25
Epidermodysplasia verruciformis, 226400 (3)  |TMC8, EVER2, EV2|605829|17q25
Epidermolysis bullosa dystrophica, AD, 131750 (3)  |COL7A1|120120|3p21.3
Epidermolysis bullosa dystrophica, AR, 226600 (3)  |COL7A1|120120|3p21.3
Epidermolysis bullosa of hands and feet, 131800 (3)  |ITGB4|147557|17q11-qter
Epidermolysis bullosa pruriginosa, 604129 (3)  |COL7A1|120120|3p21.3
Epidermolysis bullosa simplex with migratory circinate erythema, 609352 (3)  |KRT5, DDD|148040|12q13
Epidermolysis bullosa simplex with mottled pigmentation, 131960 (3)  |KRT5, DDD|148040|12q13
Epidermolysis bullosa simplex with pyloric atresia, 612138 (3)  |PLEC1, PLEC, PLTN, EBS1, LGMD2Q|601282|8q24
Epidermolysis bullosa simplex, Dowling-Meara type, 131760 (3)  |KRT14|148066|17q12-q21
Epidermolysis bullosa simplex, Dowling-Meara type, 131760 (3)  |KRT5, DDD|148040|12q13
Epidermolysis bullosa simplex, Koebner type, 131900 (3)  |KRT14|148066|17q12-q21
Epidermolysis bullosa simplex, Koebner type, 131900 (3)  |KRT5, DDD|148040|12q13
Epidermolysis bullosa simplex, Ogna type, 131950 (3)  |PLEC1, PLEC, PLTN, EBS1, LGMD2Q|601282|8q24
Epidermolysis bullosa simplex, Weber-Cockayne type, 131800 (3)  |KRT14|148066|17q12-q21
Epidermolysis bullosa simplex, Weber-Cockayne type, 131800 (3)  |KRT5, DDD|148040|12q13
Epidermolysis bullosa simplex, recessive, 601001 (3)  |KRT14|148066|17q12-q21
Epidermolysis bullosa, generalized atrophic benign, 226650 (3)  |LAMA3, LOCS|600805|18q11.2
Epidermolysis bullosa, junctional, Herlitz type, 226700 (3)  |LAMA3, LOCS|600805|18q11.2
Epidermolysis bullosa, junctional, Herlitz type, 226700 (3)  |LAMB3|150310|1q32
Epidermolysis bullosa, junctional, Herlitz type, 226700 (3)  |LAMC2, LAMNB2, LAMB2T|150292|1q25-q31
Epidermolysis bullosa, junctional, non-Herlitz type, 226650 (3)  |COL17A1, BPAG2|113811|10q24.3
Epidermolysis bullosa, junctional, non-Herlitz type, 226650 (3)  |ITGB4|147557|17q11-qter
Epidermolysis bullosa, junctional, non-Herlitz type, 226650 (3)  |LAMB3|150310|1q32
Epidermolysis bullosa, junctional, non-Herlitz type, 226650 (3)  |LAMC2, LAMNB2, LAMB2T|150292|1q25-q31
Epidermolysis bullosa, junctional, with pyloric atresia, 226730 (3)  |ITGB4|147557|17q11-qter
Epidermolysis bullosa, junctional, with pyloric stenosis, 226730 (3)  |ITGA6|147556|2q31.1
Epidermolysis bullosa, lethal acantholytic, 609638 (3)  |DSP, KPPS2, PPKS2|125647|6p24
Epidermolysis bullosa, pretibial, 131850 (3)  |COL7A1|120120|3p21.3
Epidermolytic hyperkeratosis, 113800 (3)  |KRT1, EPPK, NEPPK, EHK|139350|12q13
Epidermolytic hyperkeratosis, 113800 (3)  |KRT10, EHK, BCIE, BIE|148080|17q21-q22
Epidermolytic palmoplantar keratoderma, 144200 (3)  |KRT9, EPPK|607606|17q12-q21
Epilepsy, X-linked, with variable learning disabilities and behavior disorders, 300491 (3)  |SYN1|313440|Xp11.4-p11.2
Epilepsy, benign neonatal, type 2, 121201 (3)  |KCNQ3, EBN2, BFNC2|602232|8q24
Epilepsy, childhood absence, 1 (2)  |ECA1|600131|8q24
Epilepsy, familial adult myoclonic, 3 (2)  |FAME3, FCMTE3|613608|5p15.31-p15.1
Epilepsy, familial mesial temporal lobe (2)  |FMTLE, ETL3|611630|4q13.2-q21.3
Epilepsy, familial temporal lobe (2)  |ETL2, FTLE|608096|12q22-q23.3
Epilepsy, generalized, with febrile seizures plus, type 2, 604233 (3)  |SCN1A, GEFSP2, SMEI, FEB3A, EIEE6, FHM3|182389|2q24
Epilepsy, generalized, with febrile seizures plus, type 3, 604233 (3)  |GABRG2, GEFSP3, CAE2, ECA2|137164|5q31.1-q33.1
Epilepsy, generalized, with febrile seizures plus, type 4 (2)  |GEFSP4|609800|2p24
Epilepsy, hot water, 1 (2)  |HWE1|613339|10q21.3-q22.3
Epilepsy, hot water, 2 (2)  |HWE2|613340|4q24-q28
Epilepsy, idiopathic generalized, susceptibility to 4 (2)  |EIG4|609750|10q25-q26
Epilepsy, idiopathic generalized, susceptibility to, 5 (2)  |EIG5|611934|10p11.22
Epilepsy, juvenile myoclonic (2)  |EIG7, EJM2|604827|15q14
Epilepsy, juvenile myoclonic 3 (2)  |EJM3|608816|6p21
Epilepsy, myoclonic, benign adult familial (2)  |BAFME1, MEBA, FAME|601068|8q24
Epilepsy, myoclonic, benign adult familial, type 2 (2)  |BAFME2, ADCME, FAME|607876|2p11.1-q12.2
Epilepsy, nocturnal frontal lobe, 1, 600513 (3)  |CHRNA4, ENFL1|118504|20q13.2-q13.3
Epilepsy, nocturnal frontal lobe, 3, 605375 (3)  |CHRNB2, EFNL3|118507|1q21
Epilepsy, nocturnal frontal lobe, type 2 (2)  |ENFL2|603204|15q24
Epilepsy, nocturnal frontal lobe, type 4, 610353 (3)  |CHRNA2|118502|8p21
Epilepsy, occipitotemporal lobe, and migraine with aura (2)  |EPOLM|611631|9q21-q22
Epilepsy, partial, with auditory features, 600512 (3)  |LGI1, EPT, ETL1|604619|10q24
Epilepsy, partial, with pericentral spikes (2)  |EPPS|607221|4p15
Epilepsy, partial, with variable foci (2)  |FPEVF|604364|22q11-q12
Epilepsy, progressive myoclonic 1, 254800 (3)  |CSTB, STFB, EPM1|601145|21q22.3
Epilepsy, progressive myoclonic 1B, 612437 (3)  |PRICKLE1, RILP, EPM1B|608500|12q12
Epilepsy, progressive myoclonic 2A (Lafora), 254780 (3)  |EPM2A, MELF, EPM2|607566|6q24
Epilepsy, progressive myoclonic 2B (Lafora), 254780 (3)  |NHLRC1, EPM2A, EPM2B|608072|6p22.3
Epilepsy, progressive myoclonic 3, 611726 (3)  |KCTD7, EPM3|611725|7q11.21
Epilepsy, pyridoxine-dependent, 266100 (3)  |ALDH7A1, ATQ1, EPD, PDE|107323|5q31
Epilepsy, rolandic, with paroxysmal exercise-induced dystonia and writer's cramp (2)  |EPRPDC|608105|16p12-p11.2
Epileptic encephalopathy, Lennox-Gastaut type, 606369 (3)  |MAPK10, PRKM10, JNK3|602897|4q21.3
Epileptic encephalopathy, early infantile, 1, 308350 (3)  |ARX, ISSX, PRTS, MRXS1, MRX36, MRX54, MRX43, MRX87, MRX29, MRX32|300382|Xp22.13
Epileptic encephalopathy, early infantile, 10, 613402 (3)  |PNKP, PNK, MCSZ, EIEE10|605610|19q13.4
Epileptic encephalopathy, early infantile, 11, 613721 (3)  |SCN2A1, SCN2A, BFIC3, EIEE11|182390|2q23-q24.3
Epileptic encephalopathy, early infantile, 12, 613722 (3)  |PLCB1, KIAA0581, PLCB1A, PLCB1B, EIEE12|607120|20p12
Epileptic encephalopathy, early infantile, 2, 300672 (3)  |CDKL5, STK9, ISSX, EIEE2|300203|Xp22
Epileptic encephalopathy, early infantile, 3, 609304 (3)  |SLC25A22, GC1, EIEE3|609302|11p15.5
Epileptic encephalopathy, early infantile, 4, 612164 (2)  |STXBP1, UNC18, EIEE4|602926|9q34.1
Epileptic encephalopathy, early infantile, 5, 613477 (3)  |SPTAN1, NEAS, EIEE5|182810|9q33-q34
Epileptic encephalopathy, early infantile, 7, 613720 (3)  |KCNQ2, EBN1, EIEE7, BFNS1|602235|20q13.3
Epileptic encephalopathy, early infantile, 8, 300607 (3)  |ARHGEF9, PEM2, KIAA0424, EIEE8|300429|Xq22.1
Epileptic encephalopathy, early infantile, 9, 300088 (3)  |PCDH19, KIAA1313, EFMR, EIEE9|300460|Xq22
Epiphyseal dysplasia, multiple 1, 132400 (3)  |COMP, EDM1, MED, PSACH|600310|19p13.1
Epiphyseal dysplasia, multiple, 2, 600204 (3)  |COL9A2, EDM2|120260|1p33-p32.2
Epiphyseal dysplasia, multiple, 3, 600969 (3)  |COL9A3, EDM3, IDD|120270|20q13.3
Epiphyseal dysplasia, multiple, 4, 226900 (3)  |SLC26A2, DTD, DTDST, D5S1708, EDM4|606718|5q32-q33.1
Epiphyseal dysplasia, multiple, 5, 607078 (3)  |MATN3, EDM5, HOA, OS2|602109|2p24-p23
Epiphyseal dysplasia, multiple, 6 (3)  |COL9A1, EDM6|120210|6q13
Epiphyseal dysplasia, multiple, with myopathy (3)  |COL9A3, EDM3, IDD|120270|20q13.3
Epiphyseal dysplasia, multiple, with myopia and deafness, 132450 (3)  |COL2A1|120140|12q13.11-q13.2
Episodic ataxia, type 2, 108500 (3)  |CACNA1A, CACNL1A4, SCA6|601011|19p13
Episodic ataxia, type 3 (2)  |EA3|606554|1q42
Episodic ataxia, type 5 (3)  |CACNB4, EJM6, EA5, EIG9|601949|2q22-q23
Episodic ataxia, type 6, 612656 (3)  |SLC1A3, EAAT1, EA6|600111|5p13
Episodic ataxia, type 7 (2)  |EA7|611907|19q13
Episodic ataxia/myokymia syndrome, 160120 (3)  |KCNA1, AEMK, EA1|176260|12p13
Episodic kinesigenic dyskinesia 2 (2)  |EKD2|611031|16q13-q22.1
Episodic muscle weakness, X-linked (2)  |EMWX|300211|Xp22.3
Epithelioma, self-healing, squamous 1, Ferguson-Smith type (2)  |MSSE, ESS1|132800|9q31
Epstein syndrome, 153650 (3)  |MYH9, MHA, FTNS, DFNA17|160775|22q11.2
Erythermalgia, primary, 133020 (3)  |SCN9A, NENA, PN1, FEB3B|603415|2q24
Erythremias, alpha- (3)  |HBA1|141800|16pter-p13.3
Erythremias, beta- (3)  |HBB|141900|11p15.5
Erythrocyte lactate transporter defect, 245340 (3)  |SLC16A1, MCT1, HHF7|600682|1p13.2-p12
Erythrocytosis (3)  |HBA2|141850|16pter-p13.3
Erythrocytosis, familial, 3, 609820 (3)  |EGLN1, PHD2, HIFPH2, C1orf12, ZMYND6, SM20, ECYT3|606425|1q42-q43
Erythrocytosis, familial, 4, 611783 (3)  |EPAS1, MOP2, HIF2A, ECYT4|603349|2p21-p16
Erythrokeratodermia variabilis 3 (2)  |EKV3|609313|7q22
Erythrokeratodermia variabilis et progressiva, 133200 (3)  |GJB3, CX31, DFNA2B|603324|1p35.1
Erythrokeratodermia variabilis with erythema gyratum repens, 133200 (3)  |GJB4, CX30.3|605425|1p35.1
Escobar syndrome, 265000 (3)  |CHRNG, ACHRG|100730|2q33-q34
Esophageal cancer, 133239 (1)  |DLEC1, DLC1|604050|3p22-p21.3
Esophageal cancer, somatic, 133239 (3)  |TGFBR2, HNPCC6, AAT3, MFS2, LDS1B, LDS2B|190182|3p22
Esophageal carcinoma, somatic, 133239 (3)  |RNF6|604242|13q12.11
Esophageal squamous cell carcinoma, 133239 (1)  |DEC1|604767|9q32
Esophageal squamous cell carcinoma, 133239 (3)  |LZTS1, F37, FEZ1|606551|8p22
Esophageal squamous cell carcinoma, 133239 (3)  |WWOX, FOR|605131|16q23.3-q24.1
Estrogen resistance (3)  |ESR1, ESR|133430|6q25.1
Ethylmalonic encephalopathy, 602473 (3)  |ETHE1, HSCO, D83198|608451|19q13.32
Ewing sarcoma, 612219 (3)  |EWSR1, EWS|133450|22q12
Exfoliative ichthyosis, autosomal recessive (2)  |AREI|607936|12q13
Exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis, 612714 (3)  |COX4I2|607976|20q11.21
Exostoses, multiple, type 1, 133700 (3)  |EXT1|608177|8q24.11-q24.13
Exostoses, multiple, type 2, 133701 (3)  |EXT2|608210|11p12-p11
Exostoses, multiple, type 3 (2)  |EXT3|600209|19p
Exudative vitreoretinopathy 4, 601813 (3)  |LRP5, BMND1, LRP7, LR3, OPPG, VBCH2, OPTA1, EVR4|603506|11q13.4
Exudative vitreoretinopathy 5, 613310 (3)  |TSPAN12, NET2, EVR5|613138|7q31
Exudative vitreoretinopathy, 133780 (3)  |FZD4, EVR1|604579|11q14-q21
Exudative vitreoretinopathy, X-linked, 305390 (3)  |NDP, ND|300658|Xp11.4
Exudative vitreoretinopathy-3 (2)  |EVR3|605750|11p13-p12
FG syndrome 2 (2)  |FGS2|300321|Xq28
FG syndrome 2, 300321 ( 3)  |FLNA, FLN1, NHBP, OPD1, OPD2, FMD, MNS, CVD1|300017|Xq28
FG syndrome 3 (2)  |FGS3|300406|Xp22.3
FG syndrome 4, 300422 (3)  |CASK, MICPCH, FGS4, CMG|300172|Xp11.4
FG syndrome 5 (2)  |FGS5|300581|Xq22.3
Fabry disease, 301500 (3)  |GLA|300644|Xq22
Fabry disease, cardiac variant, 301500 (3)  |GLA|300644|Xq22
Facial paresis, hereditary congenital, 1 (2)  |HCFP1, MBS2|601471|3q21-q22
Facioscapulohumeral muscular dystrophy-1A (3)  |FSHMD1A, FSHD1A|158900|4q35
Factor V and factor VIII, combined deficiency of, 613625 (3)  |MCFD2, F5F8D2|607788|2p21-p16.3
Factor V deficiency, 227400 (3)  |F5|612309|1q23
Factor VII deficiency (3)  |F7|227500|13q34
Factor X deficiency (3)  |F10|227600|13q34
Factor XI deficiency, autosomal dominant, 612416 (3)  |F11|264900|4q35
Factor XI deficiency, autosomal recessive, 612416 (3)  |F11|264900|4q35
Factor XII deficiency, 234000 (3)  |F12, HAF, HAE3|610619|5q33-qter
Factor XIIIA deficiency, 613225 (3)  |F13A1, F13A|134570|6p25-p24
Factor XIIIB deficiency, 613235 (3)  |F13B|134580|1q31-q32.1
Failure of tooth eruption, primary, 125350 (3)  |PTHR1, PTHR, PFE|168468|3p22-p21.1
Faisalabad histiocytosis (2)  |HJCD|602782|11q25
Familial Mediterranean fever, AD, 134610 (3)  |MEFV, MEF, FMF|608107|16p13
Familial Mediterranean fever, AR, 249100 (3)  |MEFV, MEF, FMF|608107|16p13
Familial cold autoinflammatory syndrome 2, 611762 (3)  |NALP12, PYPAF7, RNO, FCAS2|609648|19q13.4
Fanconi anemia, complementation group 0, 613390 (3)  |RAD51C, FANCO, BROVCA3|602774|17q22
Fanconi anemia, complementation group A, 227650 (3)  |FANCA, FACA, FA1, FA, FAA|607139|16q24.3
Fanconi anemia, complementation group B, 300514 (3)  |FAAP95, FAAP90, FLJ34064, FANCB|300515|Xp22.31
Fanconi anemia, complementation group C (3)  |FANCC, FACC|227645|9q22.3
Fanconi anemia, complementation group D1, 605724 (3)  |BRCA2, FANCD1, BROVCA2, GLM3, PNCA2|600185|13q12.3
Fanconi anemia, complementation group D2 (3)  |FANCD2, FANCD, FACD, FAD|227646|3p25.3
Fanconi anemia, complementation group E (3)  |FANCE, FACE|600901|6p22-p21
Fanconi anemia, complementation group F (3)  |FANCF|603467|11p15
Fanconi anemia, complementation group G (3)  |XRCC9, FANCG|602956|9p13
Fanconi anemia, complementation group I, 609053 (3)  |FANCI, KIAA1794|611360|15q25-q26
Fanconi anemia, complementation group J, 609054 (3)  |BRIP1, BACH1, FANCJ|605882|17q22
Fanconi anemia, complementation group L (3)  |PHF9, FANCL|608111|2p16.1
Fanconi anemia, complementation group M (3)  |FANCM, KIAA1596|609644|14q21.3
Fanconi anemia, complementation group N, 610832 (3)  |PALB2, FANCN, PNCA3|610355|16p12
Fanconi renotubular syndrome 1 (2)  |FRTS1, FRTS, RFS|134600|15q15.3
Fanconi renotubular syndrome 2, 613388 (3)  |SLC34A1, SLC17A2, NPT2, NPHLOP1, FRTS2|182309|5q35
Fanconi-Bickel syndrome, 227810 (3)  |SLC2A2, GLUT2|138160|3q26.1-q26.3
Farber lipogranulomatosis, 228000 (3)  |ASAH1, AC|613468|8p22-p21.3
Fatty liver, acute, of pregnancy, 609016 (3)  |HADHA, MTPA|600890|2p23
Favism (3)  |G6PD, G6PD1|305900|Xq28
Fazio-Londe disease, 211500 (3)  |C20orf54, RFT2, BVVLS|613350|20p13
Febrile convulsions, familial, 10 (2)  |FEB10|612637|3q26.2-q26.33
Febrile convulsions, familial, 3A, 604403 (3)  |SCN1A, GEFSP2, SMEI, FEB3A, EIEE6, FHM3|182389|2q24
Febrile convulsions, familial, 3B, 604403 (3)  |SCN9A, NENA, PN1, FEB3B|603415|2q24
Febrile convulsions, familial, 5 (2)  |FEB5|609255|6q22-q24
Febrile convulsions, familial, 6 (2)  |FEB6|609253|18p11.2
Febrile convulsions, familial, 7 (2)  |FEB7|611515|21q22
Febrile convulsions, familial, 9 (2)  |FEB9|611634|3p24.2-p23
Febrilel, convulsions, familial, 8 611277 (3)  |GABRG2, GEFSP3, CAE2, ECA2|137164|5q31.1-q33.1
Fechtner syndrome, 153640 (3)  |MYH9, MHA, FTNS, DFNA17|160775|22q11.2
Feingold syndrome, 164280 (3)  |MYCN, NMYC, ODED, MODED|164840|2p24.1
Fertile eunuch syndrome, 228300 (3)  |GNRHR, LHRHR|138850|4q21.2
Fetal akinesia deformation sequence, 208150 (3)  |DOK7, C4orf25, CMS1B|610285|4p16.2
Fetal akinesia deformation sequence, 208150 (3)  |RAPSN, CMS1D, CMS1E|601592|11p11.2-p11.1
Fetal hemoglobin quantitative trait locus 1, 141749 (3)  |HBG1|142200|11p15.5
Fetal hemoglobin quantitative trait locus 1, 141749 (3)  |HBG2|142250|11p15.5
Fetal hemoglobin quantitative trait locus 2 (2)  |HBFQTL2, FCP|142470|6q22.3-q23.1
Fetal hemoglobin quantitative trait locus 3 (2)  |HBFQTL3, FCP1, FCPX, FCP|305435|Xp22.2
Fetal hemoglobin quantitative trait locus 4 (2)  |HBFQTL4|606789|8q
Fetal hydantoin syndrome (1) (?)  |EPHX1|132810|1q42.1
Fibrodysplasia ossificans progressiva, 135100 (3)  |ACVR1, ACVRLK2, ALK2, FOP|102576|2q23-q24
Fibromatosis, gingival, 135300 (3)  |SOS1, GINGF, GF1, HGF, NS4|182530|2p22-p21
Fibromatosis, gingival, 2 (2)  |GINGF2, GGF2, HGF2|605544|5q13-q22
Fibromatosis, gingival, 3 (2)  |GINGF3, HGF3, GGF3|609955|2p23.3-p22.3
Fibromatosis, gingival, 4 (2)  |GINGF4, HGF4, GGF4|611010|11p15
Fibromatosis, juvenile hyaline, 228600 (3)  |ANTXR2, CMG2, JHF, ISH|608041|4q21
Fibrosis of extraocular muscles, congenital, 1, 135700 (3)  |KIF21A, KIAA1708, FEOM1, CFEOM1, CFEOM3B|608283|12q12
Fibrosis of extraocular muscles, congenital, 2, 602078 (3)  |PHOX2A, ARIX, CFEOM2|602753|11q13.3-q13.4
Fibrosis of extraocular muscles, congenital, 3 (2)  |FEOM3|600638|16q24.2-q24.3
Fibrosis of extraocular muscles, congenital, 3A, 600638 (3)  |TUBB3, TUBB4, CFEOM3A|602661|16q24.3
Fibrosis of extraocular muscles, congenital, 3B, 135700 (3)  |KIF21A, KIAA1708, FEOM1, CFEOM1, CFEOM3B|608283|12q12
Fibrosis of extraocular muscles, congenital, 3C (2)  |CFEOM3C, FEOM4|609384|13q12.11
Fibrosis, congenital, of vertically acting extraocular muscles (2)  |FEOM3|600638|16q24.2-q24.3
Fibular hypoplasia and complex brachydactyly, 228900 (3)  |GDF5, CDMP1, SYNS2, OS5|601146|20q11.2
Fish-eye disease, 136120 (3)  |LCAT|606967|16q22.1
Fletcher factor deficiency, 612423 (3)  |KLKB1, KLK3|229000|4q35
Focal cortical dysplasia, Taylor balloon cell type, 607341 (3)  |TSC1, LAM|605284|9q34
Focal dermal hypoplasia, 305600 (3)  |PORCN, PORC, DHOF, FODH|300651|Xp11.23
Folate malabsorption, hereditary, 229050 (3)  |SLC46A1, HCP1, PCFT|611672|17q11.1
Follicle-stimulating hormone deficiency, isolated, 229070 (3)  |FSHB|136530|11p13
Forebrain defects (3)  |TDGF1|187395|3p23-p21
Forsythe-Wakeling syndrome (2)  |FWS|613606|1p33-p31.1
Foveal hyperplasia, 136520 (3)  |PAX6, AN2, MGDA|607108|11p13
Foveal hypoplasia and anterior segment dysgenesis (2)  |FHASD|609218|16q23.2-q24.2
Foveomacular dystrophy, adult-onset, with choroidal neovascularization, 608161 (3)  |PRPH2, DS, RP7, PRPH, AVMD, AOFMD, CACD2|179605|6p21.1-cen
Fragile X syndrome, 300624 (3)  |FMR1, FRAXA|309550|Xq27.3
Fragile X tremor/ataxia syndrome, 300623 (3)  |FMR1, FRAXA|309550|Xq27.3
Frank-ter Haar syndrome, 249420 (3)  |SH3PXD2B, TKS4, KIAA1295, FTHS|613293|5q35.1
Fraser syndrome, 219000 (3)  |FRAS1|607830|4q21
Fraser syndrome, 219000 (3)  |FREM2|608945|13q13.3
Frasier syndrome, 136680 (3)  |WT1, NPHS4|607102|11p13
Friedreich ataxia 2 (2)  |FRDA2|601992|9p23-p11
Friedreich ataxia with retained reflexes, 229300 (3)  |FXN, FRDA, FARR, X25|606829|9q13
Friedreich ataxia, 229300 (3)  |FXN, FRDA, FARR, X25|606829|9q13
Frontometaphyseal dysplasia, 305620 (3)  |FLNA, FLN1, NHBP, OPD1, OPD2, FMD, MNS, CVD1|300017|Xq28
Frontonasal dysplasia 2, 613451 (3)  |ALX4, PFM2, FPP, FND2|605420|11p11.2
Frontonasal dysplasia 3, 613456 (3)  |ALX1, CART1, FND3|601527|12q21.3-q22
Frontorhiny, 136760 (3)  |ALX3|606014|1p21-p13
Frontotemporal lobar degeneration with ubiquitin-positive inclusions, 607485 (3)  |GRN|138945|17q21.32
Frontotemporal lobar degeneration, TARDBP-related, 612069 (3)  |TARDBP, TDP43, ALS10|605078|1p36.2
Fructose intolerance, 229600 (3)  |ALDOB|612724|9q22.3
Fructose-1,6-bidphosphatase deficiency, 229700 (3)  |FBP1|611570|9q22.2-q22.3
Fucosidosis, 230000 (3)  |FUCA1|612280|1p34
Fucosyltransferase-6 deficiency (3)  |FUT6|136836|19p13.3
Fuhrmann syndrome, 228930 (3)  |WNT7A|601570|3p25
Fumarase deficiency, 606812 (3)  |FH|136850|1q42.1
Fundus albipunctatus, 136880 (3)  |RDH5|601617|12q13-q14
Fundus albipunctatus, 136880 (3)  |RLBP1|180090|15q26
Fundus flavimaculatus, 248200 (3)  |ABCA4, ABCR, STGD1, FFM, RP19, CORD3, ARMD2|601691|1p22.1
G6PD deficiency (3)  |G6PD, G6PD1|305900|Xq28
GABA-transaminase deficiency, 613163 (3)  |ABAT, GABAT|137150|16p13.3
GAMT deficiency, 612736 (3)  |GAMT|601240|19p13.3
GLUT1 deficiency syndrome 1, 606777 (3)  |SLC2A1, GLUT1, DYT18, PED, ,GLUT1DS|138140|1p35-p31.3
GLUT1 deficiency syndrome 2, 612126 (3)  |SLC2A1, GLUT1, DYT18, PED, ,GLUT1DS|138140|1p35-p31.3
GM1-gangliosidosis, type I, 230500 (3)  |GLB1, MPS4B|611458|3p21.33
GM1-gangliosidosis, type II, 230600 (3)  |GLB1, MPS4B|611458|3p21.33
GM1-gangliosidosis, type III, 230650 (3)  |GLB1, MPS4B|611458|3p21.33
GM2-gangliosidosis, AB variant, 272750 (3)  |GM2A|613109|5q31.3-q33.1
GM2-gangliosidosis, several forms, 272800 (3)  |HEXA, TSD|606869|15q23-q24
GRACILE syndrome, 603358 (3)  |BCS1L, FLNMS, GRACILE, BJS, PTD|603647|2q33
Galactokinase deficiency with cataracts, 230200 (3)  |GALK1|604313|17q24
Galactose epimerase deficiency, 230350 (3)  |GALE|606953|1p36-p35
Galactosemia, 230400 (3)  |GALT|606999|9p13
Galactosialidosis, 256540 (3)  |CTSA, PPGB, GSL, NGBE, GLB2|613111|20q13.1
Gallbladder disease 1, 600803 (3)  |ABCB4, PGY3, MDR3|171060|7q21.1
Gallbladder disease 2 (2)  |GDB2|609918|1p36.21
Gallbladder disease 3 (2)  |GDB2|609919|1p34.3
Gallbladder disease 4, 611465 (3)  |ABCG8, GBD4|605460|2p21
Gardner syndrome (3)  |APC, GS, FPC, BTPS2|611731|5q21-q22
Gastric cancer, 137215 (3)  |KRAS, KRAS2, RASK2, NS|190070|12p12.1
Gastric cancer, familial diffuse, with or without cleft lip and/or palate, 137215 (3)  |CDH1, UVO, LCAM, ECAD|192090|16q22.1
Gastric cancer, somatic, 137215 (3)  |CASP10, MCH4, ALPS2|601762|2q33-q34
Gastric cancer, somatic, 137215 (3)  |ERBB2, NGL, NEU, HER2|164870|17q21.1
Gastric cancer, somatic, 137215 (3)  |FGFR2, BEK, CFD1, JWS|176943|10q26
Gastric cancer, somatic, 137215 (3)  |IRF1, MAR|147575|5q31.1
Gastric cancer, somatic, 137215 (3)  |KLF6, COPEB, BCD1, ZF9|602053|10p15
Gastric cancer, somatic, 137215 (3)  |MUTYH, MYH|604933|1p34.3-p32.1
Gastric cancer, somatic, 137215 (3)  |PIK3CA|171834|3q26.3
Gastric cancer, somatic, 613659 (3)  |APC, GS, FPC, BTPS2|611731|5q21-q22
Gastroesophageal reflux (2)  |GER|109350|13q14
Gastrointestinal stromal tumor, somatic, 606764 (3)  |KIT, PBT|164920|4q12
Gastrointestinal stromal tumor, somatic, 606764 (3)  |PDGFRA|173490|4q12
Gaucher disease, atypical, 610539 (3)  |PSAP, SAP1|176801|10q22.1
Gaucher disease, perinatal lethal, 608013 (3)  |GBA|606463|1q21
Gaucher disease, type I, 230800(3)  |GBA|606463|1q21
Gaucher disease, type II, 230900 (3)  |GBA|606463|1q21
Gaucher disease, type III, 231000 (3)  |GBA|606463|1q21
Gaucher disease, type IIIC, 231005 (3)  |GBA|606463|1q21
Gaze palsy, horizontal, with progressive scoliosis, 607313 (3)  |ROBO3, RBIG1, RIG1, HGPPS|608630|11q23-q25
Geleophysic dysplasia, 231050 (3)  |ADAMTSL2, KIAA0605|612277|9q34.2
Generalized epilepsy and paroxysmal dyskinesia, 609446 (3)  |KCNMA1, SLO|600150|10q22.3
Generalized epilepsy with febrile seizures plus, 604233 (3)  |SCN1B, GEFSP1|600235|19q13.1
Generalized epilepsy with febrile seizures plus, type 6 (2)  |GEFSP6|612279|8p23-p21
Geniospasm (2)  |GSM1, GSP|190100|9q13-q21
Germ cell tumor (3)  |BCL10|603517|1p22
Germ cell tumors, 273300 (3)  |KIT, PBT|164920|4q12
Geroderma osteodysplasticum, 231070 (3)  |SCYL1BP1, NTKLBP1, GO|607983|1q24.2
Gerstmann-Straussler disease, 137440 (3)  |PRNP, PRIP|176640|20pter-p12
Ghosal syndrome, 231095 (3)  |TBXAS1, GHOSAL, CYP5|274180|7q34
Giant axonal neuropathy-1, 256850 (3)  |GAN, GAN1|605379|16q24.1
Giant platelet disorder, isolated (3)  |GP1BB|138720|22q11.2
Giant-cell fibroblastoma (3)  |PDGFB, SIS|190040|22q12.3-q13.1
Gigantism due to GHRF hypersecretion (1)  |GHRH, GHRF|139190|20q11.2
Gillespie syndrome, 206700 (3)  |PAX6, AN2, MGDA|607108|11p13
Gitelman syndrome, 263800 (3)  |SLC12A3, NCCT, TSC|600968|16q13
Glanzmann thrombasthenia, type A, 273800 (3)  |ITGA2B, GP2B, CD41B|607759|17q21.32
Glanzmann thrombasthenia, type B (3)  |ITGB3, GP3A|173470|17q21.32
Glaucoma 1, open angle, 1O, 613100 (3)  |NTF4 , NTF5, NT5, NT4, GLC1O|162662|19q13.3
Glaucoma 1, open angle, E, 137760 (3)  |OPTN, GLC1E, FIP2, HYPL, NRP, ALS12|602432|10p15-p14
Glaucoma 1, open angle, G, 609887 (3)  |WDR36, TAWDRP, GLC1G|609669|5q21.3-q22.1
Glaucoma 1, open angle, I (2)  |GLC1I|609745|15q11-q13
Glaucoma 1, open angle, M (2)  |GLC1M|610535|5q22.1-q32
Glaucoma 1A, primary open angle, juvenile-onset, 137750 (3)  |MYOC, TIGR, GLC1A, JOAG, GPOA|601652|1q24.3-q25.2
Glaucoma 1A, primary open angle, recessive (3)  |MYOC, TIGR, GLC1A, JOAG, GPOA|601652|1q24.3-q25.2
Glaucoma 1B, primary open angle, adult onset, 137760 (2)  |GLC1B|606689|2cen-q13
Glaucoma 1C, primary open angle (2)  |GLC1C|601682|3q21-q24
Glaucoma 1D, primary open angle (2)  |GLC1D|602429|8q23
Glaucoma 1F (2)  |GLC1F|603383|7q35-q36
Glaucoma 1K, primary open angle, juvenile-onset (2)  |GLC1K, JOAG3|608696|20p12
Glaucoma 3, primary congenital, C (2)  |GLC3C|613085|14q24.3
Glaucoma 3, primary congenital, D, 613086 (3)  |LTBP2, LTBP3, GLC3D|602091|14q24
Glaucoma 3, primary infantile, B (2)  |GLC3B|600975|1p36.2-p36.1
Glaucoma 3A, primary congenital, 231300 (3)  |CYP1B1, GLC3A|601771|2p22-p21
Glaucoma, early-onset, digenic (3)  |CYP1B1, GLC3A|601771|2p22-p21
Glaucoma, early-onset, digenic (3)  |MYOC, TIGR, GLC1A, JOAG, GPOA|601652|1q24.3-q25.2
Glaucoma, primary open angle, adult-onset, 137760 (3)  |CYP1B1, GLC3A|601771|2p22-p21
Glaucoma, primary open angle, juvenile-onset, 137750 (3)  |CYP1B1, GLC3A|601771|2p22-p21
Glaucoma, primary open angle, juvenile-onset, 2 (2)  |JOAG2|608695|9q22
Glioblastoma, somatic, 137800 (3)  |ERBB2, NGL, NEU, HER2|164870|17q21.1
Gliosis, familial progressive subcortical (2)  |GPSC|221820|17q21-q22
Globozoospermia, 102530 (1) (?)  |GOPC, PIST, FIG, CAL|606845|6q21
Globozoospermia, 102530 (3)  |SPATA16|609856|3q26.3
Glomerulocystic kidney disease with hyperuricemia and isosthenuria, 609886 (3)  |UMOD, HNFJ1, FJHN, MCKD2, ADMCKD2|191845|16p12.3
Glomerulopathy with fibronectin deposits 1 (2)  |GFND1|601894|1q32
Glomerulopathy with fibronectin deposits 2, 601894 (3)  |FN1, FN, LETS, FNZ, GFND2|135600|2q34
Glomerulosclerosis, focal segmental, 1, 603278 (3)  |ACTN4, FSGS1, FSGS|604638|19q13
Glomerulosclerosis, focal segmental, 2, 603965 (3)  |TRPC6, TRP6, FSGS2|603652|11q21-q22
Glomerulosclerosis, focal segmental, 3, 607832 (3)  |CD2AP, CMS|604241|6p12
Glomerulosclerosis, focal segmental, 5, 613237 (3)  |INF2, FSGS5, C14orf173|610982|14q32.33
Glomuvenous malformations, 138000 (3)  |GLML, GVM, VMGLOM|601749|1p22-p21
Glucocorticoid deficiency 2, 607398 (3)  |MRAP, FALP, C21orf61, GCCD2, FGD2|609196|21q22.1
Glucocorticoid deficiency 3 (2)  |GCCD3, FGD3, GCCD2|609197|8q11.2-q13.2
Glucocorticoid deficiency, due to ACTH unresponsiveness, 202200 (3)  |MC2R|607397|18p11.2
Glucose/galactose malabsorption, 606824 (3)  |SLC5A1, SGLT1|182380|22q13.1
Glutamate formiminotransferase deficiency, 229100 (3)  |FTCD|606806|21q22.3
Glutamine deficiency, congenital, 610015 (3)  |GLUL, GLNS|138290|1q31
Glutaricaciduria, type I, 231670 (3)  |GCDH|608801|19p13.2
Glutaricaciduria, type IIA, 231680 (3)  |ETFA, GA2, MADD|608053|15q23-q25
Glutaricaciduria, type IIB, 231680 (3)  |ETFB, MADD|130410|19q13.3
Glutaricaciduria, type IIC, 231680 (3)  |ETFDH, MADD|231675|4q32-qter
Glutathione synthetase deficiency, 266130 (3)  |GSS, GSHS|601002|20q11.2
Glutathioninuria (1)  |GGT1, GTG|231950|22q11.1-q11.2
Glycerol kinase deficiency, 307030 (3)  |GK|300474|Xp21.3-p21.2
Glycine N-methyltransferase deficiency, 606664 (3)  |GNMT|606628|6p12
Glycine encephalopathy, 605899 (3)  |AMT, NKH, GCE|238310|3p21.2-p21.1
Glycine encephalopathy, 605899 (3)  |GCSH, NKH|238330|16q24
Glycine encephalopathy, 605899 (3)  |GLDC, HYGN1, GCSP, GCE, NKH|238300|9p22
Glycogen storage disease 0, muscle, 611556 (3)  |GYS1, GYS|138570|19q13.3
Glycogen storage disease I (3)  |G6PC, G6PT|232200|17q21
Glycogen storage disease II, 232300 (3)  |GAA|606800|17q25.2-q25.3
Glycogen storage disease IIIa, 232400 (3)  |AGL, GDE|610860|1p21
Glycogen storage disease IIIb, 232400 (3)  |AGL, GDE|610860|1p21
Glycogen storage disease IIb, 300257 (3)  |LAMP2, LAMPB|309060|Xq24
Glycogen storage disease IV, 232500 (3)  |GBE1|607839|3p12
Glycogen storage disease IXc, 613027 (3)  |PHKG2, GSD9C|172471|16p12.1-p11.2
Glycogen storage disease Ib, 232220 (3)  |SLC37A4, G6PT1|602671|11q23
Glycogen storage disease Ic, 232240 (3)  |SLC37A4, G6PT1|602671|11q23
Glycogen storage disease Ic, 232240 (3) (?)  |SLC17A3, NPT4|611034|6p21.3
Glycogen storage disease VI (3)  |PYGL|232700|14q21-q22
Glycogen storage disease VII, 232800 (3)  |PFKM, GSD7|610681|12q13.3
Glycogen storage disease X, 261670 (3)  |PGAM2, PGAMM, GSD10|612931|7p13-p12.3
Glycogen storage disease XI, 612933 (3)  |LDHA, LDH1, GSD11|150000|11p15.4
Glycogen storage disease XII, 611881 (3)  |ALDOA, GSD12|103850|16p11.2
Glycogen storage disease XIII, 612932 (3)  |ENO3, GSD13|131370|17pter-p12
Glycogen storage disease XIV, 612934 (3)  |PGM1, GSD14|171900|1p31
Glycogen storage disease XV, 613507 (3)  |GYG1, GSD15|603942|3q24-q25.1
Glycogen storage disease of heart, lethal congenital, 261740 (3)  |PRKAG2, WPWS, CMH6|602743|7q36
Glycogen storage disease, type 0, 240600 (3)  |GYS2|138571|12p12.2
Glycogen storage disease, type IXa1, 306000 (3)  |PHKA2, PHK, XLG, PHK, PYKL, GSD9A|300798|Xp22.2-p22.1
Glycogen storage disease, type IXa2, 306000 (3)  |PHKA2, PHK, XLG, PHK, PYKL, GSD9A|300798|Xp22.2-p22.1
Glycoprotein Ia deficiency (1) (?)  |ITGA2, CD49B, BR|192974|5q23-q31
Glycosylphosphatidylinositol deficiency, 610293 (3)  |PIGM|610273|1q23.2
Gnathodiaphyseal dysplasia, 166260 (3)  |ANO5, TMEM16E, GDD1, LGMD2L|608662|11p14.3
Goeminne TKCR syndrome (2)  |TKCR, TKC|314300|Xq28
Goiter, familial, due to TTF-1 defect (1)  |NKX2-1, TITF1, NKX2A, TTF1|600635|14q13
Goiter, multinodular, 1 (2)  |MNG1|138800|14q
Goiter, multinodular, 2 (2)  |MNG2|300273|Xp22
Goiter, multinodular, 3 (2)  |MNG3|606082|3q26.1-q26.3
Golabi-Ito-Hall syndrome (3)  |PQBP1, NPW38, SHS, MRX55, MRXS3, RENS1, MRXS8|300463|Xp11.23
Goldberg-Shprintzen megacolon syndrome, 609460 (3)  |KIAA1279|609367|10q22.1
Gonadal dysgenesis, XY female type (2)  |GDXY, TDFX, SRVX|306100|Xp22.11-p21.2
Gout, PRPS-related, 300661 (3)  |PRPS1, CMTX5, DFNX1, DFN2|311850|Xq22-q24
Greig cephalopolysyndactyly syndrome, 175700 (3)  |GLI3, PAPA, PAPB, ACLS|165240|7p13
Griscelli syndrome, type 1, 214450 (3)  |MYO5A, MYH12, GS1|160777|15q21
Griscelli syndrome, type 2, 607624 (3)  |RAB27A, RAM, GS2|603868|15q21
Griscelli syndrome, type 3, 609227 (3)  |MLPH|606526|2q37
Growth hormone deficiency with pituitary anomalies, 182230 (3)  |HESX1, RPX, CPHD5|601802|3p21.2-p21.1
Growth hormone deficiency, isolated, type IA, 262400 (3)  |GH1, GHN, IGHD1B|139250|17q22-q24
Growth hormone deficiency, isolated, type IB, 612781 (3)  |GH1, GHN, IGHD1B|139250|17q22-q24
Growth hormone deficiency, isolated, type IB, 612781 (3)  |GHRHR, GHRFR, IGHD1B|139191|7p15-p14
Growth hormone deficiency, isolated, type II, 173100 (3)  |GH1, GHN, IGHD1B|139250|17q22-q24
Growth hormone insensitivity with immunodeficiency, 245590 (3)  |STAT5B|604260|17q11.2
Growth retardation with deafness and mental retardation due to IGF1 deficiency, 608747 (3)  |IGF1|147440|12q22-q24.1
Growth retardation, developmental delay, coarse facies, and early death, 612938 (3)  |FTO|610966|16q12.2
Gustavson syndrome (2)  |GUST|309555|Xq26
Guttmacher syndrome, 176305 (3)  |HOXA13, HOX1J|142959|7p15-p14.2
Gyrate atrophy of choroid and retina with or without ornithinemia, 258870 (3)  |OAT, GACR|613349|10q26
HARP syndrome, 607236 (3)  |PANK2, NBIA1, PKAN, HARP|606157|20p13-p12.3
HDL deficiency, type 2, 604091 (3)  |ABCA1, ABC1, HDLDT1, TGD|600046|9q22-q31
HELLP syndrome, maternal, of pregnancy, 609016 (3)  |HADHA, MTPA|600890|2p23
HEM skeletal dysplasia, 215140 (3)  |LBR, PHA|600024|1q42.1
HMG-CoA lyase deficiency (3)  |HMGCL|246450|1pter-p33
HMG-CoA synthase-2 deficiency, 605911 (3)  |HMGCS2|600234|1p13-p12
HPRT-related gout, 300323 (3)  |HPRT1, HPRT|308000|Xq26-q27.2
HSN I with cough and gastroesophageal reflux (2)  |HSN1B|608088|3p24-p22
Haddad syndrome, 209880 (3)  |ASCL1, ASH1|100790|12q22-q23
Hailey-Hailey disease, 169600 (3)  |ATP2C1, BCPM, HHD|604384|3q21-q24
Haim-Munk syndrome, 245010 (3)  |CTSC, CPPI, PALS, PLS, HMS, JPD|602365|11q14.1-q14.3
Hair, curly (2)  |HRM2|139450|1q21.3
Hairy ears, Y-linked (2) (?)  |HEY|425500|Yq
Hallermann-Streiff syndrome, 234100 (3)  |GJA1, CX43, ODDD, SDTY3, ODOD, HSS|121014|6q21-q23.2
Hand-foot-uterus syndrome, 140000 (3)  |HOXA13, HOX1J|142959|7p15-p14.2
Harderoporphyria, 121300 (3)  |CPOX|612732|3q12
Hartnup disorder, 234500 (3)  |SLC6A19, HND|608893|5p15.33
Hashimoto thyroiditis (2)  |HT|140300|8q23-q24
Hawkinsinuria, 140350 (3)  |HPD|609695|12q24-qter
Hay-Wells syndrome, 106260 (3)  |TP63, TP73L, KET, EEC3, SHFM4, LMS, RHS, OFC8|603273|3q27
Heart block, nonprogressive, 113900 (3)  |SCN5A, LQT3, VF1, HB1, SSS1, CMD1E, CDCD2|600163|3p21
Heart block, progressive, type IA, 113900 (3)  |SCN5A, LQT3, VF1, HB1, SSS1, CMD1E, CDCD2|600163|3p21
Heinz body anemia, 140700 (3)  |HBA2|141850|16pter-p13.3
Heinz body anemias, alpha-, 140700 (3)  |HBA1|141800|16pter-p13.3
Heinz body anemias, beta-, 140700 (3)  |HBB|141900|11p15.5
Hemangioblastoma, cerebellar, somatic (3)  |VHL|608537|3p26-p25
Hemangioma, capillary infantile (2)  |HCI, HEMC|602089|5q31-q33
Hemangioma, capillary infantile, somatic, 602089 (3)  |FLT4, VEGFR3, PCL, LMPH1A|136352|5q35.3
Hemangioma, capillary infantile, somatic, 602089 (3)  |KDR|191306|4q12
Hematopoiesis, cyclic, 162800 (3)  |ELANE, ELA2, SCN1|130130|19p13.3
Hematuria, benign familial, 141200 (3)  |COL4A3|120070|2q36-q37
Hematuria, familial benign (3)  |COL4A4|120131|2q36-q37
Heme oxygenase-1 deficiency (3)  |HMOX1|141250|22q12
Hemifacial microsomia (2)  |HFM|164210|14q32
Hemihypertrophy (2)  |IH, HHP|235000|11p15
Hemiplegic migraine, familial, 141500 (3)  |CACNA1A, CACNL1A4, SCA6|601011|19p13
Hemochromatosis, 235200 (3)  |HFE, HLA-H, HFE1, MVCD7|613609|6p21.3
Hemochromatosis, type 2A, 602390 (3)  |HJV, HFE2A|608374|1q21
Hemochromatosis, type 2B, 613313 (3)  |HAMP, LEAP1, HEPC, HFE2B|606464|19q13
Hemochromatosis, type 3, 604250 (3)  |TFR2, HFE3|604720|7q22
Hemochromatosis, type 4, 606069 (3)  |SLC40A1, SLC11A3, FPN1, IREG1, HFE4|604653|2q32
Hemoglobin H disease (3)  |HBA2|141850|16pter-p13.3
Hemolytic anemia due to G6PD deficiency (3)  |G6PD, G6PD1|305900|Xq28
Hemolytic anemia due to adenylate kinase deficiency, 612631 (3)  |AK1|103000|9q34.1
Hemolytic anemia due to bisphosphoglycerate mutase deficiency (3)  |BPGM|222800|7q31-q34
Hemolytic anemia due to gamma-glutamylcysteine synthetase deficiency, 230450 (3)  |GCLC, GLCLC|606857|6p12
Hemolytic anemia due to glutathione peroxidase deficiency (1)  |GPX1|138320|3p21.3
Hemolytic anemia due to glutathione reductase deficiency (1)  |GSR|138300|8p21.1
Hemolytic anemia due to glutathione synthetase deficiency, 231900 (3)  |GSS, GSHS|601002|20q11.2
Hemolytic anemia due to hexokinase deficiency, 235700 (3)  |HK1|142600|10q22
Hemolytic anemia due to phosphofructokinase deficiency (1)  |PFKL|171860|21q22.3
Hemolytic anemia due to triosephosphate isomerase deficiency (3)  |TPI1|190450|12p13
Hemolytic anemia, nonspherocytic, due to glucose phosphate isomerase deficiency, 613470 (3)  |GPI|172400|19q13.1
Hemolytic uremic syndrome, atypical, susceptibility to, 1}, 235400 (3)  |HF1, CFH, HUS, ARMD4, AHUS1|134370|1q32
Hemophagocytic lymphohistiocytosis, familial, 1 (2)  |FHL1, HPLH1, HLH1|267700|9q21.3-q22
Hemophagocytic lymphohistiocytosis, familial, 2, 603553 (3)  |PRF1, HPLH2, FLH2|170280|10q22
Hemophagocytic lymphohistiocytosis, familial, 3, 608898 (3)  |UNC13D, MUNC13-4, HPLH3, HLH3, FHL3|608897|17q25.1
Hemophagocytic lymphohistiocytosis, familial, 4, 603552 (3)  |STX11, FHL4, HPLH4, HLH4|605014|6q24
Hemophagocytic lymphohistiocytosis, familial, 5 (3)  |STXBP2, UNC18B, FHL5|601717|19p13.3-p13.2
Hemophilia A (3)  |F8, F8C, HEMA|306700|Xq28
Hemophilia B, 306900 (3)  |F9, HEMB|300746|Xq27.1-q27.2
Hemorrhagic destruction of the brain, subependymal calcification, and cataracts, 613730 (3)  |JAM3|606871|11q25
Hemorrhagic diathesis due to \'antithrombin\' Pittsburgh, 613490 (3)  |SERPINA1, PI, AAT|107400|14q32.1
Hemosiderosis, systemic, due to aceruloplasminemia, 604290 (3)  |CP|117700|3q23-q24
Hennekam lymphangiectasia-lymphedema syndrome, 235510 (3)  |CCBE1, KIAA1983|612753|18q21.32
Hepatic adenoma, 142330 (3)  |HNF1A, TCF1, MODY3, IDDM20|142410|12q24.2
Hepatic failure, early onset, and neurologic disorder (3)  |SCOD1, SCO1|603644|17p13-p12
Hepatic lipase deficiency (3)  |LIPC, HL, LIPH, HDLCQ12|151670|15q21-q23
Hepatic venoocclusive disease with immunodeficiency, 235550 (3)  |SP110, IFI41, IFI75, VODI|604457|2q37.1
Hepatoblastoma (3)  |CTNNB1|116806|3p22-p21.3
Hepatoblastoma, somatic, 114550 (3)  |APC, GS, FPC, BTPS2|611731|5q21-q22
Hepatocellular cancer, 114550 (3)  |PDGFRL, PDGRL, PRLTS|604584|8p22-p21.3
Hepatocellular carcinoma (1) (?)  |LCO|165320|2q14-q21
Hepatocellular carcinoma (3)  |IGF2R, MPRI|147280|6q26
Hepatocellular carcinoma, 114550 (3)  |CTNNB1|116806|3p22-p21.3
Hepatocellular carcinoma, 114550 (3)  |TP53, P53, LFS1|191170|17p13.1
Hepatocellular carcinoma, childhood type, 114550 (3)  |MET, AUTS9|164860|7q31
Hepatocellular carcinoma, somatic, 114550 (3)  |AXIN1, AXIN|603816|16p13.3
Hepatocellular carcinoma, somatic, 114550 (3)  |CASP8, MCH5, ALPS2B|601763|2q33
Hepatocellular carcinoma, somatic, 114550 (3)  |PIK3CA|171834|3q26.3
Hereditary motor and sensory neuropathy VI, 601152 (3)  |MFN2, KIAA0214, CMT2A2|608507|1p36.2
Hereditary motor and sensory neuropathy, type IIc, 606071 (3)  |TRPV4, VROAC, HMSN2C, CMT2C, SPSMA, SSQTL1|605427|12q24.1
Hereditary persistence of fetal hemoglobin (3)  |HBB|141900|11p15.5
Hermansky-Pudlak syndrome 1, 203300 (3)  |HPS1|604982|10q23.1
Hermansky-Pudlak syndrome 2, 608233 (3)  |AP3B1, ADTB3A, HPS2|603401|5q14.1
Hermansky-Pudlak syndrome 3, 203300 (3)  |HPS3|606118|3q24
Hermansky-Pudlak syndrome 4, 203300 (3)  |HPS4|606682|22q11.2-q12.2
Hermansky-Pudlak syndrome 5, 203300 (3)  |HPS5, RU2, KIAA1017|607521|11p15-p13
Hermansky-Pudlak syndrome 6, 203300 (3)  |HPS6, RU|607522|10q24.32
Hermansky-Pudlak syndrome 7, 203300 (3)  |DTNBP1, HPS7|607145|6p22.3
Hermansky-Pudlak syndrome 8, 203300 (3)  |BLOC1S3, BLOS3, HPS8|609762|19q13
Hernia, congenital diaphragmatic 1 (2)  |DIH1, HCD|142340|15q26.1
Hernia, congenital diaphragmatic 2 (2)  |DIH2|222400|8p23.1
Heterotaxy, visceral (2) (?)  |HTX3|606325|6q21
Heterotaxy, visceral, 1, X-linked 306955 (3)  |ZIC3, HTX1, HTX|300265|Xq26.2
Heterotaxy, visceral, 2, autosomal, 605376 (3)  |CFC1, CRYPTIC, HTX2|605194|2q21.1
Heterotaxy, visceral, 4, autosomal (3)  |ACVR2B, ACTRIIB|602730|3p22-p21.3
Heterotaxy, visceral, 5, 270100 (3)  |NODAL|601265|10q22.1
Heterotopia, periventricular, 300049 (3)  |FLNA, FLN1, NHBP, OPD1, OPD2, FMD, MNS, CVD1|300017|Xq28
Heterotopia, periventricular, ED variant, 300537 (3)  |FLNA, FLN1, NHBP, OPD1, OPD2, FMD, MNS, CVD1|300017|Xq28
Hip dysplasia, Beukes type (2)  |BHD, BFHD|142669|4q35
Hirschsprung disease, cardiac defects, and autonomic dysfunction (3)  |ECE1|600423|1p36.1
Hirschsprung disease, short-segment, 142623 (3)  |PMX2B, NBPHOX, PHOX2B, NBLST2|603851|4p12
Histiocytoma, angiomatoid fibrous, somatic, 612160 (3)  |CREB1|123810|2q32.3-q34
Hodgkin lymphoma, 236000 (3)  |KLHDC8B|613169|3p21.31
Holocarboxylase synthetase deficiency, 253270 (3)  |HLCS, HCS|609018|21q22.1
Holoprosencephaly-1 (2)  |HPE1|236100|21q22.3
Holoprosencephaly-2, 157170 (3)  |SIX3, HPE2|603714|2p21
Holoprosencephaly-3, 142945 (3)  |SHH, HPE3, HLP3, SMMCI, MCOPCB5|600725|7q36
Holoprosencephaly-4, 142946 (3)  |TGIF, HPE4|602630|18p11.3
Holoprosencephaly-5, 609637 (3)  |ZIC2, HPE5|603073|13q32
Holoprosencephaly-6 (2)  |HPE6|605934|2q37.1-q37.3
Holoprosencephaly-7, 610828 (3)  |PTCH1, NBCCS, BCNS, HPE7|601309|9q22.3
Holoprosencephaly-8 (2)  |HPE8|609408|14q13
Holoprosencephaly-9, 610829 (3)  |GLI2, HPE9|165230|2q14
Holt-Oram syndrome, 142900 (3)  |TBX5|601620|12q24.1
Homocysteine plasma level (2)  |NNMT|600008|11q23.1
Homocysteine, total plasma, elevated (3)  |CTH|607657|1p31.1
Homocystinuria due to MTHFR deficiency, 236250 (3)  |MTHFR|607093|1p36.3
Homocystinuria, B6-responsive and nonresponsive types, 236200 (3)  |CBS|613381|21q22.3
Homocystinuria, cblD type, variant 1, 277410 (3)  |C2orf25, MMADHC|611935|2q23.2
Homocystinuria-megaloblastic anemia, cbl E type, 236270 (3)  |MTRR|602568|5p15.3-p15.2
Hoyeraal-Hreidarsson syndrome, 300240 (3)  |DKC1, DKC|300126|Xq28
Humoral hypercalcemia of malignancy (1)  |PTHLH, BDE2|168470|12p12.1-p11.2
Huntington disease, 143100 (3)  |HTT, HD, IT15|613004|4p16.3
Huntington disease-like 1, 603218 (3)  |PRNP, PRIP|176640|20pter-p12
Huntington disease-like 2, 606438 (3)  |JPH3, JP3, HDL2|605268|16q24.3
Huntington disease-like 3 (2)  |HDL3, HLN2|604802|4p15.3
Huriez syndrome (2)  |TYS, HRZ|181600|4q23
Hutchinson-Gilford progeria, 176670 (3)  |LMNA, LMN1, EMD2, FPLD, CMD1A, HGPS, LGMD1B|150330|1q21.2
Hyalinosis, infantile systemic, 236490 (3)  |ANTXR2, CMG2, JHF, ISH|608041|4q21
Hydatidiform mole, 231090 (3)  |NALP7, NOD12, PYPAF3, HYDM|609661|19q13.4
Hydranencephaly with abnormal genitalia, 300215 (3)  |ARX, ISSX, PRTS, MRXS1, MRX36, MRX54, MRX43, MRX87, MRX29, MRX32|300382|Xp22.13
Hydrocephalus due to aqueductal stenosis, 307000 (3)  |L1CAM, CAML1, HSAS1|308840|Xq28
Hydrocephalus with Hirschsprung disease and cleft palate, 142623 (3)  |L1CAM, CAML1, HSAS1|308840|Xq28
Hydrocephalus with congenital idiopathic intestinal pseudoobstruction, 307000 (3)  |L1CAM, CAML1, HSAS1|308840|Xq28
Hydrolethalus syndrome, 236680 (3)  |HYLS1, FLJ32915|610693|11q24.2
Hyper-IgD syndrome, 260920 (3)  |MVK, MVLK|251170|12q24
Hyper-IgE recurrent infection syndrome, 147060 (3)  |STAT3, APRF, HIES|102582|17q21
Hyper-IgE recurrent infection syndrome, autosomal recessive, 243700 (3)  |DOCK8, MRD2|611432|9p24
Hyperaldosteronism, familial, type II (2)  |FHII|605635|7p22
Hyperalphalipoproteinemia, 143470 (3)  |CETP, HDLCQ10|118470|16q21
Hyperandrogenism, nonclassic type, due to 21-hydroxylase deficiency (3)  |CYP21A2, CYP21, CA21H|201910|6p21.3
Hyperbilirubinemia, familial transcient neonatal, 237900 (3)  |UGT1A1, UGT1, GNT1, BILIQTL1|191740|2q37
Hypercalciuria, absorptive (2)  |HCA1|607258|4q33-qter
Hypercalciuric hypercalcemia, type III (2)  |HHC3, FBH3|600740|19q13
Hypercarotenemia and vitamin A deficiency, autosomal dominant, 115300 (3)  |BCMO1, BCDO, BCO1|605748|16q21-q23
Hyperchlorhidrosis, isolated, 143860 (3)  |CA12|603263|15q22
Hypercholanemia, familial, 607748 (3)  |BAAT|602938|9q22.3
Hypercholanemia, familial, 607748 (3)  |EPHX1|132810|1q42.1
Hypercholanemia, familial, 607748 (3)  |TJP2, ZO2|607709|9q12-q13
Hypercholesterolemia, due to ligand-defective apo B, 144010 (3)  |APOB, FLDB, LDLCQ4|107730|2p24
Hypercholesterolemia, familial, 143890 (3)  |LDLR, FHC, FH, LDLCQ2|606945|19p13.2
Hypercholesterolemia, familial, 3, 603776 (3)  |PCSK9, NARC1, HCHOLA3, FH3, LDLCQ1|607786|1p34.1-p32
Hypercholesterolemia, familial, autosomal recessive, 603813 (3)  |LDLRAP1, ARH, FHCB2, FHCB1|605747|1p36-p35
Hypercholesterolemia, familial, modification of, 143890 (3)  |APOA2|107670|1q21-q23
Hyperchylomicronemia, late-onset, 144650 (3)  |APOA5|606368|11q23
Hyperekplexia and spastic paraparesis (3)  |GLRA1, STHE|138491|5q32
Hyperekplexia, 149400 (3)  |GPHN, GPH, KIAA1385, GEPH|603930|14q24
Hyperekplexia, 149400 (3)  |SLC6A5, GLYT2|604159|11p15.2-p15.1
Hyperekplexia, autosomal recessive, 149400 (3)  |GLRB|138492|4q31.3
Hypereosinophilic syndrome, idiopathic, resistant to imatinib, 607685 (3)  |PDGFRA|173490|4q12
Hyperferritinemia-cataract syndrome, 600886 (3)  |FTL, NBIA3|134790|19q13.3-q13.4
Hyperfibrinolysis, familial, due to increased release of PLAT, 612348 (1)  |PLAT, TPA|173370|8p12
Hyperglycinuria, 138500 (3)  |SLC36A2, PAT2|608331|5q33.1
Hyperglycinuria, 138500 (3)  |SLC6A19, HND|608893|5p15.33
Hyperglycinuria, 138500 (3)  |SLC6A20, XT3|605616|3p21.3
Hyperimmunoglobulin G1 syndrome (2) (?)  |IGHR|144120|14q32.33
Hyperinsulinemic hypoglycemia, familial, 1, 256450 (3)  |ABCC8, SUR, PHHI, SUR1, HHF1, TNDM2|600509|11p15.1
Hyperinsulinemic hypoglycemia, familial, 2, 601820 (3)  |KCNJ11, BIR, PHHI, HHF2, TNDM3|600937|11p15.1
Hyperinsulinemic hypoglycemia, familial, 3, 602485 (3)  |GCK, HHF3|138079|7p15-p13
Hyperinsulinemic hypoglycemia, familial, 4, 609975 (3)  |HADHSC, SCHAD, HHF4|601609|4q22-q26
Hyperinsulinemic hypoglycemia, familial, 5, 609968 (3)  |INSR, HHF5|147670|19p13.2
Hyperinsulinemic hypoglycemia, familial, 7, 610021 (3)  |SLC16A1, MCT1, HHF7|600682|1p13.2-p12
Hyperinsulinism-hyperammonemia syndrome, 606762 (3)  |GLUD1|138130|10q23.3
Hyperkalemic periodic paralysis, type 2, 613345 (3)  |SCN4A, HYPP, NAC1A, HOKPP2|603967|17q23.1-q25.3
Hyperkeratotic cutaneous capillary-venous malformations associated with cerebral capillary malformations, 116860 (3)  |CCM1, CAM, KRIT1|604214|7q11.2-q21
Hyperleucinemia-isoleucinemia or hypervalinemia (1) (?)  |BCAT1, BCT1|113520|12p12
Hyperlipidemia, combined, 2 (2)  |HYPLIP2|604499|11p
Hyperlipoproteinemia, type III (3)  |APOE, AD2, LPG, LDLCQ5|107741|19q13.2
Hyperlipoproteinemia, type Ib, 207750 (3)  |APOC2|608083|19q13.2
Hyperlysinemia, 238700 (3)  |AASS|605113|7q31.3
Hypermethioninemia with deficiency of S-adenosylhomocysteine hydrolase (3)  |AHCY, SAHH|180960|20cen-q13.1
Hypermethioninemia, persistent, autosomal dominant, due to methionine adenosyltransferase I/III deficiency, 250850 (3)  |MAT1A, MATA1, SAMS1|610550|10q22
Hyperornithinemia-hyperammonemia-homocitrullinemia syndrome, 238970 (3)  |SLC25A15, ORNT1, HHH|603861|13q14
Hyperostosis, endosteal, 144750 (3)  |LRP5, BMND1, LRP7, LR3, OPPG, VBCH2, OPTA1, EVR4|603506|11q13.4
Hyperoxaluria, primary, type 1, 259900 (3)  |AGXT, SPAT|604285|2q36-q37
Hyperoxaluria, primary, type II, 260000 (3)  |GRHPR, GLXR|604296|9cen
Hyperoxaluria, primary, type III, 613616 (3)  |DHDPSL, HP3|613597|10q24.2
Hyperparathyroidism 3 (2)  |HRPT3|610071|2p14-p13.3
Hyperparathyroidism, familial primary, 145000 (3)  |HRPT2, C1orf28|607393|1q25-q31
Hyperparathyroidism, neonatal, 239200 (3)  |CASR, HHC1, PCAR1, FIH, EIG8|601199|3q13.3-q21
Hyperparathyroidism-jaw tumor syndrome, 145001 (3)  |HRPT2, C1orf28|607393|1q25-q31
Hyperpehnylalaninemia, BH4-deficient, B, 233910 (3)  |GCH1, DYT5, HPABH4B|600225|14q22.1-q22.2
Hyperphenylalaninemia, BH4-deficient, A, 261640 (3)  |PTS|612719|11q22.3-q23.3
Hyperphenylalaninemia, BH4-deficient, C, 261630 (3)  |QDPR, DHPR|612676|4p15.31
Hyperphenylalaninemia, BH4-deficient, D, 264070 (3)  |PCBD, DCOH|126090|10q22
Hyperpigmentation, cutaneous, with hypertrichosis, hepatosplenomegaly, heart anomalies, hearing loss, and hypogonadism, 612391 (3)  |SLC29A3, ENT3|612373|10q22.1
Hyperpigmentation, familial progressive (2)  |FPH, MUH, HPP|145250|19pter-p13.1
Hyperpigmentation, familial progressive, 145250 (3)  |KITLG, MGF, SF, SCF, SHEP7|184745|12q22
Hyperproinsulinemia, familial, with or without diabetes (3)  |INS, MODY10, IDDM2|176730|11p15.5
Hyperprolinemia, type I, 239500 (3)  |PRODH, PRODH2, SCZD4|606810|22q11.2
Hyperprolinemia, type II, 239510 (3)  |ALDH4A1, ALDH4, P5CDH|606811|1p36
Hypertension with brachydactyly (2)  |HTNB|112410|12p12.2-p11.2
Hypertension, early-onset, autosomal dominant, with exacerbation in pregnancy, 605115 (3)  |NR3C2, MLR, MCR|600983|4q31.1
Hypertension, essential, 145500 (1) (?)  |PNMT, PENT|171190|17q21-q22
Hypertension, essential, 145500 (3)  |AGTR1, AGTR1A, AT2R1|106165|3q21-q25
Hypertension, essential, 145500 (3)  |PTGIS, CYP8A1, PGIS, CYP8|601699|20q13.11-q13.13
Hypertension, mild low-renin (3)  |HSD11B2, HSD11K|218030|16q22
Hypertension, salt-resistant (1) (?)  |NPR3, ANPRC|108962|5p14-p12
Hypertensive nephropathy (2)  |HNP1|608026|9q31-q32
Hyperthyroidism, familial gestational, 603373 (3)  |TSHR, CHNG1|603372|14q31
Hyperthyroidism, nonautoimmune, 609152 (3)  |TSHR, CHNG1|603372|14q31
Hypertrichosis terminalis, generalized, with or without gingival hyperplasia (4)  |HTGH, DEL17q24|135400|17q24.2-q24.3
Hypertrichosis universalis congenita, Ambras type (2) (?)  |ITC1|145701|8q22
Hypertrichosis, congenital generalized (2)  |HTC2, HCG, CGH|307150|Xq24-q27.1
Hypertrophic osteoarthropathy, primary, autosomal recessive, 259100 (3)  |HPGD, PGDH1|601688|4q34-q35
Hyperuricemic nephropathy, familial juvenile 1, 162000 (3)  |UMOD, HNFJ1, FJHN, MCKD2, ADMCKD2|191845|16p12.3
Hyperuricemic nephropathy, familial juvenile 2, 613092 (3)  |REN, HNFJ2|179820|1q32
Hypervalinemia or hyperleucine-isoleucinemia (1) (?)  |BCAT2, BCT2|113530|19q13
Hypoaldosteronism, congenital, due to CMO I deficiency, 203400 (3)  |CYP11B2|124080|8q21
Hypoaldosteronism, congenital, due to CMO II deficiency, 610600 (3)  |CYP11B2|124080|8q21
Hypoalphalipoproteinemia, 604091 (3)  |APOA1|107680|11q23
Hypoalphalipoproteinemia, primary (2)  |HYALP, HDLD3|605201|11q23.3
Hypobetalipoproteinemia (3)  |APOB, FLDB, LDLCQ4|107730|2p24
Hypobetalipoproteinemia, familial, 2, 605019 (3)  |ANGPTL3, ANGPT5, FHBL2|604774|1p31
Hypobetalipoproteinemia, normotriglyceridemic (3)  |APOB, FLDB, LDLCQ4|107730|2p24
Hypocalcemia, autosomal dominant, 146200 (3)  |CASR, HHC1, PCAR1, FIH, EIG8|601199|3q13.3-q21
Hypocalcemia, autosomal dominant, with Bartter syndrome (3)  |CASR, HHC1, PCAR1, FIH, EIG8|601199|3q13.3-q21
Hypocalciuric hypercalcemia, type I, 145980 (3)  |CASR, HHC1, PCAR1, FIH, EIG8|601199|3q13.3-q21
Hypocalciuric hypercalcemia, type II (2)  |HHC2, FHH2|145981|19p13.3
Hypochondroplasia, 146000 (3)  |FGFR3, ACH|134934|4p16.3
Hypochromic microcytic anemia (3)  |HBA2|141850|16pter-p13.3
Hypofibrinogenemia, gamma type (3)  |FGG|134850|4q28
Hypoglycemia due to PCK1 deficiency (1) (?)  |PCK1|261680|20q13.31
Hypoglycemia of infancy, leucine-sensitive, 240800 (3)  |ABCC8, SUR, PHHI, SUR1, HHF1, TNDM2|600509|11p15.1
Hypogonadism, hypergonadotropic (3)  |LHB|152780|19q13.32
Hypogonadism, hypogonadotropic, 146110 (3)  |PROK2, PK2, BV8, KAL4|607002|3p21.1
Hypogonadotropic hypogonadism (3)  |GNRHR, LHRHR|138850|4q21.2
Hypogonadotropic hypogonadism due to GNRH deficiency, 227200 (1) (?)  |GNRH1, LNRH|152760|8p21-p11.2
Hypogonadotropic hypogonadism, 146110 (3)  |CHD7, IS3, KAL5|608892|8q12.1
Hypogonadotropic hypogonadism, 146110 (3)  |FGFR1, FLT2, KAL2, OGD|136350|8p11.2-p11.1
Hypogonadotropic hypogonadism, 146110 (3)  |KISS1R, GPR54|604161|19p13.3
Hypogonadotropic hypogonadism, 146110 (3)  |NELF|608137|9q34.3
Hypogonadotropic hypogonadism, 146110 (3)  |TAC3, NKNB|162330|12q13-q21
Hypogonadotropic hypogonadism, 146110 (3)  |TACR3, NK3R|162332|4q25
Hypokalemic periodic paralysis, type 1, 170400 (3)  |CACNA1S, CACNL1A3, CCHL1A3, TTPP1, HOKPP1|114208|1q32
Hypomagnesemia 4, renal, 611718 (3)  |EGF, URG, HOMG4|131530|4q25
Hypomagnesemia with secondary hypocalcemia, 602014 (3)  |TRPM6, CHAK2|607009|9q22
Hypomagnesemia, primary, 248250 (3)  |CLDN16, PCLN1, HOMG3|603959|3q27
Hypomagnesemia, renal, with ocular involvement, 248190 (3)  |CLDN19|610036|1p34.2
Hypomagnesemia-2, renal, 154020 (3)  |FXYD2, ATP1G1, HOMG2|601814|11q23
Hypomyelination, global cerebral, 612949 (3)  |SLC25A12, ARALAR|603667|2q24
Hypoparathyroidism, X-linked (2)  |HPT, HPTX, HYPX|307700|Xq26-q27
Hypoparathyroidism, autosomal dominant, 146200 (3)  |PTH|168450|11p15.3-p15.1
Hypoparathyroidism, autosomal recessive, 146200 (3)  |PTH|168450|11p15.3-p15.1
Hypoparathyroidism, familial isolated, 146200 (3)  |GCMB|603716|6p24.2
Hypoparathyroidism, sensorineural deafness, and renal dysplasia, 146255 (3)  |GATA3, HDR|131320|10p15
Hypoparathyroidism-retardation-dysmorphism syndrome, 241410 (3)  |TBCE, KCS, KCS1, HRD|604934|1q42-q43
Hypophosphatasia, adult, 146300 (3)  |ALPL, HOPS, TNSALP|171760|1p36.1-p34
Hypophosphatasia, childhood, 241510 (3)  |ALPL, HOPS, TNSALP|171760|1p36.1-p34
Hypophosphatasia, infantile, 241500 (3)  |ALPL, HOPS, TNSALP|171760|1p36.1-p34
Hypophosphatemic rickets and hyperparathyroidism (2)  |HPRHP|612089|13q13.1
Hypophosphatemic rickets with hypercalciuria, 241530 (3)  |SLC34A3, NPTIIC, HHRH|609826|9q34
Hypophosphatemic rickets, 300554 (3)  |CLCN5, CLCK2, NPHL2, DENTS, NPHL1|300008|Xp11.22
Hypophosphatemic rickets, AR, 241520 (3)  |DMP1, ARHR, ARHP|600980|4q21
Hypophosphatemic rickets, X-linked dominant, 307800 (3)  |PHEX, HYP, HPDR1, LXHR|300550|Xp22.2-p22.1
Hypophosphatemic rickets, autosomal dominant, 193100 (3)  |FGF23, ADHR, HPDR2, PHPTC|605380|12p13.3
Hypophosphatemic rickets, autosomal recessive, 2, 613312 (3)  |ENPP1, PDNP1, NPPS, M6S1, PCA1, ARHR2|173335|6q22-q23
Hypoplastic left heart syndrome, 241550 (3)  |GJA1, CX43, ODDD, SDTY3, ODOD, HSS|121014|6q21-q23.2
Hypoproteinemia, hypercatabolic, 241600 (3)  |B2M|109700|15q21-q22
Hypoprothrombinemia, 613679 (3)  |F2|176930|11p11-q12
Hypospadias 1, X-linked, 300633 (3)  |AR, DHTR, TFM, SBMA, KD, SMAX1, HYSP1|313700|Xq11-q12
Hypospadias 2, X-linked, 300758 (3)  |MAMLD1, CXorf6, F18, HYSP2|300120|Xq28
Hypothryoidism, congenital, nongoitrous 4, 275100 (3)  |TSHB, CHNG4|188540|1p13
Hypothyroidism, congenital nongoitrous, 5, 225250 (3)  |NKX2E, CSX, CHNG5|600584|5q34
Hypothyroidism, congenital, due to thyroid dysgenesis or hypoplasia, 218700 (3)  |PAX8|167415|2q12-q14
Hypothyroidism, congenital, nongoitrous, 1 275200 (3)  |TSHR, CHNG1|603372|14q31
Hypothyroidism, congenital, nongoitrous, 3 (2)  |CHNG3, RTSH|609893|15q25.3-q26.1
Hypotonia-cystinuria syndrome (4)  |DEL2p21, C2DELp21|606407|2p21
Hypotrichosis and recurrent skin vesicles, 613102 (3)  |DSC3, DSC4|600271|18q12.1
Hypotrichosis simplex (2)  |HTS|605389|18p11.32-p11.23
Hypotrichosis simplex of scalp, 146520 (3)  |CDSN, HTSS|602593|6p21.3
Hypotrichosis, congenital, with juvenile macular dystrophy, 601553 (3)  |CDH3, CDHP, PCAD, HJMD|114021|16q22.1
Hypotrichosis, hereditary, Marie Unna type, 1, 146550 (3)  |HR, AU, MUHH1|602302|8p21.2
Hypotrichosis, hereditary, Marie Unna type, 2 (2)  |MUHH2|612841|1p21.1-q21.3
Hypotrichosis, localized, autosomal recessive 2, 604379 (3)  |LIPH, LAH2, ARWH2|607365|3q27-q28
Hypotrichosis, localized, autosomal recessive, 3, 611452 (3)  |P2RY5, P2Y5, LAH3, ARWH1|609239|13q14.12-q14.2
Hypotrichosis, localized, autosomal recessive, 607903 (3)  |DSG4, LAH|607892|18q12
Hypotrichosis-lymphedema-telangiectasia syndrome, 607823 (3)  |SOX18, HLTS|601618|20q13.33
Hypouricemia, renal, 2, 612076 (3)  |SLC2A9, GLUT9, UAQTL2|606142|4p16-p15.3
Hypouricemia, renal, 220150 (3)  |SLC22A12, OAT4L, URAT1|607096|11q13
Hystrix-like ichthyosis with deafness, 602540 (3)  |GJB2, CX26, DFNB1A, PPK, DFNA3A, KID, HID|121011|13q11-q12
IMAGE syndrome (2)  |IMAGE|300290|Chr.X
IRAK4 deficiency, 607676 (3)  |IRAK4, REN64, IPD1|606883|12q12
IVIC syndrome, 147750 (3)  |SALL4, HSAL4|607343|20q13.13-q13.2
Ichthyosiform erythroderma, congenital, 242100 (3)  |TGM1, ICR2, LI1|190195|14q11.2
Ichthyosiform erythroderma, congenital, nonbullous, 1, 242100 (3)  |ALOX12B|603741|17p13.1
Ichthyosiform erythroderma, congenital, nonbullous, 1, 242100 (3)  |ALOXE3|607206|17p13.1
Ichthyosis bullosa of Siemens, 146800 (3)  |KRT2, KRT2A, KRT2E|600194|12q11-q13
Ichthyosis follicularis, atrichia, and photophobia syndrome, 308205 (3)  |MBTPS2, S2P, IFAP|300294|Xp22.12-p22.11
Ichthyosis histrix, Curth-Macklin Palmoplantar keratoderma, nonepidermolytic, 600962 (3)  |KRT1, EPPK, NEPPK, EHK|139350|12q13
Ichthyosis prematurity syndrome, 608649 (3)  |SLC27A4, FATP4, IPS|604194|9q34
Ichthyosis vulgaris, 146700 (3)  |FLG, ATOD2|135940|1q21
Ichthyosis with confetti, 609165 (3)  |KRT10, EHK, BCIE, BIE|148080|17q21-q22
Ichthyosis with hypotrichosis, 610765 (3)  |ST14, MTSP1|606797|11q24-q25
Ichthyosis, X-linked, 308100 (3)  |STS, ARSC1, ARSC, SSDD, XLI|300747|Xp22.32
Ichthyosis, congenital, autosomal recessive, 612281 (3)  |ICHYN|609383|5q33
Ichthyosis, cyclic, with epidermolytic hyperkeratosis, 607602 (3)  |KRT1, EPPK, NEPPK, EHK|139350|12q13
Ichthyosis, cyclic, with epidermolytic hyperkeratosis, 607602 (3)  |KRT10, EHK, BCIE, BIE|148080|17q21-q22
Ichthyosis, harlequin, 242500 (3)  |ABCA12, ICR2B, LI2|607800|2q34
Ichthyosis, lamellar 2, 601277 (3)  |ABCA12, ICR2B, LI2|607800|2q34
Ichthyosis, lamellar, 3, 604777 (3)  |CYP4F22, LI3|611495|19p13.12
Ichthyosis, lamellar, 5 (2)  |LI5|606545|17p13.2-p13.1
Ichthyosis, lamellar, autosomal recessive, 242300 (3)  |TGM1, ICR2, LI1|190195|14q11.2
Ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis, 607626 (3)  |CLDN1, SEMP1, ILVASC|603718|3q28-q29
Ichthyosis, nonlamellar and nonerythrodermic, congenital (2)  |INLNE|604781|19p13.2-p13.1
IgG2 deficiency, selective (3)  |IGHG2|147110|14q32.33
Iminoglycinuria, digenic, 242600 (3)  |SLC36A2, PAT2|608331|5q33.1
Iminoglycinuria, digenic, 242600 (3)  |SLC6A19, HND|608893|5p15.33
Iminoglycinuria, digenic, 242600 (3)  |SLC6A20, XT3|605616|3p21.3
Immune dysfunction with T-cell inactivation due to calcium entry defect 1, 612782 (3)  |ORAI1, TMEM142A, CRACM1|610277|12q24
Immune dysfunction, with T-cell inactivation due to calcium entry defect 2, 612783 (3)  |STIM1|605921|11p15.5
Immunodeficiency due to defect in CD3-epsilon (3)  |CD3E|186830|11q23
Immunodeficiency due to defect in CD3-gamma (3)  |CD3G|186740|11q23
Immunodeficiency due to defect in CD3-zeta, 610163 (3)  |CD247, CD3Z, TCRZ|186780|1q22-q23
Immunodeficiency due to defect in MAPBP-interacting protein, 610798 (3)  |MAPBPIP, p14|610389|1q22
Immunodeficiency due to purine nucleoside phosphorylase deficiency, 613179 (3)  |PNP, NP|164050|14q13.1
Immunodeficiency with hyper IgM, type 4, 608106 (3)  |UNG, DGU, HIGM4|191525|12q23-q24.1
Immunodeficiency with hyper-IgM, type 2, 605258 (3)  |AICDA, AID, HIGM2|605257|12p13
Immunodeficiency with hyper-IgM, type 3, 606843 (3)  |TNFRSF5, CD40|109535|20q12-q13.2
Immunodeficiency, X-linked, with hyper-IgM, 308230 (3)  |TNFSF5, CD40LG, HIGM1, IGM|300386|Xq26
Immunodeficiency, common variable, 1, 607594 (3)  |ICOS, AILIM, CVID1|604558|2q33
Immunodeficiency, common variable, 2, 240500 (3)  |TNFRSF13B, TACI, CVID2|604907|17p11.2
Immunodeficiency, common variable, 3, 613493 (3)  |CD19, CVID3|107265|16p11.2
Immunodeficiency, common variable, 4, 613494 (3)  |TNFRSF13C, BAFFR, CVID4|606269|22q13.1-q13.31
Immunodeficiency, common variable, 5, 613495 (3)  |MS4A1, CD20, CVID5|112210|11q13
Immunodeficiency, common variable, 6, 613496 (3)  |CD81, TAPA1, CVID6|186845|11p
Immunodeficiency, isolated, 300584 (3)  |IKBKG, NEMO, FIP3, IP2, IPD2, AMCBX1|300248|Xq28
Immunodeficiency-centromeric instability-facial anomalies syndrome, 242860 (3)  |DNMT3B, ICF|602900|20q11.2
Immunodysregulation, polyendocrinopathy, and enteropathy, X-linked, 304790 (3)  |FOXP3, IPEX, AIID, XPID, PIDX|300292|Xp11.23-q13.3
Immunoglobulin A deficiency (2)  |IGAD1|137100|6p21.3
Immunoglobulin A deficiency 2, 609529 (3)  |TNFRSF13B, TACI, CVID2|604907|17p11.2
Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia, 167320 (3)  |VCP, IBMPFD|601023|9p13-p12
Inclusion body myopathy, autosomal recessive, 600737 (3)  |GNE, GLCNE, IBM2, DMRV, NM|603824|9p13.3
Inclusion body myopathy-3, 605637 (3)  |MYH2|160740|17p13.1
Incontinentia pigmenti, type II, 308300 (3)  |IKBKG, NEMO, FIP3, IP2, IPD2, AMCBX1|300248|Xq28
Increased responsiveness to growth hormone (3)  |GHR|600946|5p13-p12
Infantile neuroaxonal dystrophy 1, 256600 (3)  |PLA2G6, IPLA2, INAD1, NBIA2B, NBIA2A, PARK14|603604|22q13.1
Inflammatory bowel disease 25, early onset, autosomal recessive, 612567 (3)  |CRFB4, IBD25|123889|21q22.1
Inflammatory bowel disease 28, early onset, autosomal recessive, 613148 (3)  |IL10RA, IL10R, IBD28|146933|11q23.3
Insensitivity to pain, channelopathy-associated, 243000 (3)  |SCN9A, NENA, PN1, FEB3B|603415|2q24
Insensitivity to pain, congenital, with anhidrosis, 256800 (3)  |NTRK1, TRKA, MTC|191315|1q21-q22
Insomnia (3)  |GABRB3, ECA5|137192|15q11.2-q12
Insomnia, fatal familial, 600072 (3)  |PRNP, PRIP|176640|20pter-p12
Insulin resistance, severe, digenic, 604367 (3)  |PPARG, PPARG1, PPARG2, CIMT1, GLM1|601487|3p25
Insulin resistance, severe, digenic, 604367 (3)  |PPP1R3A, PPP1R3|600917|7q11.23-q21.11
Insulin-like growth factor I, resistance to, 270450 (3)  |IGF1R|147370|15q25-q26
Insulinoma (1)  |ITS|606960|22q12.1-q12.2
Interferon, alpha, deficiency (1)  |IFNA1, IFNA@|147660|9p22
Interleukin 1 receptor antagonist deficiency, 612852 (3)  |IL1RN, MVCD4, DIRA|147679|2q14.2
Interleukin-2 receptor, alpha chain, deficiency of, 606367 (3)  |IL2RA, IL2R, IDDM10|147730|10p15.1
Intestinal pseudoobstruction, neuronal, 300048 (3)  |FLNA, FLN1, NHBP, OPD1, OPD2, FMD, MNS, CVD1|300017|Xq28
Intestinal pseudoobstruction, neuronal, X-linked (2)  |IPOX, CIIPX|300048|Xq28
Intrauterine and postnatal growth retardation (1)  |IGF2|147470|11p15.5
Intrinsic factor deficiency, 261000 (3)  |GIF, IF|609342|11q13
Invasive pneumococcal d  |IKBKG, NEMO, FIP3, IP2, IPD2, AMCBX1|300248|Xq28
Invasive pneumococcal disease, recurrent isolated, 1, 610799 (3)  |IRAK4, REN64, IPD1|606883|12q12
Iridogoniodysgenesis, type 1, 601631 (3)  |FOXC1, FKHL7, FREAC3, IRID1, RIEG3|601090|6p25
Iridogoniodysgenesis, type 2, 137600 (3)  |PITX2, IDG2, RIEG1, RGS, IGDS2|601542|4q25-q26
Iris hypoplasia and glaucoma, 601631 (3)  |FOXC1, FKHL7, FREAC3, IRID1, RIEG3|601090|6p25
Iron overload, autosomal dominant (3)  |FTH1, FTHL6|134770|11q12-q13
Iron-refractory iron deficiency anemia, 206200 (3)  |TMPRSS6, IRIDA|609862|22q12-q13
Isobutyryl-CoA dehydrogenase deficiency, 611283 (3)  |ACAD8|604773|11q25
Isolated growth hormone deficiency due to defect in GHRF (1) (?)  |GHRH, GHRF|139190|20q11.2
Isovaleric acidemia, 243500 (3)  |IVD|607036|15q14-q15
Jackson-Weiss syndrome, 123150 (3)  |FGFR1, FLT2, KAL2, OGD|136350|8p11.2-p11.1
Jackson-Weiss syndrome, 123150 (3)  |FGFR2, BEK, CFD1, JWS|176943|10q26
Jacobsen syndrome (4)  |JBS|147791|11q23
Jalili syndrome, 217080 (3)  |CNNM4, ACDP4|607805|2q11.2
Jensen syndrome, 311150 (3)  |TIMM8A, DFN1, DDP, MTS, DDP1|300356|Xq22
Jervell and Lange-Nielsen syndrome 2, 612347 (3)  |KCNE1, JLNS, LQT5, JLNS2|176261|21q22.1-q22.2
Jervell and Lange-Nielsen syndrome, 220400 (3)  |KCNQ1, KCNA9, LQT1, KVLQT1, ATFB3, SQT2|607542|11p15.5
Johanson-Blizzard syndrome, 243800 (3)  |UBR1, JBS|605981|15q15-q21.1
Joubert syndrome 1, 213300 (3)  |INPP5E, MORMS, JBTS1, CORS1|613037|9q34.3
Joubert syndrome 10, 300804 (3)  |OFD1, CXorf5, SGBS2, JBTS10|300170|Xp22.3-p22.2
Joubert syndrome 2, 608091 (3)  |TMEM216, JBTS2|613277|11q13
Joubert syndrome 4, 609583 (3)  |NPHP1, NPH1, SLSN1, JBTS4|607100|2q13
Joubert syndrome 5, 610188 (3)  |CEP290, KIAA0373, 3H11AG, JBTS5, SLSN6, LCA10, BBS14|610142|12q21.3
Joubert syndrome 6, 610688 (3)  |TMEM67, MKS3, JBTS6, NPHP11|609884|8q21.13-q22.1
Joubert syndrome 7, 611560 (3)  |RPGRIP1L, KIAA1005, JBTS7, MKS5|610937|16q12.2
Joubert syndrome 8, 612291 (3)  |ARL13B, ARL2L1, JBTS8|608922|3q11.2
Joubert syndrome 9, 612285 (3)  |CC2D2A, KIAA1345, MKS6|612013|4p15.3
Joubert syndrome-1 (2)  |JBTS1|213300|9q34.3
Joubert syndrome-3, 608629 (3)  |AHI1|608894|6q23.3
Juvenile polyposis syndrome, infantile form, 174900 (3)  |BMPR1A, ACVRLK3, ALK3|601299|10q22.3
Juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome, 175050 (3)  |MADH4, DPC4, SMAD4, JIP|600993|18q21.1
Kabuki syndrome, 147920 (3)  |MLL2, ALR|602113|12q12-q14
Kahrizi syndrome (2)  |KRIZI|612713|4p12-q12
Kallmann syndrome (3)  |KAL1, KMS, ADMLX|308700|Xp22.3
Kallmann syndrome 2, 147950 (3)  |FGFR1, FLT2, KAL2, OGD|136350|8p11.2-p11.1
Kallmann syndrome 3, 244200 (3)  |PROKR2, PKR2, GPR73L1, KAL3|607123|20p13
Kallmann syndrome 4, 610628 (3)  |PROK2, PK2, BV8, KAL4|607002|3p21.1
Kallmann syndrome 5, 612370 (3)  |CHD7, IS3, KAL5|608892|8q12.1
Kallmann syndrome 6, 612702 (3)  |FGF8, KAL6|600483|10q24
Kanzaki disease, 609242 (3)  |NAGA|104170|22q11
Karak syndrome, 610217 (3)  |PLA2G6, IPLA2, INAD1, NBIA2B, NBIA2A, PARK14|603604|22q13.1
Kenny-Caffey syndrome-1, 244460 (3)  |TBCE, KCS, KCS1, HRD|604934|1q42-q43
Keratitis, 148190 (3)  |PAX6, AN2, MGDA|607108|11p13
Keratitis-ichthyosis-deafness syndrome, 148210 (3)  |GJB2, CX26, DFNB1A, PPK, DFNA3A, KID, HID|121011|13q11-q12
Keratoconus 2 (2)  |KTCN2|608932|16q22.3-q23.1
Keratoconus 3 (2)  |KTCN3|608586|3p14-q13
Keratoconus 4 (2)  |KTCN4|609271|2p24
Keratoconus, 148300 (3)  |VSX1, RINX, PPCD, PPD, KTCN|605020|20p11.2
Keratoderma, palmoplantar, punctate type 1 (2)  |PPKP1|148600|15q22-q24
Keratoderma, palmoplantar, punctate type 3 (2) (?)  |PPKP3|101850|2p25-p12
Keratoderma, palmoplantar, with deafness, 148350 (3)  |GJB2, CX26, DFNB1A, PPK, DFNA3A, KID, HID|121011|13q11-q12
Keratolytic winter erythema (2)  |KWE|148370|8p23-p22
Keratosis follicularis spinulosa decalvans, 308800 (3)  |SAT1, SSAT, KFSD, KFSDX|313020|Xp22.1
Keratosis linearis with ichthyosis congenita and sclerosing keratoderma, 601952 (3)  |POMP, UMP1|613386|13q12.3
Keratosis palmoplantaris striata I, 148700 (3)  |DSG1, PPKS1, SPPK1|125670|18q12.1-q12.2
Keratosis palmoplantaris striata II, 612908 (3)  |DSP, KPPS2, PPKS2|125647|6p24
Keratosis palmoplantaris striata III, 607654 (3)  |KRT1, EPPK, NEPPK, EHK|139350|12q13
Keratosis, seborrheic, somatic, 182000 (3)  |PIK3CA|171834|3q26.3
Keutel syndrome, 245150 (3)  |MGP, NTI|154870|12p13.1-p12.3
Kindler syndrome, 173650 (3)  |KIND1, URP1, C20orf42|607900|20p13
Kleefstra syndrome, 610253 (3)  |EHMT1, EUHMTASE1, DEL9q34|607001|9q34.3
Klippel-Feil syndrome 1, autosomal dominant, 118100 (3)  |GDF6, MCOP4, KFS1, MCOPCB6|601147|8q22.1
Klippel-Feil syndrome 2, autosomal recessive (2) (?)  |KFS2, KFM|214300|5q11.2
Klippel-Feil syndrome 3, autosomal dominant, 613702 (3)  |GDF3, KFS3, MCOPCB6, MCOP7|606522|12p13.1
Klippel-Trenaunay-Weber syndrome (2)  |KTWS, KTS|149000|8q22.3
Kniest dysplasia, 156550 (3)  |COL2A1|120140|12q13.11-q13.2
Knobloch syndrome, type 1, 267750 (3)  |COL18A1, KNO1|120328|21q22.3
Knobloch syndrome, type III (2)  |KNO3|611948|17q11.2
Kowarski syndrome, 262650 (3)  |GH1, GHN, IGHD1B|139250|17q22-q24
Krabbe disease, 245200 (3)  |GALC|606890|14q31
Krabbe disease, atypical, 611722 (3)  |PSAP, SAP1|176801|10q22.1
Kyphoscoliosis 1 (2)  |KYPSC1|610170|5p13
L-2-hydroxyglutaric aciduria, 236792 (3)  |L2HGDH, C14orf160|609584|14q22.1
LADD syndrome, 149730 (3)  |FGF10|602115|5p13-p12
LADD syndrome, 149730 (3)  |FGFR3, ACH|134934|4p16.3
LCHAD deficiency, 609016 (3)  |HADHA, MTPA|600890|2p23
LDL cholesterol level QTL2 (3)  |LDLR, FHC, FH, LDLCQ2|606945|19p13.2
LEOPARD syndrome 1, 151100 (3)  |PTPN11, PTP2C, SHP2, NS1|176876|12q24.1
LEOPARD syndrome 2, 611554 (3)  |RAF1, CRAF, NS5|164760|3p25
LEOPARD syndrome 3, 613707 (3)  |BRAF, NS7|164757|7q34
LIG4 syndrome, 606593 (3)  |LIG4|601837|13q22-q34
Lactase deficiency, congenital, 223000 (3)  |LCT, LAC, LPH|603202|2q21
Lactase persistance/nonpersistance, 223100 (3)  |MCM6|601806|2q21
Lactate dehydrogenase-B deficiency (3)  |LDHB|150100|12p12.2-p12.1
Lacticacidemia due to PDX1 deficiency, 245349 (3)  |PDX1|608769|11p13
Laing distal myopathy, 160500 (3)  |MYH7, CMH1, MPD1, CMD1S, SPMM, SPMD|160760|14q12
Langer mesomelic dysplasia, 249700 (3)  |SHOX, GCFX, SS, PHOG|312865|Xpter-p22.32
Langer mesomelic dysplasia, 249700 (3)  |SHOXY|400020|Ypter-p11.2
Laron dwarfism, 262500 (3)  |GHR|600946|5p13-p12
Larsen syndrome, 150250 (3)  |FLNB, SCT, AOI, LRS1|603381|3p14.3
Larsen-like syndrome (2)  |LRSL|608545|6p25
Laryngeal adductor paralysis (2) (?)  |LAP|150270|6p21.3-p21.2
Laryngoonychocutaneous syndrome, 245660 (3)  |LAMA3, LOCS|600805|18q11.2
Lathosterolosis, 607330 (3)  |SC5DL, ERG3|602286|11q23.3
Leber congenital amaurosis 1, 204000 (3)  |GUCY2D, GUC2D, LCA1, CORD6, RCD2|600179|17p13.1
Leber congenital amaurosis 10, 611755 (3)  |CEP290, KIAA0373, 3H11AG, JBTS5, SLSN6, LCA10, BBS14|610142|12q21.3
Leber congenital amaurosis 11 (3)  |IMPDH1, RP10, LCA11|146690|7q31.3-q32
Leber congenital amaurosis 12, 610612 (3)  |RD3, LCA12, C1orf36|180040|1q32.3
Leber congenital amaurosis 13, 612712 (3)  |RDH12, LCA13|608830|14q23.3
Leber congenital amaurosis 14, 613341 (3)  |LRAT, LCA14|604863|4q31
Leber congenital amaurosis 2, 204100 (3)  |RPE65, RP20, LCA2|180069|1p31
Leber congenital amaurosis 3, 604232 (3)  |SPATA7, HSD3, LCA3|609868|14q31.3
Leber congenital amaurosis 4, 604393 (3)  |AIPL1, LCA4|604392|17p13.1
Leber congenital amaurosis 5, 604537 (3)  |LCA5, C6orf152|611408|6q14.1
Leber congenital amaurosis 6 (3)  |RPGRIP1, LCA6, CORD13|605446|14q11
Leber congenital amaurosis 7 (3)  |CRX, CORD2, CRD, LCA7|602225|19q13.3
Leber congenital amaurosis 8 (3)  |CRB1, RP12, LCA8|604210|1q31-q32.1
Leber congenital amaurosis 9 (2)  |LCA9|608553|1p36
Left ventricular noncompaction 1, with or without congenital heart defects, 604169 (3)  |DTNA, D18S892E, DRP3, LVNC1|601239|18q12.1-q12.2
Left ventricular noncompaction 2 (2)  |LVNC2|609470|11p15
Left ventricular noncompaction 3, with or without dilated cardiomyopathy, 601493 (3)  |LDB3, ZASP, CYPHER, KIAA01613, CMD1C, LVNC3|605906|10q22.2-q23.3
Left ventricular noncompaction 4, 613424 (3)  |ACTC1, CMD1R, CMH11, ASD5, LVNC4|102540|15q14
Left ventricular noncompaction 5, 613426 (3)  |MYH7, CMH1, MPD1, CMD1S, SPMM, SPMD|160760|14q12
Left ventricular noncompaction 6, 601494 (3)  |TNNT2, CMH2, CMD1D, RCM3, LVNC6|191045|1q32
Left ventricular noncompaction, X-linked, 300183 (3)  |TAZ, EFE2, BTHS, CMD3A, LVNCX|300394|Xq28
Left-right axis malformations (3)  |EBAF, TGFB4, LEFTY2, LEFTA, LEFTYA|601877|1q42.1
Legius syndrome, 611431 (3)  |SPRED1, NFLS|609291|15q13.2
Leigh syndrome due to cytochrome c oxidase deficiency, 256000 (3)  |COX15|603646|10q24
Leigh syndrome due to mitochondrial complex I deficiency, 256000 (3)  |C8orf38|612392|8q22.1
Leigh syndrome due to mitochondrial complex I deficiency, 256000 (3)  |NDUFA2|602137|5q31.2
Leigh syndrome, 256000 (3)  |BCS1L, FLNMS, GRACILE, BJS, PTD|603647|2q33
Leigh syndrome, 256000 (3)  |DLD, LAD, PHE3|238331|7q31-q32
Leigh syndrome, 256000 (3)  |FOXRED1|613622|11q24.2
Leigh syndrome, 256000 (3)  |NDUFAF2, NDUFA12L, MMTN, B17.2L|609653|5q12.1
Leigh syndrome, 256000 (3)  |NDUFS3|603846|11p11.11
Leigh syndrome, 256000 (3)  |NDUFS4, AQDQ|602694|5q11.1
Leigh syndrome, 256000 (3)  |NDUFS7, PSST|601825|19p13
Leigh syndrome, 256000 (3)  |NDUFS8|602141|11q13
Leigh syndrome, 256000 (3)  |NDUFV1, UQOR1|161015|11q13
Leigh syndrome, 256000 (3)  |SDHA, SDH1, SDHF, CMD1GG|600857|5p15
Leigh syndrome, French-Canadian type, 220111 (3)  |LRPPRC, LRP130, LSFC|607544|2p21-p16
Leigh syndrome, X-linked, 308930 (3)  |PDHA1, PHE1A|300502|Xp22.2-p22.1
Leigh syndrome, due to COX deficiency, 256000 (3)  |SURF1|185620|9q34
Leiomyomatosis and renal cell cancer, 605839 (3)  |FH|136850|1q42.1
Leiomyomatosis, diffuse, with Alport syndrome, 308940 (4)  |COL4A6, DELXq22.3, CXDELq22.3|303631|Xq22.3
Leprechaunism, 246200 (3)  |INSR, HHF5|147670|19p13.2
Leri-Weill dyschondrosteosis, 127300 (3)  |SHOX, GCFX, SS, PHOG|312865|Xpter-p22.32
Leri-Weill dyschondrosteosis, 127300 (3)  |SHOXY|400020|Ypter-p11.2
Lesch-Nyhan syndrome, 300322 (3)  |HPRT1, HPRT|308000|Xq26-q27.2
Lethal congenital contractural syndrome 2, 607598 (3)  |ERBB3, LCCS2|190151|12q13
Lethal congenital contractural syndrome 3, 611369 (3)  |PIP5K1C, LCCS3|606102|19p13.3
Lethal congenital contracture syndrome 1, 253310 (3)  |GLE1, GLE1L, LCCS, LCCS1|603371|9q34
Leukemia, Philadelphia chromosome-positive, resistant to imatinib (3)  |ABL1|189980|9q34.1
Leukemia, T-cell acute lymphoblastic (2)  |LMO1, RBTN1, RHOM1|186921|11p15
Leukemia, T-cell acute lymphoblastic (2)  |NOTCH1, TAN1|190198|9q34.3
Leukemia, T-cell acute lymphoblastic (3)  |NUP214, D9S46E, CAN, CAIN|114350|9q34.1
Leukemia, T-cell acute lymphoblastoid (2)  |LYL1|151440|19p13.2-p13.1
Leukemia, T-cell acute lymphocytic (2)  |TLX1, HOX11, TCL3|186770|10q24
Leukemia, acute T-cell (2)  |LMO2, RBTNL1, RHOM2, TTG2|180385|11p13
Leukemia, acute T-cell lymphoblastic (3)  |AF10|602409|10p12
Leukemia, acute T-cell lymphoblastic (3)  |PICALM, CALM, CLTH, LAP|603025|11q14
Leukemia, acute T-cell lymphoblastic (3)  |SETBP1, KIAA0437, SEB|611060|18q21.1
Leukemia, acute lymphoblastic (1)  |TCF3, E2A|147141|19p13.3
Leukemia, acute lymphoblastic (2)  |LALL|247640|9p22-p21
Leukemia, acute lymphoblastic (3)  |FLT3|136351|13q12
Leukemia, acute lymphoblastic (3)  |IKZF1, ZNFN1A1, IK1, LYF1|603023|7p12
Leukemia, acute lymphoblastic (3)  |NBS1, NBS|602667|8q21
Leukemia, acute lymphocytic, 613065 (3)  |BCR, CML, PHL, ALL|151410|22q11.21
Leukemia, acute myeloblastic (3)  |ARNT|126110|1q21
Leukemia, acute myelogenous (3)  |KRAS, KRAS2, RASK2, NS|190070|12p12.1
Leukemia, acute myelogenous, 601626 (2)  |AMLCR2|602439|16q22
Leukemia, acute myelogenous, 601626 (3)  |GMPS|600358|3q24
Leukemia, acute myelogenous, 601626 (3)  |JAK2|147796|9p24
Leukemia, acute myeloid, 601626 (1)  |MLF1|601402|3q25.1
Leukemia, acute myeloid, 601626 (1)  |NSD1, ARA267, STO|606681|5q35
Leukemia, acute myeloid, 601626 (1)  |SH3GL1, EEN|601768|19p13.3
Leukemia, acute myeloid, 601626 (3)  |AF10|602409|10p12
Leukemia, acute myeloid, 601626 (3)  |ARHGEF12, LARG, KIAA0382|604763|11q23.3
Leukemia, acute myeloid, 601626 (3)  |CEBPA, CEBP|116897|19q13.1
Leukemia, acute myeloid, 601626 (3)  |FLT3|136351|13q12
Leukemia, acute myeloid, 601626 (3)  |KIT, PBT|164920|4q12
Leukemia, acute myeloid, 601626 (3)  |LPP|600700|3q28
Leukemia, acute myeloid, 601626 (3)  |NPM1|164040|5q35
Leukemia, acute myeloid, 601626 (3)  |NUP214, D9S46E, CAN, CAIN|114350|9q34.1
Leukemia, acute myeloid, 601626 (3)  |PICALM, CALM, CLTH, LAP|603025|11q14
Leukemia, acute myeloid, 601626 (3)  |RUNX1, CBFA2, AML1|151385|21q22.3
Leukemia, acute myeloid, 601626 (3)  |WHSC1L1, NSD3|607083|8p12
Leukemia, acute myeloid, reduced survival in (3)  |FLT3|136351|13q12
Leukemia, acute myeloid, somatic, 601626 (3)  |ETV6, TEL|600618|12p13
Leukemia, acute myeloid, therapy-related (1)  |SEPT9, MSF, MSF1, NAPB|604061|17q25
Leukemia, acute myeloid, with eosinophilia (1)  |ABL2, ABLL, ARG|164690|1q24-q25
Leukemia, acute myelomonocytic (3)  |MLLT11, AF1Q|604684|1q21
Leukemia, acute nonlymphocytic (2)  |DEK, D6S231E|125264|6p23
Leukemia, acute pre-B-cell (2)  |PBX1|176310|1q23
Leukemia, acute promyelocytic, 612376 (1)  |RARA|180240|17q21.1
Leukemia, acute promyelocytic, NPM/RARA type (3)  |NPM1|164040|5q35
Leukemia, acute promyelocytic, NUMA/RARA type (3)  |NUMA1|164009|11q13
Leukemia, acute promyelocytic, PL2F/RARA type (3)  |ZBTB16, ZNF145, PLZF|176797|11q23.1
Leukemia, acute promyelocytic, PML/RARA type (3)  |PML, MYL|102578|15q22
Leukemia, acute promyelocytic, STAT5B/RARA type (3)  |STAT5B|604260|17q11.2
Leukemia, chronic myeloid, 608232 (3)  |BCR, CML, PHL, ALL|151410|22q11.21
Leukemia, juvenile myelomonocytic, 607785 (3)  |ARHGAP26, GRAF|605370|5q31
Leukemia, juvenile myelomonocytic, 607785 (3)  |NF1, VRNF, WSS, NFNS|613113|17q11.2
Leukemia, juvenile myelomonocytic, 607785 (3)  |PTPN11, PTP2C, SHP2, NS1|176876|12q24.1
Leukemia, lymphocytic, acute T-cell (1)  |NUP98|601021|11p15
Leukemia, megakaryoblastic, of Down syndrome, 190685 (3)  |GATA1, GF1, ERYF1, NFE1, XLTT|305371|Xp11.23
Leukemia, megakaryoblastic, with or without Down syndrome, 190685 (3)  |GATA1, GF1, ERYF1, NFE1, XLTT|305371|Xp11.23
Leukemia, myeloid/lymphoid or mixed-lineage (2)  |MLL, HRX, HTRX1|159555|11q23
Leukemia, transient, of Down syndrome (2)  |TAM, MST|159595|21q11.2
Leukemia-1, T-cell acute lymphocytic (3)  |TAL1, TCL5, SCL|187040|1p32
Leukemia-2, T-cell acute lymphoblastic (3)  |TAL2|186855|9q31
Leukemia/lymphoma, B-cell, 2 (3)  |BCL2|151430|18q21.3
Leukemia/lymphoma, B-cell, 3 (2)  |BCL3|109560|19q13
Leukemia/lymphoma, T-cell (2)  |TCL1A, TCL1|186960|14q32.1
Leukemia/lymphoma, T-cell (2)  |TCL1B, TML1|603769|14q32.1
Leukemia/lymphoma, T-cell (2)  |TCL4|186860|2q34
Leukemia/lymphoma, T-cell (3)  |TCRA|186880|14q11.2
Leukocyte adhesion deficiency, 116920 (3)  |ITGB2, CD18, LCAMB, LAD|600065|21q22.3
Leukocyte adhesion deficiency, type III, 612840 (3)  |KIND3, URP2, MIG2B, FERMT3|607901|11q12
Leukodystrophy, adult-onset, autosomal dominant, 169500 (3)  |LMNB1|150340|5q23.3-q31.1
Leukodystrophy, dysmyelinating, and spastic paraparesis with or without dystonia, 612443 (3)  |FA2H, FAAH, FAXDC1, FAH1, SCS7|611026|16q23
Leukodystrophy, hypomyelinating, 2, 608804 (3)  |GJC2, GJA12, CX47, PMLDAR, HLD2, SPG44, LMPH1C|608803|1q41-q42
Leukodystrophy, hypomyelinating, 4, 612233 (3)  |HSPD1, SPG13, HSP60, HLD4|118190|2q33.1
Leukodystrophy, hypomyelinating, 5, 610532 (3)  |FAM126A, DRCTNNB1A, HLD5|610531|7p15.3
Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation, 611105 (3)  |DARS2, ASPRS. LBSL|610956|1q25.1
Leukoencephalopathy with dystonia and motor neuropathy, 613724 (3)  |SCP2|184755|1p32
Leukoencephalopathy with metaphyseal chondrodysplasia (2)  |LKMCD|300660|Xq25-q27
Leukoencephalopathy with vanishing white matter, 603896 (3)  |EIF2B1, EIF2BA|606686|Chr.12
Leukoencephalopathy with vanishing white matter, 603896 (3)  |EIF2B2|606454|14q24
Leukoencephalopathy with vanishing white matter, 603896 (3)  |EIF2B3|606273|1p34.1
Leukoencephalopathy with vanishing white matter, 603896 (3)  |EIF2B5, LVWM, CACH, CLE|603945|3q27
Leukoencephalopathy, cystic, without megalencephaly, 612951 (3)  |RNASET2, RNASE6PL|612944|6q27
Leukoencephaly with vanishing white matter, 603896 (3)  |EIF2B4|606687|2p23.3
Leukotriene C4 synthase deficiency (1)  |LTC4S|246530|5q35
Leydig cell adenoma, somatic, with precocious puberty, 176410 (3)  |LHCGR, LHR, LCGR|152790|2p21
Leydig cell hypoplasia with hypergonadotropic hypogonadism, 238320 (3)  |LHCGR, LHR, LCGR|152790|2p21
Leydig cell hypoplasia with pseudohermaphroditism, 238320 (3)  |LHCGR, LHR, LCGR|152790|2p21
Lhermitte-Duclos syndrome, 158350 (3)  |PTEN, MMAC1, GLM2|601728|10q23.31
Li-Fraumeni syndrome 3 (2)  |LFS3|609266|1q23
Li-Fraumeni syndrome, 151623 (3)  |CDKN2A, MTS1, P16, MLM, CMM2|600160|9p21
Li-Fraumeni syndrome, 151623 (3)  |TP53, P53, LFS1|191170|17p13.1
Li-Fraumeni syndrome, 609265 (3)  |CHEK2, RAD53, CHK2, CDS1, LFS2|604373|22q12.1
Li-Fraumeni-like syndrome, 151623 (3)  |TP53, P53, LFS1|191170|17p13.1
Liddle syndrome, 177200 (3)  |SCNN1B, BESC1|600760|16p13-p12
Liddle syndrome, 177200 (3)  |SCNN1G, PHA1, BESC3|600761|16p13-p12
Limb-girdle muscular dystrophy, type 1G (2)  |LGMD1G|609115|4q21
Limb-mammary syndrome, 603543 (3)  |TP63, TP73L, KET, EEC3, SHFM4, LMS, RHS, OFC8|603273|3q27
Lipase deficiency, combined, 246650 (3)  |LMF1, TMEM112|611761|16p13.3
Lipodystrophy, congenital generalized, type 1, 608594 (3)  |AGPAT2, LPAAB, BSCL, BSCL1|603100|9q34.3
Lipodystrophy, congenital generalized, type 2, 269700 (3)  |BSCL2, SPG17, HMN5|606158|11q13
Lipodystrophy, congenital generalized, type 3, 612526 (3)  |CAV1, BSCL3, CGL3|601047|7q31.1
Lipodystrophy, congenital generalized, type 4, 613327 (3)  |PTRF, CAVIN, CGL4|603198|17q21
Lipodystrophy, familial partial, 151660 (3)  |LMNA, LMN1, EMD2, FPLD, CMD1A, HGPS, LGMD1B|150330|1q21.2
Lipodystrophy, familial partial, type 3, 604367 (3)  |PPARG, PPARG1, PPARG2, CIMT1, GLM1|601487|3p25
Lipodystrophy, partial, acquired, 608709 (3)  |LMNB2, LMN2|150341|19p13.3
Lipoid adrenal hyperplasia, 201710 (3)  |STAR|600617|8p11.2
Lipoid congenital adrenal hyperplasia, 201710 (3)  |CYP11A, P450SCC|118485|15q23-q24
Lipoid proteinosis, 247100 (3)  |ECM1|602201|1q21
Lipoma (1) (?)  |HMGA1, HMGIY|600701|6p21
Lipoma (3)  |LPP|600700|3q28
Lipoma, somatic (3)  |MEN1|613733|11q13
Lipoprotein glomerulopathy, 611771 (3)  |APOE, AD2, LPG, LDLCQ5|107741|19q13.2
Lipoprotein lipase deficiency, 238600 (3)  |LPL, LIPD, HDLCQ11|609708|8p22
Liposarcoma (1)  |LPSA, D19S381E|164953|19p13.2-q13.3
Lissencephaly 3, 611603 (3)  |TUBA1A, TUBA3, LIS3|602529|12q12-q14
Lissencephaly syndrome, Norman-Roberts type, 257320 (3)  |RELN, RL|600514|7q22
Lissencephaly, X-linked 2, 300215 (3)  |ARX, ISSX, PRTS, MRXS1, MRX36, MRX54, MRX43, MRX87, MRX29, MRX32|300382|Xp22.13
Lissencephaly, X-linked, 300067 (3)  |DCX, DBCN, LISX|300121|Xq22.3-q23
Lissencephaly-1, 607432 (3)  |PAFAH1B1, LIS1|601545|17p13.3
Liver failure, acute infantile, 613070 (3)  |TRMU, MTO2, TRNT1|610230|22q13
Loeys-Dietz syndrome, type 1A, 609192 (3)  |TGFBR1, ALK5, AAT5, LDS2A, LDS1A|190181|9q22
Loeys-Dietz syndrome, type 1B, 610168 (3)  |TGFBR2, HNPCC6, AAT3, MFS2, LDS1B, LDS2B|190182|3p22
Loeys-Dietz syndrome, type 2A, 608967 (3)  |TGFBR1, ALK5, AAT5, LDS2A, LDS1A|190181|9q22
Loeys-Dietz syndrome, type 2B, 610380 (3)  |TGFBR2, HNPCC6, AAT3, MFS2, LDS1B, LDS2B|190182|3p22
Long QT syndrome 12, 612955 (3)  |SNT1, LQT12|601017|20q11.2
Long QT syndrome 13, 613485 (3)  |KCNJ5, GIRK4, KATP1, LQT13|600734|11q24
Long QT syndrome-1, 192500 (3)  |KCNQ1, KCNA9, LQT1, KVLQT1, ATFB3, SQT2|607542|11p15.5
Long QT syndrome-10, 611819 (3)  |SCN4B|608256|11q23
Long QT syndrome-11, 611820 (3)  |AKAP9, YOTIAO, AKAP450|604001|7q21-q22
Long QT syndrome-2, 613688 (3)  |KCNH2, LQT2, HERG, SQT1|152427|7q35-q36
Long QT syndrome-3, 603830 (3)  |SCN5A, LQT3, VF1, HB1, SSS1, CMD1E, CDCD2|600163|3p21
Long QT syndrome-4, 600919 (3)  |ANK2, LQT4|106410|4q25-q27
Long QT syndrome-5, 613695 (3)  |KCNE1, JLNS, LQT5, JLNS2|176261|21q22.1-q22.2
Long QT syndrome-6, 613693 (3)  |KCNE2, MIRP1, LQT6, ATFB4|603796|21q22.1
Long QT syndrome-7, 170390 (3)  |KCNJ2, HHIRK1, KIR2.1, IRK1, LQT7, SQT3|600681|17q23.1-q24.2
Long QT syndrome-9, 611818 (3)  |CAV3, LGMD1C, LQT9|601253|3p25
Lowe syndrome, 309000 (3)  |OCRL, LOCR, OCRL1, NPHL2|300535|Xq26.1
Lujan-Fryns syndrome, 309520 (3)  |MED12, TNRC11, TRAP230, HOPA, KIAA0192, OKS, FGS1|300188|Xq13
Lung cancer, 211980 (1)  |DLEC1, DLC1|604050|3p22-p21.3
Lung cancer, 211980 (2)  |RASSF1|605082|3p21.3
Lung cancer, 211980 (3)  |KRAS, KRAS2, RASK2, NS|190070|12p12.1
Lung cancer, 211980 (3)  |PPP2R1B|603113|11q22-q24
Lung cancer, 211980 (3)  |SLC22A1L, BWSCR1A, IMPT1|602631|11p15.5
Lung cancer, somatic, 211980 (3)  |MAP3K8, COT, EST, TPL2|191195|10p11.2
Luteinizing hormone resistance, female, 238320 (3)  |LHCGR, LHR, LCGR|152790|2p21
Lymphangioleiomyomatosis, 606690 (3)  |TSC1, LAM|605284|9q34
Lymphangioleiomyomatosis, somatic, 606690 (3)  |TSC2, LAM|191092|16p13.3
Lymphedema, hereditary I, 153100 (3)  |FLT4, VEGFR3, PCL, LMPH1A|136352|5q35.3
Lymphedema, hereditary, IB (2)  |LMPH1B|611944|6q16.2-q22.1
Lymphedema, hereditary, IC, 613480 (3)  |GJC2, GJA12, CX47, PMLDAR, HLD2, SPG44, LMPH1C|608803|1q41-q42
Lymphedema-distichiasis syndrome with renal disease and diabetes mellitus, 153400 (3)  |FOXC2, FKHL14, MFH1|602402|16q24.3
Lymphedema-distichiasis syndrome, 153400 (3)  |FOXC2, FKHL14, MFH1|602402|16q24.3
Lymphocytic leukemia, acute T-cell (3)  |RAP1GDS1|179502|4q21-q25
Lymphoma, B-cell (2)  |BCL6|109565|3q27
Lymphoma, B-cell non-Hodgkin, somatic (3)  |ATM, ATA, AT1|607585|11q22.3
Lymphoma, MALT (3)  |BCL10|603517|1p22
Lymphoma, diffuse large B-cell (2)  |IL21R|605383|16p11
Lymphoma, diffuse large cell (3)  |BCL8|601889|15q11-q13
Lymphoma, follicular (3)  |BCL10|603517|1p22
Lymphoma, mantle cell (3)  |ATM, ATA, AT1|607585|11q22.3
Lymphoma, non-Hodgkin (3)  |RAD54B|604289|8q21.3-q22
Lymphoma, non-Hodgkin, 605027 (3)  |PRF1, HPLH2, FLH2|170280|10q22
Lymphoma, non-Hodgkin, somatic, 605027 (3)  |RAD54L, HR54, HRAD54|603615|1p32
Lymphoma, somatic (3)  |MAD1L1, TXBP181|602686|7p22
Lymphoma/leukemia, B-cell, variant (1)  |FVT1|136440|18q21.3
Lymphoplasmacytoid lymphoma (1)  |PAX5, BSAP|167414|9p13
Lymphoproliferative syndrome, EBV-associated, autosomal, 1, 613011 (3)  |ITK, EMT|186973|5q32
Lymphoproliferative syndrome, X-linked, 2, 300635 (3)  |XIAP, BIRC4, API3, XLP2|300079|Xq25
Lymphoproliferative syndrome, X-linked, 308240 (3)  |SH2D1A, LYP, IMD5, XLP, XLPD|300490|Xq25
Lysinuric protein intolerance, 222700 (3)  |SLC7A7, LPI|603593|14q11.2
Lysosomal acid phosphatase deficiency, 200950 (1) (?)  |ACP2|171650|11p12-p11
Lysyl hydroxylase 3 deficiency, 612394 (3)  |PLOD3|603066|7q22
MALT lymphoma (3)  |MALT1, MLT|604860|18q21
MASA syndrome, 303350 (3)  |L1CAM, CAML1, HSAS1|308840|Xq28
MASP2 deficiency (3)  |MASP2|605102|1p36.3-p36.2
MASS syndrome, 604308 (3)  |FBN1, MFS1, WMS, SSKS|134797|15q21.1
MEHMO syndrome (2)  |MEHMO|300148|Xp22.13-p21.1
MHC class II deficiency, complementation group B, 209920 (3)  |RFXANK|603200|19p12
MODY, type I, 125850 (3)  |HNF4A, TCF14, MODY1|600281|20q12-q13.1
MODY, type II, 125851 (3)  |GCK, HHF3|138079|7p15-p13
MODY, type III, 600496 (3)  |HNF1A, TCF1, MODY3, IDDM20|142410|12q24.2
MODY, type IV, 606392 (3)  |IPF1, MODY4|600733|13q12.1
Machado-Joseph disease, 109150 (3)  |ATXN3, MJD, SCA3|607047|14q24.3-q31
Macrocephaly with multiple epiphyseal dysplasia and distinctive facies (2)  |MMEDF|607131|15q26.1
Macrocephaly, alopecia, cutis laxa, and scoliosis, 613075 (3)  |RIN2, MACS|610222|20p11.22
Macrocephaly/autism syndrome, 605309 (3)  |PTEN, MMAC1, GLM2|601728|10q23.31
Macrocytic anemia, refractory, due to 5q deletion, somatic, 153550 (3)  |RPS14, EMTB|130620|5q32
Macrostomia (2)  |MACST|613545|1p34-p32
Macrothrombocytopenia and progressive sensorineural deafness, 600208 (3)  |MYH9, MHA, FTNS, DFNA17|160775|22q11.2
Macrothrombocytopenia, 300367 (3)  |GATA1, GF1, ERYF1, NFE1, XLTT|305371|Xp11.23
Macrothrombocytopenia, autosomal dominant, TUBB1-related, 613112 (3)  |TUBB1|612901|20q13.3
Macular corneal dystrophy, 217800 (3)  |CHST6, MCDC1|605294|16q22
Macular degeneration, X-linked atrophic (3)  |RPGR, RP3, CRD, RP15, COD1, CORDX1|312610|Xp11.4
Macular degeneration, age-related, 11, 611953 (3)  |CST3, ARMD11|604312|20p11.2
Macular degeneration, age-related, 2, 153800 (3)  |ABCA4, ABCR, STGD1, FFM, RP19, CORD3, ARMD2|601691|1p22.1
Macular degeneration, age-related, 3, 608895 (3)  |FBLN5, ARMD3|604580|14q32.1
Macular degeneration, age-related, 6 (3)  |RAXL1, QRX, CORD11, ARMD6|610362|19p13.3
Macular degeneration, juvenile, 248200 (3)  |CNGB3, ACHM3, ACHM1|605080|8q21-q22
Macular dystrophy (3)  |PRPH2, DS, RP7, PRPH, AVMD, AOFMD, CACD2|179605|6p21.1-cen
Macular dystrophy, North Carolina type (2)  |MCDR1|136550|6q14-q16.2
Macular dystrophy, atypical vitelliform (2)  |VMD1|153840|8q24
Macular dystrophy, autosomal dominant, chromosome 6-linked, 600110 (3)  |ELOVL4, ADMD, STGD2, STGD3|605512|6q14
Macular dystrophy, dominant cystoid (2)  |MDDC|153880|7p21-p15
Macular dystrophy, patterned, 169150 (3)  |PRPH2, DS, RP7, PRPH, AVMD, AOFMD, CACD2|179605|6p21.1-cen
Macular dystrophy, retinal, 2, 608051 (3)  |PROM1, PROML1, AC133, RP41, CORD12, CD133, MCDR2, STGD4|604365|4p15.3
Macular dystrophy, retinal, 3 (2)  |MCDR3|608850|5p15.33-p13.1
Macular dystrophy, vitelliform, 608161 (3)  |PRPH2, DS, RP7, PRPH, AVMD, AOFMD, CACD2|179605|6p21.1-cen
Maculopathy, IMPG2-related, 613581 (3)  |IMPG2, IPM200, RP56|607056|3q11.2
Maculopathy, bull's-eye (3)  |BEST1, VMD2, ARB, RP50|607854|11q13
Majeed syndrome, 609628 (3)  |LPIN2|605519|18p
Major affective disorder 4 (2)  |MAFD4, BPAD|611247|16p12
Major depressive disorder 1, 608516 (2)  |MDD1|608520|12q22-q23.2
Major depressive disorder 2, 608516 (2)  |MDD2|608691|15q25.3-q26.2
Male germ cell tumor (2)  |MGCT|273300|12q22
Male infertility (1) (?)  |UBE2B, RAD6B|179095|5q23-q31
Male infertility due to acrosin deficiency (2) (?)  |ACR|102480|22q13.3
Male infertility with large-headed, multiflagellar, polyploid spermatozoa, 243060 (3)  |STK13, AIE2|603495|19q13.43
Male infertility, nonsyndromic, autosomal recessive, 612997 (3)  |CATSPER1, CATSPER|606389|11q13.1
Male pseudohermaphroditism due to defective LH (1) (?)  |LHB|152780|19q13.32
Malignant fibrous histiocytoma (2)  |MFHAS1, MASL1|605352|8p23.1
Malignant melanoma, cutaneous (2)  |CMM, MLM, DNS|155600|1p36
Malonyl-CoA decarboxylase deficiency, 248360 (3)  |MLYCD, MCD|606761|16q24
Mammary-digital-nail syndrome (2)  |MDNS|613689|22q12.3-q13.1
Mandibuloacral dysplasia with type B lipodystrophy, 608612 (3)  |ZMPSTE24, FACE1, STE24, MADB|606480|1p34
Mandibuloacral dysplasia, 248370 (3)  |LMNA, LMN1, EMD2, FPLD, CMD1A, HGPS, LGMD1B|150330|1q21.2
Mannose-binding protein deficiency (3)  |MBL2, MBL, MBP1|154545|10q11.2-q21
Mannosidosis, alpha-, types I and II, 248500 (3)  |MAN2B1, MANB|609458|19cen-q12
Mannosidosis, beta, 248510 (3)  |MANBA, MANB1|609489|4q22-q25
Maple syrup urine disease, type II, 248600 (3)  |DBT, BCATE2|248610|1p31
Maple syrup urine disease, type III, 248600 (3)  |DLD, LAD, PHE3|238331|7q31-q32
Maple syrup urine disease, type Ia, 248600 (3)  |BCKDHA, MSUD1|608348|19q13.1-q13.2
Maple syrup urine disease, type Ib, 248600 (3)  |BCKDHB, E1B|248611|6q14
Marfan syndrome, 154700 (3)  |FBN1, MFS1, WMS, SSKS|134797|15q21.1
Marinesco-Sjogren syndrome, 248800 (3)  |SIL1, BAP, MSS|608005|5q31
Marshall syndrome, 154780 (3)  |COL11A1, STL2|120280|1p21
Martin-Probst deafness-mental retardation syndrome (2)  |MPDMRS|300519|Xq11-q21
Martsolf syndrome, 212720 (3)  |RAB3GAP2, RAB3GAP150, p150, KIAA0839|609275|1q41
Mast cell leukemia (3)  |KIT, PBT|164920|4q12
Mast syndrome, 248900 (3)  |ACP33, MAST, SPG21|608181|15q21-q22
Mastocytosis with associated hematologic disorder (3)  |KIT, PBT|164920|4q12
Maturity-onset diabetes of the young 6, 606394 (3)  |NEUROD1, NIDDM|601724|2q32
Maturity-onset diabetes of the young, type 10, 613370 (3)  |INS, MODY10, IDDM2|176730|11p15.5
Maturity-onset diabetes of the young, type 11, 613375 (3)  |BLK, MODY11|191305|8p23-p22
Maturity-onset diabetes of the young, type IX, 612225 (3)  |PAX4, MODY9, KPD|167413|7q32
Maturity-onset diabetes of the young, type VII, 610508 (3)  |KLF11, TIEG2, FKLF1, FKLF, MODY7|603301|2p25
Maturity-onset diabetes of the young, type VIII, 609812 (3)  |CEL, BSSL, CELL, MODY8|114840|9q34.3
May-Hegglin anomaly, 155100 (3)  |MYH9, MHA, FTNS, DFNA17|160775|22q11.2
McArdle disease, 232600 (3)  |PYGM|608455|11q13
McCune-Albright syndrome, 174800 (3)  |GNAS, GNAS1, GPSA, POH, PHP1B, PHP1A, AHO, PHP1C|139320|20q13.2
McKusick-Kaufman syndrome, 236700 (3)  |MKKS, HMCS, KMS, MKS, BBS6|604896|20p12
McLeod syndrome (3)  |XK|314850|Xp21.2-p21.1
McLeod syndrome with neuroacanthosis (3)  |XK|314850|Xp21.2-p21.1
Meacham syndrome, 608978 (3)  |WT1, NPHS4|607102|11p13
Meckel syndrome 7, 267010 (3)  |NPHP3, NPH3, RHPD, MKS7|608002|3q22
Meckel syndrome type 4, 611134 (3)  |CEP290, KIAA0373, 3H11AG, JBTS5, SLSN6, LCA10, BBS14|610142|12q21.3
Meckel syndrome, type 1, 249000 (3)  |MKS1, MKS, BBS13|609883|17q23
Meckel syndrome, type 2 (2)  |MKS2|603194|11q13
Meckel syndrome, type 3, 607361 (3)  |TMEM67, MKS3, JBTS6, NPHP11|609884|8q21.13-q22.1
Meckel syndrome, type 5, 611561 (3)  |RPGRIP1L, KIAA1005, JBTS7, MKS5|610937|16q12.2
Meckel syndrome, type 6, 612284 (3)  |CC2D2A, KIAA1345, MKS6|612013|4p15.3
Medullary cystic kidney disease 1 (2)  |MCKD1|174000|1q21
Medullary cystic kidney disease 2, 603860 (3)  |UMOD, HNFJ1, FJHN, MCKD2, ADMCKD2|191845|16p12.3
Medullary thyroid carcinoma, 155240 (3)  |RET, MEN2A, HSCR1|164761|10q11.2
Medullary thyroid carcinoma, familial, 155240 (3)  |NTRK1, TRKA, MTC|191315|1q21-q22
Medulloblastoma, 155255 (3)  |PTCH2|603673|1p32
Medulloblastoma, desmoplastic, 155255 (3)  |SUFU, SUFUXL, SUFUH|607035|10q24-q25
Meesmann corneal dystrophy, 122100 (3)  |KRT12|601687|17q12
Meesmann corneal dystrophy, 122100 (3)  |KRT3|148043|12q13
Megakaryoblastic leukemia, acute (2)  |RBM15, SPEN, OTT|606077|1p13
Megakaryoblastic leukemia, acute (3)  |MKL1, AMKL, MAL|606078|22q13
Megalencephalic leukoencephalopathy with subcortical cysts, 604004 (3)  |MLC1, LVM, VL|605908|22q13.33
Megaloblastic anemia-1, Finnish type, 261100 (3)  |CUBN, IFCR, MGA1|602997|10p12.1
Megaloblastic anemia-1, Norwegian type, 261100 (3)  |AMN|605799|14q32
Megalocornea, X-linked (2)  |MGC1, MGCN|309300|Xq21.3-q22
Melanoma and neural system tumor syndrome, 155755 (3)  |CDKN2A, MTS1, P16, MLM, CMM2|600160|9p21
Melanoma, 609048 (3)  |CDK4, CMM3|123829|12q14
Melanoma, cutaneous malignant, 2, 155601 (3)  |CDKN2A, MTS1, P16, MLM, CMM2|600160|9p21
Melanoma, cutaneous malignant, 4 (2)  |CMM4|608035|1p22
Melanoma, desmoplastic neurotrophic (2)  |NF1, VRNF, WSS, NFNS|613113|17q11.2
Melanoma, malignant sporadic (3)  |STK11, PJS, LKB1|602216|19p13.3
Melanoma, malignant, somatic (3)  |BRAF, NS7|164757|7q34
Meleda disease, 248300 (3)  |SLURP1, MDM|606119|8qter
Melkersson-Rosenthal syndrome (2) (?)  |MROS|155900|9p11
Melnick-Needles syndrome, 309350 (3)  |FLNA, FLN1, NHBP, OPD1, OPD2, FMD, MNS, CVD1|300017|Xq28
Melorheostosis with osteopoikilosis, 155950 (3)  |LEMD3, MAN1|607844|12q14
Membranoproliferative glomerulonephritis with CFH deficiency, 609814 (3)  |HF1, CFH, HUS, ARMD4, AHUS1|134370|1q32
Membranous glomerulonephritis, antenatal (1)  |MME, CD10, CALLA, NEP|120520|3q21-q27
Meningioma, 607174 (3)  |MN1, MGCR|156100|22q12.3-qter
Meningioma, NF2-related, somatic, 607174 (3)  |NF2|607379|22q12.2
Meningioma, SIS-related (3)  |PDGFB, SIS|190040|22q12.3-q13.1
Meningioma, radiation-induced (2)  |MNRI|606190|1p11
Menkes disease, 309400 (3)  |ATP7A, MNK, MK, OHS, SMAX3|300011|Xq12-q13
Mental retardation and microcephaly with pontine and cerebellar hypoplasia, 300749 (3)  |CASK, MICPCH, FGS4, CMG|300172|Xp11.4
Mental retardation in cri-du-chat syndrome, 123450 (2)  |CTNND2, NPRAP|604275|5p15.2
Mental retardation syndrome, X-linked, Abidi type (2)  |MRXSAB|300262|Xq13.2
Mental retardation syndrome, X-linked, Armfield type (2)  |MRXSA|300261|Xq28
Mental retardation syndrome, X-linked, Lubs type (2)  |MRXSL|300260|Xq28
Mental retardation syndrome, X-linked, Siderius type, 300263 (3)  |PHF8, ZNF422, KIAA1111, MRXSSD|300560|Xp11.2
Mental retardation with language impairment and autistic features, 613670 (3)  |FOXP1, QRF1|605515|3p14.1
Mental retardation, FRA12A type, 136630 (3)  |DIP2B, KIAA1463|611379|12q13.12
Mental retardation, X-linked 1, 309530 (3)  |IQSEC2, KIAA0522, MRX1|300522|Xp11.22
Mental retardation, X-linked 14 (2)  |MRX14|300062|Xp11.3-q13.3
Mental retardation, X-linked 17/31, microduplication, 300705 (3)  |HSD17B10, HADH2, ERAB, MRXS10, MRX17, MRX31, DUPXp11.22|300256|Xp11.2
Mental retardation, X-linked 20 (2)  |MRX20|300047|Xp11-q21
Mental retardation, X-linked 23, nonspecific (2)  |MRX23|300046|Xq23-q24
Mental retardation, X-linked 29 (2)  |MRX29|300077|Xp22.3-p21.3
Mental retardation, X-linked 30, 300558 (3)  |PAK3, MRX30, MRX47|300142|Xq21.3-q24
Mental retardation, X-linked 36/43/54, 300419 (3)  |ARX, ISSX, PRTS, MRXS1, MRX36, MRX54, MRX43, MRX87, MRX29, MRX32|300382|Xp22.13
Mental retardation, X-linked 45, 300498 (3)  |ZNF81, MRX45|314998|Xp22.1-p11
Mental retardation, X-linked 52 (2)  |MRX52|300504|Xp11.21-q22.3
Mental retardation, X-linked 58, 300210 (3)  |TM4SF2, MXS1, A15, MRX58|300096|Xq11
Mental retardation, X-linked 59, 300630 (3)  |AP1S2, MRX59|300629|Xp22
Mental retardation, X-linked 77 (2)  |MRX77|300454|Xq12-q21.3
Mental retardation, X-linked 78 (2)  |MRX78|300551|Xp11.4-p11.23
Mental retardation, X-linked 81 (2)  |MRX81|300433|Xp11.2-q12
Mental retardation, X-linked 82 (2)  |MRX82|300518|Xq24-q25
Mental retardation, X-linked 84 (2)  |MRX84|300505|Xp11.3-q22.3
Mental retardation, X-linked 93, 300659 (3)  |BRWD3, MRX93|300553|Xq13
Mental retardation, X-linked 94, 300699 (3)  |GRIA3, GLUR3, MRX94|305915|Xq25-q26
Mental retardation, X-linked 95, 300716 (3)  |MAGT1, IAP|300715|Xq13.1-q13.2
Mental retardation, X-linked nonspecific, 309541 (3)  |GDI1, RABGD1A, MRX41, MRX48|300104|Xq28
Mental retardation, X-linked nonspecific, 42 (2)  |MRX42|300372|Xq26
Mental retardation, X-linked nonspecific, 63, 300387 (3)  |ACSL4, FACL4, ACS4, MRX63|300157|Xq22.3
Mental retardation, X-linked nonspecific, type 19 (3)  |RPS6KA3, RSK2, MRX19|300075|Xp22.2-p22.1
Mental retardation, X-linked nonspecific, type 46, 300436 (3)  |ARHGEF6, MRX46, COOL2|300267|Xq26
Mental retardation, X-linked nonspecific, type 50 (2)  |MRX50|300115|Xp11.3-p11.21
Mental retardation, X-linked syndromic (3)  |UBE2A, RAD6A|312180|Xq24-q25
Mental retardation, X-linked syndromic 10, 300220 (3)  |HSD17B10, HADH2, ERAB, MRXS10, MRX17, MRX31, DUPXp11.22|300256|Xp11.2
Mental retardation, X-linked syndromic 16 (3)  |FGD1, FGDY, AAS, MRXS16|300546|Xp11.21
Mental retardation, X-linked syndromic, Christianson type, 300243 (3)  |SLC9A6, NHE6|300231|Xq26.3
Mental retardation, X-linked syndromic, Turner type, 300706 (3)  |HUWE1, UREB1, KIAA0312, LASU1|300697|Xp11.2
Mental retardation, X-linked, 1 (2)  |MRX1|309530|Xp11.3-q21.1
Mental retardation, X-linked, 2 (2)  |MRX2|300428|Xp22.3
Mental retardation, X-linked, 21/34, 300143 (3)  |IL1RAPL1, IL1R8, MRX21, MRX34|300206|Xp22.1-p21.3
Mental retardation, X-linked, 300495 (3)  |NLGN4, KIAA1260, AUTSX2, ASPGX2|300427|Xp22.33
Mental retardation, X-linked, FRAXE type, 309548 (3)  |AFF2, FMR2, FRAXE, MRX2|300806|Xq28
Mental retardation, X-linked, Lubs type, 300260 (3)  |MECP2, RTT, PPMX, MRX16, MRX79, AUTSX3, MRXSL, MRXS13, MRX79, MRX16|300005|Xq28
Mental retardation, X-linked, Shashi type (2)  |MRXS11, SMRXS|300238|Xq26-q27
Mental retardation, X-linked, Snyder-Robinson type, 309583 (3)  |SMS, SRS, MRSR|300105|Xp22.1
Mental retardation, X-linked, South African type (2)  |MRSA|300243|Xq24-q27.3
Mental retardation, X-linked, ZDHHC9-related, 300799 (3)  |ZDHHC9, DHHC9, MRXSZ|300646|Xq26.1
Mental retardation, X-linked, syndromic 12 (2) (?)  |MRXS12|309545|Xp11
Mental retardation, X-linked, syndromic 13, 300055 (3)  |MECP2, RTT, PPMX, MRX16, MRX79, AUTSX3, MRXSL, MRXS13, MRX79, MRX16|300005|Xq28
Mental retardation, X-linked, syndromic 14, 300676 (3)  |UPF3B, RENT3B, MRXS14|300298|Xq25-q26
Mental retardation, X-linked, syndromic 15 (Cabezas type), 300354 (3)  |CUL4B, MRXSC, MRXHF2, SFM2, MRXS15|300304|Xq23
Mental retardation, X-linked, syndromic 6, with gynecomastia and obesity (2)  |WTS, MRXS6|309585|Xp21.1-q22
Mental retardation, X-linked, syndromic 7 (2)  |MRXS7|300218|Xp11.3-q22
Mental retardation, X-linked, syndromic 9 (2)  |MRXS9|300709|Xq12-q21.31
Mental retardation, X-linked, syndromic, JARID1C-related, 300534 (3)  |KDM5C, SMCX, MRXSJ, DXS1272E, XE169, JARID1C|314690|Xp11.22-p11.21
Mental retardation, X-linked, syndromic-2, with dysmorphism and cerebral atrophy (2)  |PRS, MRXS2|309610|Xp11-q21
Mental retardation, X-linked, syndromic-4, with congenital contractures and low fingertip arches (2)  |MCS, MRXS4|309605|Xq13-q22
Mental retardation, X-linked, syndromic-5, with Dandy-Walker malformation, basal ganglia disease, and seizures (2)  |PGS, MRXS5|304340|Xq25-q27
Mental retardation, X-linked, with cerebellar hypoplasia and distinctive facial appearance, 300486 (3)  |OPHN1, MRX60|300127|Xq12
Mental retardation, X-linked, with epilepsy, 300423 (3)  |ATP6AP2, ATP6M8-9, XMRE, MRXE|300556|Xp11.4
Mental retardation, X-linked, with isolated growth hormone deficiency, 300123 (3)  |SOX3, MRGH|313430|Xq26.3
Mental retardation, X-linked, with or without epilepsy, 300802 (3)  |SYP, MRXSYP|313475|Xp11.23-p11.22
Mental retardation, X-linked, with short stature (2)  |MRSS|300360|Xq24
Mental retardation, X-linked-49 (2)  |MRX49|300114|Xp22.3
Mental retardation, X-linked-53 (2)  |MRX53|300324|Xq22.2-q26
Mental retardation, X-linked-72, 300271 (3)  |RAB39B, MRX72|300774|Xq28
Mental retardation, X-linked-88 (3)  |AGTR2, MRX88|300034|Xq22-q23
Mental retardation, X-linked-89 (3)  |ZNF41, MRX89|314995|Xp22.1-cen
Mental retardation, X-linked-9, 309549 (3)  |FTSJ1, JM23, SPB1, MRX44, MRX9|300499|Xp11.23
Mental retardation, X-linked-90 (3)  |DLG3, NEDLG, SAP102, MRX90|300189|Xq13.1
Mental retardation, X-linked-91, 300577 (3)  |ZDHHC15, MRX91|300576|Xq13.3
Mental retardation, X-linked-92 (3)  |ZNF674, MRX92|300573|Xp11
Mental retardation, anterior maxillary protrusion, and strabismus, 613671 (3)  |SOBP, JXC1, MRAMS|613667|6q21
Mental retardation, autosomal dominant 1, 156200 (3)  |MBD5, KIAA1461, MRD1|611472|2q23.1
Mental retardation, autosomal dominant 2 (3)  |DOCK8, MRD2|611432|9p24
Mental retardation, autosomal dominant 3, 612580 (3)  |CDH15, CDH14, CDH3, MRD3|114019|16q24.3
Mental retardation, autosomal dominant 4, 612581 (3)  |KIRREL3, NEPH2, KIAA1867, KIRRE, MRD4|607761|11q24.2
Mental retardation, autosomal dominant 5, 612621 (3)  |SYNGAP, MRD5|603384|6p21.3
Mental retardation, autosomal recessive 1, 249500 (3)  |PRSS12, BSSP3, MRT1|606709|4q25-q26
Mental retardation, autosomal recessive 13, 613192 (3)  |TRAPPC9, NIBP, KIAA1882, MRT13|611966|8q24.3
Mental retardation, autosomal recessive 2A, 607417 (3)  |CRBN, MRT2A|609262|3p26.2
Mental retardation, autosomal recessive 3, 608443 (3)  |CC2D1A, MRT3|610055|19p13.12
Mental retardation, autosomal recessive 7, 611093 (3)  |TUSC3, M33, D8S1992, MRT7|601385|8p22
Mental retardation, autosomal recessive, 10 (2)  |MRT10|611096|16p12-q12
Mental retardation, autosomal recessive, 11 (2)  |MRT11|611097|19q13.2-q13.3
Mental retardation, autosomal recessive, 12 (2)  |MRT12|611090|1p34-p33
Mental retardation, autosomal recessive, 4 (2)  |MRT4|611107|1p21.1-p13.3
Mental retardation, autosomal recessive, 5 (2)  |MRT5|611091|5p15-p14
Mental retardation, autosomal recessive, 6, 611092 (3)  |GRIK2, GLUR6, MRT6|138244|6q21
Mental retardation, autosomal recessive, 7 (2)  |MRT7|611093|8p12
Mental retardation, autosomal recessive, 8 (2)  |MRT8|611094|10q22
Mental retardation, autosomal recessive, 9 (2)  |MRT9|611095|14q11.2-q12
Mental retardation, joint hypermobility and skin laxity, with or without metabolic abnormalities, 612652 (3)  |PYCS, GSAS|138250|10q24.3
Mental retardation, profound (2)  |RAB40AL, RLGP|300405|Xq22.2
Mental retardation, severe, with spasticity and tapetoretinal degeneration (2)  |MRST|602685|15q24
Mental retardation, stereotypic movements, epilepsy, and/or cerebral malformations, 613443 (3)  |MEF2C, C5DELq14.3; DEL5q14.3|600662|5q14
Mental retardation, truncal obesity, retinal dystrophy, and micropenis, 610156 (3)  |INPP5E, MORMS, JBTS1, CORS1|613037|9q34.3
Mental retardation-hypotonic facies syndrome, X-linked, 309580 (3)  |ATRX, XH2, XNP, SHS, SFM1, MRXHF1|300032|Xq13
Mental retardation-skeletal dysplasia (2)  |MRSD, CHRS|309620|Xq28
Mephenytoin poor metabolizer, 609535 (3)  |CYP2C, CYP2C19|124020|10q24.1-q24.3
Merkel cell carcinoma, somatic (3)  |SDHD, PGL1|602690|11q23
Mesomelia-synostoses syndrome (4)  |DEL8q13, C8DELq13|600383|8q13
Mesomelic dysplasia, Kantaputra type (2)  |MMDK, MDK|156232|2q24-q32
Mesothelioma (3)  |BCL10|603517|1p22
Metachondromatosis, 156250 (3)  |PTPN11, PTP2C, SHP2, NS1|176876|12q24.1
Metachromatic leukodystrophy due to SAP-b deficiency, 249900 (3)  |PSAP, SAP1|176801|10q22.1
Metachromatic leukodystrophy, 250100 (3)  |ARSA|607574|22q13.31-qter
Metaphyseal anadysplasia 1, 602111 (3)  |MMP13, CLG3, MANDP1|600108|11q22.3
Metaphyseal anadysplasia 2, 613073 (3)  |MMP9, CLG4B, MANDP2|120361|20q11.2-q13.1
Metaphyseal chondrodysplasia, Murk Jansen type, 156400 (3)  |PTHR1, PTHR, PFE|168468|3p22-p21.1
Metaphyseal chondrodysplasia, Schmid type (3)  |COL10A1|120110|6q21-q22.3
Metaphyseal dysplasia without hypotrichosis, 250460 (3)  |RMRP, RMRPR, CHH|157660|9p21-p12
Metastasis efficiency, modification of (1)  |SIPA1, SPA1|602180|11q13.3
Metatropic dysplasia, 156530 (3)  |TRPV4, VROAC, HMSN2C, CMT2C, SPSMA, SSQTL1|605427|12q24.1
Methemoglobinemia, type I, 250800 (3)  |CYB5R3, DIA1, B5R|613213|22q13.31-qter
Methemoglobinemia, type II, 250800 (3)  |CYB5R3, DIA1, B5R|613213|22q13.31-qter
Methemoglobinemia, type IV, 250790 (3)  |CYB5A, MCB5|613218|18q23
Methemoglobinemias, alpha- (3)  |HBA1|141800|16pter-p13.3
Methemoglobinemias, beta- (3)  |HBB|141900|11p15.5
Methionine adenosyltransferase deficiency, autosomal recessive, 250850 (3)  |MAT1A, MATA1, SAMS1|610550|10q22
Methylcobalamin deficiency, cblG type, 250940 (3)  |MTR|156570|1q43
Methylmalonate semialdehyde dehydrogenase deficiency (3)  |ALDH6A1, MMSDH|603178|14q24.3
Methylmalonic aciduria and homocystinuria, cblC type, 277400 (3)  |MMACHC|609831|1p34.1
Methylmalonic aciduria and homocystinuria, cblD type, 277410 (3)  |C2orf25, MMADHC|611935|2q23.2
Methylmalonic aciduria and homocystinuria, cblF type, 277380 (3)  |LMBRD1, LMBD1, NESI|612625|6q13
Methylmalonic aciduria due to transcobalamin receptor defect, 613646 (3)  |CD320, 8D6, 8D6A, TCBLR|606475|19p13.2
Methylmalonic aciduria, cblD type, variant 2, 277410 (3)  |C2orf25, MMADHC|611935|2q23.2
Methylmalonic aciduria, mut(0) type, 251000 (3)  |MUT, MCM|609058|6p21
Methylmalonic aciduria, vitamin B12-responsive, 251100 (3)  |MMAA|607481|4q31.1-q31.2
Methylmalonic aciduria, vitamin B12-responsive, due to defect in synthesis of adenosylcobalamin, cblB complementation type, 251110 (3)  |MMAB|607568|12q24
Methylmalonyl-CoA epimerase deficiency, 251120 (3)  |MCEE|608419|2p13.3
Mevalonic aciduria, 610377 (3)  |MVK, MVLK|251170|12q24
Micochondrial phosphate carrier deficiency, 610773 (3)  |SLC25A3, PHC|600370|12q23
Microcephalic osteodysplastic primordial dwarfism, type II, 210720 (3)  |PCNT, PCNT2, KEN, SCKL4, MOPD2|605925|21q22.3
Microcephaly and digital abnormalities with normal intelligence, 602585 (3)  |MYCN, NMYC, ODED, MODED|164840|2p24.1
Microcephaly with digital anomalies (2)  |JAWAD|251255|18p11.22-q11.2
Microcephaly, Amish type, 607196 (3)  |SLC25A19, DNC, MUP1, MCPHA|606521|17q25.3
Microcephaly, cortical malformations, and mental retardation, 600176 (3)  |WDR62, C19orf14|613583|19q13.12
Microcephaly, mental retardation, and distinctive facies, with cardiac and genitourinary malformations (2)  |MMRFCGU|613680|16p13.3
Microcephaly, postnatal progressive, with seizures and brain atrophy, 613668 (3)  |MED17, CRSP6, CRSP77, TRAP80, DRIP80|603810|11q21
Microcephaly, primary autosomal recessive, 1, 251200 (3)  |MCPH1|607117|8p23
Microcephaly, primary autosomal recessive, 2 (2)  |MCPH2|604317|19q13.1-q13.2
Microcephaly, primary autosomal recessive, 3, 604804 (3)  |CDK5RAP2, KIAA1633, MCPH3|608201|9q33.3
Microcephaly, primary autosomal recessive, 4, 604321 (3)  |CEP152, KIAA0912, MCPH4|613529|15q21.1
Microcephaly, primary autosomal recessive, 5, with or without simplified gyral pattern, 608716 (3)  |ASPM, MCPH5|605481|1q31
Microcephaly, primary autosomal recessive, 6, 608393 (3)  |CENPJ, CPAP, MCPH6, SCKL4|609279|13q12.2
Microcephaly, primary autosomal recessive, 7, 612703 (3)  |STIL, SIL, MCPH7|181590|1p32
Microcoria, congenital (2)  |MCOR|156600|13q31-q32
Microcornea, rod-cone dystrophy, cataract, and posterior staphyloma, 193220 (3)  |BEST1, VMD2, ARB, RP50|607854|11q13
Microhydranencephaly (2)  |MHAC|605013|16p13.3-p12.1
Microphthalmia with cataract 1 (2)  |MCOPCT1|156850|16p13.3
Microphthalmia with cataract 2, 212550 (3)  |SIX6, MCOPCT2|606326|14q23
Microphthalmia with cataract 4, 610426 (3)  |CRYBA4, MCOPCT4|123631|22q11.2-q13.1
Microphthalmia with coloboma 1 (2)  |MCOPCB1|300345|Chr.X
Microphthalmia with coloboma 2 (2)  |MCOPCB2|605738|15q12-q15
Microphthalmia with coloboma 3, 610092 (3)  |CHX10, HOX10, MCOP2, MCOPCB3|142993|14q24.3
Microphthalmia with coloboma 5, 611638 (3)  |SHH, HPE3, HLP3, SMMCI, MCOPCB5|600725|7q36
Microphthalmia with coloboma 6, 613703 (3)  |GDF3, KFS3, MCOPCB6, MCOP7|606522|12p13.1
Microphthalmia with coloboma 6, digenic, 613703 (3)  |GDF6, MCOP4, KFS1, MCOPCB6|601147|8q22.1
Microphthalmia, isolated 1 (2)  |MCOP1|251600|14q32
Microphthalmia, isolated 2, 610093 (3)  |CHX10, HOX10, MCOP2, MCOPCB3|142993|14q24.3
Microphthalmia, isolated 3, 611038 (3)  |RAX, RX, MCOP3|601881|18q21.3
Microphthalmia, isolated 4, 613094 (3)  |GDF6, MCOP4, KFS1, MCOPCB6|601147|8q22.1
Microphthalmia, isolated 5, 611040 (3)  |MFRP, MCOP5|606227|11q23
Microphthalmia, isolated 6 (2)  |MCOP6|613517|2q37.1
Microphthalmia, isolated 7, 613704 (3)  |GDF3, KFS3, MCOPCB6, MCOP7|606522|12p13.1
Microphthalmia, syndromic 1 (2)  |MCOPS1, MAA, LZMS|309800|Xq27-q28
Microphthalmia, syndromic 2, 300166 (3)  |BCOR, KIAA1575, MCOPS2, MAA2, ANOP2|300485|Xp11.4
Microphthalmia, syndromic 3, 206900 (3)  |SOX2, MCOPS3|184429|3q26.3-q27
Microphthalmia, syndromic 4 (2) (?)  |MCOPS4, ANOP1|301590|Xq27-q28
Microphthalmia, syndromic 5, 610125 (3)  |OTX2, MCOPS5|600037|14q21-q22
Microphthalmia, syndromic 6, 607932 (3)  |BMP4, BMP2B1, BMP2B, MCOPS6, OFC11|112262|14q22-q23
Microphthalmia, syndromic 7, 309801 (3)  |HCCS, MCOPS7|300056|Xp22
Microphthalmia, syndromic 8 (2)  |MCOPS8, MMEP|601349|6q21
Microphthalmia, syndromic 9, 601186 (3)  |STRA6, MCOPS9|610745|15q24.1
Microtia with nasolacrimal duct imperforation and eye coloboma (1)  |MNDEC|611863|4p16-p15
Microtia, hearing impairment, and cleft palate, 612290 (3)  |HOXA2|604685|7p15-p14
Microvillus inclusion disease, 251850 (3)  |MYO5B, KIAA1119|606540|18q21
Migraine with or without aura, susceptibility to (2)  |MGR6, FHM3|607516|1q31
Migraine, familial basilar, 602481 (3)  |ATP1A2, FHM2, MHP2|182340|1q21-q23
Migraine, familial hemiplegic (2)  |MGR6, FHM3|607516|1q31
Migraine, familial hemiplegic, 2, 602481 (3)  |ATP1A2, FHM2, MHP2|182340|1q21-q23
Migraine, familial hemiplegic, 3, 609634 (3)  |SCN1A, GEFSP2, SMEI, FEB3A, EIEE6, FHM3|182389|2q24
Migraine, resistance to, 157300 (3)  |EDNRA|131243|4q31.2
Miller syndrome, 264750 (3)  |DHODH, URA1, POADS|126064|16q22
Miller-Dieker lissencephaly syndrome (4)  |MDLS, MDS, MDCR, DEL17p13.3, C17DELp13.3|247200|17p13.3
Minicore myopathy with external ophthalmoplegia, 255320 (3)  |RYR1, MHS, CCO|180901|19q13.1
Mirror movements, congenital, 157600 (3)  |DCC|120470|18q21.3
Mirror-image polydactyly, 135750 (1)  |MIPOL1|606850|14q13
Mismatch repair cancer syndrome, 276300 (3)  |MLH1, COCA2, HNPCC2|120436|3p21.3
Mismatch repair cancer syndrome, 276300 (3)  |MSH2, COCA1, FCC1, HNPCC1|609309|2p22-p21
Mismatch repair cancer syndrome, 276300 (3)  |MSH6, GTBP, HNPCC5|600678|2p16
Mismatch repair cancer syndrome, 276300 (3)  |PMS2, PMSL2, HNPCC4|600259|7p22
Mitochondrial DNA depletion syndrome 1 (MNGIE type), 603041 (3)  |TYMP, ECGF1, MNGIE, PDECGF, MEDPS1, MTDPS1|131222|22q13.32-qter
Mitochondrial DNA depletion syndrome 2 (myopathic type), 609560 (3)  |TK2, MTDPS2|188250|16q22
Mitochondrial DNA depletion syndrome 3 (hepatocerebral type), 251880 (3)  |DGUOK, DGK, MTDPS3|601465|2p13
Mitochondrial DNA depletion syndrome 4A (Alpers type), 203700 (3)  |POLG, POLG1, POLGA, PEO, SANDO, SCAE, MTDPS4A, MTDPS4B, MIRAS|174763|15q25
Mitochondrial DNA depletion syndrome 4B (MNGIE type), 613662 (3)  |POLG, POLG1, POLGA, PEO, SANDO, SCAE, MTDPS4A, MTDPS4B, MIRAS|174763|15q25
Mitochondrial DNA depletion syndrome 5 (encephalomyopathic with methylmalonic aciduria), 612073 (3)  |SUCLA2, MTDPS5|603921|13q12.2-q13
Mitochondrial DNA depletion syndrome 6 (hepatocerebral type), 256810 (3)  |MPV17, MTDPS6|137960|2p23-p21
Mitochondrial DNA depletion syndrome 7 (hepatocerebral type), 271245 (3)  |C10orf2, TWINKLE, PEO1, PEOA3, IOSCA, MTDPS7|606075|10q24
Mitochondrial DNA depletion syndrome 8A (encephalomyopathic type with renal tubulopathy), 612075 (3)  |RRM2B, P53R2, PEOA5, MTDPS8A, MTDPS8B|604712|8q23.1
Mitochondrial DNA depletion syndrome 8B (MNGIE type), 612075 (3)  |RRM2B, P53R2, PEOA5, MTDPS8A, MTDPS8B|604712|8q23.1
Mitochondrial DNA depletion syndrome 9 (encephalomyopathic type with methylmalonic aciduria), 245400 (3)  |SUCLG1, SUCLA1, MTDPS9|611224|2p11.2
Mitochondrial complex 1 deficiency, 252010 (3)  |C20orf7|612360|20p12.1
Mitochondrial complex 1 deficiency, 252010 (3)  |FOXRED1|613622|11q24.2
Mitochondrial complex I deficiency, 252010 (3)  |NDUFA1, MWFE|300078|Xq24
Mitochondrial complex I deficiency, 252010 (3)  |NDUFA11|612638|19p13.3
Mitochondrial complex I deficiency, 252010 (3)  |NDUFAF2, NDUFA12L, MMTN, B17.2L|609653|5q12.1
Mitochondrial complex I deficiency, 252010 (3)  |NDUFAF3|612911|3p21.31
Mitochondrial complex I deficiency, 252010 (3)  |NDUFAF4, HRPAP20, C6orf66|611776|6q16.1
Mitochondrial complex I deficiency, 252010 (3)  |NDUFS1|157655|2q33-q34
Mitochondrial complex I deficiency, 252010 (3)  |NDUFS2|602985|1q23
Mitochondrial complex I deficiency, 252010 (3)  |NDUFS4, AQDQ|602694|5q11.1
Mitochondrial complex I deficiency, 252010 (3)  |NDUFV1, UQOR1|161015|11q13
Mitochondrial complex I deficiency, 252010 (3)  |NDUFV2|600532|18p11.31-p11.2
Mitochondrial complex I deficiency, 252010 (3)  |NUBPL, IND1|613621|14q12
Mitochondrial complex II deficiency, 252011 (3)  |SDHAF1|612848|19q12-q13.2
Mitochondrial complex III deficiency, 124000 (3)  |BCS1L, FLNMS, GRACILE, BJS, PTD|603647|2q33
Mitochondrial complex III deficiency, 124000 (3)  |UQCRB, UQBP, QPC|191330|8q22
Mitochondrial complex III deficiency, 124000 (3)  |UQCRQ, QPC|612080|5q31.1
Mitochondrial complex IV deficiency, 220110 (3)  |FASTKD2, KIAA0971|612322|2q33.3
Mitochondrial myopathy and sideroblastic anemia 1, 600462 (3)  |PUS1, MLASA1|608109|12q24.33
Mitochondrial recessive ataxia syndrome (includes SANDO and SCAE  |POLG, POLG1, POLGA, PEO, SANDO, SCAE, MTDPS4A, MTDPS4B, MIRAS|174763|15q25
Mitochondrial respiratory chain complex II deficiency, 252011 (3)  |SDHA, SDH1, SDHF, CMD1GG|600857|5p15
Mitral valve prolapse, myxomatous 1 (2)  |MMVP1, MVP, PMV|157700|16p12.1-p11.2
Mitral valve prolapse, myxomatous 2 (2)  |MMVP2|607829|11p15.4
Mitral valve prolapse, myxomatous 3 (2)  |MMVP3|610840|13q31.3-q32.1
Miyoshi muscular dystrophy 2 (2)  |MMD2|613318|8q22.3
Miyoshi muscular dystrophy 3, 613319 (3)  |ANO5, TMEM16E, GDD1, LGMD2L|608662|11p14.3
Miyoshi myopathy, 254130 (3)  |DYSF, LGMD2B|603009|2p13.3-p13.1
Moebius syndrome (2) (?)  |MBS, MBS1|157900|13q12.2-q13
Moebius syndrome-3 (2)  |MBS3|604185|10q21.3-q22.1
Mohr-Tranebjaerg syndrome, 304700 (3)  |TIMM8A, DFN1, DDP, MTS, DDP1|300356|Xq22
Molybdenum cofactor deficiency, type A, 252150 (3)  |MOCS1, MOCOD|603707|6p21.3
Molybdenum cofactor deficiency, type B, 252150 (3)  |MOCS2, MPTS|603708|5q11
Molybdenum cofactor deficiency, type C, 252150 (3)  |GPHN, GPH, KIAA1385, GEPH|603930|14q24
Monilethrix, 158000 (3)  |KRT81, KRTHB1, HB1|602153|12q13
Monilethrix, 158000 (3)  |KRT83, KRTHB3, HB3|602765|12q13
Monilethrix, 158000 (3)  |KRT86, KRTHB6, HB6|601928|12q13
Mononeuropathy of the median nerve, mild, 613353 (3)  |SH3TC2, KIAA1985, MNMN|608206|5q32
Morning glory disc anomaly, 120430 (3)  |PAX6, AN2, MGDA|607108|11p13
Mosaic variegated aneuploidy syndrome, 257300 (3)  |BUB1B, BUBR1|602860|15q15
Motor neuronopathy, distal hereditary, with vocal cord paralysis (2)  |HMN7A, DHMNVP|158580|2q14
Mowat-Wilson syndrome, 235730 (3)  |ZEB2, ZFHX1B, SMADIP1, SIP1|605802|2q22
Moyamoya disease (2)  |MYMY1, MYMY|252350|3p26-p24.2
Moyamoya disease 2 (2)  |MYMY2|607151|17q25
Moyamoya disease 3 (3)  |MYMY3|608796|8q23
Muckle-Wells syndrome, 191900 (3)  |NLRP3, CIAS1, FCU, FCAS, NALP3, PYPAF1|606416|1q44
Mucoepidermoid salivary gland carcinoma (3)  |CRTC1, MECT1, KIAA0616, FLJ14027|607536|19p13
Mucoepidermoid salivary gland carcinoma (3)  |MAML2, MAM3|607537|11q21
Mucolipidosis II alpha/beta, 252500 (3)  |GNPTAB, GNPTA|607840|12q23.3
Mucolipidosis III alpha/beta, 252600 (3)  |GNPTAB, GNPTA|607840|12q23.3
Mucolipidosis III gamma, 252605 (3)  |GNPTAG|607838|16p
Mucolipidosis IV, 252650 (3)  |MCOLN1, ML4|605248|19p13.3-p13.2
Mucopolysaccharidisis type IIIA (Sanfilippo A), 252900 (3)  |SGSH, MPS3A, SFMD|605270|17q25.3
Mucopolysaccharidosis II, 309900 (3)  |IDS, MPS2, SIDS|300823|Xq28
Mucopolysaccharidosis IVA, 253000 (3)  |GALNS, MPS4A|612222|16q24.3
Mucopolysaccharidosis Ih, 607014 (3)  |IDUA, IDA|252800|4p16.3
Mucopolysaccharidosis Ih/s, 607015 (3)  |IDUA, IDA|252800|4p16.3
Mucopolysaccharidosis Is, 607016 (3)  |IDUA, IDA|252800|4p16.3
Mucopolysaccharidosis VII, 253220 (3)  |GUSB, MPS7|611499|7q21.11
Mucopolysaccharidosis type IIIB (Sanfilippo B), 252920 (3)  |NAGLU, MPS3B|609701|17q21
Mucopolysaccharidosis type IIIC (Sanfilippo C), 252930 (3)  |HGSNAT, TMEM76, MPS3C|610453|8p11.1
Mucopolysaccharidosis type IIID, 252940 (3)  |GNS, G6S|607664|12q14
Mucopolysaccharidosis type IVB (Morquio), 253010 (3)  |GLB1, MPS4B|611458|3p21.33
Mucopolysaccharidosis type IX, 601492 (3)  |HYAL1|607071|3p21.3-p21.2
Mucopolysaccharidosis type VI (Maroteaux-Lamy), 253200 (3)  |ARSB, MPS6|611542|5q11-q13
Muenke syndrome, 602849 (3)  |FGFR3, ACH|134934|4p16.3
Muir-Torre syndrome, 158320 (3)  |MLH1, COCA2, HNPCC2|120436|3p21.3
Muir-Torre syndrome, 158320 (3)  |MSH2, COCA1, FCC1, HNPCC1|609309|2p22-p21
Mulibrey nanism, 253250 (3)  |TRIM37, MUL, KIAA0898|605073|17q22-q23
Mullerian aplasia and hyperandrogenism, 158330 (3)  |WNT4, SERKAL|603490|1p35
Multiple cutaneous and uterine leiomyomata, 150800 (3)  |FH|136850|1q42.1
Multiple endocrine neoplasia 1, 131100 (3)  |MEN1|613733|11q13
Multiple endocrine neoplasia IIA, 171400 (3)  |RET, MEN2A, HSCR1|164761|10q11.2
Multiple endocrine neoplasia IIB, 162300 (3)  |RET, MEN2A, HSCR1|164761|10q11.2
Multiple endocrine neoplasia, type IV, 610755 (3)  |CDKN1B, KIP1, CDKN4, MEN4|600778|12p13
Multiple mitochondrial dysfunctions syndrome (2)  |MMDFS|605711|2p14-p13
Multiple myeloma (3)  |IRF4, LSIRF|601900|6p25-p23
Multiple pterygium syndrome, lethal type, 253290 (3)  |CHRNA1, ACHRD, CMS2A, SCCMS, FCCMS|100690|2q24-q32
Multiple pterygium syndrome, lethal type, 253290 (3)  |CHRND, ACHRD, SCCMS, CMS2A, FCCMS|100720|2q33-q34
Multiple pterygium syndrome, lethal type, 253290 (3)  |CHRNG, ACHRG|100730|2q33-q34
Multiple sulfatase deficiency, 272200 (3)  |SUMF1, FGE|607939|3p26
Multiple synostoses syndrome 2, 6100  |GDF5, CDMP1, SYNS2, OS5|601146|20q11.2
Multiple synostoses syndrome 3, 612961 (3)  |FGF9, SYNS3|600921|13q11-q12
Mungen syndrome (2)  |MGS|611376|8q23-q24
Muscle glycogenosis, 300559 (3)  |PHKA1|311870|Xq13
Muscle hypertrophy (3)  |GDF8, MSTN|601788|2q32.2
Muscle strength quantitative trait locus 1 (2)  |MUSTQTL1|612083|14q24.3
Muscular dystrophy with epidermolysis bullosa simplex, 226670 (3)  |PLEC1, PLEC, PLTN, EBS1, LGMD2Q|601282|8q24
Muscular dystrophy with rimmed vacuoles (2)  |MDRV|601846|19p13.3
Muscular dystrophy, congenital merosin-deficient, 607855 (3)  |LAMA2, LAMM|156225|6q22-q23
Muscular dystrophy, congenital, 1B (2)  |MDC1B|604801|1q42
Muscular dystrophy, congenital, due to ITGA7 deficiency, 613204 (3)  |ITGA7|600536|12q13
Muscular dystrophy, congenital, due to partial LAMA2 deficiency, 607855 (3)  |LAMA2, LAMM|156225|6q22-q23
Muscular dystrophy, limb-girdle, type 1A, 159000 (3)  |TTID, MYOT|604103|5q31
Muscular dystrophy, limb-girdle, type 1B, 159001 (3)  |LMNA, LMN1, EMD2, FPLD, CMD1A, HGPS, LGMD1B|150330|1q21.2
Muscular dystrophy, limb-girdle, type 1D (2)  |LGMD1D|603511|7q
Muscular dystrophy, limb-girdle, type 1F (2)  |LGMD1F|608423|7q32.1-q32.2
Muscular dystrophy, limb-girdle, type 1H (2)  |LGMD1H|613530|3p25.1-p23
Muscular dystrophy, limb-girdle, type 2A, 253600 (3)  |CAPN3, CANP3|114240|15q15.1-q21.1
Muscular dystrophy, limb-girdle, type 2B, 253601 (3)  |DYSF, LGMD2B|603009|2p13.3-p13.1
Muscular dystrophy, limb-girdle, type 2C, 253700 (3)  |SGCG, LGMD2C, DMDA1, SCG3|608896|13q12
Muscular dystrophy, limb-girdle, type 2D, 608099 (3)  |SGCA, ADL, DAG2, LGMD2D, DMDA2|600119|17q12-q21.33
Muscular dystrophy, limb-girdle, type 2E, 604286 (3)  |SGCB, LGMD2E|600900|4q12
Muscular dystrophy, limb-girdle, type 2F, 601287 (3)  |SGCD, SGD, LGMD2F, CMD1L|601411|5q33
Muscular dystrophy, limb-girdle, type 2G, 601954 (3)  |TCAP, LGMD2G, CMD1N|604488|17q12
Muscular dystrophy, limb-girdle, type 2H, 254110 (3)  |TRIM32, HT2A, LGMD2H, BBS11|602290|9q31-q34.1
Muscular dystrophy, limb-girdle, type 2J, 608807 (3)  |TTN, CMD1G, TMD, LGMD2J, MPRM, HMERF, EOMFC|188840|2q31
Muscular dystrophy, limb-girdle, type 2L, 611307 (3)  |ANO5, TMEM16E, GDD1, LGMD2L|608662|11p14.3
Muscular dystrophy, limb-girdle, type 2Q, 613723 (3)  |PLEC1, PLEC, PLTN, EBS1, LGMD2Q|601282|8q24
Muscular dystrophy, limb-girdle, type IC, 607801 (3)  |CAV3, LGMD1C, LQT9|601253|3p25
Muscular dystrophy, rigid spine, 1, 602771 (3)  |SEPN1, SELN, RSMD1|606210|1p36-p35
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 1, 236670 (3)  |POMT1, MDDGA1, MDDGB1, MDDGC1|607423|9q34.1
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 2, 613150 (3)  |POMT2, MDDGA2, MDDGB2, MDDGC2|607439|14q24.3
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 3, 253280 (3)  |POMGNT1, MEB, MDDGA3, MDDGB3, MDDGC3|606822|1p34-p33
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4, 253800 (3)  |FKTN, FCMD, CMD1X, LGMD2M, MDDGA4, MDDGB4, MDDGC4|607440|9q31
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 5, 613153 (3)  |FKRP, MDC1C, LGMD2I, MDDGA5, MDDGB5, MDDGC5|606596|19q13.3
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 6, 613154 (3)  |LARGE, KIAA0609, MDC1D, MDDGA6, MDDGB6|603590|22q12.3-q13.1
Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 1, 613155 (3)  |POMT1, MDDGA1, MDDGB1, MDDGC1|607423|9q34.1
Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 2, 613156 (3)  |POMT2, MDDGA2, MDDGB2, MDDGC2|607439|14q24.3
Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 3, 613151 (3)  |POMGNT1, MEB, MDDGA3, MDDGB3, MDDGC3|606822|1p34-p33
Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 6, 608840 (3)  |LARGE, KIAA0609, MDC1D, MDDGA6, MDDGB6|603590|22q12.3-q13.1
Muscular dystrophy-dystroglycanopathy (congenital with or without mental retardation), type B, 5, 606612 (3)  |FKRP, MDC1C, LGMD2I, MDDGA5, MDDGB5, MDDGC5|606596|19q13.3
Muscular dystrophy-dystroglycanopathy (congenital without mental retardation), type B, 4, 613152 (3)  |FKTN, FCMD, CMD1X, LGMD2M, MDDGA4, MDDGB4, MDDGC4|607440|9q31
Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 1, 609308 (3)  |POMT1, MDDGA1, MDDGB1, MDDGC1|607423|9q34.1
Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 2, 613158 (3)  |POMT2, MDDGA2, MDDGB2, MDDGC2|607439|14q24.3
Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 3, 613157 (3)  |POMGNT1, MEB, MDDGA3, MDDGB3, MDDGC3|606822|1p34-p33
Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 4, 611588 (3)  |FKTN, FCMD, CMD1X, LGMD2M, MDDGA4, MDDGB4, MDDGC4|607440|9q31
Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 5, 607155 (3)  |FKRP, MDC1C, LGMD2I, MDDGA5, MDDGB5, MDDGC5|606596|19q13.3
Myasthenia gravis with thymus hyperplasia (2)  |MYAS1|607085|6p21.3
Myasthenia gravis, neonatal transient (2)  |CHRNG, ACHRG|100730|2q33-q34
Myasthenia, familial infantile, 1 (2)  |CMS1A1, FIM1|605809|17p13
Myasthenia, limb-girdle, familial, 254300 (3)  |AGRN|103320|1pter-p32
Myasthenia, limb-girdle, familial, 254300 (3)  |DOK7, C4orf25, CMS1B|610285|4p16.2
Myasthenic syndrome (3)  |SCN4A, HYPP, NAC1A, HOKPP2|603967|17q23.1-q25.3
Myasthenic syndrome, congenital, associated with acetylcholine receptor deficiency, 608931 (3)  |CHRNB1, ACHRB, SCCMS, CMS2A, CMS1D|100710|17p12-p11
Myasthenic syndrome, congenital, associated with acetylcholine receptor deficiency, 608931 (3)  |CHRNE, SCCMS, CMS2A, FCCMS, CMS1E, CMS1D|100725|17p13-p12
Myasthenic syndrome, congenital, associated with acetylcholine receptor deficiency, 608931 (3)  |MUSK|601296|9q31.3-q32
Myasthenic syndrome, congenital, associated with acetylcholine receptor deficiency, 608931 (3)  |RAPSN, CMS1D, CMS1E|601592|11p11.2-p11.1
Myasthenic syndrome, congenital, associated with episodic apnea, 254210 (3)  |CHAT, CMS1A2|118490|10q11.2
Myasthenic syndrome, congenital, associated with facial dysmorphism and acetylcholine receptor deficiency, 608931 (3)  |RAPSN, CMS1D, CMS1E|601592|11p11.2-p11.1
Myasthenic syndrome, fast-channel congenital, 608930 (3)  |CHRNA1, ACHRD, CMS2A, SCCMS, FCCMS|100690|2q24-q32
Myasthenic syndrome, fast-channel congenital, 608930 (3)  |CHRND, ACHRD, SCCMS, CMS2A, FCCMS|100720|2q33-q34
Myasthenic syndrome, fast-channel congenital, 608930 (3)  |CHRNE, SCCMS, CMS2A, FCCMS, CMS1E, CMS1D|100725|17p13-p12
Myasthenic syndrome, slow-channel congenital, 601462 (3)  |CHRNA1, ACHRD, CMS2A, SCCMS, FCCMS|100690|2q24-q32
Myasthenic syndrome, slow-channel congenital, 601462 (3)  |CHRNB1, ACHRB, SCCMS, CMS2A, CMS1D|100710|17p12-p11
Myasthenic syndrome, slow-channel congenital, 601462 (3)  |CHRND, ACHRD, SCCMS, CMS2A, FCCMS|100720|2q33-q34
Myasthenic syndrome, slow-channel congenital, 601462 (3)  |CHRNE, SCCMS, CMS2A, FCCMS, CMS1E, CMS1D|100725|17p13-p12
Mycobacterial infection, atypical, familial disseminated, 209950 (3)  |IFNGR1|107470|6q23-q24
Mycobacterial infection, atypical, familial disseminated, 209950 (3)  |STAT1|600555|2q32.2-q32.3
Myelodysplasia syndrome-1 (3)  |MDS1|600049|3q26
Myelodysplastic syndrome (3)  |ACSL6, FACL6, ACS2|604443|5q31
Myelodysplastic syndrome, preleukemic (3)  |IRF1, MAR|147575|5q31.1
Myelofibrosis, idiopathic, 254450 (3)  |JAK2|147796|9p24
Myelogenous leukemia, acute (3)  |ACSL6, FACL6, ACS2|604443|5q31
Myelogenous leukemia, acute (3)  |IRF1, MAR|147575|5q31.1
Myeloid leukemia, acute, M4Eo subtype (3)  |CBFB|121360|16q22
Myeloid malignancy, predisposition to (3)  |CSF1R, FMS|164770|5q33.2-q33.3
Myelokathexis, isolated (3)  |CXCR4, D2S201E, NPY3R, WHIM|162643|2q21
Myelomonocytic leukemia, chronic (3)  |PDGFRB, PDGFR|173410|5q31-q32
Myeloperoxidase deficiency, 254600 (3)  |MPO|606989|17q23.1
Myeloproliferative disorder (2)  |FGFR1OP, FOP|605392|6q27
Myeloproliferative disorder with eosinophilia, 131440 (3)  |PDGFRB, PDGFR|173410|5q31-q32
Myeloproliferative disorder with erythrocytosis (3)  |JAK2|147796|9p24
Myoadenylate deaminase deficiency (3)  |AMPD1|102770|1p21-p13
Myoclonic epilepsy, infantile, familial, 605021 (3)  |TBC1D24, KIAA1171, FIME|613577|16p13.3
Myoclonic epilepsy, juvenile, 4 (2)  |EJM4|611364|5q12-q14
Myoclonic epilepsy, severe, of infancy, 607208 (3)  |GABRG2, GEFSP3, CAE2, ECA2|137164|5q31.1-q33.1
Myoglobinuria, acute recurrent, autosomal recessive, 268200 (3)  |LPIN1|605518|2p21
Myokymia, 121200 (3)  |KCNQ2, EBN1, EIEE7, BFNS1|602235|20q13.3
Myopathy due to CPT II deficiency, 255110 (3)  |CPT2|600650|1p32
Myopathy with lactic acidosis, hereditary, 255125 (3)  |ISCU, HML|611911|12q24.1
Myopathy, X-linked, with excessive autophagy (2)  |MEAX, XMEA|310440|Xq28
Myopathy, X-linked, with postural muscle atrophy, 300696 (3)  |FHL1, SLIM1, XMPMA, KYOT, FHL1A, FHL1B|300163|Xq27.2
Myopathy, actin, congenital, with cores (3)  |ACTA1, ASMA, NEM3, NEM1, CFTD1|102610|1q42.1
Myopathy, actin, congenital, with excess of thin myofilaments, 161800 (3)  |ACTA1, ASMA, NEM3, NEM1, CFTD1|102610|1q42.1
Myopathy, cardioskeletal, desmin-related, with cataract, 608810 (3)  |CRYAB, CRYA2, CTPP2|123590|11q22.3-q23.1
Myopathy, centronuclear, 160150 (3)  |DNM2, CMTDIB, CMTDI1, CMT2M|602378|19p13.2
Myopathy, centronuclear, 160150 (3)  |MYF6|159991|12q21
Myopathy, centronuclear, autosomal recessive, 255200 (3)  |BIN1, AMPHL|601248|2q14
Myopathy, congenital, Compton-North, 612540 (3)  |CNTN1|600016|12q11-q12
Myopathy, congenital, with fiber-type disproportion 1, 255310 (3)  |ACTA1, ASMA, NEM3, NEM1, CFTD1|102610|1q42.1
Myopathy, congenital, with fiber-type disproportion, X-linked (2)  |CFTDX|300580|Xq13.1-q22.1
Myopathy, desmin-related, cardioskeletal, 601419 (3)  |DES, CMD1I|125660|2q35
Myopathy, distal (2)  |MPD2|606070|5q
Myopathy, distal 2, 606070 (3)  |MATR3, MPD2|164015|5q31.2
Myopathy, distal 3 (2)  |MPD3|610099|8p22-q11
Myopathy, distal, with anterior tibial onset, 606768 (3)  |DYSF, LGMD2B|603009|2p13.3-p13.1
Myopathy, distal, with decreased caveolin 3 (3)  |CAV3, LGMD1C, LQT9|601253|3p25
Myopathy, early-onset, with fatal cardiomyopathy, 611705 (3)  |TTN, CMD1G, TMD, LGMD2J, MPRM, HMERF, EOMFC|188840|2q31
Myopathy, hyaline body (2)  |MHB|255160|3p22.2-p21.32
Myopathy, lactic acidosis, and sideroblastic anemia 2, 613561 (3)  |YARS2, TYRRS, MLASA2|610957|12p11.21
Myopathy, limb-girdle, with bone fragility (2)  |LGMBF|609940|9p22-p21
Myopathy, mitochondrial progressive, with congenital cataract, hearing loss, and developmental delay, 613076 (3)  |GFER, ERV1, ALR|600924|16p13.3-p13.12
Myopathy, myofibrillar, BAG3-related, 612954 (3)  |BAG3|603883|10q25.2-q26.2
Myopathy, myofibrillar, ZASP-related, 609452 (3)  |LDB3, ZASP, CYPHER, KIAA01613, CMD1C, LVNC3|605906|10q22.2-q23.3
Myopathy, myofibrillar, filamin C-related, 609524 (3)  |FLNC, FLN2, ABPA, ABPL|102565|7q32
Myopathy, myosin storage, 608358 (3)  |MYH7, CMH1, MPD1, CMD1S, SPMM, SPMD|160760|14q12
Myopathy, nemaline, 3, 161800 (3)  |ACTA1, ASMA, NEM3, NEM1, CFTD1|102610|1q42.1
Myopathy, proximal, with early respiratory muscle involvement, 603689 (3)  |TTN, CMD1G, TMD, LGMD2J, MPRM, HMERF, EOMFC|188840|2q31
Myopathy, reducing body, X-linked, childhood-onset, 300718 (3)  |FHL1, SLIM1, XMPMA, KYOT, FHL1A, FHL1B|300163|Xq27.2
Myopathy, reducing body, X-linked, severe early-onset, 300717 (3)  |FHL1, SLIM1, XMPMA, KYOT, FHL1A, FHL1B|300163|Xq27.2
Myopathy, spheroid body, 182920 (3)  |TTID, MYOT|604103|5q31
Myopia 10 (2)  |MYP10|609259|8p23
Myopia 11 (2)  |MYP11|609994|4q22-q27
Myopia 12 (2)  |MYP12|609995|2q37.1
Myopia 13 (2)  |MYP13|300613|Xq23-q27.2
Myopia 15 (2)  |MYP15|612717|10q21.1
Myopia 16 (2)  |MYP16|612554|5p15.33-p15.2
Myopia 17 (2)  |MYP17, MYP4|608367|7p15
Myopia 18 (2)  |MYP18|613626|14q22.1-q24.2
Myopia 5 (2)  |MYP5|608474|17q21-q22
Myopia 7 (2)  |MYP7|609256|11p13
Myopia 8 (2)  |MYP8|609257|3q26
Myopia 9 (2)  |MYP9|609258|4q12
Myopia-1 (2)  |MYP1, BED|310460|Xq28
Myopia-2 (2)  |MYP2|160700|18p11.31
Myopia-3 (2)  |MYP3|603221|12q21-q23
Myopia-6 (2)  |MYP6|608908|22q12
Myosclerosis, congenital, 255600 (3)  |COL6A2|120240|21q22.3
Myotilinopathy, 609200 (3)  |TTID, MYOT|604103|5q31
Myotonia congenita, atypical, acetazolamide-responsive, 608390 (3)  |SCN4A, HYPP, NAC1A, HOKPP2|603967|17q23.1-q25.3
Myotonia congenita, dominant, 160800 (3)  |CLCN1|118425|7q35
Myotonia congenita, recessive, 255700 (3)  |CLCN1|118425|7q35
Myotonia levior, recessive (3)  |CLCN1|118425|7q35
Myotonic dystrophy, 160900 (3)  |DMPK, DM, DMK|605377|19q13.2-q13.3
Myotonic dystrophy, type 2, 602668 (3)  |ZNF9, CNBP1, DM2, PROMM|116955|3q13.3-q24
Myotubular myopathy, X-linked, 310400 (3)  |MTM1, MTMX|300415|Xq28
Myxoid liposarcoma, 613488 (1)  |DDIT3, GADD153, CHOP10|126337|12q13.1-q13.2
Myxoma, intracardiac, 255960 (3)  |PRKAR1A, TSE1, CNC1, CAR, PPNAD1|188830|17q23-q24
N syndrome, 310465 (1) (?)  |POLA|312040|Xp22.3-p21.1
N-acetylglutamate synthase deficiency, 237310 (3)  |NAGS|608300|17q21.31
Naegeli-Franceschetti-Jadassohn syndrome, 161000 (3)  |KRT14|148066|17q12-q21
Nail dysplasia, isolated congenital (2)  |NDIC|605779|17p13
Nail-patella syndrome, 161200 (3)  |LMX1B, NPS1|602575|9q34.1
Nance-Horan syndrome, 302350 (3)  |NHS, CXN|300457|Xp22.13
Nanophthalmos 3 (2)  |NNO3|611897|2q11-q14
Nanophthalmos-1 (2)  |NNO1|600165|11p
Narcolepsy 1, 161400 (3)  |HCRT, OX, NRCLP1|602358|17q21
Narcolepsy 2 (2)  |NRCLP2|605841|4p13-q21
Narcolepsy 3 (2)  |NRCLP3|609039|21q11.2
Nasopharyngeal carcinoma, 607107 (3)  |TP53, P53, LFS1|191170|17p13.1
Nasu-Hakola disease, 221770 (3)  |TREM2|605086|6p21.2
Nasu-Hakola disease, 221770 (3)  |TYROBP, PLOSL, DAP12|604142|19q13.1
Natural killer cell deficiency, familial isolated (2)  |NKCD|609981|8p11.23-q11.21
Naxos disease, 601214 (3)  |JUP, DP3, PDGB, ARVD12|173325|17q21
Nemaline myopathy 1, autosomal dominant, 609284 (3)  |TPM3, NEM1|191030|1q22-q23
Nemaline myopathy 2, autosomal recessive, 256030 (3)  |NEB, NEM2|161650|2q22
Nemaline myopathy 6 (2)  |NEM6|609273|15q15-q25
Nemaline myopathy 6, 609273 (3)  |KBTBD13, NEM6|613727|15q22.31
Nemaline myopathy 7, 610687 (3)  |CFL2, NEM7|601443|14q12
Nemaline myopathy, 609285 (3)  |TPM2, TMSB, AMCD1, DA1, DA2B, NEM4|190990|9p13.2-p13.1
Nemaline myopathy, Amish type, 605355 (3)  |TNNT1, ANM|191041|19q13.4
Neonatal alloimmune thrombocytopenia (1)  |ITGA2, CD49B, BR|192974|5q23-q31
Nephrogenic syndrome of inappropriate antidiuresis, 300539 (3)  |AVPR2, DIR, DI1, ADHR|300538|Xq28
Nephrolithiasis, type I, 310468 (3)  |CLCN5, CLCK2, NPHL2, DENTS, NPHL1|300008|Xp11.22
Nephrolithiasis/osteoporosis, hypophosphatemic, 1, 612286 (3)  |SLC34A1, SLC17A2, NPT2, NPHLOP1, FRTS2|182309|5q35
Nephrolithiasis/osteoporosis, hypophosphatemic, 2, 612287 (3)  |SLC9A3R1, EBP50, NHERF1, NPHLOP2|604990|17q25.1
Nephronophthisis 1, juvenile, 256100 (3)  |NPHP1, NPH1, SLSN1, JBTS4|607100|2q13
Nephronophthisis 11, 613550 (3)  |TMEM67, MKS3, JBTS6, NPHP11|609884|8q21.13-q22.1
Nephronophthisis 2, infantile, 602088 (3)  |INVS, INV, NPHP2, NPH2|243305|9q31
Nephronophthisis 3, 604387 (3)  |NPHP3, NPH3, RHPD, MKS7|608002|3q22
Nephronophthisis 4, 606966 (3)  |NPHP4, SLSN4|607215|1p36
Nephronophthisis 7, 611498 (3)  |GLIS2, NPHP7|608539|16p13.3
Nephronophthisis 9 (3)  |NEK8, JCK, NPHP9|609799|17q11.1
Nephronophthisis-like nephropathy 1, 613159 (3)  |XPNPEP3, APP3, NPHPL1|613553|22q13.31-q13.33
Nephropathy with pretibial epidermolysis bullosa and deafness, 609057 (3)  |CD151, PETA3, SFA1, MER2|602243|11p15.5
Nephropathy, IgA type (2)  |IGAN1|161950|6q22-q23
Nephropathy, progressive, with deafness (2)  |NEDE|609469|11q24
Nephropathy-hypertension (2)  |RFH1, AORF|161900|1q21
Nephrosis, congenital, with or without ocular abnormalities, 609049 (3)  |LAMB2, LAMS|150325|3p21
Nephrotic syndrome, type 1, 256300 (3)  |NPHS1, NPHN|602716|19q13.1
Nephrotic syndrome, type 2, 600995 (3)  |PDCN, NPHS2, SRN1|604766|1q25-q31
Nephrotic syndrome, type 3, 610725 (3)  |PLCE1, KIAA1516, NPHS3|608414|10q23
Nephrotic syndrome, type 4, 256370 (3)  |WT1, NPHS4|607102|11p13
Netherton syndrome, 256500 (3)  |SPINK5, LEKTI|605010|5q32
Neural tube defects, 182940 (3)  |VANGL1, STBM2|610132|1p13
Neuroblastoma (1) (?)  |TP73|601990|1p36
Neuroblastoma, 256700 (3)  |NME1, NM23|156490|17q21.3
Neurodegeneration due to cerebral folate transport deficiency, 613068 (3)  |FOLR1|136430|11q13.3-q13.5
Neurodegeneration with brain iron accumulation 1, 234200 (3)  |PANK2, NBIA1, PKAN, HARP|606157|20p13-p12.3
Neurodegeneration with brain iron accumulation 2B, 610217 (3)  |PLA2G6, IPLA2, INAD1, NBIA2B, NBIA2A, PARK14|603604|22q13.1
Neurodegeneration with brain iron accumulation 3, 606159 (3)  |FTL, NBIA3|134790|19q13.3-q13.4
Neuroepithelioma, 612219 (3)  |EWSR1, EWS|133450|22q12
Neurofibromatosis, familial spinal, 162210 (3)  |NF1, VRNF, WSS, NFNS|613113|17q11.2
Neurofibromatosis, type 1, 162200 (3)  |NF1, VRNF, WSS, NFNS|613113|17q11.2
Neurofibromatosis, type 2, 101000 (3)  |NF2|607379|22q12.2
Neurofibromatosis-Noonan syndrome, 601321 (3)  |NF1, VRNF, WSS, NFNS|613113|17q11.2
Neurofibrosarcoma (3)  |MXI1|600020|10q25
Neuromuscular disease, congenital, with uniform type 1 fiber, 117000 (3)  |RYR1, MHS, CCO|180901|19q13.1
Neuronopathy, distal hereditary motor, type IIC, 613376 (3)  |HSPB3, HSPL27, HMN2C, DHMN2C|604624|5q11.2
Neuronopathy, distal hereditary motor, type VI, 604320 (3)  |IGHMBP2, SMUBP2, CATF1, SMARD1, HMN6|600502|11q13.2-q13.4
Neuropathy, congenital hypomyelinating, 1, 605253 (3)  |EGR2, KROX20|129010|10q21.1-q22.1
Neuropathy, congenital hypomyelinating, 605253 (3)  |MPZ, CMT1B, CMTDI3, CHM, DSS|159440|1q22
Neuropathy, distal hereditary motor, Jerash type (2)  |HMNJ, MNDJ|605726|9p21.1-p12
Neuropathy, distal hereditary motor, type IIA, 158590 (3)  |HSPB8, H11, E2IG1, DHMN2, CMT2L, HMN2A|608014|12q24
Neuropathy, distal hereditary motor, type IIB, 608634 (3)  |HSPB1, HSP27, CMT2F, HMN2B|602195|7q11.23
Neuropathy, distal hereditary motor, type V, 600794 (3)  |BSCL2, SPG17, HMN5|606158|11q13
Neuropathy, distal hereditary motor, type V, 600794 (3)  |GARS, SMAD1, CMT2D, HMN5|600287|7p15
Neuropathy, distal hereditary motor, type VIIB, 607641 (3)  |DCTN1, HMN7B|601143|2p13
Neuropathy, hereditary motor and sensory, Okinawa type (2)  |HMSNO, HMSNP|604484|3q13.1
Neuropathy, hereditary sensory and autonomic, type 1, 162400 (3)  |SPTLC1, LBC1, SPT1, HSN1, HSAN|605712|9q22.1-q22.3
Neuropathy, hereditary sensory and autonomic, type II, 201300 (3)  |WNK1, PRKWNK1, KDP, PHA2C, HSAN2, HSN2|605232|12p13
Neuropathy, hereditary sensory and autonomic, type IIB, 613115 (3)  |FAM134B, HSAN2B|613114|5p15.1
Neuropathy, hereditary sensory and autonomic, type V, 608654 (3)  |NGFB, HSAN5|162030|1p13.1
Neuropathy, hereditary sensory, with spastic paraplegia, 256840 (3)  |CCT5, KIAA0098, CCTE|610150|5p15.2
Neuropathy, hereditary sensory/autonomic, type IC, 613640 (3)  |SPTLC2, KIAA0526, SPT2, LCB2, HSN1C, NSAN1C|605713|14q24.3-q31
Neuropathy, motor and sensory, Russe type (2)  |NMSR, HMSNR|605285|10q23.2
Neuropathy, paraneoplastic sensory (1)  |ELAVL4, HUD, PNEM|168360|1p34
Neuropathy, recurrent, with pressure palsies, 162500 (3)  |PMP22, CMT1A, CMT1E, DSS|601097|17p11.2
Neutral lipid storage disease with myopathy, 610717 (3)  |PNPLA2, TTS2, ATGL|609059|11p15.5
Neutropenia, alloimmune neonatal (3)  |FCGR3A, CD16, IGFR3|146740|1q23
Neutropenia, neonatal alloimmune (1)  |LAG5|151450|Chr.4
Neutropenia, nonimmune chronic idiopathic, of adults, 607847 (3)  |GFI1, ZNF163, SCN2|600871|1p22
Neutropenia, severe congenital, X-linked, 300299 (3)  |WAS, IMD2, THC1|300392|Xp11.23-p11.22
Neutropenia, severe congenital, autosomal dominant 1, 202700 (3)  |ELANE, ELA2, SCN1|130130|19p13.3
Neutropenia, severe congenital, autosomal dominant 2, 613107 (3)  |GFI1, ZNF163, SCN2|600871|1p22
Neutropenia, severe congenital, autosomal recessive 3, 610738 (3)  |HAX1, SCN3|605998|1q21.3
Neutropenia, severe congenital, autosomal recessive 4, 612541 (3)  |G6PC3, UGRP, SCN4|611045|17q21
Neutrophil immunodeficiency syndrome, 608203 (3)  |RAC2|602049|22q12.3-q13.2
Neutrophilia, hereditary, 162830 (3)  |CSF3R, GCSFR|138971|1p35-p34.3
Nevo syndrome, 601451 (3)  |PLOD, PLOD1|153454|1p36.3-p36.2
Nevus, epidermal, 162900 (3)  |PIK3CA|171834|3q26.3
Nevus, keratinocytic, nonepidermolytic, 162900 (3)  |FGFR3, ACH|134934|4p16.3
Newfoundland rod-cone dystrophy, 607476 (3)  |RLBP1|180090|15q26
Niemann-Pick disease, type A, 257200 (3)  |SMPD1, NPD|607608|11p15.4-p15.1
Niemann-Pick disease, type B, 607616 (3)  |SMPD1, NPD|607608|11p15.4-p15.1
Niemann-Pick disease, type C1, 257220 (3)  |NPC1, NPC|607623|18q11-q12
Niemann-Pick disease, type D, 257220 (3)  |NPC1, NPC|607623|18q11-q12
Niemann-pick disease, type C2, 607625 (3)  |NPC2, HE1|601015|14q24.3
Night blindness, congenital stationary, X-linked, type 2A, 300071 (3)  |CACNA1F, CSNB2, CORDX3, CSNB2A, AIED, OA2|300110|Xp11.23
Night blindness, congenital stationary, autosomal dominant 2, 163500 (3)  |PDE6B, PDEB, RP40, CSNBAD2|180072|4p16.3
Night blindness, congenital stationary, autosomal dominant 3, 610444 (3)  |GNAT1, CSNBAD3|139330|3p21
Night blindness, congenital stationary, type 1, 310500 (3)  |CSNB1, NYX|300278|Xp11.4
Night blindness, congenital stationary, type 1B, 257270 (3)  |GRM6, MGLUR6, CSNB1B|604096|5q35
Night blindness, congenital stationary, type 2B, 610427 (3)  |CABP4, CSNB2B|608965|11q13.1
Night blindness, congenital stationary, type IC, 613216 (3)  |TRPM1, MLSN1, CSNB1C|603576|15q13-q14
Night blindness, congenital stationery, autosomal dominant 1, 610445 (3)  |RHO, RP4, OPN2, CSNBAD1|180380|3q21-q24
Nijmegen breakage syndrome, 251260 (3)  |NBS1, NBS|602667|8q21
Nijmegen breakage syndrome-like disorder, 613078 (3)  |RAD50, NBSLD|604040|5q31
Non-Hodgkin lymphoma, somatic, 605027 (3)  |CASP10, MCH4, ALPS2|601762|2q33-q34
Nonaka myopathy, 605820 (3)  |GNE, GLCNE, IBM2, DMRV, NM|603824|9p13.3
Nonsmall cell lung cancer, response to tyrosine kinase inhibitor in, 211980 (3)  |EGFR|131550|7p12.3-p12.1
Nonsmall cell lung cancer, somatic (3)  |BRAF, NS7|164757|7q34
Nonsmall cell lung cancer, somatic, 211980 (3)  |IRF1, MAR|147575|5q31.1
Nonsmall cell lung cancer, somatic, 211980 (3)  |PIK3CA|171834|3q26.3
Noonan syndrome 1, 163950 (3)  |PTPN11, PTP2C, SHP2, NS1|176876|12q24.1
Noonan syndrome 3, 609942 (3)  |KRAS, KRAS2, RASK2, NS|190070|12p12.1
Noonan syndrome 4, 610733 (3)  |SOS1, GINGF, GF1, HGF, NS4|182530|2p22-p21
Noonan syndrome 5, 611553 (3)  |RAF1, CRAF, NS5|164760|3p25
Noonan syndrome 6, 613224 (3)  |NRAS, ALPS4, NS6|164790|1p13.2
Noonan syndrome 7, 613706 (3)  |BRAF, NS7|164757|7q34
Noonan syndrome-like disorder, 613563 (3)  |CBL, CBL2|165360|11q23.3
Noonan-like syndrome with loose anagen hair, 607721 (3)  |SHOC2, SIAA0862, SOC2, SUR8|602775|10q25
Norrie disease, 310600 (3)  |NDP, ND|300658|Xp11.4
Norum disease, 245900 (3)  |LCAT|606967|16q22.1
Nystagmus 1, congenital, X-linked, 310700 (3)  |FRMD7|300628|Xq26.2
Nystagmus 3, congenital (2)  |NYS3|608345|7p11.2
Nystagmus 4, congenital (2)  |NYS4|193003|13q31-q33
Nystagmus 5, congenital, X-linked (2)  |NYS5|300589|Xp11.4
Nystagmus 6, congenital, X-linked, 300814 (3)  |GPR143, OA1, NYS6|300808|Xp22.3
Nystagmus-2, autosomal dominant (2)  |NYS2, NYSA|164100|6p12
OI type II, 166210 (3)  |COL1A1|120150|17q21.31-q22
OI type III, 259420 (3)  |COL1A1|120150|17q21.31-q22
OI type IV, 166220 (3)  |COL1A1|120150|17q21.31-q22
Obesity with impaired prohormone processing, 600955 (3)  |PCSK1, NEC1, PC1, PC3, BMIQ12|162150|5q15-q21
Obesity, adrenal insufficiency, and red hair due to POMC deficiency, 609734 (3)  |POMC|176830|2p23.3
Obesity, autosomal dominant, 601665 (3)  |MC4R|155541|18q22
Obesity, hyperphagia, and developmental delay (3)  |AKR1C2, DDH2, DD2, HAKRD|600450|10p15-p14
Obesity, hyperphagia, and developmental delay (3)  |NTRK2, TRKB|600456|9q22.1
Obesity, mild, early-onset, 601665 (3)  |NR0B2, SHP|604630|1p36.1
Obesity, morbid, with hypogonadism (3)  |LEP, OB|164160|7q31.3
Obesity, morbid, with hypogonadism (3)  |LEPR, OBR|601007|1p31
Obesity, severe, 601665 (3)  |PPARG, PPARG1, PPARG2, CIMT1, GLM1|601487|3p25
Obesity, severe, 601665 (3)  |SIM1|603128|6q16.3-q21
Obesity, severe, due to leptin deficiency (3)  |LEP, OB|164160|7q31.3
Occipital horn syndrome, 304150 (3)  |ATP7A, MNK, MK, OHS, SMAX3|300011|Xq12-q13
Occult macular dystrophy, 613587 (3)  |RP1L1|608581|8p23
Ocular albinism with sensorineural deafness (2)  |OASD|300650|Xp22.3
Ocular albinism, type I, Nettleship-Falls type, 300500 (3)  |GPR143, OA1, NYS6|300808|Xp22.3
Oculoauricular syndrome, 612109 (3)  |HMX1, H6|142992|4p16.1
Oculocutaneous albinism, type IV, 606574 (3)  |SLC45A2, MATP, AIM1, SHEP5|606202|5p13.3
Oculodentodigital dysplasia, 164200 (3)  |GJA1, CX43, ODDD, SDTY3, ODOD, HSS|121014|6q21-q23.2
Oculodentodigital dysplasia, autosomal recessive, 257850 (3)  |GJA1, CX43, ODDD, SDTY3, ODOD, HSS|121014|6q21-q23.2
Oculomotor apraxia, congenital, Cogan-type (2)  |COMA|257550|2q13
Oculopharyngeal muscular dystrophy, 164300 (3)  |PABPN1, PABP2, PAB2|602279|14q11.2-q13
Odontohypophosphatasia, 146300 (3)  |ALPL, HOPS, TNSALP|171760|1p36.1-p34
Odontoonychodermal dysplasia, 257980 (3)  |WNT10A, SSPS|606268|2q35
Oguchi disease-1, 258100 (3)  |SAG, RP47|181031|2q37.1
Oguchi disease-2, 613411 (3)  |GRK1, RHOK, RK|180381|13q34
Oligodontia-colorectal cancer syndrome, 608615 (3)  |AXIN2|604025|17q24
Omenn syndrome, 603554 (3)  |DCLRE1C, ARTEMIS, SCIDA|605988|10p
Omenn syndrome, 603554 (3)  |RAG1|179615|11p13
Omenn syndrome, 603554 (3)  |RAG2|179616|11p13
Omodysplasia 1, 258315 (3)  |GPC6, OMIMD1|604404|13q32
Opitz G syndrome, type I, 300000 (3)  |MID1, OGS1, BBBG1, FXY, OSX|300552|Xp22
Opitz G syndrome, type II (2)  |OGS2, BBBG2, GBBB2|145410|22q11.2
Opitz-Kaveggia syndrome, 305450 (3)  |MED12, TNRC11, TRAP230, HOPA, KIAA0192, OKS, FGS1|300188|Xq13
Opremazole poor metabolizer, 609535 (3)  |CYP2C, CYP2C19|124020|10q24.1-q24.3
Optic atrophy 1, 165500 (3)  |OPA1, NTG, NPG|605290|3q28-q29
Optic atrophy 5 (2)  |OPA5|610708|22q12.1-q13.1
Optic atrophy 6 (2)  |OPA6|258500|8q21-q22
Optic atrophy and cataract, 165300 (3)  |OPA3, MGA3|606580|19q13.2-q13.3
Optic atrophy and deafness, 125250 (3)  |OPA1, NTG, NPG|605290|3q28-q29
Optic atrophy, X-linked (2)  |OPA2|311050|Xp11.4-p11.21
Optic atrophy-4 (2)  |OPA4|605293|18q12.2-q12.3
Optic atrophy-7, 612989 (3)  |TMEM126A, OPA7|612988|11q14.1-q21
Optic nerve coloboma with renal disease, 120330 (3)  |PAX2|167409|10q24.3-q25.1
Optic nerve hypoplasia and abnormalities of the central nervous system, 206900 (3)  |SOX2, MCOPS3|184429|3q26.3-q27
Optic nerve hypoplasia, 165550 (3)  |PAX6, AN2, MGDA|607108|11p13
Oral-facial-digital syndrome 1, 311200 (3)  |OFD1, CXorf5, SGBS2, JBTS10|300170|Xp22.3-p22.2
Ornithine transcarbamylase deficiency, 311250 (3)  |OTC|300461|Xp21.1
Orofacial cleft 10, 613705 (3)  |SUMO1, UBL1, SMT3, OFC10|601912|2q32.2-q33
Orofacial cleft 11, 600625 (3)  |BMP4, BMP2B1, BMP2B, MCOPS6, OFC11|112262|14q22-q23
Orofacial cleft 12 (2)  |OFC12|612858|8q24.31
Orofacial cleft 4 (2)  |OFC4|608371|4q21-q31
Orofacial cleft 5, 608874 (3)  |MSX1, HOX7, HYD1, OFC5, STHAG1|142983|4p16.1
Orofacial cleft 6, 608864 (3)  |IRF6, VWS, LPS, PIT, PPS, OFC6|607199|1q32-q41
Orofacial cleft 7, 225060 (3)  |HVEC, PVRL1, PVRR1, PRR1, ED4, OFC7, CLPED1|600644|11q23-q24
Orofacial cleft 8, 129400 (3)  |TP63, TP73L, KET, EEC3, SHFM4, LMS, RHS, OFC8|603273|3q27
Orofacial cleft 9 (2)  |OFC9|610361|13q33.1-q34
Orofacial cleft-1 (2)  |OFC1, CL|119530|6p24.3
Orofacial cleft-2 (2)  |OFC2|602966|2p13
Orofacial cleft-3 (2)  |OFC3|600757|19q13
Orolaryngeal cancer, multiple, (3)  |CDKN2A, MTS1, P16, MLM, CMM2|600160|9p21
Oroticaciduria (3)  |UMPS, OPRT|258900|3q13
Orthostatic hypotensive disorder of Streeten (2)  |OHDS|143850|18q
Orthostatic intolerance, 604715 (3)  |SLC6A2, NAT1, NET1|163970|16q12.2
Osseous dysplasia, digital, with facial pigmentary defects and multiple frenula (2)  |ODPF|300244|Xq27.3-q28
Osseous heteroplasia, progressive, 166350 (3)  |GNAS, GNAS1, GPSA, POH, PHP1B, PHP1A, AHO, PHP1C|139320|20q13.2
Ossification of posterior longitudinal ligament of spine, 602475 (3)  |ENPP1, PDNP1, NPPS, M6S1, PCA1, ARHR2|173335|6q22-q23
Osteoarthritis of distal interphalangeal joints (2) (?)  |OADIP, DIPOA|140600|2q12-q13
Osteoarthritis with mild chondrodysplasia, 604864 (3)  |COL2A1|120140|12q13.11-q13.2
Osteochondritis dissecans, short stature, and early-onset osteoarthritis, 165800 (3)  |ACAN, AGC1, CSPG1, MSK16, SEDK|155760|15q26.1
Osteogenesis imperfecta, type I, 166200 (3)  |COL1A1|120150|17q21.31-q22
Osteogenesis imperfecta, type II, 166210 (3)  |COL1A2|120160|7q22.1
Osteogenesis imperfecta, type IIB, 610854 (3)  |CRTAP, CASP|605497|3p22
Osteogenesis imperfecta, type III, 259420 (3)  |COL1A2|120160|7q22.1
Osteogenesis imperfecta, type IV, 166220 (3)  |COL1A2|120160|7q22.1
Osteogenesis imperfecta, type IX, 259440 (3)  |PPIB, CYPB, OI9|123841|15q21-q22
Osteogenesis imperfecta, type VI, 610698 (3)  |FKBP10, FKBP65, OI6|607063|17q21.2
Osteogenesis imperfecta, type VII (2)  |OI7|610682|3p24.1-p22
Osteogenesis imperfecta, type VII, 610682 (3)  |CRTAP, CASP|605497|3p22
Osteogenesis imperfecta, type VIII, 610915 (3)  |LEPRE1, P3H1, GROS1, OI8|610339|1p34
Osteoglophonic dysplasia, 166250 (3)  |FGFR1, FLT2, KAL2, OGD|136350|8p11.2-p11.1
Osteolysis, familial expansile, 174810 (3)  |TNFRSF11A, RANK, ODFR, OFE, OPTB7|603499|18q22.1
Osteomalacia, tumor-induced (1)  |FGF23, ADHR, HPDR2, PHPTC|605380|12p13.3
Osteopathia striata with cranial sclerosis, 300373 (3)  |FAM123B, WTX, FLJ39827, OSCS|300647|Xq11.1
Osteopetrosis, AD type I, 607634 (3)  |LRP5, BMND1, LRP7, LR3, OPPG, VBCH2, OPTA1, EVR4|603506|11q13.4
Osteopetrosis, autosomal dominant 2, 166600 (3)  |CLCN7, CLC7, OPTA2, OPTB4|602727|16p13
Osteopetrosis, autosomal recessive 2, 259710 (3)  |TNFSF11, OPGL, TRANCE, OPTB2|602642|13q14
Osteopetrosis, autosomal recessive 3, with renal tubular acidosis, 259730 (3)  |CA2|611492|8q22
Osteopetrosis, autosomal recessive 4, 611490 (3)  |CLCN7, CLC7, OPTA2, OPTB4|602727|16p13
Osteopetrosis, autosomal recessive 5, 259720 (3)  |OSTM1, GL, OPTB5|607649|6q21
Osteopetrosis, autosomal recessive 6, 611497 (3)  |PLEKHM1, AP162, KIAA0356, OPTB6|611466|17q21.3
Osteopetrosis, autosomal recessive 7, 612301 (3)  |TNFRSF11A, RANK, ODFR, OFE, OPTB7|603499|18q22.1
Osteopetrosis, recessive 1, 259700 (3)  |TCIRG1, TIRC7, OC116, OPTB1|604592|11q13.4-q13.5
Osteopoikilosis, 166700 (3)  |LEMD3, MAN1|607844|12q14
Osteoporosis, involutional, 166710 (1) (?)  |VDR|601769|12q12-q14
Osteoporosis-pseudoglioma syndrome, 259770 (3)  |LRP5, BMND1, LRP7, LR3, OPPG, VBCH2, OPTA1, EVR4|603506|11q13.4
Osteosarcoma, 259500 (2)  |LOH18CR1, OSTS|603045|18q21-q22
Osteosarcoma, 259500 (2)  |RB1|180200|13q14.1-q14.2
Osteosarcoma, 259500 (3)  |TP53, P53, LFS1|191170|17p13.1
Osteosarcoma, somatic, 259500 (3)  |CHEK2, RAD53, CHK2, CDS1, LFS2|604373|22q12.1
Osteosclerosis, 144750 (3)  |LRP5, BMND1, LRP7, LR3, OPPG, VBCH2, OPTA1, EVR4|603506|11q13.4
Otofaciocervical syndrome, 166780 (3)  |EYA1, BOR|601653|8q13.3
Otopalatodigital syndrome, type I, 311300 (3)  |FLNA, FLN1, NHBP, OPD1, OPD2, FMD, MNS, CVD1|300017|Xq28
Otopalatodigital syndrome, type II, 304120 (3)  |FLNA, FLN1, NHBP, OPD1, OPD2, FMD, MNS, CVD1|300017|Xq28
Otosclerosis 1 (2)  |OTSC1, OTS|166800|15q26.1-qter
Otosclerosis 2 (2)  |OTSC2|605727|7q34-q36
Otosclerosis 3 (2)  |OTSC3|608244|6p22.3-p21.3
Otosclerosis 5 (2)  |OTSC5|608787|3q22-q24
Otosclerosis 7 (2)  |OTSC7|611572|6q13-q16.1
Otosclerosis 8 (2)  |OTSC8|612096|9p13.1-q21.11
Otospondylomegaepiphyseal dysplasia, 215150 (3)  |COL11A2, STL3, DFNA13, DFNB53|120290|6p21.3
Ovalocytosis (3)  |SLC4A1, AE1, EPB3|109270|17q21-q22
Ovarian cancer (1)  |ARHI|605193|1p31
Ovarian cancer, 167000 (3)  |CTNNB1|116806|3p22-p21.3
Ovarian cancer, serous (2)  |ST8, OVCS|167000|6q26-q27
Ovarian cancer, somatic, (3)  |ERBB2, NGL, NEU, HER2|164870|17q21.1
Ovarian cancer, somatic, 604370 (3)  |AKT1|164730|14q32.3
Ovarian cancer, somatic, 604370 (3)  |PIK3CA|171834|3q26.3
Ovarian carcinoma (1)  |SEPT9, MSF, MSF1, NAPB|604061|17q25
Ovarian carcinoma (3)  |RRAS2, TC21|600098|11pter-p15.5
Ovarian carcinoma, somatic, 167000 (3)  |CDH1, UVO, LCAM, ECAD|192090|16q22.1
Ovarian dysgenesis 1, 233300 (3)  |FSHR, ODG1|136435|2p21-p16
Ovarian dysgenesis 2, 300510 (3)  |BMP15, GDF9B, ODG2, POF4|300247|Xp11.2
Ovarian failure, premature (2)  |POF1, POF|311360|Xq26-q28
Ovarian hyperstimulation syndrome, 608115 (3)  |FSHR, ODG1|136435|2p21-p16
Ovarian response to FSH stimulation, 276400 (3)  |FSHR, ODG1|136435|2p21-p16
Ovarioleukodystrophy, 603896 (3)  |EIF2B2|606454|14q24
Ovarioleukodystrophy, 603896 (3)  |EIF2B4|606687|2p23.3
Ovarioleukodystrophy, 603896 (3)  |EIF2B5, LVWM, CACH, CLE|603945|3q27
Overgrowth syndrome (3)  |RNF135|611358|17q11
PCWH syndrome, 609136 (3)  |SOX10, WS4, WS4C, PCWH|602229|22q13
PEPCK deficiency, mitochondrial (1)  |PCK2, PEPCK2|261650|14q11.2-q12
PTEN hamartoma tumor syndrome (3)  |PTEN, MMAC1, GLM2|601728|10q23.31
Pachyonychia congenita, Jackson-Lawler type, 167210 (3)  |KRT17, PC2, PCHC1|148069|17q12-q21
Pachyonychia congenita, Jackson-Lawler type, 167210 (3)  |KRT6B, PC2|148042|12q13
Pachyonychia congenita, Jadassohn-Lewandowsky type, 167200 (3)  |KRT16, FNEPPK|148067|17q12-q21
Pachyonychia congenita, Jadassohn-Lewandowsky type, 167200 (3)  |KRT6A|148041|12q13
Paget disease of bone (2) (?)  |PDB|167250|6p21.3
Paget disease of bone, 602080 (2)  |PDB4|606263|5q31
Paget disease of bone, 602080 (3)  |SQSTM1, P62, PDB3|601530|5q35
Paget disease of bone, 602080 (3)  |TNFRSF11A, RANK, ODFR, OFE, OPTB7|603499|18q22.1
Paget disease, juvenile, 239000 (3)  |TNFRSF11B, OPG, OCIF|602643|8q24
Pallister-Hall syndrome, 146510 (3)  |GLI3, PAPA, PAPB, ACLS|165240|7p13
Palmoplantar hyperkeratosis and true hermaphroditism, 610644 (3)  |RSPO1, FLJ40906|609595|1p34.3
Palmoplantar hyperkeratosis with squamous cell carcinoma of skin and sex reversal, 610644 (3)  |RSPO1, FLJ40906|609595|1p34.3
Palmoplantar keratoderma, Bothnia type (2)  |PPKB|600231|12q11-q13
Palmoplantar keratoderma, nonepidermolytic, 600962 (3)  |KRT16, FNEPPK|148067|17q12-q21
Palmoplantar keratoderma, nonepidermolytic, focal, 613000 (3)  |KRT16, FNEPPK|148067|17q12-q21
Palmoplantar verrucous nevus, unilateral, 144200 (3)  |KRT16, FNEPPK|148067|17q12-q21
Panbronchiolitis, diffuse (2)  |PBLT|604809|6p21.3
Pancreatic agenesis, 260370 (3)  |IPF1, MODY4|600733|13q12.1
Pancreatic cancer (3)  |MADH4, DPC4, SMAD4, JIP|600993|18q21.1
Pancreatic cancer, 260350 (3)  |TP53, P53, LFS1|191170|17p13.1
Pancreatic cancer, 613347 (3)  |BRCA2, FANCD1, BROVCA2, GLM3, PNCA2|600185|13q12.3
Pancreatic cancer, somatic (3)  |ACVR1B, ACVRLK4, ALK4|601300|12q13
Pancreatic cancer, sporadic (3)  |STK11, PJS, LKB1|602216|19p13.3
Pancreatic cancer/melanoma syndrome, 606719 (3)  |CDKN2A, MTS1, P16, MLM, CMM2|600160|9p21
Pancreatic carcinoma, somatic (3)  |RBBP8, RIM|604124|18q11.2
Pancreatic carcinoma, somatic, 260350 (3)  |KRAS, KRAS2, RASK2, NS|190070|12p12.1
Pancreatic endocrine tumors (1) (?)  |ST11, PETS1|602011|3p25
Pancreatic lipase deficiency (1)  |PNLIP|246600|10q26.1
Pancreatitis, hereditary, 167800 (3)  |PRSS1, TRY1|276000|7q35
Pancreatitis, hereditary, 167800 (3)  |SPINK1, PSTI, PCTT, TATI|167790|5q32
Panhypopituitarism, X-linked (2)  |PHP, GHDX, PHPX|312000|Xq27.2-q27.3
Panhypopituitarism, X-linked, 312000 (3)  |SOX3, MRGH|313430|Xq26.3
Panic disorder 2 (2)  |PAND2|607853|9q31
Panic disorder 3 (2)  |PAND3|609985|4q31-q34
Panic disorder syndrome 1 (2)  |PAND1|167870|13q22-q32
Papillon-Lefevre syndrome, 245000 (3)  |CTSC, CPPI, PALS, PLS, HMS, JPD|602365|11q14.1-q14.3
Paraganglioma and gastric stromal sarcoma, 606864 (3)  |SDHB, SDH2, SDHIP, PGL4|185470|1p36.1-p35
Paraganglioma and gastric stromal sarcoma, 606864 (3)  |SDHC, PGL3|602413|1q21
Paraganglioma and gastric stromal sarcoma, 606864 (3)  |SDHD, PGL1|602690|11q23
Paraganglioma, familial chromaffin, 4, 115310 (3)  |SDHB, SDH2, SDHIP, PGL4|185470|1p36.1-p35
Paragangliomas 2, 601650 (3)  |SDHAF2, SDH5, PGL2|613019|11q13.1
Paragangliomas, familial nonchromaffin, 1, with or without deafness, 168000 (3)  |SDHD, PGL1|602690|11q23
Paragangliomas, familial nonchromaffin, 3, 605373 (3)  |SDHC, PGL3|602413|1q21
Paramyotonia congenita, 168300 (3)  |SCN4A, HYPP, NAC1A, HOKPP2|603967|17q23.1-q25.3
Parastremm  |TRPV4, VROAC, HMSN2C, CMT2C, SPSMA, SSQTL1|605427|12q24.1
Parathyroid adenoma with cystic changes, 145001 (3)  |HRPT2, C1orf28|607393|1q25-q31
Parathyroid adenoma, somatic (3)  |MEN1|613733|11q13
Parathyroid carcinoma, 608266 (3)  |HRPT2, C1orf28|607393|1q25-q31
Parietal foramina 1, 168500 (3)  |MSX2, CRS2, HOX8|123101|5q34-q35
Parietal foramina 2, 609597 (3)  |ALX4, PFM2, FPP, FND2|605420|11p11.2
Parietal foramina with cleidocranial dysplasia, 168550 (3)  |MSX2, CRS2, HOX8|123101|5q34-q35
Parkes Weber slndrome, 608355 (3)  |RASA1, GAP, CMAVM, PKWS|139150|5q13.3
Parkinson disease 1, 168601 (3)  |SNCA, NACP, PARK1, PARK4|163890|4q21
Parkinson disease 10 (2)  |PARK10, AAOPD|606852|1p32
Parkinson disease 11, 607688 (3)  |GIGYF2, KIAA0642, PARK11|612003|2q37.1
Parkinson disease 12 (2)  |PARK12|300557|Xq21-q25
Parkinson disease 13, 610297 (3)  |HTRA2, OMI, PARK13, PRSS25|606441|2p12
Parkinson disease 14, 612953 (3)  |PLA2G6, IPLA2, INAD1, NBIA2B, NBIA2A, PARK14|603604|22q13.1
Parkinson disease 15, autosomal recessive, 260300 (3)  |FBXO7, FBX7, FBX, PKPS, PARK15|605648|22q12-q13
Parkinson disease 3 (2)  |PARK3|602404|2p13
Parkinson disease 4, 605543 (3)  |SNCA, NACP, PARK1, PARK4|163890|4q21
Parkinson disease 6, early onset, 605909 (3)  |PINK1, PARK6|608309|1p36
Parkinson disease 7, autosomal recessive early-onset, 606324 (3)  |DJ1, PARK7|602533|1p36
Parkinson disease 9, 606693 (3)  |ATP13A2, PARK9, KRPPD|610513|1p36
Parkinson disease, juvenile, type 2, 600116 (3)  |PRKN, PARK2, PDJ, LPRS2|602544|6q25.2-q27
Parkinson disease-8, 607060 (3)  |LRRK2, PARK8|609007|12q12
Parkinsonism-dystonia, infantile, 613135 (3)  |SLC6A3, DAT1|126455|5p15.3
Paroxysmal extreme pain disorder, 167400 (3)  |SCN9A, NENA, PN1, FEB3B|603415|2q24
Paroxysmal kinesigenic choreoathetosis (2)  |PKC, DYT10|128200|16p11.2-q12.1
Paroxysmal nocturnal hemoglobinuria, somatic, 300818 (3)  |PIGA|311770|Xp22.1
Paroxysmal nonkinesigenic dyskinesia 2 (2)  |PNKD2|611147|2q31
Paroxysmal nonkinesigenic dyskinesia, 118800 (3)  |MR1, TAHCCP2, KIPP1184, BRP17, PNKD, FPD1, PDC, DYT8|609023|2q35
Partington syndrome, 309510 (3)  |ARX, ISSX, PRTS, MRXS1, MRX36, MRX54, MRX43, MRX87, MRX29, MRX32|300382|Xp22.13
Patella aplasia or hypoplasia (2)  |PTLAH, FPAH|168860|17q21-q22
Peeling skin syndrome, acral type, 609796 (3)  |TGM6, TGX|603805|15q15.2
Pelger-Huet anomaly, 169400 (3)  |LBR, PHA|600024|1q42.1
Pelizaeus-Merzbacher disease, 312080 (3)  |PLP1, PMD, HLD1|300401|Xq22
Pelviureteric junction obstruction (2)  |PUJO|143400|6p
Pendred syndrome, 274600 (3)  |SLC26A4, PDS, DFNB4, EVA, TDH2B|605646|7q31
Pentosuria, 260800 (1)  |DCXR, P34H|608347|17q25.3
Periodic fever, familial, 142680 (3)  |TNFRSF1A, TNFR1, TNFAR, FPF|191190|12p13.2
Periodontitis, aggressive, 2 (2)  |PDON2|608526|1q25
Periodontitis, juvenile, 170650 (3)  |CTSC, CPPI, PALS, PLS, HMS, JPD|602365|11q14.1-q14.3
Peripheral arterial occlusive disease 1 (2)  |PAOD1|606787|1p31
Periventricular heterotopia with microcephaly, 608097 (3)  |ARFGEF2, BIG2, PVNH2|605371|20q13.13
Periventricular nodular heterotopia 3 (2)  |PVNH3|608098|5p15.1
Periventricular nodular heterotopia 5 (2)  |PVNH5|612881|5q14.3-q15
Peroxisomal acyl-CoA oxidase deficiency, 264470 (3)  |ACOX1, ACOX, SCOX|609751|17q25
Peroxisomal biogenesis disorder, complementation group 4 (3)  |PEX6, PXAAA1, PAF2|601498|6p21.1
Peroxisomal biogenesis disorder, complementation group 6 (3)  |PEX6, PXAAA1, PAF2|601498|6p21.1
Peroxisome biogenesis factor 12 (3)  |PEX12|601758|Chr.17
Perry syndrome, 168605 (3)  |DCTN1, HMN7B|601143|2p13
Persistent Mullerian duct syndrome, type I, 261550 (3)  |AMH, MIF|600957|19p13.3-p13.2
Persistent Mullerian duct syndrome, type II, 261550 (3)  |AMHR2, AMHR|600956|12q13
Persistent truncus arteriosus, 217095 (3)  |NKX2-6, CSX2|611770|8p21
Peters anomaly, 604229 (3)  |CYP1B1, GLC3A|601771|2p22-p21
Peters anomaly, 604229 (3)  |PAX6, AN2, MGDA|607108|11p13
Peters anomaly, 604229 (3)  |PITX2, IDG2, RIEG1, RGS, IGDS2|601542|4q25-q26
Peters-plus syndrome, 261540 (3)  |B3GALTL; B3GTL, B3GLCT|610308|13q12.3
Peutz-Jeghers syndrome, 175200 (3)  |STK11, PJS, LKB1|602216|19p13.3
Pfeiffer syndrome, 101600 (3)  |FGFR1, FLT2, KAL2, OGD|136350|8p11.2-p11.1
Pfeiffer syndrome, 101600 (3)  |FGFR2, BEK, CFD1, JWS|176943|10q26
Phenylketonuria, 261600 (3)  |PAH, PKU1|612349|12q24.1
Pheochromocytoma, 171300 (3)  |KIF1B, CMT2A, CMT2A1, NBLST1|605995|1p36.2
Pheochromocytoma, 171300 (3)  |RET, MEN2A, HSCR1|164761|10q11.2
Pheochromocytoma, 171300 (3)  |SDHB, SDH2, SDHIP, PGL4|185470|1p36.1-p35
Pheochromocytoma, 171300 (3)  |SDHD, PGL1|602690|11q23
Pheochromocytoma, 171300 (3)  |VHL|608537|3p26-p25
Phobia, specific (2)  |PHOBS|608251|Chr.14
Phosphoglycerate dehydrogenase deficiency, 601815 (3)  |PHGDH|606879|1q12
Phosphoglycerate kinase 1 deficiency, 300653 (3)  |PGK1, PGKA|311800|Xq13
Phospholipase A2, group IV A, deficiency of (3)  |PLA2G4A, PLA2G4|600522|1q25
Phosphoribosylpyrophosphate synthetase superactivity, 300661 (3)  |PRPS1, CMTX5, DFNX1, DFN2|311850|Xq22-q24
Phosphorylase kinase deficiency of liver and muscle, autosomal recessive, 261750 (3)  |PHKB|172490|16q12-q13
Phosphoserine aminotransferase deficiency, 610992 (3)  |PSAT1, PSAT, EPIP|610936|9q21.31
Phosphoserine phosphatase deficiency (3)  |PSP|172480|7p15.2-p15.1
Photoparoxysmal response 1 (2)  |PPR1|132100|6p21.1
Photoparoxysmal response 2 (2)  |PPR2|609572|13q31.3
Photoparoxysmal response 3 (2)  |PPR3|609573|7q32
Pick disease, 172700 (3)  |MAPT, MTBT1, DDPAC, MSTD|157140|17q21.1
Pick disease, 172700 (3)  |PSEN1, AD3|104311|14q24.3
Piebaldism (3)  |KIT, PBT|164920|4q12
Piebaldism, 172800 (3)  |SNAI2, SLUG, WS2D|602150|8q11
Pierre Robin syndrome (2)  |PRBNS|261800|17q24.3-q25.1
Pierson syndrome, 609049 (3)  |LAMB2, LAMS|150325|3p21
Pigment disorder, reticulate (2)  |PDR|301220|Xp22-p21
Pigment dispersion syndrome (2)  |GPDS1, PDS1|600510|7q35-q36
Pigmented adrenocortical disease, primary, 1, 610489 (3)  |PRKAR1A, TSE1, CNC1, CAR, PPNAD1|188830|17q23-q24
Pigmented nodular adrenocortical disease, primary, 2, 610475 (3)  |PDE11A, PDE11A1, PDE11A2, PDE11A3, PPNAD2|604961|2q31.2
Pigmented nodular adrenocortical disease, primary, 3 (3)  |PDE8B, PPNAD3, ADSD|603390|5q13
Pigmented paravenous chorioretinal atrophy, 172870 (3)  |CRB1, RP12, LCA8|604210|1q31-q32.1
Pilomatricoma, 132600 (3)  |CTNNB1|116806|3p22-p21.3
Pinealoma with bilateral retinoblastoma (2)  |RB1|180200|13q14.1-q14.2
Pitt-Hopkins like syndrome 1, 610042 (3)  |CNTNAP2, CASPR2, NRXN4, CDFE, AUTS15, PTHSL1|604569|7q35-q36
Pitt-Hopkins syndrome, 610954 (3)  |TCF4, SEF2, ITF2, PTHS|602272|18q21.2
Pitt-Hopkins-like syndrome 2 (3)  |NRXN1, PTHSL2|600565|2p16.3
Pituitary ACTH-secreting adenoma (3)  |GNAI2, GNAI2B, GIP|139360|3p21
Pituitary adenoma, ACTH-secreting, 219090 (3)  |AIP, XAP2, ARA9|605555|11q13.3
Pituitary adenoma, growth hormone-secreting, 102200 (3)  |AIP, XAP2, ARA9|605555|11q13.3
Pituitary adenoma, prolactin-secreting, 600634 (3)  |AIP, XAP2, ARA9|605555|11q13.3
Pituitary anomalies with holoprosencephaly-like features (3)  |GLI2, HPE9|165230|2q14
Pituitary hormone deficiency, combined, 1, 613038 (3)  |POU1F1, PIT1, CPHD1|173110|3p11
Pituitary hormone deficiency, combined, 2, 262600 (3)  |PROP1, CPHD2|601538|5q
Pituitary hormone deficiency, combined, 3, 221750 (3)  |LHX3, CPHD3|600577|9q34.3
Pituitary hormone deficiency, combined, 4, 262700 (3)  |LHX4, CPHD4|602146|1q25
Pituitary hormone deficiency, combined, 5, 182230 (3)  |HESX1, RPX, CPHD5|601802|3p21.2-p21.1
Pituitary tumor, invasive (3)  |PRKCA, PKCA|176960|17q22-q23.2
Plamoplantar keratoderma, epidermolytic, 144200 (3)  |KRT1, EPPK, NEPPK, EHK|139350|12q13
Plasminogen Tochigi disease (3)  |PLG|173350|6q26
Plasminogen activator inhibitor, type I, 613329 (3)  |PAI1, PLANH1, SERPINE1|173360|7q21.3-q22
Plasminogen deficiency, types I and II (1)  |PLG|173350|6q26
Platelet PLC beta-2 deficiency (1)  |PLCB2|604114|15q15
Platelet alpha/delta storage pool deficiency (1)  |SELP, GRMP|173610|1q23-q25
Platelet disorder, familial, with associated myeloid malignancy, 601399 (3)  |RUNX1, CBFA2, AML1|151385|21q22.3
Platelet glycoprotein IV deficiency, 608404 (3)  |CD36, CHDS7|173510|7q11.2
Platelet-activating factor acetylhydrolase deficiency (3)  |PLA2G7, PAFAH|601690|6p21.2-p12
Pleuropulmonary blastoma, 601200 (3)  |DICER1, HERNA, KIAA0928|606241|14q31
Pneumothorax, primary spontaneous, 173600 (3)  |FLCN, BHD|607273|17p11.2
Poikiloderma with neutropenia, 604173 (3)  |C16orf57, PN|613276|16q13
Polycystic kidney and hepatic disease, 263200 (3)  |FCYT, PKHD1, ARPKD|606702|6p21.1-p12
Polycystic kidney disease 2, 613095 (3)  |PKD2|173910|4q21-q23
Polycystic kidney disease, adult type I, 173900 (3)  |PKD1|601313|16p13.3-p13.12
Polycystic kidney disease, infantile severe, with tuberous sclerosis (3)  |PKDTS|600273|16p13.3
Polycystic liver disease, 174050 (3)  |PRKCSH, G19P1, PCLD|177060|19p13.2-p13.1
Polycystic liver disease, 174050 (3)  |SEC63|608648|6q21
Polycystic ovary syndrome, 184700 (2)  |FST, FS|136470|5q11.2
Polycythemia vera, 263300 (3)  |JAK2|147796|9p24
Polycythemia, benign familial, 263400 (3)  |VHL|608537|3p26-p25
Polydactyly, postaxial, type A3 (2)  |PAPA3|607324|19p13.2-p13.1
Polydactyly, postaxial, type A4 (2)  |PAPA4|608562|7q22
Polydactyly, postaxial, types A1 and B, 174200 (3)  |GLI3, PAPA, PAPB, ACLS|165240|7p13
Polydactyly, preaxial type II, 174500 (3)  |LMBR1, ACHP, C7orf2, PPD2|605522|7q36
Polydactyly, preaxial, type IV, 174700 (3)  |GLI3, PAPA, PAPB, ACLS|165240|7p13
Polyhydramnios, megalencephaly, and symptomatic epilepsy, 611087 (3)  |STRADA, STRAD, LYK5|608626|17q23.3
Polymicrogyria with optic nerve hypoplasia, 613180 (3)  |TUBA8, TUBAL2|605742|22q11
Polymicrogyria, asymmetric, 610031 (3)  |TUBB2B|612850|6p25.2
Polymicrogyria, bilateral frontoparietal, 606854 (3)  |GPR56, TM7XN1, BFPP|604110|16q13
Polymicrogyria, bilateral occipital (2)  |BOP|612691|6q16.3-q22.1
Polymicrogyria, bilateral perisylvian (2)  |BPP, PMGX, CBPS|300388|Xq27.2-q28
Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract, 612674 (3)  |ABHD12, PHARC|613599|20p11.21
Polyposis syndrome, hereditary mixed, 2, 610069 (3)  |BMPR1A, ACVRLK3, ALK3|601299|10q22.3
Polyposis syndrome, mixed hereditary 1 (2)  |HMPS1, CRAC1, CRCS4|601228|15q15.3-q22.1
Polyposis, juvenile intestinal, 174900 (3)  |BMPR1A, ACVRLK3, ALK3|601299|10q22.3
Polyposis, juvenile intestinal, 174900 (3)  |MADH4, DPC4, SMAD4, JIP|600993|18q21.1
Pontocerebellar hypoplasia type 1, 607596 (3)  |VRK1, PCH1|602168|14q32
Pontocerebellar hypoplasia type 2A, 277470 (3)  |TSEN54, SEN54, PCH2A, PCH4|608755|17q25.1
Pontocerebellar hypoplasia type 2B, 612389 (3)  |TSEN2, SEN2, PCH2B|608753|3p25.1
Pontocerebellar hypoplasia type 2C, 612390 (3)  |TSEN34, PCH2C, LENG5, SEN34|608754|19q13.4
Pontocerebellar hypoplasia type 4, 225753 (3)  |TSEN54, SEN54, PCH2A, PCH4|608755|17q25.1
Pontocerebellar hypoplasia, type 6, 611523 (3)  |RARS2, RARSL, PCH6|611524|6q16.1
Popliteal pterygium syndrome, 119500 (3)  |IRF6, VWS, LPS, PIT, PPS, OFC6|607199|1q32-q41
Porencephaly, 175780 (3)  |COL4A1|120130|13q34
Porokeratosis, disseminated superficial actinic, 1, 175900 (3)  |SART3, P100, KIAA0156, TIP110, DSAP1|611684|12q24.1
Porokeratosis, disseminated superficial actinic, 2 (2)  |DSAP2|607728|15q25.1-q26.1
Porokeratosis, disseminated superficial actinic, 3 (2)  |DSAP3|612293|1p31.3-p31.1
Porokeratosis, disseminated superficial actinic, 4 (2)  |DSAP4|612353|18p11.3
Porokeratosis, palmar, plantar, and disseminated 1 (2)  |PPPD1|175850|12q24.1-q24.2
Porphyria cutanea tarda, 176100 (3)  |UROD|613521|1p34
Porphyria variegata, 176200 (3)  |PPOX|600923|1q22
Porphyria, acute hepatic, 612740 (3)  |ALAD, ALADH, PBGS|125270|9q34
Porphyria, acute intermittent, 176000 (3)  |HMBS, PBGD, UPS|609806|11q23.3
Porphyria, acute intermittent, nonerythroid variant, 176000 (3)  |HMBS, PBGD, UPS|609806|11q23.3
Porphyria, congenital erythropoietic, 263700 (3)  |UROS|606938|10q25.2-q26.3
Porphyria, hepatoerythropoietic, 176100 (3)  |UROD|613521|1p34
Postaxial polydactyly, type A2 (2)  |PAPA2|602085|13q21-q32
Potocki-Lupski syndrome (4)  |PTLS|610883|17p11.2
Potocki-Shaffer syndrome (4)  |PSS|601224|11p11.2
Prader-Willi syndrome, 176270 (3)  |NDN|602117|15q11-q13
Prader-Willi syndrome, 176270 (3)  |SNRPN|182279|15q12
Preauricular fistulae, congenital (2) (?)  |PAFC|128700|8q11.1-q13.3
Precocious puberty, central, 176400 (3)  |KISS1R, GPR54|604161|19p13.3
Precocious puberty, male, 176410 (3)  |LHCGR, LHR, LCGR|152790|2p21
Preeclampsia/eclampsia 1 (2)  |PEE1, PREG1|189800|2p13
Preeclampsia/eclampsia 2 (2)  |PEE2|609402|2p25
Preeclampsia/eclampsia 3 (2)  |PEE3|609403|9p13
Preeclampsia/eclampsia 4 (3)  |STOX1, PEE4|609397|10q22.1
Premature chromosome condensation with microcephaly and mental retardation, 606858 (3)  |MCPH1|607117|8p23
Premature ovarian failure 2B, 300604 (3)  |FLJ22792, POF1B, POF2B|300603|Xq21
Premature ovarian failure 3, 608996 (3)  |FOXL2, BPES, BPES1, PFRK, POF3|605597|3q23
Premature ovarian failure 4, 300510 (3)  |BMP15, GDF9B, ODG2, POF4|300247|Xp11.2
Premature ovarian failure 5, 611548 (3)  |NOBOX, POF5|610934|7q35
Premature ovarian failure 6, 612310 (3)  |FIGLA, POF6|608697|2p12
Premature ovarian failure 7, 612964 (3)  |NR5A1, FTZF1, FTZ1, SF1, AD4BP, POF7|184757|9q33
Premature ovarian failure, 300511 (3)  |DIAPH2, DIA, POF2|300108|Xq22
Primary lateral sclerosis, adult, 1 (2)  |PLSA1, PLSA|611637|4p16
Primary lateral sclerosis, juvenile, 606353 (3)  |ALS2, ALSJ, PLSJ, IAHSP|606352|2q33
Prinzmetal angina (1) (?)  |KCNJ8|600935|12p11.23
Prion disease with protracted course, 606688 (3)  |PRNP, PRIP|176640|20pter-p12
Progesterone resistance, 264080 (2) (?)  |PGR|607311|11q22
Progressive external ophthalmoplegia with mitochondrial DNA deletions 3, 609283 (3)  |SLC25A4, ANT1, T1, PEO3, PEO2|103220|4q35
Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 4, 610131 (3)  |POLG2, POLGB, PEOA4|604983|17q23-q24
Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 5, 613077 (3)  |RRM2B, P53R2, PEOA5, MTDPS8A, MTDPS8B|604712|8q23.1
Progressive external ophthalmoplegia, autosomal dominant, 157640 (3)  |POLG, POLG1, POLGA, PEO, SANDO, SCAE, MTDPS4A, MTDPS4B, MIRAS|174763|15q25
Progressive external ophthalmoplegia, autosomal dominant, 3, 609286 (3)  |C10orf2, TWINKLE, PEO1, PEOA3, IOSCA, MTDPS7|606075|10q24
Progressive external ophthalmoplegia, autosomal recessive, 258450 (3)  |POLG, POLG1, POLGA, PEO, SANDO, SCAE, MTDPS4A, MTDPS4B, MIRAS|174763|15q25
Progressive familial heart block, type IB, 604559 (3)  |TRPM4, PFHB1B|606936|19q13.32
Proguanil poor metabolizer, 609535 (3)  |CYP2C, CYP2C19|124020|10q24.1-q24.3
Prolidase deficiency, 170100 (3)  |PEPD|613230|19cen-q13.11
Proliferative vasculopathy and hydraencephaly-hydrocephaly syndrome, 225790 (3)  |FLVCR2, C14orf58, CCT, PVHH, EPV|610865|14q24.3
Prolonged bleeding time, brachydactyly and mental retardation (3)  |GNAS, GNAS1, GPSA, POH, PHP1B, PHP1A, AHO, PHP1C|139320|20q13.2
Properdin deficiency, X-linked, 312060 (3)  |PFC, PFD|300383|Xp11.4-p11.23
Propionicacidemia, 606054 (3)  |PCCA|232000|13q32
Propionicacidemia, 606054 (3)  |PCCB|232050|3q21-q22
Prostate adenocarcinoma (2)  |ST12, PAC1|601188|10pter-q11
Prostate cancer 1, 176807, 601518 (3)  |RNASEL, RNS4, PRCA1, HPC1|180435|1q25
Prostate cancer, 176807 (3)  |BRCA2, FANCD1, BROVCA2, GLM3, PNCA2|600185|13q12.3
Prostate cancer, hereditary, 176807 (3)  |MSR1|153622|8p22
Prostate cancer, progression and metastasis of, 603688 (3)  |EPHB2, EPHT3, DRT, ERK, PCBC, CAPB|600997|1p36.1-p35
Prostate cancer, somatic, 176807 (3)  |KLF6, COPEB, BCD1, ZF9|602053|10p15
Prostate cancer, somatic, 176807 (3)  |MAD1L1, TXBP181|602686|7p22
Proteinuria, low molecular weight, with hypercalciuric nephrocalcinosis, 308990 (3)  |CLCN5, CLCK2, NPHL2, DENTS, NPHL1|300008|Xp11.22
Protoporphyria, erythropoietic, X-linked dominant, 300752 (3)  |ALAS2, ANH1, ASB, XLDPP, XLSA, ANH1|301300|Xp11.21
Protoporphyria, erythropoietic, autosomal dominant, 177000 (3)  |FECH, FCE|612386|18q21.3
Protoporphyria, erythropoietic, autosomal recessive, 177000 (3)  |FECH, FCE|612386|18q21.3
Proud syndrome, 300004 (3)  |ARX, ISSX, PRTS, MRXS1, MRX36, MRX54, MRX43, MRX87, MRX29, MRX32|300382|Xp22.13
Pseudoachondroplasia, 177170 (3)  |COMP, EDM1, MED, PSACH|600310|19p13.1
Pseudohermaphroditism, male, with gynecomastia, 264300 (3)  |HSD17B3, EDH17B3|605573|9q22
Pseudohyperkalemia, familial, 177720 (2)  |DHS|194380|16q23-q24
Pseudohyperkalemia, familial, 2, due to red cell leak (2)  |PSHK2|609153|2q35-q36
Pseudohypoaldosteronism type I, autosomal dominant, 177735 (3)  |NR3C2, MLR, MCR|600983|4q31.1
Pseudohypoaldosteronism type II, 145260 (3)  |WNK4, PRKWNK4, PHA2B|601844|17q21-q22
Pseudohypoaldosteronism, type I, 264350 (3)  |SCNN1A, BESC2|600228|12p13
Pseudohypoaldosteronism, type I, 264350 (3)  |SCNN1B, BESC1|600760|16p13-p12
Pseudohypoaldosteronism, type I, 264350 (3)  |SCNN1G, PHA1, BESC3|600761|16p13-p12
Pseudohypoaldosteronism, type II (2)  |PHA2A, PHA2|145260|1q31-q42
Pseudohypoaldosteronism, type IIC, 145260 (3)  |WNK1, PRKWNK1, KDP, PHA2C, HSAN2, HSN2|605232|12p13
Pseudohypoparathyroidism Ia, 103580 (3)  |GNAS, GNAS1, GPSA, POH, PHP1B, PHP1A, AHO, PHP1C|139320|20q13.2
Pseudohypoparathyroidism Ib, 603233 (3)  |GNAS, GNAS1, GPSA, POH, PHP1B, PHP1A, AHO, PHP1C|139320|20q13.2
Pseudohypoparathyroidism Ic, 612462 (3)  |GNAS, GNAS1, GPSA, POH, PHP1B, PHP1A, AHO, PHP1C|139320|20q13.2
Pseudohypoparathyroidism, type IB, 603233 (3)  |GNASAS, NESPAS|610540|20q13.2
Pseudohypoparathyroidism, type IB, 603233 (3)  |STX16, SYN16|603666|20q13.32
Pseudovaginal perineoscrotal hypospadias, 264600 (3)  |SRD5A2|607306|2p23
Pseudoxanthoma elasticum, 264800 (3)  |ABCC6, ARA, ABC34, MLP1, PXE|603234|16p13.1
Pseudoxanthoma elasticum, forme fruste, 177850 (3)  |ABCC6, ARA, ABC34, MLP1, PXE|603234|16p13.1
Pseudoxanthoma elasticum-like disorder with multiple coagulation factor deficiency, 610842 (3)  |GGCX|137167|2p12
Ptosis, congenital, 178300 (2) (?)  |ZFHX4, ZFH4|606940|8q21.12
Ptosis, hereditary congenital 2 (2)  |PTOS2, PTOSX|300245|Xq24-q27.1
Ptosis, hereditary congenital, 1 (2)  |PTOS1|178300|1p34.1-p32
Pulmonary alveolar microlithiasis, 265100 (3)  |SLC34A2|604217|4p15.31-p15.2
Pulmonary alveolar proteinosis, 300770 (3)  |CSF2RA|306250|Xp22.32
Pulmonary disease, chronic obstructive, severe early-onset (2)  |COPD|606963|2q
Pulmonary fibrosis, idiopathic, 178500 (3)  |SFTPA2, SPA2, COLEC5|178642|10q22-q23
Pulmonary hypertension, familial primary, 178600 (3)  |BMPR2, PPH1|600799|2q33
Pulmonary hypertension, primary, 178600 (3)  |MADH9, SMAD9, MADH6|603295|13q12-q14
Pulmonary hypertension, primary, fenfluramine-associated, 178600 (3)  |BMPR2, PPH1|600799|2q33
Pulmonary venoocclusive disease, 265450 (3)  |BMPR2, PPH1|600799|2q33
Pycnodysostosis, 265800 (3)  |CTSK|601105|1q21
Pyloric stenosis, infantile hypertrophic 1 (2)  |IHPS1, IHPS|179010|12q
Pyloric stenosis, infantile hypertrophic, 2 (2)  |IHPS2|610260|16p13-p12
Pyloric stenosis, infantile hypertrophic, 3 (2)  |IHPS3|612017|11q14-q22
Pyloric stenosis, infantile hypertrophic, 4 (2)  |IHPS4|300711|Xq23
Pyloric stenosis, infantile hypertrophic, 5 (2)  |IHPS5|612525|16q24.3
Pyogenic bacterial infections, recurrent, due to MYD88 deficiency, 612260 (3)  |MYD88, MYD88D|602170|3p22-p21.3
Pyogenic sterile arthritis, pyoderma gangrenosum, and acne, 604416 (3)  |PSTPIP1, PSTPIP, CD2BP1, PAPAS|606347|15q24-q25.1
Pyridoxamine 5'-phosphate oxidase deficiency, 610090 (3)  |PNPO|603287|17q21.32
Pyropoikilocytosis, 266140 (3)  |SPTA1, EL2, SPH3, HS3, HPP|182860|1q21
Pyruvate carboxylase deficiency, 266150 (3)  |PC|608786|11q13.4-q13.5
Pyruvate dehydrogenase E1-beta deficiency (3)  |PDHB|179060|3p13-q23
Pyruvate dehydrogenase E2 deficiency, 245348 (3)  |DLAT, PDCE2|608770|11q23.1
Pyruvate dehydrogenase deficiency, 312170 (3)  |PDHA1, PHE1A|300502|Xp22.2-p22.1
Pyruvate dehydrogenase phosphatase deficiency, 608782 (3)  |PDP1, PPM2C, PDP1, PDPC|605993|8q22.1
Pyruvate kinase deficiency, 266200 (3)  |PKLR, PK1|609712|1q21
RAPADILINO syndrome, 266280 (3)  |RECQL4, RTS, RECQ4|603780|8q24.3
RIDDLE syndrome, 611943 (3)  |RNF168|612688|3q29
Rabson-Mendenhall syndrome, 262190 (3)  |INSR, HHF5|147670|19p13.2
Radial ray deficiency (2)  |RRDX|300378|Xq24-q25
Radiation sensitivity/chromosome instability syndrome, autosomal dominant (1)  |RSCIS|605463|14q11.2
Radioulnar synostosis with amegakaryocytic thrombocytopenia, 605432 (3)  |HOXA11, HOX1I|142958|7p15-p14.2
Ragweed sensitivity (2) (?)  |RWS|179450|6p21.3
Raine syndrome, 259775 (3)  |FAM20C, DMP4|611061|7p22
Rajab syndrome (2)  |RJBS|613658|2q36.2
Rapp-Hodgkin syndrome, 129400 (3)  |TP63, TP73L, KET, EEC3, SHFM4, LMS, RHS, OFC8|603273|3q27
Recombination rate QTL 1, 612042 (3)  |RNF212, ZHP3|612041|4p16.3
Refsum disease, 266500 (3)  |PEX7, RCDP1|601757|6q22-q24
Refsum disease, 266500 (3)  |PHYH, PAHX|602026|10pter-p11.2
Refsum disease, adult, with increased pipecolicacidemia (2)  |RDPA|600964|10pter-p11.2
Refsum disease, infantile form, 266510 (3)  |PEX26|608666|22q11.21
Refsum disease, infantile form, 266510 (3)  |PXMP3, PAF1, PMP35, PEX2|170993|8q21.1
Refsum disease, infantile, 266510 (3)  |PEX1, ZWS1|602136|7q21-q22
Renal adysplasia, 191830 (3)  |UPK3A, UPK3, UPIII|611559|22q13.31
Renal agenesis, 191830 (3)  |RET, MEN2A, HSCR1|164761|10q11.2
Renal carcinoma, chromophobe, somatic, 144700 (3)  |FLCN, BHD|607273|17p11.2
Renal cell carcinoma, 144700 (2)  |DIRC2, RCC4|602773|3q21
Renal cell carcinoma, 144700 (3)  |HNF1A, TCF1, MODY3, IDDM20|142410|12q24.2
Renal cell carcinoma, 144700 (3)  |RNF139, TRC8, RCA1|603046|8q24.1
Renal cell carcinoma, clear cell, somatic, 144700 (3)  |OGG1|601982|3p26.2
Renal cell carcinoma, papillary, 1, 605074 (3)  |PRCC, RCCP1|179755|1q21
Renal cell carcinoma, papillary, 1, 605074 (3)  |TFE3|314310|Xp11.22
Renal cell carcinoma, papillary, 3 (2)  |RCCP3|605075|17q21.32
Renal cell carcinoma, papillary, familial and sporadic, 605074 (3)  |MET, AUTS9|164860|7q31
Renal cell carcinoma, somatic, 144700 (3)  |VHL|608537|3p26-p25
Renal cysts and diabetes syndrome, 137920 (3)  |HNF1B, TCF2, HNF2, MODY5, FJHN, HPC11|189907|17q12
Renal glucosuria, 233100 (3)  |SLC5A2, SGLT2|182381|16p11.2
Renal hypodysplasia, nonsyndromic, 1 (2)  |RHDNS1|610805|1p33-p32
Renal hypoplasia, isolated (3)  |PAX2|167409|10q24.3-q25.1
Renal tubular acidosis with deafness, 267300 (3)  |ATP6B1, VPP3|192132|2cen-q13
Renal tubular acidosis, distal, AD, 179800 (3)  |SLC4A1, AE1, EPB3|109270|17q21-q22
Renal tubular acidosis, distal, AR, 611590 (3)  |SLC4A1, AE1, EPB3|109270|17q21-q22
Renal tubular acidosis, distal, autosomal recessive, 602722 (3)  |ATP6V0A4, ATP6N1B, VPP2, RTA1C, RTADR|605239|7q33-q34
Renal tubular acidosis, proximal, with ocular abnormalities, 604278 (3)  |SLC4A4, NBC1, KNBC, SLC4A5|603345|4q21
Renal tubular dysgenesis, 267430 (3)  |ACE, DCP1, ACE1, MVCD3|106180|17q23
Renal tubular dysgenesis, 267430 (3)  |AGT, SERPINA8|106150|1q42-q43
Renal tubular dysgenesis, 267430 (3)  |AGTR1, AGTR1A, AT2R1|106165|3q21-q25
Renal tubular dysgenesis, 267430 (3)  |REN, HNFJ2|179820|1q32
Renal-hepatic-pancreatic dysplasia, 208540 (3)  |NPHP3, NPH3, RHPD, MKS7|608002|3q22
Renpenning syndrome, 309500 (3)  |PQBP1, NPW38, SHS, MRX55, MRXS3, RENS1, MRXS8|300463|Xp11.23
Restrictive dermopathy, lethal  |LMNA, LMN1, EMD2, FPLD, CMD1A, HGPS, LGMD1B|150330|1q21.2
Restrictive dermopathy, lethal, 275210 (3)  |ZMPSTE24, FACE1, STE24, MADB|606480|1p34
Reticular dysgenesis, 267500 (3)  |AK2|103020|1p34
Retinal cone dystrophy 3, 610024 (3)  |PDE6H, RCD3|601190|12p13
Retinal cone dystrophy 3B, 610356 (3)  |KCNV2, KV11.1, RCD3B|607604|9p24.2
Retinal cone dystrophy 4, 610478 (3)  |CACNA2D4, RCD4|608171|12p13.3
Retinal cone dystrophy-1 (2) (?)  |RCD1|180020|6q25-q26
Retinal degeneration, autosomal recessive, clumped pigment type (3)  |NRL, D14S46E, RP27|162080|14q11.1-q11.2
Retinal degeneration, late-onset, autosomal dominant, 605670 (3)  |C1QTNF5, CTRP5, LORD|608752|11q23.3
Retinal dystrophy, early-onset severe, 248200 (3)  |ABCA4, ABCR, STGD1, FFM, RP19, CORD3, ARMD2|601691|1p22.1
Retinal dystrophy, early-onset severe, 613341 (3)  |LRAT, LCA14|604863|4q31
Retinal nonattachment, nonsyndromic congenital (2)  |RNANC, NCRNA|221900|10q21
Retinitis pigmentosa 28, 606068 (3)  |FAM161A, RP28|613596|2p15
Retinitis pigmentosa 33, 610359 (3)  |SNRNP200, ASCC3L1, KIAA0788, RP33|601664|2q11.2
Retinitis pigmentosa 34 (2)  |RP34|300605|Xq28
Retinitis pigmentosa 4, autosomal dominant or recessive, 613731 (3)  |RHO, RP4, OPN2, CSNBAD1|180380|3q21-q24
Retinitis pigmentosa 51, 613464 (3)  |TTC8, BBS8, RP51|608132|14q32.1
Retinitis pigmentosa 54, 613428 (3)  |C2orf71|613425|2p24.1-p23.1
Retinitis pigmentosa 55, 613575 (3)  |ARL6, BBS3, RP55|608845|3p12-q13
Retinitis pigmentosa 56, 613581 (3)  |IMPG2, IPM200, RP56|607056|3q11.2
Retinitis pigmentosa 57, 613582 (3)  |PDE6G, PDEG, RP57|180073|17q25
Retinitis pigmentosa 58, 613617 (3)  |ZNF513, RP58|613598|2p24.1-p22.3
Retinitis pigmentosa, X-linked, and sinorespiratory infections, with or without deafness, 300455 (3)  |RPGR, RP3, CRD, RP15, COD1, CORDX1|312610|Xp11.4
Retinitis pigmentosa, Y-linked (2)  |RPY|400004|Chr.Y
Retinitis pigmentosa, concentric, 613194 (3)  |BEST1, VMD2, ARB, RP50|607854|11q13
Retinitis pigmentosa, digenic, 608133 (3)  |PRPH2, DS, RP7, PRPH, AVMD, AOFMD, CACD2|179605|6p21.1-cen
Retinitis pigmentosa, juvenile (3)  |AIPL1, LCA4|604392|17p13.1
Retinitis pigmentosa, juvenile, 613341 (3)  |LRAT, LCA14|604863|4q31
Retinitis pigmentosa, juvenile, autosomal recessive, 268000 (3)  |SPATA7, HSD3, LCA3|609868|14q31.3
Retinitis pigmentosa, late-onset dominant, 268000 (3)  |CRX, CORD2, CRD, LCA7|602225|19q13.3
Retinitis pigmentosa-1, 180100 (3)  |RP1, ORP1|603937|8q11-q13
Retinitis pigmentosa-10, 180105 (3)  |IMPDH1, RP10, LCA11|146690|7q31.3-q32
Retinitis pigmentosa-11, 600138 (3)  |PRPF31, PRP31, RP11|606419|19q13.4
Retinitis pigmentosa-12, autosomal recessive, 600105 (3)  |CRB1, RP12, LCA8|604210|1q31-q32.1
Retinitis pigmentosa-13, 600059 (3)  |PRPF8, PRPC8, RP13|607300|17p13.3
Retinitis pigmentosa-14, 600132 (3)  |TULP1, RP14|602280|6p21.3
Retinitis pigmentosa-17, 600852 (3)  |CA4, RP17|114760|17q23
Retinitis pigmentosa-18, 601414 (3)  |HPRP3, RP18|607301|1q21.2
Retinitis pigmentosa-19, 601718 (3)  |ABCA4, ABCR, STGD1, FFM, RP19, CORD3, ARMD2|601691|1p22.1
Retinitis pigmentosa-2, 312600 (3)  |RP2|300757|Xp11.23
Retinitis pigmentosa-20 (3)  |RPE65, RP20, LCA2|180069|1p31
Retinitis pigmentosa-22 (2)  |RP22|602594|16p12.3-p12.1
Retinitis pigmentosa-23 (2)  |RP23|300424|Xp22
Retinitis pigmentosa-24 (2)  |RP24|300155|Xq26-q27
Retinitis pigmentosa-25, 602772 (3)  |EYS, RP25|612424|6q12
Retinitis pigmentosa-26, 608380 (3)  |CERKL, RP26|608381|2q31.2-q32.3
Retinitis pigmentosa-27 (3)  |NRL, D14S46E, RP27|162080|14q11.1-q11.2
Retinitis pigmentosa-28 (2)  |RP28|606068|2p15-p11
Retinitis pigmentosa-29 (2)  |RP29|612165|4q32-q34
Retinitis pigmentosa-3, 300029 (3)  |RPGR, RP3, CRD, RP15, COD1, CORDX1|312610|Xp11.4
Retinitis pigmentosa-30, 607921 (3)  |FSCN2, RFSN, RP30|607643|17q25
Retinitis pigmentosa-31, 609923 (3)  |TOPORS, P53BP3, LUN, RP31|609507|9p21
Retinitis pigmentosa-32 (2)  |RP32|609913|1p21.3-p13.3
Retinitis pigmentosa-35, 610282 (3)  |SEMA4A, SEMB, RP35, CORD10|607292|1q22
Retinitis pigmentosa-36, 610599 (3)  |PRCD, RP36|610598|17q22
Retinitis pigmentosa-37, 611131 (3)  |NR2E3, PNR, ESCS, RP37|604485|15q23
Retinitis pigmentosa-38, 268000 (3)  |MERTK, RP38|604705|2q14.1
Retinitis pigmentosa-39, 268000 (3)  |USH2A, RP39|608400|1q41
Retinitis pigmentosa-40 (3)  |PDE6B, PDEB, RP40, CSNBAD2|180072|4p16.3
Retinitis pigmentosa-41, 612095 (3)  |PROM1, PROML1, AC133, RP41, CORD12, CD133, MCDR2, STGD4|604365|4p15.3
Retinitis pigmentosa-42, 612943 (3)  |KLHL7, RP42|611119|7p15.3
Retinitis pigmentosa-43 (3)  |PDE6A, PDEA, RP43|180071|5q31.2-q34
Retinitis pigmentosa-44 (3)  |RGR, RP44|600342|10q23
Retinitis pigmentosa-45, 268000 (3)  |CNGB1, CNCG3L, CNCG2, RP45|600724|16q13
Retinitis pigmentosa-46 (3)  |IDH3B, RP46|604526|20p13
Retinitis pigmentosa-47 (3)  |SAG, RP47|181031|2q37.1
Retinitis pigmentosa-48 (3)  |GUCA1B, GCAP2, GUCA2, RP48|602275|6p21.1
Retinitis pigmentosa-49 (3)  |CNGA1, CNCG1, RP49|123825|4p12-cen
Retinitis pigmentosa-50, 613194 (3)  |BEST1, VMD2, ARB, RP50|607854|11q13
Retinitis pigmentosa-6 (2) (?)  |RP6|312612|Xp21.3-p21.2
Retinitis pigmentosa-7, 608133 (3)  |PRPH2, DS, RP7, PRPH, AVMD, AOFMD, CACD2|179605|6p21.1-cen
Retinitis pigmentosa-7, digenic (3)  |ROM1, ROSP1, RP7|180721|11q13
Retinitis pigmentosa-9, 180104 (3)  |RP9|607331|7p14.2
Retinitis punctata albescens, 136880 (3)  |PRPH2, DS, RP7, PRPH, AVMD, AOFMD, CACD2|179605|6p21.1-cen
Retinitis punctata albescens, 136880 (3)  |RHO, RP4, OPN2, CSNBAD1|180380|3q21-q24
Retinitis punctata albescens, 136880 (3)  |RLBP1|180090|15q26
Retinoblastoma (3)  |RB1|180200|13q14.1-q14.2
Retinol binding protein, deficiency of (3)  |RBP4|180250|10q24
Retinopathy of prematurity, 133780 (3)  |FZD4, EVR1|604579|11q14-q21
Retinoschisis (3)  |RS1, XLRS1|312700|Xp22.2-p22.1
Rett syndrome, 312750 (3)  |MECP2, RTT, PPMX, MRX16, MRX79, AUTSX3, MRXSL, MRXS13, MRX79, MRX16|300005|Xq28
Rett syndrome, congenital variant, 613454 (3)  |FOXG1B, FKHL1, FKH2, QIN, BF1|164874|14q13
Rett syndrome, preserved speech variant, 312750 (3)  |MECP2, RTT, PPMX, MRX16, MRX79, AUTSX3, MRXSL, MRXS13, MRX79, MRX16|300005|Xq28
Revesz syndrome, 268130 (3)  |TINF2, TIN2|604319|14q12
Reynolds syndrome, 613471 (3)  |LBR, PHA|600024|1q42.1
Rh-mod syndrome (3)  |RHAG, RH50A|180297|6p21.1-p11
Rh-null disease, amorph type (3)  |RHCE|111700|1p36.2-p34
Rhabdoid predisposition syndrome 1, 609322 (3)  |SMARCB1, SNF5, INI1, RDT, RTPS1|601607|22q11
Rhabdoid tumor predisposition syndrome 2, 613325 (3)  |SMARCA4, BRG1, RTPS2|603254|19p13.2
Rhabdoid tumors (3)  |SMARCB1, SNF5, INI1, RDT, RTPS1|601607|22q11
Rhabdomyolysis, cerivastatin-induced (3)  |CYP2C8|601129|10q23.3
Rhabdomyosarcoma 2, alveolar, 268220 (3)  |PAX3, WS1, HUP2, CDHS, WS3|606597|2q35
Rhabdomyosarcoma 2, alveolar, 268220 (3)  |PAX7, RMS2|167410|1p36.2-p36.12
Rhabdomyosarcoma, 268210 (3)  |SLC22A1L, BWSCR1A, IMPT1|602631|11p15.5
Rhabdomyosarcoma, alveolar, 268220 (3)  |FOXO1A, FKHR|136533|13q14.1
Rhizomelic chondrodysplasia punctata, type 1, 215100 (3)  |PEX7, RCDP1|601757|6q22-q24
Rhizomelic chondrodysplasia punctata, type 3, 600121 (3)  |AGPS, ADHAPS|603051|2q31
Ribose 5-phosphate isomerase deficiency, 608611 (3)  |RPIA, RPI|180430|2p11.2
Rickets due to defect in vitamin D 25-hydroxylation, 600081 (3)  |CYP2R1|608713|11p15.2
Rickets, vitamin D-resistant, type IIA, 277440 (3)  |VDR|601769|12q12-q14
Rieger or Axenfeld anomalies, 602482 (3)  |FOXC1, FKHL7, FREAC3, IRID1, RIEG3|601090|6p25
Rieger syndrome, type 2 (2)  |RIEG2, RGS2|601499|13q14
Ring dermoid of cornea, 180550 (3)  |PITX2, IDG2, RIEG1, RGS, IGDS2|601542|4q25-q26
Rippling muscle disease, 606072 (3)  |CAV3, LGMD1C, LQT9|601253|3p25
Rippling muscle disease-1, 606072 (2)  |RMD1|600332|1q41
Roberts syndrome, 268300 (3)  |ESCO2|609353|8p21.1
Robinow syndrome, autosomal recessive, 268310 (3)  |ROR2, BDB1, BDB, NTRKR2|602337|9q22
Roifman syndrome (2)  |RFMN|300258|Chr.X
Roifman-Chitayat syndrome (2) (?)  |RCHTS|613328|15q11-q21.1
Rolandic epilepsy, mental retardation, and speech dyspraxia, 300643 (3)  |SRPX2, SRPUL, RESDX|300642|Xq21.33-q23
Rothmund-Thomson syndrome, 268400 (3)  |RECQL4, RTS, RECQ4|603780|8q24.3
Roussy-Levy syndrome, 180800 (3)  |MPZ, CMT1B, CMTDI3, CHM, DSS|159440|1q22
Roussy-Levy syndrome, 180800 (3)  |PMP22, CMT1A, CMT1E, DSS|601097|17p11.2
Rubinstein-Taybi syndrome 2, 613684 (3)  |EP300, RSTS2|602700|22q13
Rubinstein-Taybi syndrome, 180849 (3)  |CREBBP, CBP, RSTS|600140|16p13.3
SARS infection, protection against (2)  |CLEC4M, CD209L, LSIGN, DCSIGNR|605872|19p13.3
SC phocomelia syndrome, 269000 (3)  |ESCO2|609353|8p21.1
SCID due to LCK deficiency (1)  |LCK|153390|1p35-p34.3
SCID, autosomal recessive, T-negative/B-positive type (3)  |JAK3, JAKL|600173|19p13.1
SED congenita, 183900 (3)  |COL2A1|120140|12q13.11-q13.2
SED, Namaqualand type (3)  |COL2A1|120140|12q13.11-q13.2
SEMD, Pakistani type, 612847 (3)  |PAPSS2, ATPSK2|603005|10q22-q24
SERKAL syndrome, 611812 (3)  |WNT4, SERKAL|603490|1p35
SESAME syndrome, 612780 (3)  |KCNJ10, SESAME|602208|1q23.2
SMED Strudwick type, 184250 (3)  |COL2A1|120140|12q13.11-q13.2
STAR syndrome, 300707 (3)  |FAM58A, STAR|300708|Xq28
STAT1 deficiency, complete (3)  |STAT1|600555|2q32.2-q32.3
Saccharopinuria, 268700 (1)  |AASS|605113|7q31.3
Saethre-Chotzen syndrome with eyelid anomalies, 101400 (3)  |TWIST1, ACS3, SCS, CRS1|601622|7p21
Saethre-Chotzen syndrome, 101400 (3)  |FGFR2, BEK, CFD1, JWS|176943|10q26
Saethre-Chotzen syndrome, 101400 (3)  |TWIST1, ACS3, SCS, CRS1|601622|7p21
Salla disease, 604369 (3)  |SLC17A5, SIASD, SLD|604322|6q14-q15
Sandhoff disease, infantile, juvenile, and adult forms, 268800 (3)  |HEXB|606873|5q13
Sarcoidosis, early-onset, 609464 (3)  |NOD2, CARD15, IBD1, CD, ACUG, PSORAS1|605956|16q12
Sarcoma, synovial (1)  |SS18, SSXT, SYT|600192|18q11.2
Sarcoma, synovial (1)  |SSX4|300326|Xp11.2
Sarcoma, synovial (3)  |SSX2|300192|Xp11.2
Scapuloperoneal myopathy, X-linked dominant, 300695 (3)  |FHL1, SLIM1, XMPMA, KYOT, FHL1A, FHL1B|300163|Xq27.2
Scapuloperoneal spinal muscular atrophy, 181405 (3)  |TRPV4, VROAC, HMSN2C, CMT2C, SPSMA, SSQTL1|605427|12q24.1
Scapuloperoneal syndrome, myopathic type, 181430 (3)  |MYH7, CMH1, MPD1, CMD1S, SPMM, SPMD|160760|14q12
Scapuloperoneal syndrome, neurogenic, Kaeser type, 181400 (3)  |DES, CMD1I|125660|2q35
Schimke immunoosseous dysplasia, 242900 (3)  |SMARCAL1, HARP, SIOD|606622|2q34-q36
Schindler disease, type I, 609241 (3)  |NAGA|104170|22q11
Schindler disease, type III, 609241 (3)  |NAGA|104170|22q11
Schinzel-Giedion midface retraction syndrome, 269150 (3)  |SETBP1, KIAA0437, SEB|611060|18q21.1
Schizencephaly, 269160 (3)  |EMX2|600035|10q26.1
Schizophrenia, 181500 (2)  |DISC2|606271|1q42.1
Schizophrenia, neurophysiologic defect in (2)  |CHRNA7|118511|15q14
Schneckenbecken dysplasia, 269250 (3)  |SLC35D1, UGTREL7, KIAA0260|610804|1p32-p31
Schopf-Schulz-Passarge syndrome, 224750 (3)  |WNT10A, SSPS|606268|2q35
Schwannomatosis, 162091 (3)  |NF2|607379|22q12.2
Schwartz-Jampel syndrome, type 1, 255800 (3)  |HSPG2, PLC, SJS, SJA, SJS1|142461|1p36.1
Sclerosteosis, 269500 (3)  |SOST, VBCH|605740|17q12-q21
Scoliosis, idiopathic 1 (2)  |IS1, AIS|181800|19p13.3
Scoliosis, idiopathic 2 (2)  |IS2, AIS2|607354|17p11.2
Scott syndrome, 262890 (3)  |ANO6, TMEM16F|608663|12q12
Scurvy (3)  |GULOP, GULO|240400|8p21.1
Sea-blue histiocyte disease, 269600 (3)  |APOE, AD2, LPG, LDLCQ5|107741|19q13.2
Sebaceous tumors, somatic (3)  |LEF1|153245|4q23-q25
Sebastian syndrome, 605249 (3)  |MYH9, MHA, FTNS, DFNA17|160775|22q11.2
Seborrhea-like dermatitis with psoriasiform elements, 610227 (3)  |ZNF750, FLJ13841|610226|17q25.3
Seckel syndrome 1, 210600 (3)  |ATR, FRP1, SCKL|601215|3q22-q24
Seckel syndrome 2 (2)  |SCKL2|606744|18p11.31-q11.2
Seckel syndrome 3 (2)  |SCKL3|608664|14q21-q22
Seckel syndrome 4, 613676 (3)  |CENPJ, CPAP, MCPH6, SCKL4|609279|13q12.2
Segawa syndrome, recessive, 605407 (3)  |TH, TYH|191290|11p15.5
Seizures, benign familial infantile, 3, 607745 (3)  |SCN2A1, SCN2A, BFIC3, EIEE11|182390|2q23-q24.3
Seizures, benign neonatal, 1, 121200 (3)  |KCNQ2, EBN1, EIEE7, BFNS1|602235|20q13.3
Selective T-cell defect (3)  |ZAP70, SRK, STD|176947|2q12
Self-healing collodion baby, 242300 (3)  |TGM1, ICR2, LI1|190195|14q11.2
Senior-Loken syndrome 3 (2)  |SLSN3|606995|3q22
Senior-Loken syndrome 4, 606996 (3)  |NPHP4, SLSN4|607215|1p36
Senior-Loken syndrome 5, 609254 (3)  |IQCB1, NPHP5, KIAA0036|609237|3q21.1
Senior-Loken syndrome 6, 610189 (3)  |CEP290, KIAA0373, 3H11AG, JBTS5, SLSN6, LCA10, BBS14|610142|12q21.3
Senior-Loken syndrome-1, 266900 (3)  |NPHP1, NPH1, SLSN1, JBTS4|607100|2q13
Sensorineural deafness with mild renal dysfunction, 602522 (3)  |BSND|606412|1p31
Septooptic dysplasia, 182230 (3)  |HESX1, RPX, CPHD5|601802|3p21.2-p21.1
Sertoli-cell-only syndrome (1) (?)  |DAZ|400003|Yq11
Sertoli-cell-only syndrome, 400042 (1) (?)  |ZNF148, ZFP148|601897|3q21
Severe combined immunodeficiency due to ADA deficiency, 102700 (3)  |ADA|608958|20q13.11
Severe combined immunodeficiency due to IL2 deficiency (1)  |IL2|147680|4q26-q27
Severe combined immunodeficiency with microcephaly, growth retardation, and sensitivity to ionizing radiation, 611291 (3)  |NHEJ1, XLF|611290|2q35
Severe combined immunodeficiency, Athabascan type, 602450 (3)  |DCLRE1C, ARTEMIS, SCIDA|605988|10p
Severe combined immunodeficiency, B cell-negative, 601457 (3)  |RAG1|179615|11p13
Severe combined immunodeficiency, B cell-negative, 601457 (3)  |RAG2|179616|11p13
Severe combined immunodeficiency, T cell-negative, B-cell/natural killer-cell positive, 608971 (3)  |CD3D, T3D|186790|11q23
Severe combined immunodeficiency, T cell-negative, B-cell/natural killer-cell positive, 608971 (3)  |CD3E|186830|11q23
Severe combined immunodeficiency, T cell-negative, B-cell/natural killer-cell positive, 608971 (3)  |PTPRC, CD45, LCA|151460|1q31-q32
Severe combined immunodeficiency, T-cell negative, B-cell/natural killer cell-positive type, 608971 (3)  |IL7R, IL7RA, CD127|146661|5p13
Severe combined immunodeficiency, X-linked, 300400 (3)  |IL2RG, SCIDX1, SCIDX, IMD4|308380|Xq13
Sezary syndrome (3)  |BCL10|603517|1p22
Short QT syndrome-1, 609620 (3)  |KCNH2, LQT2, HERG, SQT1|152427|7q35-q36
Short QT syndrome-2, 609621 (3)  |KCNQ1, KCNA9, LQT1, KVLQT1, ATFB3, SQT2|607542|11p15.5
Short QT syndrome-3, 609622 (3)  |KCNJ2, HHIRK1, KIR2.1, IRK1, LQT7, SQT3|600681|17q23.1-q24.2
Short rib-polydactyly syndorme, type II, 253520 (3)  |NEK1, SRPS2|604588|4q33
Short rib-polydactyly syndrome, type II, digenic, 263520 (3)  |DYNC2H1, DNCH2, DHC2, ATD3|603297|11q13.5
Short rib-polydactyly syndrome, type III, 263510 (3)  |DYNC2H1, DNCH2, DHC2, ATD3|603297|11q13.5
Short stature, 604271 (3)  |GHR|600946|5p13-p12
Short stature, 604271 (3)  |GHSR|601898|3q26.3
Short stature, idiopathic familial, 300582 (3)  |SHOX, GCFX, SS, PHOG|312865|Xpter-p22.32
Short stature, idiopathic familial, 300582 (3)  |SHOXY|400020|Ypter-p11.2
Shprintzen-Goldberg syndrome, 182212 (3)  |FBN1, MFS1, WMS, SSKS|134797|15q21.1
Shwachman-Bodian-Diamond syndrome, 260400 (3)  |SBDS, SDS|607444|7q11
Sialic acid storage disorder, infantile, 269920 (3)  |SLC17A5, SIASD, SLD|604322|6q14-q15
Sialidosis, type I, 256550 (3)  |NEU1, NEU, SIAL1|608272|6p21.3
Sialidosis, type II, 256550 (3)  |NEU1, NEU, SIAL1|608272|6p21.3
Sialuria, 269921 (3)  |GNE, GLCNE, IBM2, DMRV, NM|603824|9p13.3
Sick sinus syndrome 1, 608567 (3)  |SCN5A, LQT3, VF1, HB1, SSS1, CMD1E, CDCD2|600163|3p21
Sick sinus syndrome 2, 163800 (3)  |HCN4, SSS2|605206|15q24-q25
Sickle cell anemia, 603903 (3)  |HBB|141900|11p15.5
Silver spastic paraplegia syndrome, 270685 (3)  |BSCL2, SPG17, HMN5|606158|11q13
Silver-Russell syndrome (2)  |SRS, RSS|180860|7p11.2
Silver-Russell syndrome, 180860 (3)  |H19, D11S813E, ASM1, BWS, WT2|103280|11p15.5
Simpson-Golabi-Behmel syndrome, type 1, 312870 (3)  |GPC3, SDYS, SGBS1|300037|Xq26
Simpson-Golabi-Behmel syndrome, type 2 (2)  |SGBS2|300209|Xp22
Simpson-Golabi-Behmel syndrome, type 2, 300209 (3)  |OFD1, CXorf5, SGBS2, JBTS10|300170|Xp22.3-p22.2
Sitosterolemia, 210250 (3)  |ABCG5|605459|2p21
Sitosterolemia, 210250 (3)  |ABCG8, GBD4|605460|2p21
Sjogren-Larsson syndrome, 270200 (3)  |ALDH3A2, ALDH10, SLS, FALDH|609523|17p11.2
Skeletal defects, genital hypoplasia, and mental retardation, 612447 (3)  |ZBTB16, ZNF145, PLZF|176797|11q23.1
Skin fragility-woolly hair syndrome, 607655 (3)  |DSP, KPPS2, PPKS2|125647|6p24
Skin/hair/eye pigmentation 9, dark/light hair, 611742 (3)  |ASIP, AGTIL, SHEP9|600201|20q11.2
Slowed nerve conduction velocity, AD, 608236 (3)  |ARHGEF10, KIAA0294|608136|8p23
Small patella syndrome, 147891 (3)  |TBX4|601719|17q21-q22
Small-cell cancer of lung (2)  |SCLC1|182280|3p23-p21
Smith-Lemli-Opitz syndrome, 270400 (3)  |DHCR7, SLOS|602858|11q12-q13
Smith-Magenis syndrome, 182290 (3)  |RAI1, SMCR, SMS|607642|17p11.2
Smith-McCort dysplasia, 607326 (3)  |DYM, FLJ90130, DMC, SMC|607461|18q12-q21.1
Snowflake vitreoretinal degeneration, 193230 (3)  |KCNJ13, SVD|603208|2q37
Solitary median maxillary central incisor, 147250 (3)  |SHH, HPE3, HLP3, SMMCI, MCOPCB5|600725|7q36
Somatostatin analog, resistance to, 102200 (3)  |SSTR5|182455|16p13.3
Sorsby fundus dystrophy, 136900 (3)  |TIMP3, SFD|188826|22q12.1-q13.2
Sotos syndrome, 117550 (3)  |NSD1, ARA267, STO|606681|5q35
Spastic ataxia 1, autosomal dominant (2)  |SPAX1|108600|12p13
Spastic ataxia, Charlevoix-Saguenay type, 270550 (3)  |SACS, ARSACS|604490|13q12
Spastic paralysis, infantile onset ascending, 607225 (3)  |ALS2, ALSJ, PLSJ, IAHSP|606352|2q33
Spastic paraplegia 10, 604187 (3)  |KIF5A, NKHC, SPG10|602821|12q13
Spastic paraplegia 14, autosomal recessive (2)  |SPG14|605229|3q27-q28
Spastic paraplegia 15, 270700 (3)  |ZFYVE26, KIAA0321, SPG15|612012|14q24.1
Spastic paraplegia 24 (2)  |SPG24|607584|13q14
Spastic paraplegia 25 (2)  |SPG25|608220|6q23-q24.1
Spastic paraplegia 26 (2)  |SPG26|609195|12p11.1-q14
Spastic paraplegia 31, 610250 (3)  |REEP1, C2ORF23, SPG31|609139|2p11.2
Spastic paraplegia 33, 610244 (3)  |ZFYVE27, SPG33|610243|10q24.2
Spastic paraplegia 34, X-linked (2)  |SPG34|300750|Xq24-q25
Spastic paraplegia 39, 612020 (3)  |PNPLA6, NTE, SPG39, NTEMND|603197|19p13.3
Spastic paraplegia 41 (2) (?)  |SPG41|613364|11p14.1-p11.2
Spastic paraplegia 45 (2)  |SPG45|613162|10q24.3-q25.1
Spastic paraplegia 48, autosomal recessive, 613647 (3)  |KIAA0415, SPG48|613653|7p22.1
Spastic paraplegia, 44, 613206 (3)  |GJC2, GJA12, CX47, PMLDAR, HLD2, SPG44, LMPH1C|608803|1q41-q42
Spastic paraplegia, optic atrophy, and neuropathy (2)  |SPOAN|609541|11q13
Spastic paraplegia-11, 604360 (3)  |SPG11, KIAA1840, FLJ21439|610844|15q21.1
Spastic paraplegia-12 (2)  |SPG12|604805|19q13
Spastic paraplegia-13, 605280 (3)  |HSPD1, SPG13, HSP60, HLD4|118190|2q33.1
Spastic paraplegia-16, X-linked, complicated (2)  |SPG16|300266|Xq11.2
Spastic paraplegia-18 (2)  |SPG18|611225|8p12-p11.21
Spastic paraplegia-19 (2)  |SPG19|607152|9q
Spastic paraplegia-2, 312920 (3)  |PLP1, PMD, HLD1|300401|Xq22
Spastic paraplegia-27 (2)  |SPG27|609041|10q22.1-q24.1
Spastic paraplegia-28 (2)  |SPG28|609340|14q21.3-q22.3
Spastic paraplegia-29 (2)  |SPG29|609727|1p31.1-p21.1
Spastic paraplegia-32 (2)  |SPG32|611252|14q12-q21
Spastic paraplegia-35 (2)  |SPG35|612319|16q21-q23.1
Spastic paraplegia-36 (2)  |SPG36|613096|12q23-q24
Spastic paraplegia-37 (2)  |SPG37|611945|8p21.1-q13.3
Spastic paraplegia-38 (2)  |SPG38|612335|4p16-p15
Spastic paraplegia-3A, 182600 (3)  |SPG3A|606439|14q11-q21
Spastic paraplegia-4, 182601 (3)  |SPAST, SPG4|604277|2p22-p21
Spastic paraplegia-42, 612539 (3)  |SLC33A1, ACATN, AT1|603690|3q25.31
Spastic paraplegia-5A, 270800 (3)  |CYP7B1, CBAS3, SPG5A|603711|8q21.3
Spastic paraplegia-6, 600363 (3)  |NIPA1, SPG6|608145|15q11.1
Spastic paraplegia-7, 607259 (3)  |PGN, SPG7, CMAR, CAR|602783|16q24.3
Spastic paraplegia-8, 603563 (3)  |KIAA0196, SPG8|610657|8q24.13
Spastic paraplegia-9 (2)  |SPG9|601162|10q23.3-q24.1
Specific granule deficiency, 245480 (3)  |CEBPE, CRP1|600749|14q11.2
Specific language impairment QTL, 1 (2)  |SLI1|606711|16q
Specific language impairment QTL, 2 (2)  |SLI2|606712|19q
Specific language impairment QTL, 3 (2)  |SLI3|607134|13q21
Speech-language disorder-1, 602081 (3)  |FOXP2, SPCH1, TNRC10, CAGH44|605317|7q31
Spherocytosis, hereditary, type 5, 612690 (3)  |EPB42, SPH5|177070|15q15
Spherocytosis, type 1, 182900 (3)  |ANK1, SPH2|612641|8p11.2
Spherocytosis, type 2 (3)  |SPTB, SPH2, EL3, HS2|182870|14q22-q23.2
Spherocytosis, type 3, 270970 (3)  |SPTA1, EL2, SPH3, HS3, HPP|182860|1q21
Spherocytosis, type 4, 612653 (3)  |SLC4A1, AE1, EPB3|109270|17q21-q22
Spiegler-Brooke syndrome (2)  |SBS|605041|16q12-q13
Spinal and bulbar muscular atrophy of Kennedy, 313200 (3)  |AR, DHTR, TFM, SBMA, KD, SMAX1, HYSP1|313700|Xq11-q12
Spinal cerebellar ataxia 18 (2)  |SCA18, SMNA|607458|7q22-q32
Spinal muscular atrophy, X-linked 2, infantile, 301830 (3)  |UBE1, GXP1, A1ST, SMAX2, AMCX1|314370|Xp11.23
Spinal muscular atrophy, chronic distal, autosomal recessive (2)  |SMAR|607088|11q13
Spinal muscular atrophy, congenital nonprogressive, of lower limbs (2)  |SMAL|600175|12q23-q24
Spinal muscular atrophy, distal, X-linked 3 (2)  |SMAX3, DSMAX|300489|Xq13.1-q21
Spinal muscular atrophy, distal, X-linked 3, 300489 (3)  |ATP7A, MNK, MK, OHS, SMAX3|300011|Xq12-q13
Spinal muscular atrophy, distal, autosomal recessive, 4, 611067 (3)  |PLEKHG5, KIAA0720, DSMA4|611101|1p36
Spinal muscular atrophy, late-onset, Finkel type, 182980 (3)  |VAPB, VAPC, ALS8|605704|20q13.3
Spinal muscular atrophy, lower extremity, autosomal dominant (2)  |SMALED|158600|14q32
Spinal muscular atrophy-1, 253300 (3)  |SMN1, SMA1, SMA2, SMA3, SMA4|600354|5q12.2-q13.3
Spinal muscular atrophy-2, 253550 (3)  |SMN1, SMA1, SMA2, SMA3, SMA4|600354|5q12.2-q13.3
Spinal muscular atrophy-3, 253400 (3)  |SMN1, SMA1, SMA2, SMA3, SMA4|600354|5q12.2-q13.3
Spinal muscular atrophy-4, 271150 (3)  |SMN1, SMA1, SMA2, SMA3, SMA4|600354|5q12.2-q13.3
Spinocerebellar ataxia 12, 604326 (3)  |PPP2R2B|604325|5q31-q33
Spinocerebellar ataxia 14, 605361 (3)  |PRKCG, PKCC, PKCG, SCA14|176980|19q13.4
Spinocerebellar ataxia 15, 606658 (3)  |ITPR1, SCA15, SCA16|147265|3p26-p25
Spinocerebellar ataxia 17, 607136 (3)  |TBP, SCA17, HDL4|600075|6q27
Spinocerebellar ataxia 19 (2)  |SCA19|607346|1p21-q21
Spinocerebellar ataxia 20 (2)  |SCA20|608687|11p13-q11
Spinocerebellar ataxia 21 (2)  |SCA21|607454|7p21.3-p15.1
Spinocerebellar ataxia 23, 610245 (3)  |PDYN, SCA23|131340|20p13
Spinocerebellar ataxia 25 (2)  |SCA25|608703|2p21-p13
Spinocerebellar ataxia 26 (2)  |SCA26|609306|19p13.3
Spinocerebellar ataxia 28, 610246 (3)  |AFG3L2, SCA28|604581|18p11
Spinocerebellar ataxia 29 (2)  |SCA29, CLA4|117360|3p26
Spinocerebellar ataxia 30 (2) (?)  |SCA30|613371|4q34.3-q35.1
Spinocerebellar ataxia 31, 117210 (3)  |BEAN, SCA31|612051|16q21
Spinocerebellar ataxia 8, 608768 (3)  |ATXN8OS, SCA8, KLHL1AS|603680|13q21
Spinocerebellar ataxia 8, 608768 (3)  |ATXN8|613289|13q21
Spinocerebellar ataxia, X-linked 1 (2)  |SCAX1, CLA2, OPCA|302500|Xp11.21-q21.3
Spinocerebellar ataxia, X-linked 5 (2)  |SCAX5|300703|Xq25-q27.1
Spinocerebellar ataxia, autosomal recessive 10, 613726 (3)  |CXCL7, PPBP, TGB1, SCAR10|121010|4q12-q13
Spinocerebellar ataxia, autosomal recessive 2 (2)  |SCAR2, CPD3|213200|9q34-qter
Spinocerebellar ataxia, autosomal recessive 3 (2)  |SCAR3, SCABD|271250|6p23-p21
Spinocerebellar ataxia, autosomal recessive 4 (2)  |SCAR4, SCASI|607317|1p36
Spinocerebellar ataxia, autosomal recessive 5, 606937 (3)  |ZNF592, KIAA0211, SCAR5, CAMOS|613624|15q25.3
Spinocerebellar ataxia, autosomal recessive 6 (2)  |SCAR6|608029|20q11-q13
Spinocerebellar ataxia, autosomal recessive 7 (2)  |SCAR7|609270|11p15
Spinocerebellar ataxia, autosomal recessive 8, 610743 (3)  |SYNE1, KIAA0796, KIAA1756, KIAA1262, SCAR8, EDMD4|608441|6q25
Spinocerebellar ataxia, autosomal recessive 9, 612016 (3)  |CABC1, COQ8, ADCK3, SCAR9, ARCA2|606980|1q42.2
Spinocerebellar ataxia, autosomal recessive with axonal neuropathy, 607250 (3)  |TDP1|607198|14q31-q32
Spinocerebellar ataxia-1, 164400 (3)  |ATXN1, ATX1, SCA1|601556|6p23
Spinocerebellar ataxia-10, 603516 (3)  |ATXN10, SCA10|611150|22q13
Spinocerebellar ataxia-11, 604432 (3)  |TTBK2, SCA11|611695|15q15.2
Spinocerebellar ataxia-13, 605259 (3)  |KCNC3, SCA13|176264|19q13.3-q13.4
Spinocerebellar ataxia-2, 183090 (3)  |ATXN2, ATX2, SCA2|601517|12q24
Spinocerebellar ataxia-27, 609307 (3)  |FGF14, FHF4, SCA27|601515|13q34
Spinocerebellar ataxia-4 (2)  |SCA4|600223|16q22.1
Spinocerebellar ataxia-5, 600224 (3)  |SPTBN2, SCA5|604985|11q13
Spinocerebellar ataxia-6, 183086 (3)  |CACNA1A, CACNL1A4, SCA6|601011|19p13
Spinocerebellar ataxia-7, 164500 (3)  |ATXN7, SCA7, OPCA3|607640|3p21.1-p12
Split hand/foot malformation 1 (2)  |SHFM1, SHFD1, SHSF1|183600|7q21.2-q21.3
Split hand/foot malformation 1 with deafness (2)  |SHFM1D|220600|7q21.2-q21.3
Split hand/foot malformation 2 (2)  |SHFM2, SHFD2|313350|Xq26
Split-hand/foot malformation 3, gene duplication syndrome (4)  |SHFM3, SHSF3, DUP10q24, C10DUPq24|246560|10q24
Split-hand/foot malformation 4, 605289 (3)  |TP63, TP73L, KET, EEC3, SHFM4, LMS, RHS, OFC8|603273|3q27
Split-hand/foot malformation 5 (2)  |SHFM5|606708|2q31
Split-hand/foot malformation 6, 225300 (3)  |WNT10B, SHFM6|601906|12q13
Split-hand/foot malformation with long bone deficiency 1 (2)  |SHFL1, SHFLD|119100|1q42.2-q43
Split-hand/foot malformation with long bone deficiency 3 (2)  |SHFLD3|612576|17p13.3-p13.1
Split-hand/foot malformation with long deficiency 2 (2)  |SHFLD2|610685|6q14.1
Spondylo-megaepiphyseal-metaphyseal dysplasia, 613330 (3)  |NKX3-2, BAPX1, SMMD|602183|4p16.1
Spondylocarpotarsal synostosis syndrome, 272460 (3)  |FLNB, SCT, AOI, LRS1|603381|3p14.3
Spondylocheirodysplasia, Ehlers-Danlos syndrome-like, 612350 (3)  |SLC39A13|608735|11p11.2
Spondylocostal dysostosis 4, autosomal recessive, 613686 (3)  |HES7, SCDO4|608059|17p13.2
Spondylocostal dysostosis, autosomal recessive 2, 608681 (3)  |MESP2, SCDO2|605195|15q26.1
Spondylocostal dysostosis, autosomal recessive 3, 609813 (3)  |LFNG, SCDO3|602576|7p22
Spondylocostal dysostosis, autosomal recessive, 1, 277300 (3)  |DLL3, SCDO1|602768|19q13
Spondyloepimetaphyseal dysplasia, 608728 (3)  |MATN3, EDM5, HOA, OS2|602109|2p24-p23
Spondyloepimetaphyseal dysplasia, Missouri type, 602111 (3)  |MMP13, CLG3, MANDP1|600108|11q22.3
Spondyloepimetaphyseal dysplasia, aggrecan type, 612813 (3)  |ACAN, AGC1, CSPG1, MSK16, SEDK|155760|15q26.1
Spondyloepiphyseal dysplasia tarda with progressive arthropathy, 208230 (3)  |WISP3, PPAC, PPD|603400|6q22-q23
Spondyloepiphyseal dysplasia tarda, 313400 (3)  |TRAPPC2, SEDL, SEDT|300202|Xp22.2-p22.1
Spondyloepiphyseal dysplasia with congenital joint dislocations, 143095 (3)  |CHST3, C6ST, C6ST1, HSD|603799|10q22.1
Spondyloepiphyseal dysplasia, Kimberley type, 608361 (3)  |ACAN, AGC1, CSPG1, MSK16, SEDK|155760|15q26.1
Spondylometaepiphyseal dysplasia, short limb-hand type, 271665 (3)  |DDR2, NTRKR3, TKT|191311|1q12-qter
Spondylometaphyseal dysplasia, Japanese type (3)  |COL10A1|120110|6q21-q22.3
Spondylometaphyseal dysplasia, Kozlowski type, 184252 (3)  |TRPV4, VROAC, HMSN2C, CMT2C, SPSMA, SSQTL1|605427|12q24.1
Spondyloperipheral dysplasia, 271700 (3)  |COL2A1|120140|12q13.11-q13.2
Squamous cell carcinoma, burn scar-related, somatic (3)  |TNFRSF6, APT1, FAS, CD95, ALPS1A|134637|10q24.1
Squamous cell carcinoma, head and neck, 275355 (3)  |ING1|601566|13q34
Squamous cell carcinoma, head and neck, 275355 (3)  |TNFRSF10B, DR5, TRAILR2|603612|8p22-p21
Stapes ankylosis with broad thumb and toes, 184460 (3)  |NOG, SYM1, SYNS1|602991|17q22
Stargardt disease 3, 600110 (3)  |ELOVL4, ADMD, STGD2, STGD3|605512|6q14
Stargardt disease 4 (2)  |STGD4|603786|4p
Stargardt disease 4, 603786 (3)  |PROM1, PROML1, AC133, RP41, CORD12, CD133, MCDR2, STGD4|604365|4p15.3
Stargardt disease-1, 248200 (3)  |ABCA4, ABCR, STGD1, FFM, RP19, CORD3, ARMD2|601691|1p22.1
Startle disease, autosomal recessive (3)  |GLRA1, STHE|138491|5q32
Startle disease/hyperekplexia, autosomal dominant, 149400 (3)  |GLRA1, STHE|138491|5q32
Steatocystoma multiplex, 184500 (3)  |KRT17, PC2, PCHC1|148069|17q12-q21
Stickler syndrome, type I, 108300 (3)  |COL2A1|120140|12q13.11-q13.2
Stickler syndrome, type II, 604841 (3)  |COL11A1, STL2|120280|1p21
Stickler syndrome, type III, 184840 (3)  |COL11A2, STL3, DFNA13, DFNB53|120290|6p21.3
Stiff skin syndrome, 184900 (3)  |FBN1, MFS1, WMS, SSKS|134797|15q21.1
Stocco dos Santos X-linked mental retardation syndrome, 300434 (3)  |SHROOM4, KIAA1202, SDSX|300579|Xp11.2
Stomatocytosis I, 185000 (1) (?)  |EPB72|133090|9q34.1
Striatal degeneration, autosomal dominant, 609161 (3)  |PDE8B, PPNAD3, ADSD|603390|5q13
Striatonigral degeneration, infantile, 271930 (3)  |NUP62, SNDI, IBSN|605815|19q13.33
Stuttering, familial persistent 1 (2)  |STUT1|184450|18p11.3-p11.2
Stuttering, familial persistent 2 (2)  |STUT2|609261|12q24.1
Stuve-Wiedemann syndrome/Schwartz-Jampel type 2 syndrome, 601559 (3)  |LIFR, STWS, SWS, SJS2|151443|5p13.1
Subcortical laminal heteropia, X-linked, 300067 (3)  |DCX, DBCN, LISX|300121|Xq22.3-q23
Subcortical laminar heterotopia (3)  |PAFAH1B1, LIS1|601545|17p13.3
Succinic semialdehyde dehydrogenase deficiency, 271980 (3)  |ALDH5A1, SSADH|610045|6p22
Succinyl CoA:3-oxoacid CoA transferase deficiency, 245050 (3)  |OXCT1, OXCT, SCOT|601424|5p13
Sucrase-isomaltase deficiency, congenital, 222900 (3)  |SI|609845|3q25-q26
Sudden infant death with dysgenesis of the testes syndrome, 608800 (3)  |TSPYL1, TSPYL, SIDDT|604714|6q22-q23
Sulfite oxidase deficiency, 272300 (3)  |SUOX|606887|Chr.12
Supernumerary der(22)t(8-22) syndrome (4)  |DER22t8-22|613700|22q11.2
Supranuclear palsy, progressive atypical, 260540 (3)  |MAPT, MTBT1, DDPAC, MSTD|157140|17q21.1
Supranuclear palsy, progressive, 2 (2)  |PSNP2|609454|1q31.1
Supranuclear palsy, progressive, 3 (2)  |PSNP3|610898|11p12-p11
Supranuclear palsy, progressive, 601104 (3)  |MAPT, MTBT1, DDPAC, MSTD|157140|17q21.1
Supravalvar aortic stenosis, 185500 (3)  |ELN|130160|7q11.2
Surfactant metabolism dysfunction, pulmonary, 1, 265120 (3)  |SFTPB, SFTB3, SMDP1|178640|2p12-p11.2
Surfactant metabolism dysfunction, pulmonary, 2, 610913 (3)  |SFTPC, SFTP2, SMDP2|178620|8p21
Surfactant metabolism dysfunction, pulmonary, 3, 610921 (3)  |ABCA3, ABC3, SMDP3|601615|16p13.3
Sveinsson choreoretinal atrophy, 108985 (3)  |TEAD1, TCF13, REF1|189967|11p15.2
Sweat chloride elevation without CF (3)  |CFTR, ABCC7, CF, MRP7|602421|7q31.2
Symphalangism, proximal, 185800 (3)  |GDF5, CDMP1, SYNS2, OS5|601146|20q11.2
Symphalangism, proximal, 185800 (3)  |NOG, SYM1, SYNS1|602991|17q22
Syndactyly, type 1 (2)  |SDTY1, SD1|185900|2q34-q36
Syndactyly, type III, 186100 (3)  |GJA1, CX43, ODDD, SDTY3, ODOD, HSS|121014|6q21-q23.2
Syndactyly, type IV, 186200 (3)  |LMBR1, ACHP, C7orf2, PPD2|605522|7q36
Syndactyly, type V, 186300 (3)  |HOXD13, HOX4I, SPD, BDSD|142989|2q31-q32
Synesthesia (2)  |SYNSTH|612759|2q24.1
Synostoses syndrome, multiple, 1, 186500 (3)  |NOG, SYM1, SYNS1|602991|17q22
Synpolydactyly 3 (2)  |SPD3|610234|14q11.2-q12
Synpolydactyly with foot anomalies, 186000 (3)  |HOXD13, HOX4I, SPD, BDSD|142989|2q31-q32
Synpolydactyly, 3/3'4, associated with metacarpal and metatarsal synostoses, 608180 (3)  |FBLN1|135820|22q13.3
Synpolydactyly, type II, 186000 (3)  |HOXD13, HOX4I, SPD, BDSD|142989|2q31-q32
T-cell acute lymphoblastic leukemia (3)  |BAX|600040|19q13.3-q13.4
T-cell immunodeficiency, congenital alopecia, and nail dystrophy, 601705 (3)  |FOXN1, WHN|600838|17q11-q12
T-cell prolymphocytic leukemia, sporadic (3)  |ATM, ATA, AT1|607585|11q22.3
TARP syndrome (2)  |TARPS|311900|Xp11.23-q13.3
TARP syndrome, 311900 (3)  |RBM10, DXS8237E, KIAA0122, TARPS|300080|Xp11.23
Tangier disease, 205400 (3)  |ABCA1, ABC1, HDLDT1, TGD|600046|9q22-q31
Tarsal-carpal coalition syndrome, 186570 (3)  |NOG, SYM1, SYNS1|602991|17q22
Tauopathy and respiratory failure (3)  |MAPT, MTBT1, DDPAC, MSTD|157140|17q21.1
Tay-Sachs disease, 272800 (3)  |HEXA, TSD|606869|15q23-q24
Taybi-Linder syndrome (2)  |MOPD1, TALS|210710|2q14.2-q14.3
Telangiectasia, hereditary hemorrhagic, type 1, 187300 (3)  |ENG, END, HHT1, ORW|131195|9q34.1
Telangiectasia, hereditary hemorrhagic, type 2, 600376 (3)  |ACVRL1, ACVRLK1, ALK1, HHT2|601284|12q11-q14
Telangiectasia, hereditary hemorrhagic, type 3 (2)  |HHT3, ORW3|601101|5q31.3-q32
Telangiectasia, hereditary hemorrhagic, type 4 (2)  |HHT4|610655|7p14
Testicular germ cell tumor (2)  |TGCT1|300228|Xq27
Testicular microlithiasis, 610441 (3) (?)  |SLC34A2|604217|4p15.31-p15.2
Testicular tumor, sporadic, 273300 (3)  |STK11, PJS, LKB1|602216|19p13.3
Tetra-amelia, autosomal recessive, 273395 (3)  |WNT3, INT4|165330|17q21
Tetralogy of Fallot, 187500 (3)  |GDF1|602880|19p12
Tetralogy of Fallot, 187500 (3)  |JAG1, AGS, AHD|601920|20p12
Tetralogy of Fallot, 187500 (3)  |ZFPM2, FOG2, DIH3|603693|8q23
Tetramelic mirror-image polydactyly (2) (?)  |TMIP|135750|14q13
Tetrology of Fallot, 187500 (3)  |NKX2E, CSX, CHNG5|600584|5q34
Thalassemia due to Hb Lepore (3)  |HBD|142000|11p15.5
Thalassemia, Hispanic gamma-delta-beta, 604131 (3)  |LCRB|152424|11p15.5
Thalassemia, alpha-, 604131 (3)  |HBA2|141850|16pter-p13.3
Thalassemia, delta- (3)  |HBD|142000|11p15.5
Thalassemia-beta, dominant inclusion-body, 603902 (3)  |HBB|141900|11p15.5
Thalassemias, alpha-, 604131 (3)  |HBA1|141800|16pter-p13.3
Thalassemias, beta-, 604131 (3)  |HBB|141900|11p15.5
Thanatophoric dysplasia, type I, 187600 (3)  |FGFR3, ACH|134934|4p16.3
Thiamine-responsive megaloblastic anemia syndrome, 249270 (3)  |SLC19A2, THTR1|603941|1q23.3
Thoracoabdominal syndrome (2)  |THAS, TAS|313850|Xq25-q26.1
Three M syndrome 2, 612921 (3)  |OBSL1, KIAA0657, 3M2|610991|2q35
Thrombocythemia, essential, 187950 (3)  |JAK2|147796|9p24
Thrombocythemia, essential, 187950 (3)  |MPL, TPOR, MPLV|159530|1p34
Thrombocythemia, essential, 187950 (3)  |THPO, MGDF, MPLLG, TPO|600044|3q26.3-q27
Thrombocytopenia 4, 612004 (3)  |CYCS, CYC, THC4|123970|7p15.2
Thrombocytopenia with beta-thalassemia, X-linked, 314050 (3)  |GATA1, GF1, ERYF1, NFE1, XLTT|305371|Xp11.23
Thrombocytopenia, Paris-Trousseau type (2) (?)  |TCPT|188025|11q23
Thrombocytopenia, X-linked, 313900 (3)  |WAS, IMD2, THC1|300392|Xp11.23-p11.22
Thrombocytopenia, X-linked, intermittent, 313900 (3)  |WAS, IMD2, THC1|300392|Xp11.23-p11.22
Thrombocytopenia, congenital amegakaryocytic, 604498 (3)  |MPL, TPOR, MPLV|159530|1p34
Thrombocytopenia, neonatal alloimmune (1)  |ITGA2B, GP2B, CD41B|607759|17q21.32
Thrombocytopenia-2, 188000 (3)  |FLJ14813, THC2|608221|10p12.1
Thrombocytopenia-absent radius syndrome (2)  |TAR|274000|1q21.1
Thrombocytopenic purpura, autoimmune, 188030 (1)  |FCGR2C, CD32C|612169|1q23
Thrombocytosis, familial X-linked (2)  |FTX|300331|Chr.X
Thrombophilia due to HRG deficiency, 613116 (3)  |HRG|142640|3q27
Thrombophilia due to elevated HRG, 613116 (1)  |HRG|142640|3q27
Thrombophilia due to heparin cofactor II deficiency, 612356 (3)  |HCF2, HC2, SERPIND1|142360|22q11
Thrombophilia due to protein C deficiency, autosomal dominant, 176860 (3)  |PROC, PC|612283|2q13-q14
Thrombophilia due to protein C deficiency, autosomal recessive, 612304 (3)  |PROC, PC|612283|2q13-q14
Thrombophilia due to protein S deficiency, 612336 (3)  |PROS1|176880|3q11.2
Thrombophilia due to thrombomodulin defect (3)  |THBD, THRM, AHUS6|188040|20p11.2
Thrombophilia, X-linked, due to factor IX defect, 300807 (3)  |F9, HEMB|300746|Xq27.1-q27.2
Thrombophilia, dysfibrinogenemic (3)  |FGB|134830|4q28
Thrombophilia, dysfibrinogenemic (3)  |FGG|134850|4q28
Thrombophilia, dysplasminogenemic (1)  |PLG|173350|6q26
Thrombophilia, familial, due to decreased release of PLAT, 612348 (1)  |PLAT, TPA|173370|8p12
Thrombosis, hyperhomocysteinemic, 236200 (3)  |CBS|613381|21q22.3
Thrombotic thrombocytopenic purpura, familial, 274150 (3)  |ADAMTS13, VWFCP, TTP|604134|9q34
Thromboxane synthase deficiency (2)  |TBXAS1, GHOSAL, CYP5|274180|7q34
Thryoid dyshormonogenesis 6, 607200 (3)  |DUOX2, THOX2, TDH6|606759|15q15.3
Thyroid adenoma, hyperfunctioning, somatic (3)  |TSHR, CHNG1|603372|14q31
Thyroid carcinoma with thyrotoxicosis (3)  |TSHR, CHNG1|603372|14q31
Thyroid carcinoma, follicular, 188470 (3)  |MINPP1, HIPER1|605391|10q23
Thyroid carcinoma, follicular, 188470 (3)  |NRAS, ALPS4, NS6|164790|1p13.2
Thyroid carcinoma, nonmedullary, 1 (2)  |NMTC1|606240|2q21
Thyroid carcinoma, nonmedullary, with cell oxyphilia (2)  |TCO|603386|19p13.2
Thyroid carcinoma, papillary, 188550 (3)  |GOLGA5, RFG5, PTC5|606918|14q
Thyroid carcinoma, papillary, 188550 (3)  |NCOA4, ELE1, PTC3|601984|10q11.2
Thyroid carcinoma, papillary, 188550 (3)  |PCM1, PTC4|600299|8p22-p21.3
Thyroid carcinoma, papillary, 188550 (3)  |PRKAR1A, TSE1, CNC1, CAR, PPNAD1|188830|17q23-q24
Thyroid carcinoma, papillary, 188550 (3)  |TRIM24, TIF1, TIF1A, PTC6|603406|7q32-q34
Thyroid carcinoma, papillary, 188550 (3)  |TRIM33, TIF1G, RFG7, PTC7|605769|1p13
Thyroid carcinoma, papillary, with papillary renal neoplasia (2)  |PTCPRN, PRN1|605642|1q21
Thyroid dyshormonogenesis 1, 274400 (3)  |SLC5A5, NIS, TDH1|601843|19p13.2-p12
Thyroid dyshormonogenesis 2A, 274500 (3)  |TPO, TPX, TDH2A|606765|2p25
Thyroid dyshormonogenesis 3, 274700 (3)  |TG, AITD3, TDH3|188450|8q24.2-q24.3
Thyroid dyshormonogenesis 4, 274800 (3)  |IYD, DEHAL1, TDH4|612025|6q24-q25
Thyroid dyshormonogenesis 5, 274900 (3)  |DUOXA2, TDH5|612772|15q15
Thyroid hormone metabolism, abnormal, 609698 (3)  |SECISBP2, SBP2|607693|9q22.2
Thyroid hormone resistance, 188570 (3)  |THRB, ERBA2, THR1, PRTH|190160|3p24.3
Thyroid hormone resistance, autosomal recessive, 274300 (3)  |THRB, ERBA2, THR1, PRTH|190160|3p24.3
Thyroid hormone resistance, selective pituitary, 145650 (3)  |THRB, ERBA2, THR1, PRTH|190160|3p24.3
Thyroid papillary carcinoma, 188550 (1)  |CCDC6, D10S170, H4, TST1, PTC, TPC|601985|10q21
Thyrotropin-releasing hormone deficiency (1)  |TRH|275120|3q13.3-q21
Thyrotropin-releasing hormone resistance, generalized (3)  |TRHR|188545|8q23
Thyroxine-binding globulin deficiency (3)  |TBG|314200|Xq22.2
Tibial hemimelia (2) (?)  |THM|275220|8q24.1
Tibial muscular dystrophy, tardive, 600334 (3)  |TTN, CMD1G, TMD, LGMD2J, MPRM, HMERF, EOMFC|188840|2q31
Tietz albinism-deafness syndrome, 103500 (3)  |MITF, WS2A|156845|3p14.1-p12.3
Timothy syndrome, 601005 (3)  |CACNA1C, CACNL1A1, CCHL1A1, TS|114205|12p13.3
Tn syndrome, 300622 (3)  |C1GALT1C1, COSMC, C1GALT2|300611|Xq23
Toenail dystrophy, isolated, 607523 (3)  |COL7A1|120120|3p21.3
Tolbutamide poor metabolizer (3)  |CYP2C9|601130|10q24
Tooth agenesis, selective, 1, with or without orofacial cleft, 106600 (3)  |MSX1, HOX7, HYD1, OFC5, STHAG1|142983|4p16.1
Tooth agenesis, selective, 2 (2)  |STHAG2, HYD2|602639|16q12.1
Tooth agenesis, selective, 3, 604625 (3)  |PAX9, STHAG3|167416|14q12-q13
Tooth agenesis, selective, 5 (2)  |STHAG5|610926|10q11.2-q21
Tooth agenesis, selective, 6, 613097 (3)  |LTBP3, LTBP2, STHAG6|602090|11q12
Tooth agenesis, selective, X-linked 1, 313500 (3)  |ED1, EDA, HED, STHAGX1|300451|Xq12-q13.1
Torg-Winchester syndrome, 259600 (3)  |MMP2, CLG4A, MONA|120360|16q13
Total anomalous pulmonary venous return (2)  |TAPVR1|106700|4q12
Tourette syndrome (2)  |GTS|137580|11q23
Tourette syndrome, 137580 (3)  |SLITRK1, KIAA1910, TTM|609678|13q31
Townes-Brocks branchiootorenal-like syndrome, 107480 (3)  |SALL1, HSAL1, TBS|602218|16q12.1
Townes-Brocks syndrome, 107480 (3)  |SALL1, HSAL1, TBS|602218|16q12.1
Transaldolase deficiency, 606003 (3)  |TALDO1|602063|11p15.5-p15.4
Transcobalamin II deficiency, 275350 (3)  |TCN2, TC2|613441|22q11.2-qter
Transient bullous of the newborn, 131705 (3)  |COL7A1|120120|3p21.3
Transient erythroblastopenia of childhood (2)  |TEC|227050|19q13.2
Transposition of great arteries, dextro-looped 3 (3)  |GDF1|602880|19p12
Transposition of the great arteries, dextro-looped 1, 608808 (3)  |MED13L, THRAP2, PROSIT240, TRAP240L, KIAA1025|608771|12q24
Transposition of the great arteries, dextro-looped 2 (3)  |CFC1, CRYPTIC, HTX2|605194|2q21.1
Treacher Collins syndrome 1, 154500 (3)  |TCOF1, MFD1, TCS1|606847|5q32-q33.1
Treacher Collins syndrome 2, 613717 (3)  |POLR1D, RPA16, RPAC2, TCS2|613715|13q12.2
Treacher Collins syndrome 3, 248390 (3)  |POLR1C, RPA39, RPA40, RPAC1, RPA5, TCS3|610060|6p22.3
Trehalase deficiency, 612119 (1)  |TREH|275360|11q23
Tremor, hereditary essential, 2 (2)  |ETM2, ETM|602134|2p25-p22
Trichilemmal cyst 1 (2)  |TRICY1|609649|3p24-p21.2
Trichodontoosseous syndrome, 190320 (3)  |DLX3, TDO, AI4|600525|17q21.3-q22
Trichoepithelioma, multiple familial, 1, 601606 (3)  |CYLD1, CDMT, EAC, MFT1|605018|16q12-q13
Trichoepithelioma, multiple familial, 2 (2)  |MFT2, TEM|612099|9p21
Trichorhinophalangeal syndrome, type I, 190350 (3)  |TRPS1|604386|8q24.12
Trichorhinophalangeal syndrome, type II (4)  |TRPS2, LGCR, LGS|150230|8q24.11-q24.13
Trichorhinophalangeal syndrome, type III, 190351 (3)  |TRPS1|604386|8q24.12
Trichothiodystrophy, 601675 (3)  |ERCC2, EM9, XPD, COFS2|126340|19q13.2-q13.3
Trichothiodystrophy, 601675 (3)  |ERCC3, XPB|133510|2q21
Trichothiodystrophy, complementation group A, 601675 (3)  |GTF2H5, TTDA, TFB5, C6orf175|608780|6q25.3
Trichothiodystrophy, nonphotosensitive 1, 234050 (3)  |C7orf11, ABHS, TTDN1|609188|7p14
Trichotillomania, 613229 (3)  |SLITRK1, KIAA1910, TTM|609678|13q31
Trifunctional protein deficiency, 609015 (3)  |HADHA, MTPA|600890|2p23
Trifunctional protein deficiency, 609015 (3)  |HADHB|143450|2p23
Trigonocephaly, 190440 (3)  |FGFR1, FLT2, KAL2, OGD|136350|8p11.2-p11.1
Trimethylaminuria, 602079 (3)  |FMO3, TMAU|136132|1q23-q25
Triphalangeal thumb, type I, 174500 (3)  |LMBR1, ACHP, C7orf2, PPD2|605522|7q36
Triphalangeal thumb-polysyndactyly syndrome, 174500 (3)  |LMBR1, ACHP, C7orf2, PPD2|605522|7q36
Trismus-pseudocamptodactyly syndrome, 158300 (3)  |MYH8|160741|17p13.1
Tropical calcific pancreatitis, 608189 (3)  |SPINK1, PSTI, PCTT, TATI|167790|5q32
Troyer syndrome, 275900 (3)  |SPG20|607111|13q12.3
Trypsinogen deficiency (1)  |PRSS1, TRY1|276000|7q35
Tuberous sclerosis-1, 191100 (3)  |TSC1, LAM|605284|9q34
Tuberous sclerosis-2, 191100 (3)  |TSC2, LAM|191092|16p13.3
Tukel syndrome (2)  |TUKLS|609428|21q22
Tumoral calcinosis, familial, normophosphatemic, 610455 (3)  |SAMD9, NFTC|610456|7q21
Tumoral calcinosis, hyperphosphatemic, 211900 (3)  |KL, KLOTHO|604824|13q12
Tumoral calcinosis, hyperphosphatemic, familial, 211900 (3)  |FGF23, ADHR, HPDR2, PHPTC|605380|12p13.3
Tumoral calcinosis, hyperphosphatemic, familial, 211900 (3)  |GALNT3, HHS, HFTC|601756|2q24-q31
Turner syndrome-associated neurocognitive phenotype (2)  |VSPA|313000|Xp22.33
Tylosis with esophageal cancer (2)  |TOC, TEC|148500|17q25
Tyrosine kinase 2 deficiency, 611521 (3)  |TYK2|176941|19p13.2
Tyrosinemia, type I (3)  |FAH|276700|15q23-q25
Tyrosinemia, type II, 277660 (3)  |TAT|613018|16q22.1-q22.3
Tyrosinemia, type III, 276710 (3)  |HPD|609695|12q24-qter
Tyrosinemia, type Ib (1)  |GSTZ1, MAAI|603758|14q24.3
UV-sensitive syndrome, 600630 (3)  |ERCC6, CKN2, COFS1, CSB, ARMD5|609413|10q11
Ullrich congenital muscular dystrophy, 254090 (3)  |COL6A1, OPLL|120220|21q22.3
Ullrich congenital muscular dystrophy, 254090 (3)  |COL6A2|120240|21q22.3
Ullrich congenital muscular dystrophy, 254090 (3)  |COL6A3|120250|2q37
Ulna and fibula, absence of, with sever limb deficiency, 276820 (3)  |WNT7A|601570|3p25
Ulnar-mammary syndrome, 181450 (3)  |TBX3|601621|12q24.1
Urocanase deficiency, 276880 (3)  |UROC1|613012|3q21.3
Urofacial syndrome, 236730 (3)  |HPSE2, HPA2, UFS|613469|10q23-q24
Urolithiasis, 2,8-dihydroxyadenine (3)  |APRT|102600|16q24.3
Usher syndrome, type 1B, 276900 (3)  |MYO7A, USH1B, DFNB2, DFNA11|276903|11q13.5
Usher syndrome, type 1C, 276904 (3)  |USH1C, DFNB18|605242|11p15.1
Usher syndrome, type 1D, 601067 (3)  |CDH23, USH1D|605516|10q21-q22
Usher syndrome, type 1D/F digenic, 601067 (3)  |CDH23, USH1D|605516|10q21-q22
Usher syndrome, type 1D/F digenic, 601067 (3)  |PCDH15, DFNB23, USH1F|605514|10q21-q22
Usher syndrome, type 1E (2)  |USH1E|602097|21q21
Usher syndrome, type 1F, 602083 (3)  |PCDH15, DFNB23, USH1F|605514|10q21-q22
Usher syndrome, type 1G, 606943 (3)  |SANS, USH1G|607696|17q24-q25
Usher syndrome, type 1H (2)  |USH1H|612632|15q22-q23
Usher syndrome, type 2A, 276901 (3)  |USH2A, RP39|608400|1q41
Usher syndrome, type 3, 276902 (3)  |CLRN1, USH3A, USH3|606397|3q21-q25
Usher syndrome, type IIC, 605472 (3)  |GPR98, MASS1, VLGR1, KIAA0686, FEB4, USH2C, USH2B|602851|5q14.3
Usher syndrome, type IID, 611383 (3)  |WHRN, CIP98, KIAA1526, DFNB31, USH2D|607928|9q32-q34
VACTERL association, 192350 (3)  |HOXD13, HOX4I, SPD, BDSD|142989|2q31-q32
VATER association with macrocephaly and ventriculomegaly, 276950 (3)  |PTEN, MMAC1, GLM2|601728|10q23.31
VLCAD deficiency, 201475 (3)  |ACADVL, VLCAD|609575|17p13
Van Buchem disease, 239100 (3)  |SOST, VBCH|605740|17q12-q21
Vasculopathy, retinal, with cerebral leukodystrophy, 192315 (3)  |TREX1, AGS1, CRV, HERNS|606609|3p21.3-p21.2
Velocardiofacial syndrome, 192430 (3)  |TBX1, DGS, CTHM, CAFS, TGA, DORV, VCFS, DGCR|602054|22q11.2
Venous malformations, multiple cutaneous and mucosal, 600195 (3)  |TEK, TIE2, VMCM|600221|9p21
Ventricular fibrillation, familial, 1, 603829 (3)  |SCN5A, LQT3, VF1, HB1, SSS1, CMD1E, CDCD2|600163|3p21
Ventricular fibrillation, paroxysmal familial, 2, 612956 (3)  |DPP6, VF2|126141|7q36.2
Ventricular tachycardia, catecholaminergic polymorphic, 1, 604772 (3)  |RYR2, VTSIP, ARVD2, ARVC2|180902|1q42.1-q43
Ventricular tachycardia, catecholaminergic polymorphic, 2, 611938 (3)  |CASQ2|114251|1p13.3-p11
Ventricular tachycardia, idiopathic, 192605 (3)  |GNAI2, GNAI2B, GIP|139360|3p21
Vertical talus, congenital, 192950 (3)  |HOXD10, HOX4D|142984|2q31-q32
Vertigo, benign recurrent, 2 (2)  |BRV2|613106|22q12
Vesicoureteral reflux (2)  |VUR|193000|1p13
Vesicoureteral reflux 2, 610878 (3)  |ROBO2, SAX3, KIAA1568|602431|3p12.3
Vesicoureteral reflux 3, 613674 (3)  |SOX17, VUR3|610928|8q12-q13
Vestibulopathy, familial (2)  |BPPV|193007|6q
Vitamin D-dependent rickets, type I, 264700 (3)  |CYP27B1, VDD1, PDDR|609506|12q13.1-q13.3
Vitamin K-dependent clotting factors, combined deficiency of, 2, 607473 (3)  |VKORC1, VKOR, VKCFD2, FLJ00289|608547|16p11.2
Vitamin K-dependent coagulation defect, 277450 (3)  |GGCX|137167|2p12
Vitelliform macular dystrophy, adult-onset, 608161 (3)  |BEST1, VMD2, ARB, RP50|607854|11q13
Vitreoretinochoroidopathy, 193220 (3)  |BEST1, VMD2, ARB, RP50|607854|11q13
Vitreoretinopathy with phalan  |COL2A1|120140|12q13.11-q13.2
Vitreoretinopathy, neovascular inflammatory (2)  |VRNI|193235|11q13
Vohwinkel syndrome with ichthyosis, 604117 (3)  |LOR|152445|1q21
Vohwinkel syndrome, 124500 (3)  |GJB2, CX26, DFNB1A, PPK, DFNA3A, KID, HID|121011|13q11-q12
WAGRO syndrome (4)  |WAGRO, DEL11p14p12|612469|11p13-p12
WHIM syndrome, 193670 (3)  |CXCR4, D2S201E, NPY3R, WHIM|162643|2q21
Waardenburg syndrome, type 1, 193500 (3)  |PAX3, WS1, HUP2, CDHS, WS3|606597|2q35
Waardenburg syndrome, type 2A, 193510 (3)  |MITF, WS2A|156845|3p14.1-p12.3
Waardenburg syndrome, type 2B (2)  |WS2B|600193|1p21-p13.3
Waardenburg syndrome, type 2C (2)  |WS2C|606662|8p23
Waardenburg syndrome, type 2D, 608890 (3)  |SNAI2, SLUG, WS2D|602150|8q11
Waardenburg syndrome, type 2E, with or without neurologic involvement, 611584 (3)  |SOX10, WS4, WS4C, PCWH|602229|22q13
Waardenburg syndrome, type 3, 148820 (3)  |PAX3, WS1, HUP2, CDHS, WS3|606597|2q35
Waardenburg syndrome, type 4A, 277580 (3)  |EDNRB, HSCR2, ABCDS, WS4A|131244|13q22
Waardenburg syndrome, type 4B, 613265 (3)  |EDN3, WS4B, HSCR4|131242|20q13.2-q13.3
Waardenburg syndrome, type 4C, 613266 (3)  |SOX10, WS4, WS4C, PCWH|602229|22q13
Waardenburg syndrome/albinism, digenic, 103470 (3)  |TYR, SHEP3, CMM8|606933|11q14-q21
Waardenburg syndrome/ocular albinism, digenic, 103470 (3)  |MITF, WS2A|156845|3p14.1-p12.3
Wagner syndrome 1, 143200 (3)  |VCAN, CSPG2, WGN, WGN1, ERVR|118661|5q12-q14
Waisman parkinsonism-mental retardation syndrome (2)  |WSN, BGMR|311510|Xq28
Warburg micro syndrome 1, 600118 (3)  |RAB3GAP1, WARBM1, P130|602536|2q21.3
Warfarin resistance, 122700 (3)  |VKORC1, VKOR, VKCFD2, FLJ00289|608547|16p11.2
Warfarin sensitivity, 122700 (3)  |CYP2C9|601130|10q24
Warsaw breakage syndrome, 613398 (3)  |DDX11, CHLR1, KRG2|601150|12p11
Watson syndrome, 193520 (3)  |NF1, VRNF, WSS, NFNS|613113|17q11.2
Weaver syndrome, 277590 (3)  |NSD1, ARA267, STO|606681|5q35
Wegener granulomatosis (2)  |WG|608710|6p21.3
Wegener-like granulomatosis (3)  |TAP2, ABCB3, PSF2, RING11|170261|6p21.3
Weill-Marchesani syndrome, dominant, 608328 (3)  |FBN1, MFS1, WMS, SSKS|134797|15q21.1
Weill-Marchesani syndrome, recessive, 277600 (3)  |ADAMTS10, WMS|608990|19p13.3-p13.2
Weill-Marchesani-like syndrome, 613195 (3)  |ADAMTS17|607511|15q24
Weissenbacher-Zweymuller syndrome, 277610 (3)  |COL11A2, STL3, DFNA13, DFNB53|120290|6p21.3
Welander distal myopathy (2)  |WDM|604454|2p13
Werner syndrome, 277700 (3)  |RECQL2, RECQ3, WRN|604611|8p12-p11.2
Weyers acrodental dysostosis, 193530 (3)  |EVC|604831|4p16
White sponge nevus, 193900 (3)  |KRT13|148065|17q21-q22
White sponge nevus, 193900 (3)  |KRT4, CYK4|123940|12q13
Wieacker-Wolff syndrome (2)  |WWS|314580|Xq13-q21
Williams-Beuren syndrome (4)  |WBS, WMS, WS, DEL7q11, C7DELq11|194050|7q11.23
Wilms tumor 2, 194071 (3)  |H19, D11S813E, ASM1, BWS, WT2|103280|11p15.5
Wilms tumor, 194070 (3)  |BRCA2, FANCD1, BROVCA2, GLM3, PNCA2|600185|13q12.3
Wilms tumor, aniridia, genitourinary anomalies and mental retardation syndrome (4)  |DEL11p13, C11DELp13, WAGR|194072|11p13
Wilms tumor, somatic, 194070 (3)  |GPC3, SDYS, SGBS1|300037|Xq26
Wilms tumor, type 1, 194070 (3)  |WT1, NPHS4|607102|11p13
Wilms tumor, type 3 (2)  |WT3|194090|16q
Wilms tumor, type 4 (2)  |WT4|601363|17q12-q21
Wilson disease, 277900 (3)  |ATP7B, WND|606882|13q14.3-q21.1
Wiskott-Aldrich syndrome, 301000 (3)  |WAS, IMD2, THC1|300392|Xp11.23-p11.22
Witkop syndrome, 189500 (3)  |MSX1, HOX7, HYD1, OFC5, STHAG1|142983|4p16.1
Wolcott-Rallison syndrome, 226980 (3)  |EIF2AK3, PEK, PERK, WRS|604032|2p12
Wolf-Hirschhorn syndrome (4)  |WHS|194190|4p16.3
Wolff-Parkinson-White syndrome, 194200 (3)  |PRKAG2, WPWS, CMH6|602743|7q36
Wolfram syndrome 2, 604928 (3)  |CISD2, WFS2, ZCD2, ERIS|611507|4q22-q24
Wolfram syndrome, 222300 (3)  |WFS1, WFRS, WFS, DFNA6, DFNA14, DFNA38|606201|4p16.1
Wolfram-like syndrome, autosomal dominant, 222300 (3)  |WFS1, WFRS, WFS, DFNA6, DFNA14, DFNA38|606201|4p16.1
Wolman disease, 278000 (3)  |LIPA, CESD|613497|10q23.31
Wood neuroimmunologic syndrome (2)  |INDX|300076|Xq26-qter
Woodhouse-Sakati syndrome, 241080 (3)  |C2orf37|612515|2q22.3-q35
Woolly hair, autosomal dominant, 194300 (3)  |KRT74, K6IRS4, KRT6IRS4|608248|12q13
Woolly hair, autosomal recessive 1, 278150 (3)  |P2RY5, P2Y5, LAH3, ARWH1|609239|13q14.12-q14.2
Woolly hair, autosomal recessive 2 with or without hypotrichosis, 604379 (3)  |LIPH, LAH2, ARWH2|607365|3q27-q28
Wrinkly skin syndrome, 278250 (3)  |ATP6V0A2, WSS, ARCL|611716|12q24.3
X inactivation, familial skewed, 2 (2)  |SXI2|300179|Xq25-q26
X-inactivation, familial skewed, 300087 (3)  |XIC, XCE, XIST, SXI1|314670|Xq13.2
XFE progeroid syndrome, 610965 (3)  |ERCC4, XPF|133520|16p13.3-p13.13
Xanthinuria, type I, 278300 (3)  |XDH|607633|2p23-p22
Xeroderma pigmentosum (1) (?)  |PARP1, ADPRT, PPOL, PARP|173870|1q42
Xeroderma pigmentosum, group A, 278700 (3)  |XPA, XPAC|611153|9q22.3
Xeroderma pigmentosum, group B, 610651 (3)  |ERCC3, XPB|133510|2q21
Xeroderma pigmentosum, group C, 278720 (3)  |XPC, XPCC|613208|3p25
Xeroderma pigmentosum, group D, 278730 (3)  |ERCC2, EM9, XPD, COFS2|126340|19q13.2-q13.3
Xeroderma pigmentosum, group E, DDB-negative subtype, 278740 (3)  |DDB2|600811|11p12-p11
Xeroderma pigmentosum, group E, subtype 2 (1)  |DDB1|600045|11q12-q13
Xeroderma pigmentosum, group F, 278760 (3)  |ERCC4, XPF|133520|16p13.3-p13.13
Xeroderma pigmentosum, group G, 278780 (3)  |ERCC5, XPG, COFS3|133530|13q33
Xeroderma pigmentosum, variant type, 278750 (3)  |POLH, XPV|603968|6p21.1-p12
Zellweger syndrome, 214100 (3)  |PEX10, NALD|602859|1p36.32
Zellweger syndrome, 214100 (3)  |PEX13, ZWS, NALD|601789|2p15
Zellweger syndrome, 214100 (3)  |PEX14|601791|1p36.2
Zellweger syndrome, 214100 (3)  |PEX26|608666|22q11.21
Zellweger syndrome, 214100 (3)  |PEX5, PXR1, PTS1R|600414|12p13.3
Zellweger syndrome, 214100 (3)  |PXF, HK33, D1S2223E, PEX19|600279|1q22
Zellweger syndrome, complementation group 9 (3)  |PEX16|603360|11p12-p11.2
Zellweger syndrome, complementation group G, 214100 (3)  |PEX3|603164|6q23-q24
Zellweger syndrome-1, 214100 (3)  |PEX1, ZWS1|602136|7q21-q22
Zellweger syndrome-2 (3)  |ABCD3, PXMP1, PMP70|170995|1p22-p21
Zellweger syndrome-3 (3)  |PXMP3, PAF1, PMP35, PEX2|170993|8q21.1
Zimmermann-Laband syndrome (2) (?)  |ZLS|135500|3p14.3
Zygodactyly 1 (2)  |ZD1|609815|3p21.31
[?Homosexuality, male] (2)  |HMS1, GAY1|306995|Xq28
[?Hyperproglucagonemia] (1)  |GCG|138030|2q36-q37
[AFP deficiency, congenital] (1)  |AFP, HPAFP|104150|4q11-q13
[AMP deaminase deficiency, erythrocytic], 612874 (3)  |AMPD3|102772|11pter-p13
[Acetylation, slow], 243400 (3)  |NAT2, AAC2|612182|8p23.1-p21.3
[Alpha-actinin-3 deficiency] (3)  |ACTN3|102574|11q13-q14
[Analgesia from kappa-opioid receptor agonist, female-specific], 613098 (3)  |MC1R, SHEP2, CMM5|155555|16q24.3
[Angiotensin I-converting enzyme, benign serum increase] (3)  |ACE, DCP1, ACE1, MVCD3|106180|17q23
[Anhaptoglobinemia] (3)  |HP|140100|16q22.1
[Aquaporin-1 deficiency] (3)  |AQP1, CHIP28, CO|107776|7p14
[Axillary odor, variation in], 117800 (3)  |ABCC11, MRP8, EWWD, WW|607040|16q12.1
[Beta-glycopyranoside tasting] (3)  |RCBTB1, CLLD7, GLP|607867|13q14
[Bilirubin, serum level of, QTL1], 601816 (3)  |UGT1A1, UGT1, GNT1, BILIQTL1|191740|2q37
[Birbeck granule deficiency], 613393 (3)  |CD207, LANGERIN, CLEC4K|604862|2p13
[Birth weight QTL 1] (2)  |FGQTL2, BWQTL1|613219|7p15-p13
[Birth weight QTL 2] (2)  |BWQTL2|613459|3q25.3
[Birth weight QTL 3] (2)  |FGQTL6, BWQTL3, PGQTL1|613460|3q21
[Blood group Cromer] (3)  |CD55, DAF, CROM|125240|1q32
[Blood group GIL], 607457 (3)  |AQP3|600170|9p13
[Blood group, ABO system] (3)  |ABO|110300|9q34
[Blood group, Auberger system], 111200 (3)  |LU, AU, BCAM|612773|19q13.2
[Blood group, Cad system] (3)  |B4GALGT2, GALGT2, SD|111730|17q21.2
[Blood group, Colton], 110450 (3)  |AQP1, CHIP28, CO|107776|7p14
[Blood group, Diego], 110500 (3)  |SLC4A1, AE1, EPB3|109270|17q21-q22
[Blood group, Dombrock] (3)  |ART4, DO, DOK1|110600|12p13-p12
[Blood group, Duffy system], 110700 (3)  |DARC, FY, GPD, WBCQ1|613665|1q23.2
[Blood group, Froese], 601551  |SLC4A1, AE1, EPB3|109270|17q21-q22
[Blood group, Gerbich] (3)  |GYPC, GE, GPC|110750|2q14-q21
[Blood group, Ii], 110800 (3)  |GCNT2|600429|6p24-p23
[Blood group, Indian system] (3)  |CD44, MDU2, MDU3, MIC4|107269|11pter-p13
[Blood group, John-Milton-Hagen] (3)  |SEMA7A, SEMAL, SEMAK1, CDW108, JMH|607961|15q22.2-q23
[Blood group, Kell] (3)  |KEL|110900|7q33
[Blood group, Kidd] (3)  |SLC14A1, JK, UTE, UT1|111000|18q11-q12
[Blood group, Knops system], 607486 (3)  |CR1, C3BR|120620|1q32
[Blood group, Landsteiner-Wiener] (3)  |LW|111250|19p13.3
[Blood group, Lewis] (3)  |FUT3, LE|111100|19p13.3
[Blood group, Lutheran null], 247420 (3)  |LU, AU, BCAM|612773|19q13.2
[Blood group, Lutheran system], 111200 (3)  |LU, AU, BCAM|612773|19q13.2
[Blood group, MN] (3)  |GYPA, MN, GPA|111300|4q28.2-q31.1
[Blood group, OK], 111380 (3)  |BSG|109480|19p13.3
[Blood group, P system], 111400 (3)  |A4GALT, PK|607922|22q13.2
[Blood group, P system], 111400 (3)  |B3GALT3, GLCT3, P|603094|3q25
[Blood group, Radin], 111620 (3)  |ERMAP, SC, RD|609017|1p34
[Blood group, Raph], 179620 (3)  |CD151, PETA3, SFA1, MER2|602243|11p15.5
[Blood group, Rhesus] (3)  |RHCE|111700|1p36.2-p34
[Blood group, Rodgers] (2)  |C4A, C4S|120810|6p21.3
[Blood group, Scianna system], 111750 (3)  |ERMAP, SC, RD|609017|1p34
[Blood group, Sd system] (3)  |B4GALGT2, GALGT2, SD|111730|17q21.2
[Blood group, Ss] (3)  |GYPB, SS, MNS|111740|4q28-q31
[Blood group, Stoltzfus system] (2)  |SF|111800|4q28-q31
[Blood group, Waldner], 112010 (3)  |SLC4A1, AE1, EPB3|109270|17q21-q22
[Blood group, Wright], 112050 (3)  |SLC4A1, AE1, EPB3|109270|17q21-q22
[Blood group, XG system] (3)  |XG|314700|Xpter-p22.32
[Blood group, Yt system], 112100 (3)  |ACHE, YT|100740|7q22
[Blood pressure regulation QTL], 145500 (2)  |ATP1B1|182330|1q22-q25
[Blood pressure regulation QTL], 145500 (2)  |RGS5|603276|1q23
[Blood pressure regulation QTL], 145500 (2)  |SELE, ELAM1|131210|1q23-q25
[Body mass index QTL 15] (2)  |BMIQ15|612967|17q23.2-q25.1
[Body mass index QTL13] (2)  |BMIQ13|612459|2q14.1
[Body mass index QTL14] (2)  |BMIQ14|612460|16q12.2
[Body mass index QTL1] (2)  |BMIQ1|606641|7q32.3
[Body mass index QTL2] (2)  |BMIQ2|606643|13q14
[Body mass index QTL3] (2)  |BMIQ3|607446|6q23-q25
[Body mass index QTL5] (2)  |BMIQ5|608558|16p13
[Body mass index QTL6] (2)  |BMIQ6|608559|20pter-p11.2
[Bombay phenotype] (3)  |FUT1, H, HH|211100|19q13.3
[Bombay phenotype] (3)  |FUT2, SE, B12QTL1|182100|19q13.3
[Bone mineral density QTL 10] (2)  |BMND10|612113|8q24
[Bone mineral density QTL 11] (2)  |BMND11|612114|6q25
[Bone mineral density QTL 12], 612560 (3)  |FBXO33, FBX33, BMND12|609103|14q13.3
[Bone mineral density QTL 13] (2)  |BMND13|612727|16q23
[Bone mineral density QTL 14] (2)  |BMND14|612728|1p33-p32
[Bone mineral density QTL 15], 613418 (3)  |MIR2861, MIRN2861, BMND15|613405|9q34.11
[Bone mineral density QTL 2] (2)  |BMND2|605833|1q21-q23
[Bone mineral density QTL 3] (2)  |BMND3|606928|1p36
[Bone mineral density QTL 4] (2)  |BMND4|300536|Xq27
[Bone mineral density QTL 5] (2)  |BMND5|609354|11q23
[Bone mineral density QTL 6] (2)  |BMND6|609876|21q22.13-qter
[Bone mineral density QTL 9] (2)  |BMND9|612110|13q14
[Bone mineral density variability 1], 601884 (3)  |LRP5, BMND1, LRP7, LR3, OPPG, VBCH2, OPTA1, EVR4|603506|11q13.4
[Bone mineral density variation QTL] (3)  |COL1A1|120150|17q21.31-q22
[Bone size quantitative trait locus 3] (2)  |BSZQTL3|610649|8q24
[C-reactive protein QTL] (2)  |CPROTQ|611920|10q23-q24
[CD4+ lymphocyte deficiency] (2)  |CD4|186940|12pter-p12
[CETP deficiency], 607322 (3)  |CETP, HDLCQ10|118470|16q21
[Chitotriosidase deficiency] (3)  |CHIT|600031|1q31-q32
[Cholesterol level QTL 1] (2)  |CLQTL1, CLF|604595|13q
[Cholesterol level QTL 2] (2)  |CLQTL2|610760|2p24-p22
[Cinnamon odor, pleasantness of] (2)  |CINN|611109|4q32.3
[Colostrum secretion, variation in], 117800 (3)  |ABCC11, MRP8, EWWD, WW|607040|16q12.1
[Creatine kinase, brain type, ectopic expression of] (2)  |CKBE|123270|14q32
[Dopamine-beta-hydroxylase activity levels, plasma] (3)  |DBH|609312|9q34
[Dysalbuminemic hyperthyroxinemia] (3)  |ALB|103600|4q11-q13
[Dysalbuminemic hyperzincemia], 194470 (1)  |ALB|103600|4q11-q13
[Dystransthyretinemic hyperthyroxinemia], 145680 (3)  |TTR, PALB|176300|18q11.2-q12.1
[Earwax, wet/dry], 117800 (3)  |ABCC11, MRP8, EWWD, WW|607040|16q12.1
[Erythrocytosis, familial], 133100 (3)  |EPOR|133171|19p13.3-p13.2
[Ezetimibe, nonresponse to] (3)  |NPC1L1|608010|7p13
[Fasting insulin level quantitative trait locus 1] (2)  |FIQTL1|606035|6q22-q24
[Fasting plasma glucose level QTL 1] (2)  |FGQTL1|612108|2q24-q32
[Fasting plasma glucose level QTL 2] (2)  |FGQTL2, BWQTL1|613219|7p15-p13
[Fasting plasma glucose level QTL 3] (2)  |FGQTL3|613233|11q21-q22
[Fasting plasma glucose level QTL 4] (2)  |FGQTL4|613462|7p21.2
[Fasting plasma glucose level QTL 5] (2)  |FGQTL5|613463|2p23.3-p23.2
[Fasting plasma glucose level QTL 5], 613463 (3)  |GCKR, GKRP, FGQTL5|600842|2p23.3-p23.2
[Fasting plasma glucose level QTL 6] (2)  |FGQTL6, BWQTL3, PGQTL1|613460|3q21
[Fetal hemoglobin QTL5] (2)  |HBFQTL5|142335|7q36
[Fructosuria] (3)  |KHK|229800|2p23.3-p23.2
[Gamma-glutamyltransferase, familial high serum] (2)  |GGT2|137181|22q11.1
[Gilbert syndrome], 143500 (3)  |UGT1A1, UGT1, GNT1, BILIQTL1|191740|2q37
[Glycerol release during exercise, defective] (3)  |AQP9|602914|15q22
[Glyoxalase II deficiency] (1)  |HAGH, GLO2|138760|16p13
[Hair morphology 1, hair thickness], 612630 (3)  |EDAR, DL, ED3, EDA3, HRM1|604095|2q11-q13
[Handedness] (2)  |HSR|139900|2p12-q22
[Hematocrit/hemoglobin quantitative trait locus 1] (2)  |HCHGQ1|609319|6q23
[Hematocrit/hemoglobin quantitative trait locus 2] (2)  |HCHGQ2|609320|9q
[Hematocrit/hemoglobin quantitative trait locus 3] (2)  |HCHGQ3|613284|22q12-q13
[Hereditary persistence of alpha-fetoprotein] (3)  |AFP, HPAFP|104150|4q11-q13
[Hereditary persistence of fetal hemoglobin], 613566 (3)  |KLF1, EKLF, INLU, HBFQTL6|600599|19p13.13-p13.12
[Hex A pseudodeficiency], 272800 (3)  |HEXA, TSD|606869|15q23-q24
[High density lipoprotein cholesterol level QTL 10] (3)  |CETP, HDLCQ10|118470|16q21
[High density lipoprotein cholesterol level QTL 11] (3)  |LPL, LIPD, HDLCQ11|609708|8p22
[High density lipoprotein cholesterol level QTL 12], 612797 (3)  |LIPC, HL, LIPH, HDLCQ12|151670|15q21-q23
[High density lipoprotein cholesterol level QTL 1] (2)  |HDLCQ1|606613|9p
[High density lipoprotein cholesterol level QTL 2] (2)  |HDLCQ2|607053|8q23
[High density lipoprotein cholesterol level QTL 4] (2)  |HDLCQ4|610239|4q32.3
[High density lipoprotein cholesterol level QTL 5] (2)  |HDLCQ5|610761|3q24-q26
[High density lipoprotein cholesterol level QTL 7] (3)  |EDN1, HDLCQ7|131240|6p24-p23
[High density lipoprotein cholesterol level QTL 8] (3)  |VNN1, HDLCQ8|603570|6q23-q24
[High density lipoprotein cholesterol level QTL 9] (3)  |PLTP, HDLCQ9|172425|20q12-q13.1
[High density lipoprotien cholesterol level QTL6], 610762 (3)  |SCARB1, CD36L1, CLA1, HDLQTL6|601040|12q24.31
[High molecular weight kininogen deficiency], 228960 (3)  |KNG1, KNG|612358|3q27
[Histidinemia], 235800 (3)  |HAL, HSTD|609457|12q22-q23
[Hyperphenylalaninemia, non-PKU mild], 261600 (3)  |PAH, PKU1|612349|12q24.1
[Hyperproreninemia] (3)  |REN, HNFJ2|179820|1q32
[Hypoceruloplasminemia, hereditary], 604290 (3)  |CP|117700|3q23-q24
[Hypohaptoglobinemia] (3)  |HP|140100|16q22.1
[IMPDH2 enzyme activity, variation in] (3)  |IMPDH2, IMPD2|146691|3p21.2
[IgE levels QTL], 147050 (3)  |PHF11, NYREN34|607796|13q14.1
[IgE, elevated level of], 147050 (3)  |IL21R|605383|16p11
[IgG receptor I, phagocytic, familial deficiency of] (3)  |FCGR1A, IGFR1, CD64|146760|1q21.2-q21.3
[Inosine triphosphatase deficiency] (3)  |ITPA|147520|20p
[Kallikrein, decreased urinary activity of] (3)  |KLK1, KLKR|147910|19q13.4
[Kappa light chain deficiency] (3)  |IGKC|147200|2p12
[Kininogen deficiency], 228960 (3)  |KNG1, KNG|612358|3q27
[LPA deficiency, congenital] (3)  |LPA|152200|6q27
[Lean body mass QTL 1] (2)  |LBMQTL1|612729|8q23
[Leptin serum levels QTL1] (2)  |LEPQTL1, LSL|601694|2p21
[Longevity 1] (2)  |LGV1|152430|4q25
[Longevity 2] (2)  |LGV2|606460|6q21
[Low density lipoprotein cholesterol level QTL 3] (3)  |HMGCR, LDLCQ3|142910|5q13.3-q14
[Low density lipoprotein cholesterol level QTL6], 613589 (3)  |SORT1, NT3, LDLCQ6|602458|1p21.3-p13.1
[Macrothrombocytopenia] (1)  |CD36, CHDS7|173510|7q11.2
[Malaria, resistance to], 611162 (3)  |SLC4A1, AE1, EPB3|109270|17q21-q22
[Mean platelet volume QTL1] (2)  |MPVQTL1|612573|12q24.31
[Mean platelet volume QTL2] (2)  |MPVQTL2|612574|3p21-p13
[Mean platelet volume QTL3] (2)  |MPVQTL3|612575|17q11.2
[Memory, enhanced, association with] (3)  |WWC1, KIBRA, KIAA0869|610533|5q34-q35.2
[Musical aptitude QTL 1] (2)  |MUSQTL1|612343|4q22
[Neutral endopeptidase deficiency] (1)  |MME, CD10, CALLA, NEP|120520|3q21-q27
[Novelty seeking personality], 601696 (1)  |DRD4|126452|11p15.5
[Obesity, resistance to] (3)  |PPARG, PPARG1, PPARG2, CIMT1, GLM1|601487|3p25
[Phenylthiocarbamide tasting], 171200 (3)  |TAS2R38, T2R61, PTC|607751|7q35-q36
[Placental lactogen deficiency] (1)  |CSH1, CSA, PL|150200|17q22-q24
[Plasma glucose, 2-hour, QTL 1] (2)  |FGQTL6, BWQTL3, PGQTL1|613460|3q21
[Plasma glucose, 2-hour, QTL 2] (2)  |GIPR, PGQTL2|137241|19q13.3
[Polyunsaturated fatty acids plasma level QTL1] (2)  |PURAQTL1|612795|11q12-q13.1
[Premature chromatid separation trait], 176430 (3)  |BUB1B, BUBR1|602860|15q15
[QT interval, variation in] (2)  |QTV|610141|1q23.3
[Respiratory rhythmicity in sleep] (2)  |RRIS|609116|10q26
[Resting heart rate], 607276 (3)  |ADRB1, ADRB1R, RHR|109630|10q24-q26
[Rh-negative blood type] (3)  |RHD|111680|1p36.2-p34
[Sarcosinemia], 268900 (2)  |SARDH, SARD, SAR|604455|9q33-q34
[Sex hormone-binding blobulin circulating level QTL 1] (2)  |SXGQTL1|613498|17p13
[Short sleeper], 612975 (3)  |BHLHE41, BHLHB3, DEC2, SHARP1|606200|12p12.1-p11.23
[Skin/hair/eye pigmentation 1, blond/brown hair], 227220 (3)  |HERC2, SHEP1|605837|15q13.1
[Skin/hair/eye pigmentation 1, blond/brown hair], 227220 (3)  |OCA2, P, PED, D15S12, BOCA, EYCL3, HCL3, SHEP1|611409|15q11.2-q12
[Skin/hair/eye pigmentation 1, blue/nonblue eyes], 227220 (3)  |HERC2, SHEP1|605837|15q13.1
[Skin/hair/eye pigmentation 1, blue/nonblue eyes], 227220 (3)  |OCA2, P, PED, D15S12, BOCA, EYCL3, HCL3, SHEP1|611409|15q11.2-q12
[Skin/hair/eye pigmentation 10, blond/brown hair], 612267 (3)  |TPCN2, TPC2, SHEP10|612163|11q13.2
[Skin/hair/eye pigmentation 11, blue/nonblue eyes] (2)  |SHEP11|612271|9p23
[Skin/hair/eye pigmentation 2, blond hair/fair skin], 266300 (3)  |MC1R, SHEP2, CMM5|155555|16q24.3
[Skin/hair/eye pigmentation 2, red hair/fair skin], 266300 (3)  |MC1R, SHEP2, CMM5|155555|16q24.3
[Skin/hair/eye pigmentation 3, freckling], 601800 (3)  |TYR, SHEP3, CMM8|606933|11q14-q21
[Skin/hair/eye pigmentation 4, fair/dark skin], 113750 (3)  |SLC24A5, NCKX5, SHEP4|609802|15q21.1
[Skin/hair/eye pigmentation 5, black/nonblack hair], 227240 (3)  |SLC45A2, MATP, AIM1, SHEP5|606202|5p13.3
[Skin/hair/eye pigmentation 5, dark/fair skin], 227240 (3)  |SLC45A2, MATP, AIM1, SHEP5|606202|5p13.3
[Skin/hair/eye pigmentation 5, dark/light eyes], 227240 (3)  |SLC45A2, MATP, AIM1, SHEP5|606202|5p13.3
[Skin/hair/eye pigmentation 6, blond/brown hair], 210750 (3)  |SLC24A2, NCKX4, SHEP6|609840|14q32
[Skin/hair/eye pigmentation 6, blue/green eyes], 210750 (3)  |SLC24A2, NCKX4, SHEP6|609840|14q32
[Skin/hair/eye pigmentation 7, blond/brown hair], 611664 (3)  |KITLG, MGF, SF, SCF, SHEP7|184745|12q22
[Skin/hair/eye pigmentation 8, freckling] (2)  |SHEP8|611724|6p25.3
[Social cognition] (2)  |CGF1|300082|Xq
[Sodium serum level QTL 1], 613508 (3)  |TRPV4, VROAC, HMSN2C, CMT2C, SPSMA, SSQTL1|605427|12q24.1
[Sprinting performance] (3)  |ACTN3|102574|11q13-q14
[Statins, attenuated cholesterol lowering by] (3)  |HMGCR, LDLCQ3|142910|5q13.3-q14
[Superoxide dismutase, elevated extracellular] (3)  |SOD3|185490|4p15.3-p15.1
[Telomere length, mean leukocyte] (2)  |TELM|609113|14q23.2
[Thyroid-stimulating hormone level QTL 1] (2)  |TSHQTL1|612306|5q13
[Transferrin serum level QTL], 190000 (3)  |HFE, HLA-H, HFE1, MVCD7|613609|6p21.3
[Tuberculin skin test reactivity QTL] (2)  |TST2|613637|5p15
[Tuberculin skin test reactivity, absence of] (2)  |TST1|613636|11p14
[Urate oxidase deficiency] (1)  |UOX|191540|1p22
[Urea transport defect, compensated] (1)  |SLC14A1, JK, UTE, UT1|111000|18q11-q12
[Uric acid concentration, serum, QTL3] (2)  |UAQTL3, GOUT3|612670|4q22
[Uric acid concentration, serum, QTL4] (2)  |UAQTL4, GOUT4|612671|6p21
[Visuospatial/perceptual abilities] (2)  |VSPA|313000|Xp22.33
[White blood cell count QTL], 611862 (3)  |DARC, FY, GPD, WBCQ1|613665|1q23.2
van Buchem disease, type 2, 607636 (3)  |LRP5, BMND1, LRP7, LR3, OPPG, VBCH2, OPTA1, EVR4|603506|11q13.4
van der Woude syndrome 2 (2)  |VWS2|606713|1p34
van der Woude syndrome, 119300 (3)  |IRF6, VWS, LPS, PIT, PPS, OFC6|607199|1q32-q41
von Hippel-Lindau disease, modification of, 193300 (3)  |CCND1, PRAD1, BCL1|168461|11q13
von Hippel-Lindau syndrome, 193300 (3)  |VHL|608537|3p26-p25
von Willebrand disease, platelet-type, 177820 (3)  |GP1BA|606672|17pter-p12
von Willebrand disease, type 1, 193400 (3)  |VWF, F8VWF|613160|12p13.3
von Willebrand disease, type 2A, 2B, 2M, and 2N, 613554 (3)  |VWF, F8VWF|613160|12p13.3
von Willibrand disease, type 3, 277480 (3)  |VWF, F8VWF|613160|12p13.3
{?Allergy and asthma susceptibility} (2)  |IGES|147061|5q31.1
{?Amyloidosis, secondary, susceptibility to} (1)  |APCS, SAP|104770|1q21-q23
{?Bladder cancer susceptibility}, 109800 (2)  |TACC3|605303|4p16.3
{?Breast cancer susceptibility}, 114480 (1)  |NQO2, NMOR2|160998|6p25
{?Hearing loss, cisplatin-induced, susceptibility to} (2)  |CIHL|613290|6p22.3
{?Hypertension, essential} (1)  |ACSM3, SAH|145505|16p13.11
{?Major affective disorder 2} (2)  |MAFD2, MDX|309200|Xq28
{?SLE susceptibility} (1)  |CR1, C3BR|120620|1q32
{?Schizophrenia, susceptibility to}, 603013 (1)  |NRG1, HGL, HRGA, ARIA|142445|8p22-p11
{?Schizophrenia}, 181500 (2)  |SCZD2|603342|11q14-q21
{AIDS, delayed/rapid progression to}, 609423 (3)  |KIR3DL1, NKAT3, NKB1, AMB11, KIR3DS1|604946|19q13.4
{AIDS, rapid progression to}, 609423 (3)  |IFNG, IFG, IFI|147570|12q14
{AIDS, resistance to}, 609423 (3)  |CXCL12, SDF1|600835|10q11.1
{AIDS, slow progression to}, 609423 (3)  |CXCR1, IL8RA|146929|2q35
{AIDS, slow progression to}, 609423 (3)  |IL4R, IL4RA|147781|16p12.1-p11.2
{Abacavir hypersensitivity, susceptibility to} (3)  |HLA-B, SPDA1|142830|6p21.3
{Abruptio placentae, susceptibility to} (3)  |MTHFD, MTHFC|172460|14q24
{Accelerated tumor formation, susceptibility to} (3)  |MDM2|164785|12q14.3-q15
{Acquired long QT syndrome, reduced susceptibility to}, 152427 (3)  |ALG10, KCR1|603313|12p11.1
{Adiponectin, serum level of, QTL2} (2)  |ADIPQTL2, CAQ5|606770|5p15.2-p14
{Adiponectin, serum level of, QTL3} (2)  |ADIPQTL3, CAQ14|606771|14p11.2-q13
{Adiponectin, serum level of, QTL4} (2)  |ADIPQTL4|612629|11q23-q24
{Age-related hearing impairment 1} (2)  |ARHI1|612448|8q24.13-q24.22
{Age-related hearing impairment 2} (2)  |ARHI2|612976|3p26.1-p25.1
{Age-related maculopathy, susceptibility to}, 603075 (2)  |PLEKHA1, TAPP1|607772|10q25.3-q26.2
{Alcohol dependence, protection against}, 103780 (3)  |ADH1C, ADH3|103730|4q22
{Alcohol dependence, susceptibility to}, 103780 (3)  |HTR2A|182135|13q14-q21
{Alcohol dependence, susceptibility to}, 103780 (3)  |RCBTB1, CLLD7, GLP|607867|13q14
{Alcohol dependence}, 103780 (3)  |TAS2R16, T2R16|604867|7q31
{Alcoholism, susceptibility to}, 103780 (3)  |ADH1B, ADH2|103720|4q22
{Alcoholism, susceptibility to}, 103780 (3)  |GABRA2|137140|4p13-p12
{Alkaline phosphatase, plasma level of, QTL 2} (2)  |ALPQTL2|612367|1p36
{Alkaline phosphatase, plasma level of, QTL1} (2)  |ALPQTL1|171720|9q34.13
{Alkaline phosphatase, plasma level of, QTL3} (2)  |ALPQTL3|612368|6p22
{Alkaline phosphatase, plasma level of, QTL4} (2)  |ALPQTL4|612369|10q21
{Allergic rhinitis, susceptibility to}, 607154 (3)  |IL13, ALRH, BHR1|147683|5q31
{Alzheimer disease 12} (2)  |AD12|611073|8p12-q22
{Alzheimer disease 16} (2)  |AD16|300756|Xq21.3
{Alzheimer disease 9, late onset, susceptibility to}, 104300 (3)  |AD9|608907|19p13.2
{Alzheimer disease, late-onset, susceptibility to}, 104300 (3)  |PLAU, URK|191840|10q24
{Alzheimer disease, late-onset}, 104300 (3)  |APBB2, FE65L1|602710|4p14
{Alzheimer disease, pathogenesis, association with}, 104300 (3)  |SORL1, LR11, SORLA|602005|11q23.2-q24.2
{Alzheimer disease, susceptibility to}, 104300 (3)  |A2M|103950|12p13.3-p12.3
{Alzheimer disease, susceptibility to}, 104300 (3)  |ACE, DCP1, ACE1, MVCD3|106180|17q23
{Alzheimer disease, susceptibility to}, 104300 (3)  |BLMH, BMH|602403|17q11.2
{Alzheimer disease, susceptibility to}, 104300 (3)  |HFE, HLA-H, HFE1, MVCD7|613609|6p21.3
{Alzheimer disease, susceptibility to}, 104300 (3)  |MPO|606989|17q23.1
{Alzheimer disease, susceptibility to}, 104300 (3)  |PACIP1, PAXIP1L, PTIP|608254|7q36
{Alzheimer disease-13} (2)  |AD13|611152|1q21
{Alzheimer disease-14} (2)  |AD14|611154|1q25
{Alzheimer disease-15} (2)  |AD15|611155|3q22-q24
{Amyotrophic lateral sclerosis, susceptibility to}, 105400 (3)  |DCTN1, HMN7B|601143|2p13
{Amyotrophic lateral sclerosis, susceptibility to}, 105400 (3)  |NEFH|162230|22q12.2
{Amyotrophic lateral sclerosis, susceptibility to}, 105400 (3)  |PRPH|170710|12q12-q13
{Amyotrophic lateral sclerosis-parkinsonism/dementia complex 1, susceptibility to}, 105500 (3)  |TRPM7, LTRPC7, CHAK|605692|15q21
{Aneurysm, familial abdominal 3} (2)  |AAA3|611891|9p21
{Aneurysm, intracranial berry, 10} (2)  |ANIB10|612587|8q12.1
{Aneurysm, intracranial berry, 6} (2)  |ANIB6|611892|9p21
{Aneurysm, intracranial berry, 9} (2)  |ANIB9|612586|2q33.1
{Angioedema induced by ACE inhibitors, susceptibility to} (3)  |XPNPEP2|300145|Xq25
{Anorexia nervosa, susceptibility to} (2)  |ANON|606788|1p
{Anorexia nervosa, susceptibility to}, 606788 (3)  |BDNF|113505|11p13
{Anorexia nervosa, susceptibility to}, 606788 (3)  |HTR2A|182135|13q14-q21
{Aplastic anemia, susceptibility to}, 609135 (3)  |TERT, TCS1, EST2|187270|5p15.33
{Aplastic anemia}, 609135 (3)  |IFNG, IFG, IFI|147570|12q14
{Asperger syndrome susceptibility 1} (2)  |ASPG1|608638|3q25-q27
{Asperger syndrome susceptibility 2} (2)  |ASPG2|608631|17p13
{Asperger syndrome susceptibility 3} (2)  |ASPG3|608781|1q21-q22
{Asperger syndrome susceptibility 4} (2)  |ASPG4|609954|3p24-p21
{Asperger syndrome susceptibility, X-linked 1}, 300494 (3)  |NLGN3, ASPGX1, AUTSX1|300336|Xq13
{Asperger syndrome susceptibility, X-linked 2}, 300497 (3)  |NLGN4, KIAA1260, AUTSX2, ASPGX2|300427|Xp22.33
{Asthma susceptibility 5}, 611064 (3)  |IRAK3, IRAKM, ASRT5|604459|12q14.3
{Asthma, aspirin-induced, susceptibility to}, 208550 (3)  |PTGER2|176804|14q22
{Asthma, aspirin-induced, susceptibility to}, 208550 (3)  |TBX21, TBET|604895|17q21.3
{Asthma, diminished response to antileukotriene treatment in}, 600807 (3)  |ALOX5|152390|10q11.2
{Asthma, nocturnal, susceptibility to}, 600807 (3)  |ADRB2|109690|5q32-q34
{Asthma, protection against}, 600807 (3)  |MUC7|158375|4q13-q21
{Asthma, susceptibility to, 1}, 607277 (3)  |PTGDR, AS1, ASRT1|604687|14q22.1
{Asthma, susceptibility to, 2}, 608584 (3)  |NPSR1, GPR154, GPRA, VRR1, PGR14, ASRT2|608595|7p15-p14
{Asthma, susceptibility to}, 600807 (2)  |HLA-G|142871|6p21.3
{Asthma, susceptibility to}, 600807 (3)  |CCL11, SCYA11|601156|17q21.1-q21.2
{Asthma, susceptibility to}, 600807 (3)  |HNMT|605238|2q22
{Asthma, susceptibility to}, 600807 (3)  |IL12B, NKSF2|161561|5q31.1-q33.1
{Asthma, susceptibility to}, 600807 (3)  |IL13, ALRH, BHR1|147683|5q31
{Asthma, susceptibility to}, 600807 (3)  |PLA2G7, PAFAH|601690|6p21.2-p12
{Asthma, susceptibility to}, 600807 (3)  |SCGB1A1, UGB, CC10, CCSP, SCGB1A1|192020|11q12.3-q13.1
{Asthma, susceptibility to}, 600807 (3)  |SCGB3A2, UGRP1|606531|5q31-q34
{Asthma, susceptibility to}, 600807 (3)  |TNF, TNFA|191160|6p21.3
{Asthma-related traits, susceptibility to, 3} (2)  |ASRT3|609958|2p16
{Asthma-related traits, susceptibility to, 4} (2)  |ASRT4|610906|1p31
{Asthma-related traits, susceptibility to, 6} (2)  |ASRT6|611403|17q21
{Asthma-related traits, susceptibility to, 7}, 611960 (3)  |CHI3L1, GP39, YKL40, ASRT7|601525|1q32.1
{Asthma-related traits, susceptibility to, 8} (2)  |ASRT8|613207|9q33
{Asthma}, 600807 (3)  |PHF11, NYREN34|607796|13q14.1
{Atherosclerosis, susceptibility to} (2)  |ATHS, ALP|108725|19p13.3-p13.2
{Atherosclerosis, susceptibility to} (2)  |SELE, ELAM1|131210|1q23-q25
{Atherosclerosis, susceptibility to} (3)  |ALOX5|152390|10q11.2
{Atherosclerosis, susceptibility to} (3)  |ESR1, ESR|133430|6q25.1
{Atopy, resistance to}, 147050 (3)  |HAVCR1, HAVCR|606518|5q33.2
{Atopy, susceptibility to}, 147050 (3)  |IL4R, IL4RA|147781|16p12.1-p11.2
{Atopy, susceptibility to}, 147050 (3)  |MS4A2, FCER1B|147138|11q13
{Atopy, susceptibility to}, 147050 (3)  |PLA2G7, PAFAH|601690|6p21.2-p12
{Atopy, susceptibility to}, 147050 (3)  |SELP, GRMP|173610|1q23-q25
{Atrial fibrillation, familial, 5} (2)  |ATFB5|611494|4q25
{Atrioventricular septal defect, susceptibility to, 2}, 606217 (3)  |CRELD1, AVSD2|607170|3p25.3
{Attention deficit-hyperactivity disorder, susceptibility to, 5} (2)  |ADHD5|612311|2q21.1
{Attention deficit-hyperactivity disorder, susceptibility to, 6} (2)  |ADHD6|612312|13q12.11
{Attention deficit-hyperactivity disorder, susceptibility to, 7}, 613003 (3)  |TPH2, NTPH, ADHD7|607478|12q21.1
{Attention deficit-hyperactivity disorder, susceptibility to}, 143465 (3)  |DRD5, DRD1B, DRD1L2|126453|4p16.1-p15.3
{Attention deficit-hyperactivity disorder}, 143465 (2)  |ADHD1|608903|16p13
{Attention deficit-hyperactivity disorder}, 143465 (2)  |ADHD2|608904|17p11
{Attention deficit-hyperactivity disorder}, 143465 (2)  |ADHD3|608905|6q12
{Attention deficit-hyperactivity disorder}, 143465 (2)  |ADHD4|608906|5p13
{Attention deficit-hyperactivity disorder}, 143465 (3)  |DRD4|126452|11p15.5
{Attention-deficit hyperactivity disorder, susceptibility to}, 143465 (2)  |SLC6A3, DAT1|126455|5p15.3
{Atypical mycobacteriosis, familial, X-linked 2} (2)  |AMCBX2|300645|Xp21.2-q26.3
{Atypical mycobacteriosis, familial}, 300636 (3)  |IKBKG, NEMO, FIP3, IP2, IPD2, AMCBX1|300248|Xq28
{Autism susceptibility 10}, 611016 (3)  |EN2, AUTS10|131310|7q36
{Autism susceptibility 11} (2)  |AUTS11|610836|1q41-q42
{Autism susceptibility 12} (2)  |AUTS12|610838|21p13-q11
{Autism susceptibility 13} (2)  |AUTS13|610908|12q14.2
{Autism susceptibility 14} (2)  |AUTS14|611913|16p11.2
{Autism susceptibility 15}, 612100 (3)  |CNTNAP2, CASPR2, NRXN4, CDFE, AUTS15, PTHSL1|604569|7q35-q36
{Autism susceptibility 16}, 613410 (3)  |SLC9A9, AUTS16|608396|3q24
{Autism susceptibility 17}, 613436 (3)  |SHANK2, CORTBP1, AUTS17|603290|11q13.3-q13.4
{Autism susceptibility 1} (2)  |AUTS1|209850|7q22
{Autism susceptibility 3} (2)  |AUTS3|608049|13q14.2-q14.1
{Autism susceptibility 4} (2)  |AUTS4|608636|15q11
{Autism susceptibility 5} (2)  |AUTS5|606053|2q
{Autism susceptibility 6} (2)  |AUTS6|609378|17q11
{Autism susceptibility 7} (2)  |AUTS7|610676|17q21
{Autism susceptibility 8} (2)  |AUTS8|607373|3q25-q27
{Autism susceptibility, X-linked 1}, 300425 (3)  |NLGN3, ASPGX1, AUTSX1|300336|Xq13
{Autism susceptibility, X-linked 2}, 300495 (3)  |NLGN4, KIAA1260, AUTSX2, ASPGX2|300427|Xp22.33
{Autism susceptibility, X-linked 3}, 300496 (3)  |MECP2, RTT, PPMX, MRX16, MRX79, AUTSX3, MRXSL, MRXS13, MRX79, MRX16|300005|Xq28
{Autism susceptibility, X-linked 4} (4)  |DELXp22.11, CXDELp22.11, AUTSX4|300830|Xp22.11
{Autism suseptibility 9}, 611015 (3)  |MET, AUTS9|164860|7q31
{Autoimmune disease, susceptibility to, 1}, 607836 (3)  |FOXD3, AIS1|611539|1p31
{Autoimmune disease, susceptibility to, 2} (2)  |AIS2|608391|Chr.7
{Autoimmune disease, susceptibility to, 3} (2)  |AIS3|608392|Chr.8
{Autoimmune disease, susceptibility to, 4} (2)  |AIS4|609400|4q13-q21
{Autoimmune disease, susceptibility to, 5} (2)  |CELIAC6, AIS5|611598|4q27
{Autoimmune lymphoproliferative syndrome}, 601859 (3)  |TNFRSF6, APT1, FAS, CD95, ALPS1A|134637|10q24.1
{Autoimmune thyroid disease, susceptibility to 3}, 608175 (3)  |TG, AITD3, TDH3|188450|8q24.2-q24.3
{Autoimmune thyroid disease, susceptibility to, 1} (2)  |AITD1|608173|6p11
{Autoimmune thyroid disease, susceptibility to, 2} (2)  |AITD2|608174|5q31-q33
{Autoimmune thyroid disease, susceptibility to, 3}, 608175 (3)  |ZFAT1, ZNF406, AITD3|610931|8q23-q24
{Autoimmune thyroid disease, susceptibility to, 4} (2)  |AITD4|608176|10q
{Azoospremia, nonobstructive} (2)  |AZON|606766|6p21.3
{Bacteremia, protection against} (3)  |TIRAP|606252|11q23-q24
{Bacteremia, susceptibility to} (3)  |CISH|602441|3p21.3
{Bardet-Biedl syndrome 1, modifier of}, 209900 (3)  |ARL6, BBS3, RP55|608845|3p12-q13
{Bardet-Biedl syndrome 14, modifier of}, 209900 (3)  |TMEM67, MKS3, JBTS6, NPHP11|609884|8q21.13-q22.1
{Basal cell carcinoma, susceptibility to, 1} (2)  |BCC1|605462|1p36
{Basal cell carcinoma, susceptibility to, 2} (2)  |BCC2|613058|1q42
{Basal cell carcinoma, susceptibility to, 3} (2)  |BCC3|613059|5p15.33
{Basal cell carcinoma, susceptibility to, 4} (2)  |BCC4|613061|12q13
{Basal cell carcinoma, susceptibility to, 5} (2)  |BCC5|613062|9p21
{Basal cell carcinoma, susceptibility to, 6} (2)  |BCC6|613063|7q32
{Becker muscular dystrophy modifier}, 300376 (3)  |MYF6|159991|12q21
{Benzene toxicity, susceptibility to} (3)  |NQO1, DIA4, NMOR1|125860|16q22.1
{Beryllium disease, chronic, susceptibility to} (3)  |HLA-DPB1|142858|6p21.3
{Biliary cirrhosis, primary, 2} (2)  |PBC2|613007|6p21.3
{Biliary cirrhosis, primary, 3} (2)  |PBC3|613008|1p31.2
{Bladder cancer, somatic}, 109800 (3)  |HRAS|190020|11p15.5
{Blepharospasm, primary benign}, 606798 (3)  |DRD5, DRD1B, DRD1L2|126453|4p16.1-p15.3
{Bone size QTL} (2)  |BSZQTL2|609657|5q
{Bone size QTL} (2)  |BSZQTL|609656|17q23
{Breast and colorectal cancer, susceptibility to} (3)  |CHEK2, RAD53, CHK2, CDS1, LFS2|604373|22q12.1
{Breast cancer, male, susceptibility to}, 114480 (3)  |BRCA2, FANCD1, BROVCA2, GLM3, PNCA2|600185|13q12.3
{Breast cancer, poor survival after chemotherapy for} (3)  |NQO1, DIA4, NMOR1|125860|16q22.1
{Breast cancer, protection against}, 114480 (3)  |CASP8, MCH5, ALPS2B|601763|2q33
{Breast cancer, susceptibility to} (3)  |XRCC3, CMM6|600675|14q32.3
{Breast cancer, susceptibility to}, 114480 (3)  |ATM, ATA, AT1|607585|11q22.3
{Breast cancer, susceptibility to}, 114480 (3)  |BARD1|601593|2q34-q35
{Breast cancer, susceptibility to}, 114480 (3)  |CHEK2, RAD53, CHK2, CDS1, LFS2|604373|22q12.1
{Breast cancer, susceptibility to}, 114480 (3)  |HMMR|600936|5q33.2
{Breast cancer, susceptibility to}, 114480 (3)  |PALB2, FANCN, PNCA3|610355|16p12
{Breast cancer, susceptibility to}, 114480 (3)  |PHB|176705|17q21
{Breast cancer, susceptibility to}, 114480 (3)  |RAD51A, RECA|179617|15q15.1
{Breast-ovarian cancer, familial, 1}, 604370 (3)  |BRCA1, PSCP, BROVCA1, PNCA4|113705|17q21
{Breast-ovarian cancer, familial, 2}, 612555 (3)  |BRCA2, FANCD1, BROVCA2, GLM3, PNCA2|600185|13q12.3
{Breast-ovarian cancer, familial, susceptibility to, 3}, 613399 (3)  |RAD51C, FANCO, BROVCA3|602774|17q22
{Bronchiectasis with or without elevated sweat chloride 1, modifier of}, 211400 (3)  |CFTR, ABCC7, CF, MRP7|602421|7q31.2
{Budd-Chiari syndrome}, 600880 (3)  |F5|612309|1q23
{Budd-Chiari syndrome}, 600880 (3)  |JAK2|147796|9p24
{Bulimia nervosa, age of onset of weight loss in}, 607499 (3)  |BDNF|113505|11p13
{Bulimia nervosa, susceptibility to} (2)  |BULN|607499|10p
{Buruli ulcer, susceptibility to}, 610446 (3)  |NRAMP1, NRAMP, SLC11A1|600266|2q35
{Cancer progression/metastasis} (3)  |FGFR4|134935|5q35.1-qter
{Cardiac conduction defect, susceptibility to}, 115080 (3)  |AKAP10|604694|17p11.1
{Carotid stenosis, susceptibility to} (3)  |HABP2, PHBP, HGFAL, FSAP|603924|10q25-q26
{Cataract, age-related cortical, susceptibility to} (2)  |ARCC1|609026|6p12-q12
{Celiac disease, susceptibility to, 10} (2)  |CELIAC10|612008|3q25-q26
{Celiac disease, susceptibility to, 11} (2)  |CELIAC11|612009|3q28
{Celiac disease, susceptibility to, 12} (2)  |CELIAC12|612010|6q25.3
{Celiac disease, susceptibility to, 13} (2)  |CELIAC13|612011|12q24
{Celiac disease, susceptibility to, 2} (2)  |CELIAC2|609754|5q31-q33
{Celiac disease, susceptibility to, 3}, 609755 (3)  |CTLA4, IDDM12, CELIAC3, GRD4|123890|2q33
{Celiac disease, susceptibility to, 4}, 609753 (3)  |MYO9B, MYR5, CELIAC4|602129|19p13.1
{Celiac disease, susceptibility to, 5} (2)  |CELIAC5, GSES|607202|15q11-q13
{Celiac disease, susceptibility to, 6} (2)  |CELIAC6, AIS5|611598|4q27
{Celiac disease, susceptibility to, 7} (2)  |CELIAC7|612005|1q31
{Celiac disease, susceptibility to, 8} (2)  |CELIAC8|612006|2q11-q12
{Celiac disease, susceptibility to, 9} (2)  |CELIAC9|612007|3p21
{Celiac disease, susceptibility to}, 212750 (3)  |HLA-DQA1, CELIAC1|146880|6p21.3
{Celiac disease, susceptibility to}, 212750 (3)  |HLA-DQB1, CELIAC1|604305|6p21.3
{Centronuclear myopathy, autosomal, modifier of}, 160150 (3)  |MTMR14, C3orf29, HJUMPY|611089|3p25.3
{Cerebral infarction, susceptibility to}, 601367 (3)  |PRKCH, PKCL, PRKCL|605437|14q22-q23
{Chronic infections, due to MBL deficiency} (3)  |MBL2, MBL, MBP1|154545|10q11.2-q21
{Cirrhosis, noncryptogenic, susceptibility to}, 215600 (3)  |KRT18|148070|12q13
{Cirrhosis, noncryptogenic, susceptibility to}, 215600 (3)  |KRT8|148060|12q13
{Codeine sensitivity}, 608902 (3)  |CYP2D6, CPD6, P450DB1|124030|22q13.1
{Colon cancer, susceptibility to}, 114500 (3)  |AURKA, STK15, AURORA2, BTAK, ARK1, STK6, AIK|603072|20q13.2-q13.3
{Colonic adenoma recurrence, reduced risk of}, 114500 (3)  |ODC1|165640|2p25
{Colorectal cancer, susceptibility to, 10} (2)  |CRCS10|612591|19q13.1
{Colorectal cancer, susceptibility to, 11} (2)  |CRCS11|612592|20p12.3
{Colorectal cancer, susceptibility to, 1}, 608812 (3)  |GALNT12, CRCS1|610290|9q22
{Colorectal cancer, susceptibility to, 2} (2)  |CRCS2|611469|8q24
{Colorectal cancer, susceptibility to, 3}, 612229 (3)  |SMAD7, MADH7, CRCS3|602932|18q21.1
{Colorectal cancer, susceptibility to, 4} (1)  |HMPS1, CRAC1, CRCS4|601228|15q15.3-q22.1
{Colorectal cancer, susceptibility to, 5} (2)  |CRCS5|612230|10p14
{Colorectal cancer, susceptibility to, 6} (2)  |CRCS6|612231|8q23
{Colorectal cancer, susceptibility to, 7} (2)  |CRCS7|612232|11q23
{Colorectal cancer, susceptibility to, 8} (2)  |CRCS8|612589|14q22.2
{Colorectal cancer, susceptibility to, 9} (2)  |CRCS9|612590|16q22.1
{Colorectal cancer, susceptibility to}, 114500 (3)  |CCND1, PRAD1, BCL1|168461|11q13
{Colorectal cancer, susceptibility to}, 114500 (3)  |TLR2, TIL4|603028|4q32
{Colorectal cancer, susceptibility to}, 114500 (3)  |TLR4, ARMD10|603030|9q32-q33
{Colorectal cancer}, 114500 (3)  |PLA2G2A, PLA2B, PLA2L, MOM1|172411|1p35
{Congestive heart failure and beta-blocker response, modifier of} (3)  |ADRA2C, ADRA2L2|104250|4p16.1
{Congestive heart failure and beta-blocker response, modifier of} (3)  |ADRB1, ADRB1R, RHR|109630|10q24-q26
{Coronary artery disease in familial hypercholesterolemia, protection against}, 143890 (3)  |ABCA1, ABC1, HDLDT1, TGD|600046|9q22-q31
{Coronary artery disease, autosomal dominant, 1}, 608320 (3)  |MEF2A, ADCAD1|600660|15q26
{Coronary artery disease, autosomal dominant, 2}, 610947 (3)  |LRP6, ADCAD2|603507|12p13.3-p11.2
{Coronary artery disease, modifier of} (3)  |CCL2, SCYA2, MCP1, MCAF|158105|17q11.2-q12
{Coronary artery disease, resistance to}, 607339 (3)  |CX3CR1, GPR13, V28|601470|3pter-p21
{Coronary artery disease, susceptibility to} (1)  |LPA|152200|6q27
{Coronary artery disease, susceptibility to} (3)  |IRS1|147545|2q36
{Coronary artery disease, susceptibility to} (3)  |KL, KLOTHO|604824|13q12
{Coronary artery disease, susceptibility to} (3)  |PON1, PON, ESA, MVCD5|168820|7q21.3
{Coronary artery disease, susceptibility to} (3)  |PON2|602447|7q21.3
{Coronary artery spasm 1, susceptibility to} (3)  |NOS3|163729|7q36
{Coronary artery spasm 2, susceptibility to (3)  |PON1, PON, ESA, MVCD5|168820|7q21.3
{Coronary artery spasm 3, susceptibility to} (3)  |ARHGAP9|610576|12q14
{Coronary heart disease, susceptibility to, 2} (2)  |CHDS2|608316|2q21.1-q22
{Coronary heart disease, susceptibility to, 3} (2)  |CHDS3|300464|Xq23-q26
{Coronary heart disease, susceptibility to, 4} (2)  |CHDS4|608318|14q32
{Coronary heart disease, susceptibility to, 5} (2)  |CHD5|608901|3q13
{Coronary heart disease, susceptibility to, 6} (3)  |MMP3, STMY1, CHDS6|185250|11q23
{Coronary heart disease, susceptibility to, 7}, 610938 (3)  |CD36, CHDS7|173510|7q11.2
{Coronary heart disease, susceptibility to, 8} (2)  |CHDS8|611139|9p21
{Coronary heart disease, susceptibility to, 9} (2)  |CHDS9|612030|8p22
{Coronary heart disease, susceptibility to} (2)  |CHDS1|607339|16pter-p13
{Creutzfeldt-Jakob disease, variant, resistance to}, 123400 (3)  |HLA-DQB1, CELIAC1|604305|6p21.3
{Crohn disease-associated growth failure}, 266600 (3)  |IL6, IFNB2, BSF2, HSF, HGF|147620|7p21
{Cystic fibrosis lung disease, modifier of}, 219700 (3)  |TGFB1, DPD1, CED|190180|19q13.1
{Deafness, autosomal recessive 12, modifier of}, 601386 (3)  |ATP2B2, PMCA2|108733|3p26-p25
{Deafness, mitochondrial, modifier of}, 580000 (3)  |TRMU, MTO2, TRNT1|610230|22q13
{Deafness, nonsyndromic, modifier 1} (2)  |DFNM1|605429|1q24
{Debrisoquine sensitivity}, 608902 (3)  |CYP2D6, CPD6, P450DB1|124030|22q13.1
{Delayed sleep phase syndrome, susceptibility to} (3)  |AANAT, SNAT|600950|17q25
{Dementia, vascular, susceptibility to} (3)  |TNF, TNFA|191160|6p21.3
{Dengue fever, protection against} (3)  |CD209, CDSIGN|604672|19p13.3
{Dermatitis, atopic, susceptibility to, 1} (2)  |ATOD1|603165|3q21
{Dermatitis, atopic, susceptibility to, 2}, 605803 (3)  |FLG, ATOD2|135940|1q21
{Dermatitis, atopic, susceptibility to, 3} (2)  |ATOD3|605804|20p
{Dermatitis, atopic, susceptibility to, 4} (2)  |ATOD4|605805|17q25.3
{Dermatitis, atopic, susceptibility to, 5} (2)  |ATOD5|605844|13q12-q14
{Dermatitis, atopic, susceptibility to, 6} (2)  |ATOD6|605845|5q31-q33
{Dermatitis, atopic, susceptibility to, 7} (2)  |ATOD7|613064|11q13.5
{Diabetes mellitus, gestational, susceptibility to} (3)  |MBL2, MBL, MBP1|154545|10q11.2-q21
{Diabetes mellitus, insulin-dependent, 11} (2)  |IDDM11|601208|14q24.3-q31
{Diabetes mellitus, insulin-dependent, 13} (2)  |IDDM13|601318|2q34
{Diabetes mellitus, insulin-dependent, 15} (2)  |IDDM15|601666|6q21
{Diabetes mellitus, insulin-dependent, 17} (2)  |IDDM17|603266|10q25
{Diabetes mellitus, insulin-dependent, 18} (2)  |IDDM18|605598|5q31.1-q33.1
{Diabetes mellitus, insulin-dependent, 19} (2)  |IDDM19|610155|2q24.3
{Diabetes mellitus, insulin-dependent, 21} (2)  |IDDM21|612521|6q25
{Diabetes mellitus, insulin-dependent, 22}, 612522 (3)  |CCR5, CMKBR5, CCCKR5, IDDM22|601373|3p21
{Diabetes mellitus, insulin-dependent, 23} (2)  |IDDM23|612622|4q27
{Diabetes mellitus, insulin-dependent, 24} (2)  |IDDM24|613006|10q23.31
{Diabetes mellitus, insulin-dependent, 3} (2)  |IDDM3|600318|15q26
{Diabetes mellitus, insulin-dependent, 4} (2)  |IDDM4|600319|11q13
{Diabetes mellitus, insulin-dependent, 5}, 600320 (3)  |SUMO4, IDDM5|608829|6q25
{Diabetes mellitus, insulin-dependent, 6} (2)  |IDDM6|601941|18q21
{Diabetes mellitus, insulin-dependent, 7} (2)  |IDDM7|600321|2q31
{Diabetes mellitus, insulin-dependent, 8} (2)  |IDDM8|600883|6q25-q27
{Diabetes mellitus, insulin-dependent, X-linked} (2)  |IDDMX|300136|Xp11
{Diabetes mellitus, insulin-dependent, susceptibility to}, 601388 (3)  |CTLA4, IDDM12, CELIAC3, GRD4|123890|2q33
{Diabetes mellitus, insulin-dependent-1} (2)  |IDDM1|222100|6p21.3
{Diabetes mellitus, insulin-dependent}, 222100 (3)  |HNF1A, TCF1, MODY3, IDDM20|142410|12q24.2
{Diabetes mellitus, non-insulin-dependent, susceptibility to}, 125853 (3)  |ENPP1, PDNP1, NPPS, M6S1, PCA1, ARHR2|173335|6q22-q23
{Diabetes mellitus, noninsulin-dependent 1}, 601283 (3)  |CAPN10, NIDDM1|605286|2q37.3
{Diabetes mellitus, noninsulin-dependent, 2}, 125853 (3)  |HNF1A, TCF1, MODY3, IDDM20|142410|12q24.2
{Diabetes mellitus, noninsulin-dependent, association with}, 125853 (3)  |WFS1, WFRS, WFS, DFNA6, DFNA14, DFNA38|606201|4p16.1
{Diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3)  |CDKAL1|611259|6p22.3
{Diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3)  |IGF2BP2, IMP2|608289|3q28
{Diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3)  |RETN, RSTN, FIZZ3|605565|19p13.2
{Diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3)  |SLC30A8, ZNT8|611145|8q24.11
{Diabetes mellitus, noninsulin-dependent} (3)  |SLC2A2, GLUT2|138160|3q26.1-q26.3
{Diabetes mellitus, noninsulin-dependent}, 125853 (2)  |NIDDM3|603694|20q12-q13.1
{Diabetes mellitus, noninsulin-dependent}, 125853 (2)  |NIDDM4|608036|5q34-q35.2
{Diabetes mellitus, noninsulin-dependent}, 125853 (3)  |GCGR|138033|17q25
{Diabetes mellitus, noninsulin-dependent}, 125853 (3)  |HNF4A, TCF14, MODY1|600281|20q12-q13.1
{Diabetes mellitus, noninsulin-dependent}, 125853 (3)  |IRS1|147545|2q36
{Diabetes mellitus, noninsulin-dependent}, 125853 (3)  |IRS2|600797|13q34
{Diabetes mellitus, noninsulin-dependent}, 125853 (3)  |LIPC, HL, LIPH, HDLCQ12|151670|15q21-q23
{Diabetes mellitus, noninsulin-dependent}, 125853 (3)  |MAPK8IP1, IB1|604641|11p12-p11.2
{Diabetes mellitus, noninsulin-dependent}, 125853 (3)  |NEUROD1, NIDDM|601724|2q32
{Diabetes mellitus, noninsulin-dependent}, 125853 (3)  |SLC2A4, GLUT4|138190|17p13
{Diabetes mellitus, transient neonatal}, 601410 (1)  |PLAGL1, ZAC, LOT1|603044|6q24
{Diabetes mellitus, type 1, susceptibility to}, 222100 (3)  |OAS1, OIAS|164350|12q24.2
{Diabetes mellitus, type 2, susceptibility to}, 125853 (3)  |KCNJ11, BIR, PHHI, HHF2, TNDM3|600937|11p15.1
{Diabetes mellitus, type 2, susceptibility to}, 125853 (3)  |TCF7L2, TCF4|602228|10q25.3
{Diabetes mellitus, type I, susceptibility to}, 222100 (3)  |FOXP3, IPEX, AIID, XPID, PIDX|300292|Xp11.23-q13.3
{Diabetes mellitus, type II, susceptibility to}, 125853 (3)  |IPF1, MODY4|600733|13q12.1
{Diabetes, mellitus, insulin-dependent, susceptibility to, 10}, 601942 (3)  |IL2RA, IL2R, IDDM10|147730|10p15.1
{Diabetes, susceptibility to}, 222100, 125853 (3)  |IL6, IFNB2, BSF2, HSF, HGF|147620|7p21
{Diabetes, type 1, susceptibility to}, 222100 (2)  |ITPR3|147267|6pter-p21
{Diabetes, type 1, susceptibility to}, 222100 (3)  |PTPN22, PEP, PTPN8, LYP|600716|1p13
{Diabetes, type 2, susceptibility to}, 125853 (3)  |GPD2|138430|2q24.1
{Diabetes, type 2}, 125853 (3)  |PPARG, PPARG1, PPARG2, CIMT1, GLM1|601487|3p25
{Diphtheria, susceptibility to} (1)  |HBEGF, DTR, DTSF, HEGFL|126150|5q23
{Down syndrome, susceptibility to}, 190685 (3)  |MTR|156570|1q43
{Drug addiction, susceptibility to} (3)  |FAAH|602935|1p35-p34
{Drug-induced liver injury due to flucloxacillin} (3)  |HLA-B, SPDA1|142830|6p21.3
{Dyslexia, susceptibility to, 1}, 127700 (3)  |DYX1C1, DYXC1, DYX1|608706|15q21
{Dyslexia, susceptibility to, 2}, 600202 (3)  |KIAA0319, DYX2, DYLX2, DLX2|609269|6p22.2
{Dyslexia, susceptibility to, 3} (2)  |DYX3|604254|2p16-p15
{Dyslexia, susceptibility to, 5} (2)  |DYX5|606896|3p12-q13
{Dyslexia, susceptibility to, 6} (2)  |DYX6, DYXQTL18|606616|18p11.2
{Dyslexia, susceptibility to, 8} (2)  |DYX8|608995|1p36-p34
{Dyslexia, susceptibility to, 9} (2)  |DYX9|300509|Xq27.3
{Dystonia-1, modifier of} (3)  |DYT1, TOR1A|605204|9q34
{Encephalopathy, acute necrotizing 1}, 608033 (3)  |RANBP2, NUP358, ANE1|601181|2q11-q13
{End-stage renal disease, nondiabetic, susceptibility to}, 612551 (3)  |APOL1, FSGS4|603743|22q12.3
{Endometriosis, susceptibility to, 1} (2)  |ENDO1|131200|10q26
{Epidermolysis bullosa dystrophica, autosomal recessive, modifier of}, 226600 (3)  |MMP1, CLG|120353|11q22-q23
{Epilepsy, childhood absence, susceptibility to, 2}, 607681 (3)  |GABRG2, GEFSP3, CAE2, ECA2|137164|5q31.1-q33.1
{Epilepsy, childhood absence, susceptibility to, 4}, 611136 (3)  |GABRA1, EJM5, ECA4|137160|5q34-q35
{Epilepsy, childhood absence, susceptibility to, 5}, 612269 (3)  |GABRB3, ECA5|137192|15q11.2-q12
{Epilepsy, childhood absence, susceptibility to, 6}, 611942 (3)  |CACNA1H, EIG6, ECA6|607904|16p13.3
{Epilepsy, idiopathic generalized, 10}, 613060 (3)  |GABRD, GEFSP5, EIG10, EJM7|137163|1p36.3
{Epilepsy, idiopathic generalized, susceptibility to, 11}, 607628 (3)  |CLCN2, EGMA, ECA2, EGI11, EJM8|600570|3q26
{Epilepsy, idiopathic generalized, susceptibility to, 1} (2)  |EIG1|600669|8q24
{Epilepsy, idiopathic generalized, susceptibility to, 2} (2)  |EIG2|606972|14q23
{Epilepsy, idiopathic generalized, susceptibility to, 3} (2)  |EIG3|608762|9q32-q33
{Epilepsy, idiopathic generalized, susceptibility to, 6}, 611942 (3)  |CACNA1H, EIG6, ECA6|607904|16p13.3
{Epilepsy, idiopathic generalized, susceptibility to, 7} (2)  |EIG7, EJM2|604827|15q14
{Epilepsy, idiopathic generalized, susceptibility to, 8}, 612899 (3)  |CASR, HHC1, PCAR1, FIH, EIG8|601199|3q13.3-q21
{Epilepsy, idiopathic generalized, susceptibility to, 9}, 607682 (3)  |CACNB4, EJM6, EA5, EIG9|601949|2q22-q23
{Epilepsy, idiopathic generalized, susceptibility to}, 600669 (3)  |ME2, ODS1|154270|18q21
{Epilepsy, juvenile absence, susceptibility to, 1}, 607631 (3)  |EFHC1, FLJ10466, EJM1, JAE, EJA1|608815|6p12-p11
{Epilepsy, juvenile absence, susceptibility to, 2}, 607628 (3)  |CLCN2, EGMA, ECA2, EGI11, EJM8|600570|3q26
{Epilepsy, juvenile myoclonic, susceptibility to, 5}, 611136 (3)  |GABRA1, EJM5, ECA4|137160|5q34-q35
{Epilepsy, juvenile myoclonic, susceptibility to, 6}, 607682 (3)  |CACNB4, EJM6, EA5, EIG9|601949|2q22-q23
{Epilepsy, juvenile myoclonic, susceptibility to, 8}, 607628 (3)  |CLCN2, EGMA, ECA2, EGI11, EJM8|600570|3q26
{Epilepsy, juvenile myoclonic, susceptibility to}, 613060 (3)  |GABRD, GEFSP5, EIG10, EJM7|137163|1p36.3
{Esophageal cancer, alcohol-related, susceptibility to} (3)  |ALDH2|100650|12q24.2
{Esophagitis, eosinophilic, 1} (2)  |EOE1, EE|610247|17q11.2
{Esophagitis, eosinophilic, 2} (2)  |EOE2|613412|5q22
{Essential tremor, susceptibility to}, 190300 (3)  |DRD3, ETM1, FET1|126451|3q13.3
{Exfoliation syndrome, susceptibility to}, 177650 (3)  |LOXL1, LOXL|153456|15q22
{Fatty liver disease, nonalcoholic, susceptibility to, 1} (2)  |NAFLD1|613282|22q13
{Fatty liver disease, nonalcoholic, susceptibility to, 2} (2)  |NAFLD2|613387|11q23
{Fibrocalculous pancreatic diabetes, susceptibility to} (3)  |SPINK1, PSTI, PCTT, TATI|167790|5q32
{Follicular lymphoma, susceptibility to, 1} (2)  |FL1|613024|6p21.33
{Gastric cancer risk after H. pylori infection}, 137215 (3)  |IL1B|147720|2q14
{Gastric cancer risk after H. pylori infection}, 137215 (3)  |IL1RN, MVCD4, DIRA|147679|2q14.2
{Gene expression, variation in, QTL} (2)  |GEVQ1|608875|14q32
{Gene expression, variation in, QTL} (2)  |GEVQ2|608878|20q13
{Generalized epilepsy with febrile seizures plus, type 5, susceptibility to}, 604233 (3)  |GABRD, GEFSP5, EIG10, EJM7|137163|1p36.3
{Glaucoma, normal tension, susceptibility to}, 606657 (3)  |OPA1, NTG, NPG|605290|3q28-q29
{Glaucoma, normal tension, susceptibility to}, 606657 (3)  |OPTN, GLC1E, FIP2, HYPL, NRP, ALS12|602432|10p15-p14
{Glioblastoma 3}, 613029 (3)  |BRCA2, FANCD1, BROVCA2, GLM3, PNCA2|600185|13q12.3
{Glioblastoma, susceptibility to}, 137800 (3)  |PPARG, PPARG1, PPARG2, CIMT1, GLM1|601487|3p25
{Glioma susceptibility 2}, 613028 (3)  |PTEN, MMAC1, GLM2|601728|10q23.31
{Glioma susceptibility 4} (2)  |GLM4|607248|15q23-q26.3
{Glioma susceptibility 5} (2)  |GLM5|613030|9p21.3
{Glioma susceptibility 6} (2)  |GLM6|613031|20q13.33
{Glioma susceptibility 8} (2)  |GLM8|613033|5p15.33
{Glomerulosclerosis, focal segmental, 4, susceptibility to}, 612551 (3)  |APOL1, FSGS4|603743|22q12.3
{Gout, susceptibility to} (2)  |GOUT1|138900|4q25
{Graft-versus-host disease, protection against} (3)  |IL10, CSIF|124092|1q31-q32
{Graves disease, susceptibility to, 1} (2)  |GRD1|275000|14q31
{Graves disease, susceptibility to, 2} (2)  |GRD2|603388|20q13.11
{Graves disease, susceptibility to, 3} (3)  |GC, DBP, GRD3|139200|4q12
{Graves disease, susceptibility to, 4} (3)  |CTLA4, IDDM12, CELIAC3, GRD4|123890|2q33
{Graves disease, susceptibility to, X-linked} (2)  |GRDX, GD3|300351|Xp11
{H. pylori infection, susceptibility to}, 600263 (1)  |PTPRZ1, PTP18|176891|7q31.3
{H. pylori infection, susceptibility to}, 600263 (3)  |IFNGR1|107470|6q23-q24
{HDL response to hormone replacement, augmented} (3)  |ESR1, ESR|133430|6q25.1
{HFE hemochromatosis, modifier of}, 235200 (3)  |BMP2, BMP2A|112261|20p12
{HIV infection, resistance to}, 609423 (2)  |CCL3, SCYA3, MIP1A|182283|17q12
{HIV infection, susceptibility/resistance to} (3)  |CCR2, CMKBR2|601267|3p21
{HIV infection, susceptibility/resistance to} (3)  |CCR5, CMKBR5, CCCKR5, IDDM22|601373|3p21
{HIV type 1, susceptibility to}, 609423 (3)  |CD209, CDSIGN|604672|19p13.3
{HIV-1 disease, delayed progression of} (3)  |CCL5, SCYA5, D17S136E, TCP228|187011|17q11.2-q12
{HIV-1 disease, rapid progression of} (3)  |CCL5, SCYA5, D17S136E, TCP228|187011|17q11.2-q12
{HIV-1 viremia, susceptibility to}, 609423 (3)  |HLA-C, PSORS1|142840|6p21.3
{HIV-1, resistance to}, 609423 (3)  |CCL2, SCYA2, MCP1, MCAF|158105|17q11.2-q12
{HIV-1, susceptibility to} (3)  |IL10, CSIF|124092|1q31-q32
{HIV/AIDS, susceptibility to}, 609423 (3)  |CCL3L1, SCYA3L1, LD78|601395|17q11.2
{HIV1, resistance to}, 609423 (3)  |CCL11, SCYA11|601156|17q21.1-q21.2
{Hangover, susceptibility to}, 610251 (3)  |ALDH2|100650|12q24.2
{Hemangioma, capillary infantile, susceptibility to}, 602089 (3)  |ANTXR1, TEM8, ATR|606410|2p13.1
{Hemangioma, capillary infantile, susceptibility to}, 602089 (3)  |KDR|191306|4q12
{Hemolytic uremic syndrome, atypical, susceptibility to, 2}, 612922 (3)  |MCP, CD46, AHUS2|120920|1q32
{Hemolytic uremic syndrome, atypical, susceptibility to, 3}, 612923 (3)  |CFI, FI, AHUS3|217030|4q25
{Hemolytic uremic syndrome, atypical, susceptibility to, 4}, 612924 (3)  |CFB, BF, GBG, AHUS4|138470|6p21.3
{Hemolytic uremic syndrome, atypical, susceptibility to, 5}, 612925 (3)  |C3, ARMD9, AHUS5|120700|19p13.3-p13.2
{Hemolytic uremic syndrome, atypical, susceptibility to, 6}, 612926 (3)  |THBD, THRM, AHUS6|188040|20p11.2
{Hemolytic uremic syndrome, atypical, susceptibility to}, 235400 (3)  |CFHR1, FHR1, HFL1, CFHL1|134371|1q31-q32.1
{Hemolytic uremic syndrome, atypical, susceptibility to}, 235400 (3)  |CFHR3, FHR3, HLF4, CFHL3|605336|1q31-q32.1
{Hepatic fibrosis susceptibility due to Schistosoma mansoni infection} (2)  |SM2|604201|6q22-q23
{Hepatitic C virus, susceptibility to}, 609532 (3)  |PTPRC, CD45, LCA|151460|1q31-q32
{Hepatitis B virus infection, susceptibility to}, 610424 (3)  |IFNGR1|107470|6q23-q24
{Hepatitis B virus, susceptibility to}, 610424 (3)  |CRFB4, IBD25|123889|21q22.1
{Hepatitis B virus, susceptibility to}, 610424 (3)  |IFNAR2|602376|21q22.1
{Hepatitis C virus infection, response to therapy of}, 609532 (3)  |IL28B|607402|19q13.13
{Hepatitis C virus, resistance to}, 609532 (3)  |CCR5, CMKBR5, CCCKR5, IDDM22|601373|3p21
{Hepatitis C virus, response to therapy of}, 609532 (3)  |IFNG, IFG, IFI|147570|12q14
{Herpes simplex encephalitis, susceptibility to, 1}, 610551 (3)  |UNC93B1|608204|11q13
{Herpes simplex encephalitis, susceptibility to, 2}, 613002 (3)  |TLR3|603029|4q35
{High density lipoprotein cholesterol, low serum, 3} (2)  |HDLC3|607687|16q24.1
{Hirschsprung disease, susceptibility to, 1}, 142623 (3)  |RET, MEN2A, HSCR1|164761|10q11.2
{Hirschsprung disease, susceptibility to, 2}, 600155 (3)  |EDNRB, HSCR2, ABCDS, WS4A|131244|13q22
{Hirschsprung disease, susceptibility to, 3}, 613711 (3)  |GDNF, HSCR3|600837|5p13.1-p12
{Hirschsprung disease, susceptibility to, 4}, 613712 (3)  |EDN3, WS4B, HSCR4|131242|20q13.2-q13.3
{Hirschsprung disease, susceptibility to, 5} (2)  |HSCR5|600156|9q31
{Hirschsprung disease, susceptibility to, 6} (2)  |HSCR6|606874|3p21
{Hirschsprung disease, susceptibility to, 7} (2)  |HSCR7|606875|19q12
{Hirschsprung disease, susceptibility to, 8} (2)  |HSCR8|608462|16q23
{Hirschsprung disease, susceptibility to, 9} (2)  |HSCR9|611644|4q31.3-q32.3
{Hodgkin disease susceptibility, pseudoautosomal} (2)  |HDPA|300221|Xpter-p22.32
{Hyperapobetalipoproteinemia, susceptibility to} (3)  |PPARA, PPAR|170998|22q12-q13.1
{Hypercalciuria, absorptive, susceptibility to}, 143870 (3)  |SAC, HCA2|605205|1q24
{Hypercholesterolemia, familial, due to LDLR defect, modifier of}, 143890 (3)  |EPHX2|132811|8p21-p12
{Hypercholesterolemia, familial, modification of}, 143890 (3)  |GHR|600946|5p13-p12
{Hypercholesterolemia, susceptibility to}, 143890 (3)  |GSBS|604088|7p15
{Hypercholesterolemia, susceptibility to}, 143890 (3)  |ITIH4, PK120, ITIHL1|600564|3p21.2-p14.1
{Hyperlipidemia, familial combined, susceptibility to}, 602491 (3)  |USF1, HYPLIP1|191523|1q22-q23
{Hypertension, diastolic, resistance to}, 608622 (3)  |KCNMB1|603951|5q34
{Hypertension, essential, salt-sensitive}, 145500 (3)  |ADD1|102680|4p16.3
{Hypertension, essential, susceptibility to, 1}, 145500 (2)  |HYT1|603918|17q
{Hypertension, essential, susceptibility to, 2}, 145500 (2)  |HYT2|604329|15q
{Hypertension, essential, susceptibility to, 3}, 145500 (2)  |HYT3|607329|2p25-p24
{Hypertension, essential, susceptibility to, 4}, 145500 (2)  |HYT4|608742|12p12.2-p12.1
{Hypertension, essential, susceptibility to, 5}, 145500 (2)  |HYT5|610261|20q11-q13
{Hypertension, essential, susceptibility to, 6}, 145500 (2)  |HYT6|610262|5p13-q12
{Hypertension, essential, susceptibility to, 7} (2)  |HYT7|610948|3p14.1-q12.3
{Hypertension, essential, susceptibility to, 8} (2)  |HYT8|611014|18q21.2
{Hypertension, essential, susceptibility to}, 145500 (3)  |AGT, SERPINA8|106150|1q42-q43
{Hypertension, essential, susceptibility to}, 145500 (3)  |ECE1|600423|1p36.1
{Hypertension, essential, susceptibility to}, 145500 (3)  |GNB3|139130|12p13
{Hypertension, insulin resistance-related, susceptibility to}, 125853 (3)  |RETN, RSTN, FIZZ3|605565|19p13.2
{Hypertension, pregnancy-induced}, 189800 (3)  |NOS3|163729|7q36
{Hypertension, salt-sensitive essential, susceptibility to}, 145500 (3)  |CYP3A5, P450PCN3|605325|7q22.1
{Hypertension, susceptibility to}, 145500 (2)  |NOS2A, NOS2|163730|17cen-q11.2
{Hypertension, susceptibility to}, 145500 (3)  |NOS3|163729|7q36
{Hypertriglyceridemia, susceptibility to} (2)  |HTGS|145750|15q11.2-q13.1
{Hypertriglyceridemia, susceptibility to}, 145750 (3)  |APOA5|606368|11q23
{Hypertriglyceridemia, susceptibility to}, 145750 (3)  |LIPI, LPDL, PRED5|609252|21q11.2
{Hypertriglyceridemia, susceptibility to}, 145750 (3)  |RP1, ORP1|603937|8q11-q13
{Hypertrypsinemia, neonatal} (3)  |CFTR, ABCC7, CF, MRP7|602421|7q31.2
{Hypothalamic hamartomas, somatic}, 241800 (3)  |GLI3, PAPA, PAPB, ACLS|165240|7p13
{Hypothyroidism, autoimmune}, 140300 (3)  |CTLA4, IDDM12, CELIAC3, GRD4|123890|2q33
{IgA nephropathy susceptibility to}, 161950 (3)  |SELL, LYAM1, LAM1, LNHR|153240|1q23-q25
{IgA nephropathy, susceptibility to}, 161950 (3)  |PIGR|173880|1q31-q42
{IgA nephropathy, susceptibility to}, 161950 (3)  |SELE, ELAM1|131210|1q23-q25
{Inflammatory bowel disease 10}, 611081 (3)  |ATG16L1, APG16L, IBD10|610767|2q37.1
{Inflammatory bowel disease 11} (2)  |IBD11|191390|7q22
{Inflammatory bowel disease 12} (2)  |IBD12|612241|3p21.3
{Inflammatory bowel disease 13}, 612244 (3)  |ABCB1, PGY1, MDR1, IBD13|171050|7q21.1
{Inflammatory bowel disease 14}, 612245 (3)  |IRF5, IBD14, SLEB10|607218|7q32
{Inflammatory bowel disease 15} (2)  |IBD15|612255|10q21
{Inflammatory bowel disease 16} (2)  |IBD16|612259|9q32
{Inflammatory bowel disease 17, protection against}, 612261 (3)  |IL23R, IBD17|607562|1p31.3
{Inflammatory bowel disease 18} (2)  |IBD18|612262|5p13.1
{Inflammatory bowel disease 19} (2)  |IBD19|612278|5q33.1
{Inflammatory bowel disease 1}, 266600 (3)  |NOD2, CARD15, IBD1, CD, ACUG, PSORAS1|605956|16q12
{Inflammatory bowel disease 20} (2)  |IBD20|612288|10q23-q24
{Inflammatory bowel disease 21} (2)  |IBD21|612354|18p11
{Inflammatory bowel disease 22} (2)  |IBD22|612380|17q21.2
{Inflammatory bowel disease 23} (2)  |IBD23|612381|1q32.1
{Inflammatory bowel disease 24} (2)  |IBD24|612566|20q13
{Inflammatory bowel disease 26} (2)  |IBD26|612639|12q15
{Inflammatory bowel disease 27} (2)  |IBD27|612796|13q13.3
{Inflammatory bowel disease 2} (2)  |IBD2|601458|12p13.2-q24.1
{Inflammatory bowel disease 3} (2)  |IBD3|604519|6p21.3
{Inflammatory bowel disease 4} (2)  |IBD4|606675|14q11-q12
{Inflammatory bowel disease 5} (2)  |IBD5|606348|5q31
{Inflammatory bowel disease 6} (2)  |IBD6|606674|19p13
{Inflammatory bowel disease 7} (2)  |IBD7|605225|1p36
{Inflammatory bowel disease 8} (2)  |IBD8|606668|16p
{Inflammatory bowel disease 9} (2)  |IBD9|608448|3p26
{Inflammatory response, modulation of} (3)  |SEPS1, SELS, VIMP, ADO15|607918|15q26.3
{Insulin resistance, susceptibility to}, 125853 (3)  |PTPN1, PTP1B|176885|20q13.1-q13.2
{Intelligence QTL1} (2)  |INTLQ1|603783|4p16-q34
{Intelligence QTL3} (2)  |INTLQ2|610295|2q24.1-q31.1
{Intelligence QTL3} (2)  |INTLQ3|610294|6p25.3-p22.3
{Intervertebral disc disease, susceptibility to}, 603932 (3)  |COL9A2, EDM2|120260|1p33-p32.2
{Intervertebral disc disease, susceptibility to}, 603932 (3)  |COL9A3, EDM3, IDD|120270|20q13.3
{Intracranial hemorrhage in brain cerebrovascular malformations, susceptibility to}, 108010 (3)  |IL6, IFNB2, BSF2, HSF, HGF|147620|7p21
{Ischemic stroke, susceptibility to}, 601367 (3)  |NOS3|163729|7q36
{Kala-azar, susceptibility to} (2)  |KAZA|608207|22q12
{Kaposi sarcoma, susceptibility to}, 148000 (3)  |IL6, IFNB2, BSF2, HSF, HGF|147620|7p21
{Kawasaki disease, susceptibility to}, 611775 (3)  |ITPKC|606476|19q13.2
{Lead poisoning, susceptibility to}, 612740 (3)  |ALAD, ALADH, PBGS|125270|9q34
{Leanness, inherited} (3)  |AGRP, ART, AGRT|602311|16q22
{Leber optic atrophy, susceptibility to} (2)  |LOAS|308905|Xp11
{Legionaire disease, susceptibility to}, 608556 (3)  |TLR5, TIL3, SLEB1|603031|1q41-q42
{Leprosy, paucibacillary type, susceptibility to} (2)  |LPRS|609888|10p13
{Leprosy, protection against}, 613223 (3)  |TLR1, TIL. LPRS5|601194|4p14
{Leprosy, susceptibility to, 4}, 610988 (3)  |LTA, TNFB|153440|6p21.3
{Leprosy, susceptibility to, 5}, 613223 (3)  |TLR1, TIL. LPRS5|601194|4p14
{Leprosy, susceptibility to}, 246300 (3)  |TLR2, TIL4|603028|4q32
{Leprosy, susceptibility to}, 607572 (3)  |PRKN, PARK2, PDJ, LPRS2|602544|6q25.2-q27
{Leprosy, susceptiblity to, 6} (2)  |LPRS6|613407|13q14.11
{Leukemia, acute lymphoblastic, susceptibility to, 2} (2)  |ALL2|613067|7p12.2
{Leukemia, acute lymphoblastic, susceptibility to} (3)  |HOXD4, HOX4B|142981|2q31-q32
{Leukemia, acute lymphocytic, susceptibility to, 1} (2)  |ALL1|613065|10q21
{Leukemia, acute myeloid}, 601626 (3)  |CHIC2, BTL|604332|4q11-q12
{Leukemia, chronic lymphocytic susceptibility to, 4} (2)  |CLLS4|612558|6p25
{Leukemia, chronic lymphocytic susceptibility to, 5} (2)  |CLLS5|612559|11q24.1
{Leukemia, chronic lymphocytic, susceptibility to, 1} (2)  |CLLS1|609630|11q13.3
{Leukemia, chronic lymphocytic, susceptibility to, 2} (2)  |CLLS2, D13S25, DBM|109543|13q14
{Leukemia, chronic lymphocytic, susceptibility to, 3} (2)  |CLLS3|612557|9q34.1
{Leukemia, post-chemotherapy, susceptibility to} (3)  |NQO1, DIA4, NMOR1|125860|16q22.1
{Liver fibrosis, susceptibility to} (3)  |C5|120900|9q34.1
{Long QT syndrome 1, acquired, susceptibility to}, 192500 (3)  |KCNQ1, KCNA9, LQT1, KVLQT1, ATFB3, SQT2|607542|11p15.5
{Long QT syndrome-2, acquired, susceptibility to}, 613688 (3)  |KCNH2, LQT2, HERG, SQT1|152427|7q35-q36
{Low density lipoprotein cholesterol level QTL 1} (3)  |PCSK9, NARC1, HCHOLA3, FH3, LDLCQ1|607786|1p34.1-p32
{Low renin hypertension, susceptibility to} (3)  |CYP11B2|124080|8q21
{Lumbar disc degeneration}, 603932 (3)  |ASPN, PLAP1, OS3|608135|9q21.3-q22
{Lumbar disc disease, susceptibility to}, 603932 (3)  |CILP|603489|15q22
{Lumbar disc herniation, susceptibility to}, 603932 (3)  |COL11A1, STL2|120280|1p21
{Lumbar disc herniation, susceptibility to}, 603932 (3)  |THBS2|188061|6q27
{Lung cancer susceptibility 2}, 612052 (3)  |CHRNA3, LNCR2, PAOD2|118503|15q25.1
{Lung cancer susceptibility 2}, 612052 (3)  |CHRNA5, LNCR2|118505|15q25.1
{Lung cancer susceptibility 3} (2)  |LNCR3|612571|5p15.33
{Lung cancer susceptibility 4} (2)  |LNCR4|612593|6p21.33
{Lung cancer susceptibility} (2)  |LNCR1|608935|6q23-q25
{Lung cancer, protection against, in smokers} (3)  |MPO|606989|17q23.1
{Lung cancer, protection against}, 211980 (3)  |CASP8, MCH5, ALPS2B|601763|2q33
{Lung cancer, resistance to}, 211980 (3)  |CYP2A6, CYP2A3, CYP2A, P450C2A|122720|19q13.2
{Lung cancer}, 211980 (3)  |ERCC6, CKN2, COFS1, CSB, ARMD5|609413|10q11
{Lupus erythematosus, susceptibility to} (2)  |CD4|186940|12pter-p12
{Lupus erythematosus, systemic, susceptibility}, 152700 (1)  |FCGR3A, CD16, IGFR3|146740|1q23
{Lupus nephritis, susceptibility to} (3)  |FCGR2A, IGFR2, CD32|146790|1q21-q23
{Macroglobulinemia, Waldenstrom, susceptibility to, 1} (2)  |WM1|153600|6p21.3
{Macroglobulinemia, Waldenstrom, susceptibility to, 2} (2)  |WM2|610430|4q
{Macular degeneration, age-related, 10}, 611488 (3)  |TLR4, ARMD10|603030|9q32-q33
{Macular degeneration, age-related, 1}, 603075 (3)  |HMCN1, FBLN6, FIBL6, ARMD1|608548|1q24-q25
{Macular degeneration, age-related, 4}, 610698 (3)  |HF1, CFH, HUS, ARMD4, AHUS1|134370|1q32
{Macular degeneration, age-related, 7}, 610149 (3)  |HTRA1, PRSS11, ARMD7|602194|10q25.3-q26.2
{Macular degeneration, age-related, 8} (3)  |LOC387715, ARMD8|611313|10q26.13
{Macular degeneration, age-related, 9}, 611378 (3)  |C3, ARMD9, AHUS5|120700|19p13.3-p13.2
{Macular degeneration, age-related, neovascular type}, 610149 (3)  |HTRA1, PRSS11, ARMD7|602194|10q25.3-q26.2
{Macular degeneration, age-related, reduced risk of}, 603075 (3)  |C2|217000|6p21.3
{Macular degeneration, age-related, reduced risk of}, 603075 (3)  |CFB, BF, GBG, AHUS4|138470|6p21.3
{Macular degeneration, age-related, reduced risk of}, 603075 (3)  |CFHR1, FHR1, HFL1, CFHL1|134371|1q31-q32.1
{Macular degeneration, age-related, reduced risk of}, 603075 (3)  |CFHR3, FHR3, HLF4, CFHL3|605336|1q31-q32.1
{Macular degeneration, age-related, susceptibility to 5} (3)  |ERCC6, CKN2, COFS1, CSB, ARMD5|609413|10q11
{Macular degeneration, age-related, susceptibility to}, 603075 (3)  |CX3CR1, GPR13, V28|601470|3pter-p21
{Macular degeneration, age-related}, 603075 (3)  |APOE, AD2, LPG, LDLCQ5|107741|19q13.2
{Major affective disorder 1} (2)  |MAFD1, BPAD, MD1|125480|18p
{Major affective disorder 3, early onset} (2)  |MAFD3, BPEO|609633|21q22.13
{Major affective disorder 5} (2)  |MAFD5|611535|2q22-q24
{Major affective disorder 6} (2)  |MAFD6, BPAD|611536|6q23-q24
{Major affective disorder-7, susceptibility to}, 612371 (3)  |XBP1, XBP2|194355|22q12
{Major affective disorder-8, susceptibility to} (2)  |MAFD8|612357|10q21
{Major affective disorder-9, susceptibility to} (2)  |MAFD9|612372|12p13.3
{Major affective disorder}, 125480 (3)  |SLC6A3, DAT1|126455|5p15.3
{Major depressive disorder and accelerated response to antidepressant drug treatment}, 608516 (3)  |FKBP5, FKBP51|602623|6p21.3-p21.2
{Major depressive disorder, response to citalopram therapy in}, 608516 (3)  |HTR2A|182135|13q14-q21
{Malaria, cerebral, reduced risk of}, 611162 (3)  |CD36, CHDS7|173510|7q11.2
{Malaria, cerebral, susceptibility to}, 611162 (3)  |CD36, CHDS7|173510|7q11.2
{Malaria, cerebral, susceptibility to}, 611162 (3)  |ICAM1|147840|19p13.3-p13.2
{Malaria, cerebral, susceptibility to}, 611162 (3)  |TNF, TNFA|191160|6p21.3
{Malaria, intensity of infection} (2)  |PFBI|248310|5q31-q33
{Malaria, mild, susceptibility to} (2)  |MALS|609148|6p21.3
{Malaria, mild, susceptibility to}, 609148 (3)  |NCR3, 1C7, NKP30, CD337|611550|6p21.3
{Malaria, protection against}, 611162 (3)  |TIRAP|606252|11q23-q24
{Malaria, resistance to}, 611162 (3)  |FCGR2B, CD32|604590|1q22
{Malaria, resistance to}, 611162 (3)  |GYPA, MN, GPA|111300|4q28.2-q31.1
{Malaria, resistance to}, 611162 (3)  |GYPC, GE, GPC|110750|2q14-q21
{Malaria, resistance to}, 611162 (3)  |NOS2A, NOS2|163730|17cen-q11.2
{Malaria, severe, resistance to}, 611162 (3)  |CR1, C3BR|120620|1q32
{Malaria, susceptibility to}, 611162 (3)  |CISH|602441|3p21.3
{Malaria, vivax, protection against}, 611162 (3)  |DARC, FY, GPD, WBCQ1|613665|1q23.2
{Malignant hyperthermia susceptibility 1}, 145600 (3)  |RYR1, MHS, CCO|180901|19q13.1
{Malignant hyperthermia susceptibility 2} (2)  |MHS2|154275|17q11.2-q24
{Malignant hyperthermia susceptibility 3} (2)  |MHS3|154276|7q21-q22
{Malignant hyperthermia susceptibility 4} (2)  |MHS4|600467|3q13.1
{Malignant hyperthermia susceptibility 5}, 601887 (3)  |CACNA1S, CACNL1A3, CCHL1A3, TTPP1, HOKPP1|114208|1q32
{Malignant hyperthermia susceptibility 6} (2)  |MHS6|601888|5p
{Malignant mesothelioma, susceptibility to} (2)  |MMS|156240|9p
{Meconium ileus in cystic fibrosis, susceptibility to} (2)  |CFM1|603855|19q13.2-q13.4
{Medulloblastoma}, 155255 (3)  |BRCA2, FANCD1, BROVCA2, GLM3, PNCA2|600185|13q12.3
{Melanoma susceptibility 5}, 613099 (3)  |MC1R, SHEP2, CMM5|155555|16q24.3
{Melanoma, cutaneous malignant, susceptibility to, 6} (3)  |XRCC3, CMM6|600675|14q32.3
{Melanoma, cutaneous malignant, susceptibility to, 7} (2)  |CMM7|612263|20q11.2
{Melanoma, cutaneous malignant, susceptibility to, 8}, 601800 (3)  |TYR, SHEP3, CMM8|606933|11q14-q21
{Melanoma, uveal, susceptibility to, 1} (2)  |UVM1|606660|3q24-q26
{Melanoma, uveal, susceptibility to, 2} (2)  |UBM2|606661|3p25.2-p25.1
{Memory impairment, susceptibility to} (3)  |BDNF|113505|11p13
{Menarche, age at, QTL2} (2)  |MENAQ2|612882|6q21
{Menarche, age at, QTL3} (2)  |MENAQ3|612883|9q31.2
{Menarche, age at, QTL} (2)  |MENAQ1|610873|22q13
{Meningioma}, 607174 (3)  |PTEN, MMAC1, GLM2|601728|10q23.31
{Meningococcal disease, susceptibility to} (3)  |MBL2, MBL, MBP1|154545|10q11.2-q21
{Menopause, natural, age at, QTL1} (2)  |MENOQ1|300488|Xp21.3
{Menopause, natural, age at, QTL2} (2)  |MENOQ2|612884|19q13.4
{Menopause, natural, age at, QTL3} (2)  |MENOQ3|612885|20p12.3
{Menopause, natural, age at, QTL4} (2)  |MENOQ4|612886|5q35.2
{Mental health wellness-1} (2)  |MHW1|603663|4p
{Mental health wellness-2} (2)  |MHW2|603664|4q
{Metabolic syndrome, protection against}, 605552 (3)  |MTP|157147|4q22-q24
{Microvascular complications of diabetes 1}, 603933 (3)  |VEGF, MVCD1|192240|6p12
{Microvascular complications of diabetes 2}, 612623 (3)  |EPO, MVCD2|133170|7q21
{Microvascular complications of diabetes 3}, 612624 (3)  |ACE, DCP1, ACE1, MVCD3|106180|17q23
{Microvascular complications of diabetes 4}, 612628 (3)  |IL1RN, MVCD4, DIRA|147679|2q14.2
{Microvascular complications of diabetes 5}, 612633 (3)  |PON1, PON, ESA, MVCD5|168820|7q21.3
{Microvascular complications of diabetes 6}, 612634 (3)  |SOD2, MNSOD, MVCD6|147460|6q25.3
{Microvascular complications of diabetes 7}, 612635 (3)  |HFE, HLA-H, HFE1, MVCD7|613609|6p21.3
{Migraine with aura, susceptibility to, 7} (2)  |MGR7|609179|15q11.2-q12
{Migraine with aura, susceptibility to, 9} (2)  |MGR9|609670|11q24
{Migraine with or without aura, susceptibility to, 3} (2)  |MGR3|607498|6p21.1-p12.2
{Migraine with or without aura, susceptibility to, 5} (2)  |MGR5|607508|19p13
{Migraine with or without aura, susceptibility to} (2)  |MGR1, MA|157300|4q24
{Migraine without aura, susceptibility to, 4} (2)  |MGR4, MGOA|607501|14q21.2-q22.3
{Migraine without aura, susceptibility to}, 157300 (3)  |TNF, TNFA|191160|6p21.3
{Migraine, familial typical, susceptibility to, 1} (2)  |MGR2|300125|Xq
{Migraine, susceptibility to, 8} (2)  |MGR8|609570|5q21
{Migraine, susceptibility to}, 157300 (3)  |ESR1, ESR|133430|6q25.1
{Migraine, with or without aura, susceptibility to, 12} (2)  |MGR12|611706|10q22-q23
{Migraine, with or without aura, susceptibility to, 13}, 613656 (3)  |KCNK18, TRESK, TRIK, MGR13|613655|10q25.3
{Multiple myeloma, resistance to}, 254500 (3)  |LIG4|601837|13q22-q34
{Multiple sclerosis, disease progression, modifier of}, 126200 (3)  |PDCD1, SLEB2|600244|2q37.3
{Multiple sclerosis, susceptibility to, 2} (2)  |MS2|612594|10p15.1
{Multiple sclerosis, susceptibility to, 3} (2)  |MS3|612595|5p13.2
{Multiple sclerosis, susceptibility to, 4} (2)  |MS4|612596|1p36
{Multiple sclerosis, susceptibility to}, 126200 (3)  |CD24|600074|6q21
{Multiple sclerosis, susceptibility to}, 126200 (3)  |HLA-DQB1, CELIAC1|604305|6p21.3
{Multiple sclerosis, susceptibility to}, 126200 (3)  |HLA-DR1B, SS1|142857|6p21.3
{Mycobacterial and salmonella infections, susceptibility to}, 209950 (3)  |IL12RB1|601604|19p13.1
{Mycobacterial infection, atypical, familial disseminated}, 209950 (3)  |IFNGR2, IFNGT1, IFGR2|147569|21q22.1-q22.2
{Mycobacterium tuberculosis infection, protection against}, 600263 (3)  |IFNGR1|107470|6q23-q24
{Mycobacterium tuberculosis, protection against}, 607948 (3)  |IRGM, LRG47, IFI1|608212|5q33.1
{Mycobacterium tuberculosis, protection against}, 607948 (3)  |MC3R, BMIQ9|155540|20q13.2
{Mycobacterium tuberculosis, susceptibility to infection by}, 607948 (3)  |NRAMP1, NRAMP, SLC11A1|600266|2q35
{Mycobacterium tuberculosis, susceptibility to, 2} (2)  |MTBS2|611046|8q12-q13
{Mycobacterium tuberculosis, susceptibility to, 3} (2)  |MTBS3|612929|19q13.31-q33
{Mycobacterium tuberculosis, susceptibility to}, 607948 (3)  |CCL2, SCYA2, MCP1, MCAF|158105|17q11.2-q12
{Mycobacterium tuberculosis, susceptibility to}, 607948 (3)  |CD209, CDSIGN|604672|19p13.3
{Mycobacterium tuberculosis, susceptibility to}, 607948 (3)  |SP110, IFI41, IFI75, VODI|604457|2q37.1
{Myocardial infarcation, susceptibility to} (3)  |PSMA6, PROS27, P27K|602855|14q13
{Myocardial infarction susceptibility} (3)  |APOE, AD2, LPG, LDLCQ5|107741|19q13.2
{Myocardial infarction, decreased susceptibility to} (3)  |F7|227500|13q34
{Myocardial infarction, susceptibility to, 2} (2)  |MCI2|608557|13q12
{Myocardial infarction, susceptibility to} (3)  |ACE, DCP1, ACE1, MVCD3|106180|17q23
{Myocardial infarction, susceptibility to} (3)  |GCLM, GLCLR|601176|1p22.1
{Myocardial infarction, susceptibility to} (3)  |LGALS2|150571|22q13.1
{Myocardial infarction, susceptibility to} (3)  |LTA, TNFB|153440|6p21.3
{Myocardial infarction, susceptibility to} (3)  |MIAT, C22orf35|611082|22q12.1
{Myocardial infarction, susceptibility to} (3)  |OLR1, LOX1|602601|12p13-p12
{Myocardial infarction, susceptibility to} (3)  |THBD, THRM, AHUS6|188040|20p11.2
{Myocardial infarction, susceptibility to}, 608446 (3)  |ESR1, ESR|133430|6q25.1
{Myocardial infarction, susceptibility to}, 608446 (3)  |GCLC, GLCLC|606857|6p12
{Myocardial infarction, susceptibility to}, 608446 (3)  |LRP8, APOER2, MCI1|602600|1p34
{Myocardial infarction, susceptibility to}, 608446 (3)  |TNFSF4, GP34, OX4OL|603594|1q25
{Myoclonic epilepsy, juvenile, susceptibility to, 1}, 254770 (3)  |EFHC1, FLJ10466, EJM1, JAE, EJA1|608815|6p12-p11
{Narcolepsy 4} (2)  |NRCLP4|612417|22q13
{Narcolepsy 5} (2)  |NRCLP5|612851|14q11.2
{Nasopharyngeal carcinoma 1} (2)  |NPC1, NPCA1|607107|4p15.1-q12
{Nasopharyngeal carcinoma, susceptibility to, 2} (2)  |NPCA2|161550|6p21.3
{Natural teeth remaining intact} (2)  |MGP, NTI|154870|12p13.1-p12.3
{Nephrolithiasis, uric acid, susceptibility to}, 605990 (3)  |ZNF365, UAN|607818|10q21.2
{Neural tube defects, folate-sensitive, susceptibility to}, 601634 (3)  |MTRR|602568|5p15.3-p15.2
{Neural tube defects, folate-sensitive, susceptibility to}, 601634 (3)  |MTR|156570|1q43
{Neural tube defects, susceptibility to}, 182940 (3)  |T, TFT|601397|6q27
{Neural tube defects, susceptibility to}, 601634 (3)  |MTHFR|607093|1p36.3
{Neuroblastoma, susceptibility to, 1}, 256700 (3)  |KIF1B, CMT2A, CMT2A1, NBLST1|605995|1p36.2
{Neuroblastoma, susceptibility to, 2}, 613013 (3)  |PMX2B, NBPHOX, PHOX2B, NBLST2|603851|4p12
{Neuroblastoma, susceptibility to, 3}, 613014 (3)  |ALK, NBLST3|105590|2p23
{Neuroblastoma, susceptibility to, 4} (2)  |NBLST4|613015|6p22
{Neuroblastoma, susceptibility to, 5} (2)  |NBLST5|613016|2q35
{Neuroblastoma, susceptibility to, 6} (2)  |NBLST6|613017|1q21.1
{Nicotine addiction, protection from}, 188890 (3)  |CYP2A6, CYP2A3, CYP2A, P450C2A|122720|19q13.2
{Nicotine addiction, susceptibility to}, 188890 (3)  |CHRNA4, ENFL1|118504|20q13.2-q13.3
{Nicotine dependence, protection against}, 188890 (3)  |GPR51, GABBR2|607340|9q22.1
{Nicotine dependence, protection against}, 188890 (3)  |SLC6A3, DAT1|126455|5p15.3
{Nicotine dependence, susceptibility to}, 188890 (3)  |GPR51, GABBR2|607340|9q22.1
{Nonarteritic anterior ischemic optic neuropathy, susceptibility to}, 258660 (3)  |GP1BA|606672|17pter-p12
{Nonsmall cell lung cancer, susceptibility to}, 211980 (3)  |EGFR|131550|7p12.3-p12.1
{Nonsmall cell lung cancer} (2)  |DDX26, DICE1|604331|13q14.12-q14.2
{Nonsmall cell lung cancer} (2)  |TSG11|603040|11q23
{Norwalk virus infection, resistance to} (3)  |FUT2, SE, B12QTL1|182100|19q13.3
{Obesity, association with}, 601665 (3)  |SDC3, SYND3, SDCN|186357|1pter-p22.3
{Obesity, early-onset, susceptibility to}, 601665 (3)  |POMC|176830|2p23.3
{Obesity, late-onset}, 601665 (3)  |AGRP, ART, AGRT|602311|16q22
{Obesity, severe, and type II diabetes}, 601665 (3)  |UCP3|602044|11q13
{Obesity, severe, susceptibility to, BMIQ9}, 602025 (3)  |MC3R, BMIQ9|155540|20q13.2
{Obesity, susceptibility to, BMIQ10} (2)  |BMIQ10|607514|10q
{Obesity, susceptibility to, BMIQ11}, 300306 (3)  |SLC6A14, OBX, BMIQ11|300444|Xq23-q24
{Obesity, susceptibility to, BMIQ12}, 612362 (3)  |PCSK1, NEC1, PC1, PC3, BMIQ12|162150|5q15-q21
{Obesity, susceptibility to, BMIQ4}, 607447 (3)  |UCP2, BMIQ4|601693|11q13
{Obesity, susceptibility to, BMIQ7} (2)  |BMIQ7|608410|4p15-p14
{Obesity, susceptibility to, BMIQ8} (2)  |BMIQ8|603188|10p
{Obesity, susceptibility to, BMIQ9} (2)  |BMIQ9|602025|20q13.11-q13.2
{Obesity, susceptibility to}, 601665 (3)  |ADRB2|109690|5q32-q34
{Obesity, susceptibility to}, 601665 (3)  |ADRB3|109691|8p12-p11.2
{Obesity, susceptibility to}, 601665 (3)  |CART|602606|5q13.2
{Obesity, susceptibility to}, 601665 (3)  |ENPP1, PDNP1, NPPS, M6S1, PCA1, ARHR2|173335|6q22-q23
{Obesity, susceptibility to}, 601665 (3)  |GHRL|605353|3p26-p25
{Obesity, susceptibility to}, 601665 (3)  |UCP1|113730|4q31
{Obesity, variation in}, 601665 (3)  |PPARGC1B, PGC1B, PERC|608886|5q33
{Obesity}, 601665 (3)  |PYY|600781|17q21
{Obsessive-compulsive disorder 1}, 164230 (3)  |SLC6A4, HTT, OCD1|182138|17q11.1-q12
{Obsessive-compulsive disorder, protection against}, 164230 (3)  |BDNF|113505|11p13
{Obsessive-compulsive disorder, susceptibility to}, 164230 (3)  |HTR2A|182135|13q14-q21
{Oculocutaneous albinism, type II, modifier of},0 203200 (3)  |MC1R, SHEP2, CMM5|155555|16q24.3
{Opioid dependence, susceptibility to, 1} (2)  |ODS1|610064|Chr.17
{Opioid dependence, susceptibility to}, 610064 (3)  |ME2, ODS1|154270|18q21
{Organophosphate poisoning, sensitivity to} (3)  |PON1, PON, ESA, MVCD5|168820|7q21.3
{Ossification of the posterior longitudinal spinal ligaments}, 602475 (2)  |COL6A1, OPLL|120220|21q22.3
{Osteoarthritis susceptibility 1}, 165720 (3)  |FRZB, FRZB1, SRFP3, OS1|605083|2q31-q33
{Osteoarthritis susceptibility 2}, 140600 (3)  |MATN3, EDM5, HOA, OS2|602109|2p24-p23
{Osteoarthritis susceptibility 3}, 607850 (3)  |ASPN, PLAP1, OS3|608135|9q21.3-q22
{Osteoarthritis susceptibility 4} (2)  |OS4, GOA1|610839|2q33.3
{Osteoarthritis susceptibility 6} (2)  |OS6|612401|3p24.3
{Osteoporosis, postmenopausal, susceptibility}, 166710 (3)  |CALCR, CRT|114131|7q21.3
{Osteoporosis, postmenopausal}, 166710 (3)  |COL1A2|120160|7q22.1
{Osteoporosis, susceptibility to}, 166710 (3)  |RIL|603422|5q31.1
{Osteoporosis}, 166710 (2)  |BMND7|611738|20p12.3
{Osteoporosis}, 166710 (2)  |BMND8|611739|11p12
{Osteoporosis}, 166710 (3)  |COL1A1|120150|17q21.31-q22
{Osteoporosis}, 166710 (3)  |LRP5, BMND1, LRP7, LR3, OPPG, VBCH2, OPTA1, EVR4|603506|11q13.4
{Otitis media, susceptibility to} (2)  |OMS|166760|10q26.3
{Otosclerosis 4} (2)  |OTSC4|611571|16q22.1-q23.1
{Ovarian cancer, somatic}, 167000 (3)  |OPCML|600632|11q25
{Ovarian cancer, susceptibility to} (2)  |OVCAS1|607893|3p25-p22
{Pancreatic cancer, susceptibility to, 1}, 606856 (3)  |PALLD, KIAA0992, PNCA1|608092|4q32.3
{Pancreatic cancer, susceptibility to, 3}, 613348 (3)  |PALB2, FANCN, PNCA3|610355|16p12
{Pancreatic cancer, susceptibility to, 4} (3)  |BRCA1, PSCP, BROVCA1, PNCA4|113705|17q21
{Pancreatitis, chronic, protection against} (3)  |PRSS2, TRY2|601564|7q35
{Pancreatitis, chronic, susceptibility to}, 167800 (3)  |CTRC, CLCR|601405|1p36.21
{Pancreatitis, idiopathic}, 167800 (3)  |CFTR, ABCC7, CF, MRP7|602421|7q31.2
{Panic disorder, susceptibility to}, 167870 (3)  |COMT|116790|22q11.2
{Parkinson disease 5, susceptibility to}, 613643 (3)  |UCHL1, PARK5|191342|4p14
{Parkinson disease, resistance to}, 613643 (3)  |UCHL1, PARK5|191342|4p14
{Parkinson disease, susceptibility to}, 168600 (3)  |ADH1C, ADH3|103730|4q22
{Parkinson disease, susceptibility to}, 168600 (3)  |MAPT, MTBT1, DDPAC, MSTD|157140|17q21.1
{Parkinson disease, susceptibility to}, 168600 (3)  |TBP, SCA17, HDL4|600075|6q27
{Parkinson disease-16} (2)  |PARK16|613164|1q32
{Pelvic organ prolapse, susceptibility to, 1} (2)  |PVOP1|176780|1q31
{Pelvic organ prolapse, susceptibility to, 2} (2)  |PVOP2|613088|9q21
{Pemphigoid, susceptibility to} (2)  |HLA-DR1B, SS1|142857|6p21.3
{Pheochromocytoma, modifier of}, 171300 (3)  |GDNF, HSCR3|600837|5p13.1-p12
{Pheochromocytoma, susceptibility to}, 171300 (3)  |TMEM127|613403|2q11
{Placental abruption} (3)  |NOS3|163729|7q36
{Pneumococcal disease, invasive, protection against}, 610799 (3)  |TIRAP|606252|11q23-q24
{Polio, susceptibility to} (2)  |PVR, PVS|173850|19q13.2-q13.3
{Porphyria cutanea tarda, susceptibility to}, 176100 (3)  |HFE, HLA-H, HFE1, MVCD7|613609|6p21.3
{Porphyria variegata, susceptibility to}, 176200 (3)  |HFE, HLA-H, HFE1, MVCD7|613609|6p21.3
{Pre-B-cell acute lymphoblastic leukemia}, (3)  |BRCA2, FANCD1, BROVCA2, GLM3, PNCA2|600185|13q12.3
{Preeclampsia, susceptibility to} (3)  |AGT, SERPINA8|106150|1q42-q43
{Preeclampsia, susceptibility to}, 189800 (3)  |EPHX1|132810|1q42.1
{Preterm delivery, susceptibility to} (3)  |MBL2, MBL, MBP1|154545|10q11.2-q21
{Preterm premature rupture of the membranes, susceptibility to}, 610504 (3)  |CBP2, SERPINH2, PPROM|600943|11q13.5
{Prostate cancer aggressiveness QTL}, 176807 (2)  |HPCQTL19|607592|19q
{Prostate cancer, familial, susceptibility to}, 176807 (3)  |CHEK2, RAD53, CHK2, CDS1, LFS2|604373|22q12.1
{Prostate cancer, hereditary, 10} (2)  |HPC10|611100|8q24
{Prostate cancer, hereditary, 11} (2)  |HPC11|611955|17q12
{Prostate cancer, hereditary, 12}, 611868 (3)  |EHBP1, KIAA0903, HPC12|609922|2p15
{Prostate cancer, hereditary, 13}, 611928 (3)  |MSMB, HPC13|157145|10q11.2
{Prostate cancer, hereditary, 14} (2)  |HPC14|611958|11q13
{Prostate cancer, hereditary, 15} (2)  |HPC15|611959|19q13.4
{Prostate cancer, hereditary, 5}, 176807 (2)  |HPC5|609299|3p26
{Prostate cancer, hereditary, 7} (2)  |HPC7|610321|15q12
{Prostate cancer, hereditary, 9} (2)  |HPC9|610997|17q21-q22
{Prostate cancer, hereditary, X-linked 1} (2)  |HPCX1|300147|Xq27-q28
{Prostate cancer, hereditary, X-linked 2} (2)  |HPCX2|300704|Xp11.22
{Prostate cancer, progression of}, 176807 (1)  |HIP1|601767|7q11.23
{Prostate cancer, somatic}, 176  |PTEN, MMAC1, GLM2|601728|10q23.31
{Prostate cancer, susceptibility to, 3}, 176807 (2)  |HPC3|608656|20q13
{Prostate cancer, susceptibility to, 4}, 176807 (2)  |HPC4|608658|7p11-q21
{Prostate cancer, susceptibility to}, 176807 (2)  |CD82, SAR2, KAI1, ST6|600623|11p11.2
{Prostate cancer, susceptibility to}, 176807 (2)  |HPC6|609558|22q12.3
{Prostate cancer, susceptibility to}, 176807 (2)  |PCAP|602759|1q42.2-q43
{Prostate cancer, susceptibility to}, 176807 (3)  |AR, DHTR, TFM, SBMA, KD, SMAX1, HYSP1|313700|Xq11-q12
{Prostate cancer, susceptibility to}, 176807 (3)  |CDH1, UVO, LCAM, ECAD|192090|16q22.1
{Prostate cancer, susceptibility to}, 176807 (3)  |ELAC2, HPC2|605367|17p11
{Prostate cancer, susceptibility to}, 176807 (3)  |MXI1|600020|10q25
{Prostate cancer, susceptibility to}, 176807 (3)  |ZFHX3, ATBF1|104155|16q22.3-q23.1
{Pseudofolliculitis barbae, susceptibility to}, 612318 (3)  |KRT75, K6HF, PFB|609025|12q13
{Pseudoxanthoma elasticum, modifier of severity of}, 264800 (3)  |XYLT1, XT1|608124|16p13.1
{Pseudoxanthoma elasticum, modifier of severity of}, 264800 (3)  |XYLT2, XT2|608125|17q21.3-q22
{Psoraisis susceptibility 9} (2)  |PSORS9|607857|4q31-q34
{Psoriasis susceptibility 10} (3)  |PSORS10|612410|18p11.23
{Psoriasis susceptibility 11} (2)  |PSORS11|612599|5q31.1-q33.1
{Psoriasis susceptibility 12} (2)  |PSORS12|612950|20q13
{Psoriasis susceptibility 1}, 177900 (3)  |HLA-C, PSORS1|142840|6p21.3
{Psoriasis susceptibility 2} (2)  |PSORS2, PSS1|602723|17q25
{Psoriasis susceptibility 3} (2)  |PSORS3|601454|4q
{Psoriasis susceptibility 4} (2)  |PSORS4|603935|1q21
{Psoriasis susceptibility 5} (2)  |PSORS5|604316|3q21
{Psoriasis susceptibility 6} (3)  |PSORS6|605364|19p13
{Psoriasis susceptibility 7} (2)  |PSORS7|605606|1p
{Psoriasis susceptibility 8} (2)  |PSORS8|610707|16q
{Psoriasis, protection against}, 177900 (3)  |IL23R, IBD17|607562|1p31.3
{Psoriatic arthritis, susceptibility to}, 607507 (3)  |LTA, TNFB|153440|6p21.3
{Psoriatic arthritis, susceptibility to}, 607507 (3)  |NOD2, CARD15, IBD1, CD, ACUG, PSORAS1|605956|16q12
{Pulmonary disease, chronic obstructive, susceptibility to}, 606963 (1)  |SERPINA1, PI, AAT|107400|14q32.1
{Pulmonary disease, chronic obstructive, susceptibility to}, 606963 (3)  |HMOX1|141250|22q12
{Pulmonary fibrosis, idiopathic, susceptibility to}, 178500 (3)  |SFTPA1, SFTP1|178630|10q22.2-q23.1
{Pulmonary fibrosis, idiopathic, susceptibility to}, 178500 (3)  |TERC, TRC3, TR|602322|3q21-q28
{Pulmonary fibrosis,idiopathic, susceptibility to}, 178500 (3)  |TERT, TCS1, EST2|187270|5p15.33
{Pulmonary function} (2)  |PLF|608852|6q21-q22
{Pulmonary hypertension, chronic thromboembolic, without deep vein thrombosis, susceptibility to} (2)  |CTEPH1|612862|6p21.3
{Pulmonary hypertension, familial persistent, of the newborn}, 265380 (3)  |CPS1|608307|2q35
{Rapid progression to AIDS from HIV1 infection}, 609423 (3)  |CX3CR1, GPR13, V28|601470|3pter-p21
{Reduced triglycerides, susceptibility to} (3)  |ANGPTL4, PGAR, HFARP, FIAF|605910|19p13.3
{Renal cell carcinoma}, 144700 (3)  |HNF1B, TCF2, HNF2, MODY5, FJHN, HPC11|189907|17q12
{Restless legs syndrome 1} (2)  |RLS1|102300|12q12-q21
{Restless legs syndrome 2} (2)  |RLS2|608831|14q13-q21
{Restless legs syndrome 3} (2)  |RLS3|610438|9p24-p22
{Restless legs syndrome 4} (2)  |RLS4|610439|2q33
{Restless legs syndrome 7} (2)  |RLS7|612853|2p14-p13
{Restless legs syndrome, susceptibility to, 5} (2)  |RLS5|611242|20p13
{Restless legs syndrome, susceptibility to, 6} (2)  |RLS6|611185|6p21
{Rheumatoid arthritis, association with}, 180300 (3)  |STAT4, SLEB11|600558|2q32.2-q32.3
{Rheumatoid arthritis, progression of}, 180300 (3)  |IL10, CSIF|124092|1q31-q32
{Rheumatoid arthritis, susceptibility to} (2)  |RA|180300|6q23
{Rheumatoid arthritis, susceptibility to}, 180300 (3)  |CD244, NAIL, NKR2B4, SLAMF4|605554|1q22
{Rheumatoid arthritis, susceptibility to}, 180300 (3)  |HLA-DR1B, SS1|142857|6p21.3
{Rheumatoid arthritis, susceptibility to}, 180300 (3)  |MHC2TA, C2TA|600005|16p13
{Rheumatoid arthritis, susceptibility to}, 180300 (3)  |NFKBIL1|601022|6p21.3
{Rheumatoid arthritis, susceptibility to}, 180300 (3)  |PADI4, PADI5, PAD|605347|1p36.13
{Rheumatoid arthritis, susceptibility to}, 180300 (3)  |PTPN22, PEP, PTPN8, LYP|600716|1p13
{Rheumatoid arthritis, susceptibility to}, 180300 (3)  |SLC22A4, OCTN1|604190|5q31
{Rheumatoid arthritis, systemic juvenile, susceptibility to}, 604302 (3)  |MIF|153620|22q11.2
{Rheumatoid arthritis, systemic juvenile}, 604302 (3)  |IL6, IFNB2, BSF2, HSF, HGF|147620|7p21
{SARS, progression of} (3)  |ACE, DCP1, ACE1, MVCD3|106180|17q23
{Sarcoidosis, susceptibility l, 1}, 181000 (3)  |HLA-DR1B, SS1|142857|6p21.3
{Sarcoidosis, susceptibility to, 2}, 612387 (3)  |BTNL2, SS2|606000|6p21.3
{Sarcoidosis, susceptibility to, 3} (2)  |SS3|612388|10q22.3
{Schistosoma mansoni infection, susceptibility/resistance to} (2)  |SM1|181460|5q31-q33
{Schizoaffective disorder, susceptibility to}, 181500 (3)  |DISC1, SCZD9|605210|1q42.1
{Schizophrenia 12}, 181500 (2)  |SCZD12|608543|1p36.2
{Schizophrenia, susceptibility to, 13} (2)  |SCZD13|613025|15q13
{Schizophrenia, susceptibility to, 14} (2)  |SCZD14|612361|2q32.1
{Schizophrenia, susceptibility to, 4}, 600850 (3)  |PRODH, PRODH2, SCZD4|606810|22q11.2
{Schizophrenia, susceptibility to}, 181500 (2)  |AKT1|164730|14q32.3
{Schizophrenia, susceptibility to}, 181500 (3)  |CHI3L1, GP39, YKL40, ASRT7|601525|1q32.1
{Schizophrenia, susceptibility to}, 181500 (3)  |COMT|116790|22q11.2
{Schizophrenia, susceptibility to}, 181500 (3)  |DRD3, ETM1, FET1|126451|3q13.3
{Schizophrenia, susceptibility to}, 181500 (3)  |GPR48, LGR4|606666|11p14-p13
{Schizophrenia, susceptibility to}, 181500 (3)  |HTR2A|182135|13q14-q21
{Schizophrenia, susceptibility to}, 181500 (3)  |MTHFR|607093|1p36.3
{Schizophrenia, susceptibility to}, 181500 (3)  |RTN4R, NOGOR|605566|22q11
{Schizophrenia, susceptibility to}, 181500 (3)  |SYN2|600755|3p25
{Schizophrenia, susceptibility to}, 604906 (3)  |DISC1, SCZD9|605210|1q42.1
{Schizophrenia}, 181500 (1)  |APOL2|607252|22q12.3
{Schizophrenia}, 181500 (1)  |APOL4|607254|22q12.3
{Schizophrenia}, 181500 (2)  |DAO, DAMOX|124050|12q24
{Schizophrenia}, 181500 (2)  |DAOA, G72|607408|13q34
{Schizophrenia}, 181500 (2)  |DTNBP1, HPS7|607145|6p22.3
{Schizophrenia}, 181500 (2)  |SCZD10|605419|15q15
{Schizophrenia}, 181500 (2)  |SCZD11|608078|10q22.3
{Schizophrenia}, 181500 (2)  |SCZD1|181510|5q23-q35
{Schizophrenia}, 181500 (2)  |SCZD3|600511|6p23
{Schizophrenia}, 181500 (2)  |SCZD5|603175|6q13-q26
{Schizophrenia}, 181500 (2)  |SCZD6|603013|8p21
{Schizophrenia}, 181500 (2)  |SCZD7|603176|13q32
{Schizophrenia}, 181500 (2)  |SCZD8|603206|18p
{Scoliosis, idiopathic 3}, 608765 (3)  |CHD7, IS3, KAL5|608892|8q12.1
{Scoliosis, idiopathic, susceptibility to, 4} (2)  |IS4|612238|9q31.2-q34.2
{Seasonal affective disorder, susceptibility to}, 608516 (3)  |HTR2A|182135|13q14-q21
{Sepsis, susceptibility to} (3)  |CASP12, CASP12P1|608633|11q22.3
{Septic shock, susceptibility to} (3)  |TNF, TNFA|191160|6p21.3
{Severe cutaneous adverse reaction, susceptibiliyt to}, 608579 (3)  |HLA-A|142800|6p21.3
{Smoking as a quantitative trait locus 1} (2)  |SQTL1|611003|10q22
{Smoking as a quantitative trait locus 2} (2)  |SQTL2|611004|22q12
{Specific language impairment 4} (2)  |SLI4|612514|7q35-q36
{Speech-sound disorder} (2)  |SSD|608445|3p12-q13
{Spermatogenic failure, susceptibility to} (3)  |DAZL, DAZH, SPGYLA|601486|3p24
{Spina bifida, folate-sensitive, susceptibility to}, 601634 (3)  |MTHFD, MTHFC|172460|14q24
{Spina bifida, susceptibility to}, 182940 (3)  |CCL2, SCYA2, MCP1, MCAF|158105|17q11.2-q12
{Spinal muscular atrophy, type III, modifier of}, 253400 (3)  |SMN2|601627|5q12.2-q13.3
{Spondylarthropathy, susceptibility to, 3} (2)  |SPDA3|613238|2q36.1-q36.3
{Spondyloarthropathy, susceptibility to, 1}, 106300 (3)  |HLA-B, SPDA1|142830|6p21.3
{Spondyloarthropathy, susceptibility to, 2} (2)  |SPDA2|183840|9q31-q34
{Stature QTL 10} (2)  |STQTL10|612221|3q23
{Stature QTL 11} (2)  |STQTL11|612223|7q21
{Stature QTL 12} (2)  |STQTL12|612224|4q31
{Stature QTL 13} (2)  |STQTL13|612226|4p15.3
{Stature QTL 14} (2)  |STQTL14|612228|20q11.22
{Stature QTL 15} (2)  |STQTL15|612578|8q21.13
{Stature QTL 16} (2)  |STQTL16|612579|15q22.32
{Stature QTL 17} (2)  |STQTL17|612737|7p15
{Stature QTL 18} (2)  |STQTL18|612892|6p22.1
{Stature QTL 19} (2)  |STQTL19|612893|6p21.31
{Stature QTL 1} (2)  |STQTL1|606255|6q24-q25
{Stature QTL 20} (2)  |STQTL20|612894|13q14.3
{Stature QTL 21} (2)  |STQTL21|613440|2q37.1
{Stature QTL 22} (2)  |STQTL22|613547|16q24
{Stature QTL 23} (2)  |STQTL23|613548|1p32
{Stature QTL 24} (2)  |STQTL24|613549|2p16
{Stature QTL 2} (2)  |STQTL2|606256|7q31.3
{Stature QTL 3} (2)  |STQTL3|606257|12p11.2-q14
{Stature QTL 4} (2)  |STQTL4|606258|13q32-q33
{Stature QTL 5} (2)  |STQTL5|608982|3p26
{Stature QTL 6} (2)  |STQTL6|300591|Xq24-q25
{Stature QTL 7} (2)  |STQTL7|609822|1p21
{Stature QTL 8} (2)  |STQTL8|610114|9q22
{Stature QTL 9} (2)  |STQTL9|611547|12q14.3
{Stevens-Johnson syndrome, carbamazepine-induced, susceptibility to}, 608579 (3)  |HLA-B, SPDA1|142830|6p21.3
{Strabismus, susceptibility to, 1} (2)  |STBMS1|185100|7p22.1
{Stroke, ischemic, susceptibility to}, 601367 (3)  |F2|176930|11p11-q12
{Stroke, ischemic, susceptibility to}, 601367 (3)  |F5|612309|1q23
{Stroke, susceptibility to, 1}, 606799 (3)  |PDE4D, DPDE3, STRK1|600129|5q12
{Stroke, susceptibility to}, 601367 (3)  |ALOX5AP, FLAP|603700|13q12
{Sublingual nitroglycerin, susceptibility to poor response to} (3)  |ALDH2|100650|12q24.2
{Sudden infant death syndrome, susceptibility to}, 272120 (3)  |SCN5A, LQT3, VF1, HB1, SSS1, CMD1E, CDCD2|600163|3p21
{Synovitis, chronic, susceptibility to} (3)  |HLA-B, SPDA1|142830|6p21.3
{Systemic lupus erthematosus, susceptibility to, 15} (2)  |SLEB15|300809|Xq28
{Systemic lupus erythematosus susceptibility to}, 152700 (3)  |PTPN22, PEP, PTPN8, LYP|600716|1p13
{Systemic lupus erythematosus with hemolytic anemia}, 152700 (2)  |SLEH1|607279|11q14
{Systemic lupus erythematosus with nephritis, susceptibility to, 1} (2)  |SLEN1|607965|10q22.3
{Systemic lupus erythematosus with nephritis, susceptibility to, 2} (2)  |SLEN2|607966|2q34-q35
{Systemic lupus erythematosus with nephritis, susceptibility to, 3} (2)  |SLEN3|607967|11p15.5
{Systemic lupus erythematosus, association with}, 152700 (3)  |BANK1, FLJ20706, BANK|610292|4q22-q24
{Systemic lupus erythematosus, resistance to}, 601744 (3)  |TLR5, TIL3, SLEB1|603031|1q41-q42
{Systemic lupus erythematosus, susceptibility to or protection against}, 152700 (2)  |C4A, C4S|120810|6p21.3
{Systemic lupus erythematosus, susceptibility to, 10}, 612251 (3)  |IRF5, IBD14, SLEB10|607218|7q32
{Systemic lupus erythematosus, susceptibility to, 12} (2)  |SLEB12|612254|8p23.1
{Systemic lupus erythematosus, susceptibility to, 13} (2)  |SLEB13|612378|6q23
{Systemic lupus erythematosus, susceptibility to, 14} (2)  |SLEB14|613145|1q21-q23
{Systemic lupus erythematosus, susceptibility to, 1}, 601744 (2)  |TLR5, TIL3, SLEB1|603031|1q41-q42
{Systemic lupus erythematosus, susceptibility to, 2}, 605218 (3)  |PDCD1, SLEB2|600244|2q37.3
{Systemic lupus erythematosus, susceptibility to, 3}, 152700 (2)  |SLEB3|605480|4p16-p15.2
{Systemic lupus erythematosus, susceptibility to, 4} (2)  |SLEB4|608437|12q24
{Systemic lupus erythematosus, susceptibility to, 5} (2)  |SLEB5|609903|13q32
{Systemic lupus erythematosus, susceptibility to, 7} (2)  |SLEB7|610065|20p12
{Systemic lupus erythematosus, susceptibility to, 8} (2)  |SLEB8|610066|20q13
{Systemic lupus erythematosus, susceptibility to, 9}, 610927 (3)  |CR2, C3DR, SLEB9|120650|1q32
{Systemic lupus erythematosus, susceptibility to}, 152700 (3)  |DNASE1, DNL1|125505|16p13.3
{Systemic lupus erythematosus, susceptibility to}, 152700 (3)  |FCGR2B, CD32|604590|1q22
{Systemic lupus erythematosus, susceptibility to}, 152700 (3)  |TREX1, AGS1, CRV, HERNS|606609|3p21.3-p21.2
{Systemic lupus erythematosus, susceptibility}, 152700 (3)  |TNFSF6, APT1LG1, FASL|134638|1q23
{Systemic lupus erythematous, association with susceptibility to, 11}, 612253 (3)  |STAT4, SLEB11|600558|2q32.2-q32.3
{Systemic lupus erythematous, association with susceptibility to, 6}, 609939 (3)  |ITGAM, CR3A, CD11B, MAC1A, SLEB6|120980|16p11.2
{T-cell acute lymphoblastic leukemia} (3)  |MYB|189990|6q22
{TSC2 angiomyolipomas, renal, modifier of}, 613254 (3)  |IFNG, IFG, IFI|147570|12q14
{Thromboembolism, susceptibility to}, 188050 (3)  |MTHFR|607093|1p36.3
{Thrombophilia, susceptibility to, due to activated protein C resistance}, 188055 (3)  |F5|612309|1q23
{Thrombophilia, susceptibility to, due to factor V Leiden}, 188055 (3)  |F5|612309|1q23
{Thrombosis, susceptibility to}, 188050 (3)  |F2|176930|11p11-q12
{Thrombycytosis, susceptibility to}, 187950 (3)  |MPL, TPOR, MPLV|159530|1p34
{Thyroid carcinoma, Hurthle cell}, 607464 (3)  |NDUFA13, GRIM19|609435|19p13.2-p13.1
{Thyroid carcinoma, follicular, somatic}, 188470 (3)  |HRAS|190020|11p15.5
{Thyrotoxic periodic paralysis, susceptibility to, 1}, 188580 (3)  |CACNA1S, CACNL1A3, CCHL1A3, TTPP1, HOKPP1|114208|1q32
{Thyrotoxic periodic paralysis, susceptibility to, 2}, 613239 (3)  |KCNJ18, KIR2.6, TTPP2|613236|17p11.2
{Transcription of plasminogen activator inhibitor, modulator of} (3)  |PAI1, PLANH1, SERPINE1|173360|7q21.3-q22
{Tuberculosis, protection against}, 607948 (3)  |IFNG, IFG, IFI|147570|12q14
{Tuberculosis, protection against}, 607948 (3)  |TIRAP|606252|11q23-q24
{Tuberculosis, susceptibility to} (2)  |MTBS1|607949|2q35
{Tuberculosis, susceptibility to}, 607948 (3)  |CISH|602441|3p21.3
{Tuberculosis, susceptibility to}, 607948 (3)  |IFNGR1|107470|6q23-q24
{UV-induced skin damage}, 266300 (3)  |MC1R, SHEP2, CMM5|155555|16q24.3
{Unipolar depression, susceptibility to}, 608516 (3)  |TPH2, NTPH, ADHD7|607478|12q21.1
{Uric acid concentration, serum, QTL 2}, 612076 (3)  |SLC2A9, GLUT9, UAQTL2|606142|4p16-p15.3
{Urinary tract infection, susceptibility to} (1)  |B3GALT3, GLCT3, P|603094|3q25
{Vascular disease, susceptibility to} (3)  |MTHFR|607093|1p36.3
{Venoocclusive disease after bone marrow transplantation} (3)  |CPS1|608307|2q35
{Venous thromboembolism, susceptibility to}, 188050 (3)  |HABP2, PHBP, HGFAL, FSAP|603924|10q25-q26
{Venous thrombosis, susceptibility to} (3)  |SERPINA10, ZPI|605271|14q32.1
{Viral infection, susceptibility to} (3)  |OAS1, OIAS|164350|12q24.2
{Viral infections, recurrent} (3)  |FCGR3A, CD16, IGFR3|146740|1q23
{Vitamin B12 plasma level QTL1}, 612542 (3)  |FUT2, SE, B12QTL1|182100|19q13.3
{Vitamin B6 plasma level QTL 1} (2)  |B6QTL1|612957|1p36.12
{Vitiligo, susceptibility to} (2)  |VTLG|193200|6p21.3
{Vitiligo-associated multiple autoimmune disease susceptibility 1}, 606579 (3)  |NALP1, KIAA0926, DEFCAP, CARD7, SLEV1, VAMAS1|606636|17p13
{Warfarin sensitivity}, 122700 (3)  |F9, HEMB|300746|Xq27.1-q27.2
{West nile virus, susceptibility to}, 610379 (3)  |CCR5, CMKBR5, CCCKR5, IDDM22|601373|3p21
{Wilms tumor susceptibility-5}, 601583 (3)  |POU6F2, WTSL, WT5|609062|7p14-p13
